Patent Publication Number: US-11040966-B2

Title: Benzimidazole-proline derivatives

Description:
CROSS REFERENCE TO RELATED APPLICATIONS 
     This application is a continuation of U.S. application Ser. No. 15/644,547, filed Jul. 7, 2017, which is a continuation of U.S. application Ser. No. 14/405,649, filed on Dec. 4, 2014, which claims benefit of PCT Application No. PCT/1132013/054567, filed on Jun. 3, 2013, which claims the benefit of European Patent Application 13158520.0, filed on Mar. 11, 2013, and European Patent Application 12170748.3, filed on Jun. 4, 2012, the contents of each of which are incorporated herein by reference. 
    
    
     The present invention relates to novel benzimidazole-proline derivatives of formula (I) and their use as pharmaceuticals. The invention also concerns related aspects including processes for the preparation of the compounds, pharmaceutical compositions containing one or more compounds of formula (I), and their use as orexin receptor antagonists, especially as orexin-1 receptor antagonists. 
     Orexins (orexin A or OX-A and orexin B or OX-B) are neuropeptides found in 1998 by two research groups, orexin A is a 33 amino acid peptide and orexin B is a 28 amino acid peptide (Sakurai T. et al., Cell, 1998, 92, 573-585). Orexins are produced in discrete neurons of the lateral hypothalamus and bind to the G-protein-coupled receptors (OX 1  and OX 2  receptors). The orexin-1 receptor (OX 1 ) is selective for OX-A, and the orexin-2 receptor (OX 2 ) is capable to bind OX-A as well as OX-B. Orexin receptor antagonists are a novel type of nervous system or psychotropic drugs. Their mode of action in animals and humans involves either blockade of both orexin-1 and orexin-2 receptor (dual antagonists), or individual and selective blockade of either the orexin-1 or the orexin-2 receptor (selective antagonists) in the brain. Orexins were initially found to stimulate food consumption in rats suggesting a physiological role for these peptides as mediators in the central feedback mechanism that regulates feeding behaviour (Sakurai T. et al., Cell, 1998, 92, 573-585). 
     On the other hand, orexin neuropeptides and orexin receptors play an essential and central role in regulating circadian vigilance states. In the brain, orexin neurons collect sensory input about internal and external states and send short intrahypothalamic axonal projections as well as long projections to many other brain regions. The particular distribution of orexin fibers and receptors in basal forebrain, limbic structures and brainstem regions—areas related to the regulation of waking, sleep and emotional reactivity—suggests that orexins exert essential functions as regulators of behavioral arousal; by activating wake-promoting cell firing, orexins contribute to orchestrate all brain arousal systems that regulate circadian activity, energy balance and emotional reactivity. This role opens large therapeutic opportunities for medically addressing numerous mental health disorders possibly relating to orexinergic dysfunctions [see for example: Tsujino N and Sakurai T, “Orexin/hypocretin: a neuropeptide at the interface of sleep, energy homeostasis, and reward systems.”, Pharmacol Rev. 2009, 61:162-176; and Carter M E et al., “The brain hypocretins and their receptors: mediators of allostatic arousal.”, Curr Op Pharmacol. 2009, 9: 39-45] that are described in the following sections. It was also observed that orexins regulate states of sleep and wakefulness opening potentially novel therapeutic approaches to insomnia and other sleep disorders (Chemelli R. M. et al., Cell, 1999, 98, 437-451). 
     Human memory is comprised of multiple systems that have different operating principles and different underlying neuronal substrates. The major distinction is between the capacity for conscious, declarative memory and a set of unconscious, non-declarative memory abilities. Declarative memory is further subdivided into semantic and episodic memory. Non-declariative memory is further subdivided into priming and perceptual learning, procedural memory for skills and habits, associative and non-associative learning, and some others. While semantic memory refers to the general knowledge about the world, episodic memory is autobiographical memory of events. Procedural memories refer to the ability to perform skill-based operations, as e.g. motor skills. Long-term memory is established during a multiple stage process through gradual changes involving diverse brain structures, beginning with learning, or memory acquisition, or formation. Subsequently, consolidation of what has been learned may stabilize memories. When long-term memories are retrieved, they may return to a labile state in which original content may be updated, modulated or disrupted. Subsequently, reconsolidation may again stabilize memories. At a late stage, long-term memory may be resistant to disruption. Long-term memory is conceptually and anatomically different from working memory, the latter of which is the capacity to maintain temporarily a limited amount of information in mind. Behavioural research has suggested that the human brain consolidates long-term memory at certain key time intervals. The initial phase of memory consolidation may occur in the first few minutes after we are exposed to a new idea or learning experience. The next, and possibly most important phase, may occur over a longer period of time, such as during sleep; in fact, certain consolidation processes have been suggested to be sleep-dependent [R. Stickgold et al., Sleep-dependent memory consolidation; Nature 2005, 437, 1272-1278]. Learning and memory processes are believed to be fundamentally affected in a variety of neurological and mental disorders, such as e.g. mental retardation, Alzheimer&#39;s disease or depression. Indeed, memory loss or impairment of memory acquisition is a significant feature of such diseases, and no effective therapy to prevent this detrimental process has emerged yet. 
     In addition, both anatomical and functional evidence from in vitro and in vivo studies suggest an important positive interaction of the endogenous orexin system with reward pathways of the brain [Aston-Jones G et al., Brain Res 2010, 1314, 74-90; Sharf R et al., Brain Res 2010, 1314, 130-138]. Selective pharmacological OXR-1 blockade reduced cue- and stress-induced reinstatement of cocaine seeking [Boutrel B, et al., “Role for hypocretin in mediating stress-induced reinstatement of cocaine-seeking behavior.” Proc Natl Acad Sci 2005, 102(52), 19168-19173; Smith R J et al., “Orexin/hypocretin signaling at the orexin 1 receptor regulates cue-elicited cocaine-seeking.” Eur J Neurosci 2009, 30(3), 493-503; Smith R J et al., “Orexin/hypocretin is necessary for context-driven cocaine-seeking.” Neuropharmacology 2010, 58(1), 179-184], cue-induced reinstatement of alcohol seeking [Lawrence A J et al., Br J Pharmacol 2006, 148(6), 752-759] and nicotine self-administration [Hollander J A et al., Proc Natl Acad Sci 2008, 105(49), 19480-19485; LeSage M G et al., Psychopharmacology 2010, 209(2), 203-212]. Orexin-1 receptor antagonism also attenuated the expression of amphetamine- and cocaine-induced CPP [Gozzi A et al., PLoS One 2011, 6(1), e16406; Hutcheson D M et al., Behav Pharmacol 2011, 22(2), 173-181], and reduced the expression or development of locomotor sensitization to amphetamine and cocaine [Borgland S L et al., Neuron 2006, 49(4), 589-601; Quarta D et al., “The orexin-1 receptor antagonist SB-334867 reduces amphetamine-evoked dopamine outflow in the shell of the nucleus accumbens and decreases the expression of amphetamine sensitization.” Neurochem Int 2010, 56(1), 11-15]. 
     The effect of a drug to diminish addictions may be modelled in normal or particularly sensitive mammals used as animal models [see for example Spealman et al, Pharmacol. Biochem. Behav. 1999, 64, 327-336; or T. S. Shippenberg, G. F. Koob, “Recent advances in animal models of drug addiction” in Neuropsychopharmacology: The fifth generation of progress; K. L. Davis, D. Charney, J. T. Doyle, C. Nemeroff (eds.) 2002; chapter 97, pages 1381-1397]. 
     Several converging lines of evidence furthermore demonstrate a direct role of the orexin system as modulator of the acute stress response. For instance, stress (i.e. psychological stress or physical stress) is associated with increased arousal and vigilance which in turn is controlled by orexins [Sutcliffe, J G et al., Nat Rev Neurosci 2002, 3(5), 339-349]. Orexin neurons are likely to be involved in the coordinated regulation of behavioral and physiological responses in stressful environments [Y. Kayaba et al., Am. J. Physiol. Regul. Integr. Comp. Physiol. 2003, 285:R581-593]. Hypocretin/orexin contributes to the expression of some but not all forms of stress and arousal [Furlong T M et al., Eur J Neurosci 2009, 30(8), 1603-1614]. Stress response may lead to dramatic, usually time-limited physiological, psychological and behavioural changes that may affect appetite, metabolism and feeding behavior [Chrousos, G P et al., JAMA 1992, 267(9), 1244-1252]. The acute stress response may include behavioural, autonomic and endocrinological changes, such as promoting heightened vigilance, decreased libido, increased heart rate and blood pressure, or a redirection of blood flow to fuel the muscles, heart and the brain [Majzoub, J A et al., European Journal of Endocrinology 2006, 155 (suppl_1) S71-S76]. 
     As outlined above the orexin system regulates homeostatic functions such as sleep-wake cycle, energy balance, emotions and reward. Orexins are also involved in mediating the acute behavioral and autonomous nervous system response to stress [Zhang W et al., “Multiple components of the defense response depend on orexin: evidence from orexin knockout mice and orexin neuron-ablated mice.” Auton Neurosci 2006, 126-127, 139-145]. Mood disorders including all types of depression and bipolar disorder are characterized by disturbed “mood” and feelings, as well as by sleeping problems (insomnia as well as hypersomnia), changes in appetite or weight and reduced pleasure and loss of interest in daily or once enjoyed activities [Liu X et al., Sleep 2007, 30(1): 83-90]. Thus, there is a strong rationale that disturbances in the orexin system may contribute to the symptoms of mood disorders. Evidence in humans, for instance, exists that depressed patients show blunted diurnal variation in CSF orexin levels [Salomon R M et al., Biol Psychiatry 2003, 54(2), 96-104]. In rodent models of depression, orexins were also shown to be involved. Pharmacological induction of a depressive behavioral state in rats, for instance, revealed an association with increased hypothalamic orexin levels [Feng P et al., J Psychopharmacol 2008, 22(7): 784-791]. A chronic stress model of depression in mice also demonstrated an association of molecular orexin system disturbances with depressed behavioral states and a reversal of these molecular changes by antidepressant treatment [Nollet et al., NeuroPharm 2011, 61(1-2):336-46]. 
     The orexin system is also involved in stress-related appetitive/reward seeking behaviour (Berridge C W et al., Brain Res 2009, 1314, 91-102). In certain instances, a modulatory effect on stress may be complementary to an effect on appetitive/reward seeking behaviour as such. For instance, an OX 1  selective orexin receptor antagonist was able to prevent footshock stress induced reinstatement of cocaine seeking behaviour [Boutrel, B et al., Proc Natl Acad Sci 2005, 102(52), 19168-19173]. In addition, stress is also known to play an integral part in withdrawal which occurs during cessation of drug taking (Koob, G F et al., Curr Opin Investig Drugs 2010, 11(1), 63-71). 
     Orexins have been found to increase food intake and appetite [Tsujino, N, Sakurai, T, Pharmacol Rev 2009, 61(2) 162-176]. As an additional environmental factor, stress can contribute to binge eating behaviour, and lead to obesity [Adam, T C et al. Physiol Behav 2007, 91(4) 449-458]. Animal models that are clinically relevant models of binge eating in humans are described for example in W. Foulds Mathes et al.; Appetite 2009, 52, 545-553. 
     A number of recent studies report that orexins may play a role into several other important functions relating to arousal, especially when an organism must respond to unexpected stressors and challenges in the environment [Tsujino N and Sakurai T. Pharmacol Rev. 2009, 61:162-176; Carter M E, Borg J S and deLecea L., Curr Op Pharmacol. 2009, 9: 39-45; C Boss, C Brisbare-Roch, F Jenck, Journal of Medicinal Chemistry 2009, 52: 891-903]. The orexin system interacts with neural networks that regulate emotion, reward and energy homeostasis to maintain proper vigilance states. Dysfunctions in its function may thus relate to many mental health disorders in which vigilance, arousal, wakefulness or attention is disturbed. 
     The compound (2R)-2-{(1S)-6,7-dimethoxy-1-[2-(4-trifluoromethyl-phenyl)-ethyl]-3,4-dihydro-1H-isoquinolin-2-yl}-N-methyl-2-phenyl-acetamide (WO2005/118548), a dual orexin receptor antagonist, showed clinical efficacy in humans when tested for the indication primary insomnia. In the rat, the compound has been shown to decrease alertness, characterized by decreases in both active wake and locomotion; and to dose-dependently increase the time spent in both REM and NREM sleep [Brisbare et al., Nature Medicine 2007, 13, 150-155]. The compound further attenuated cardiovascular responses to conditioned fear and novelty exposure in rats [Furlong T M et al., Eur J Neurosci 2009, 30(8), 1603-1614]. It is also active in an animal model of conditioned fear: the rat fear-potentiated startle paradigm (WO2009/047723) which relates to emotional states of fear and anxiety diseases such as anxieties including phobias and post traumatic stress disorders (PTSDs). In addition, intact declarative and non-declarative learning and memory has been demonstrated in rats treated with this compound [WO2007/105177, H Dietrich, F Jenck, Psychopharmacology 2010, 212, 145-154]. Said compound furthermore decreased brain levels of amyloid-beta (Aβ) as well as Aβ plaque deposition after acute sleep restriction in amyloid precursor protein transgenic mice [J E Kang et al., “Amyloid-beta dynamics are regulated by orexin and the sleep-wake cycle.”, Science 2009, 326(5955): 1005-1007]. The accumulation of the Aβ in the brain extracellular space is hypothesized to be a critical event in the pathogenesis of Alzheimer&#39;s disease. The so-called and generally known “amyloid cascade hypothesis” links Aβ to Alzheimer&#39;s disease and, thus, to the cognitive dysfunction, expressed as impairment of learning and memory. The compound has also been shown to induce antidepressant-like activity in a mouse model of depression, when administered chronically [Nollet et al., NeuroPharm 2011, 61(1-2):336-46]. Moreover, the compound has been shown to attenuate the natural activation induced by orexin A in fasted hungry rats exposed to food odors [M J Prud&#39;homme et al., Neuroscience 2009, 162(4), 1287-1298]. The compound also displayed pharmacological activity in a rat model of nicotine self-administration [LeSage M G et al., Psychopharmacology 2010, 209(2), 203-212]. Another dual orexin receptor antagonist, N-biphenyl-2-yl-1-{[(1-methyl-1H-benzimidazol-2-yl)sulfanyl]acetyl}-L-prolinamide inhibited nicotine-reinstatement for a conditioned reinforcer and reduced behavioral (locomotor sensitization) and molecular (transcriptional responses) changes induced by repeated amphetamine administration in rodents [Winrow et al., Neuropharmacology 2009, 58(1), 185-94]. 
     Orexin receptor antagonists comprising a 2-substituted saturated cyclic amide derivatives (such as 2-substituted pyrrolidine-1-carboxamides) are known for example from WO2008/020405, WO2008/038251, WO2008/081399, WO2008/087611, WO2008/117241, WO2008/139416, WO2009/004584, WO2009/016560, WO2009/016564, WO2009/040730, WO2009/104155, WO2010/004507, WO2010/038200, WO2001/096302, WO2002/044172, WO2002/089800, WO2002/090355, WO2003/002559, WO2003/032991, WO2003/041711, WO2003/051368, WO2003/051873, WO2004/026866, WO2004/041791, WO2004/041807, WO2004/041816, WO2009/003993, WO2009/003997, WO2009/124956, WO2010/060470, WO2010/060471, WO2010/060472, WO2010/063662, WO2010/063663, WO2010/072722, WO2010/122151, and WO2008/150364. A particular pyrrolidine derived compound is disclosed in Langmead et. al, Brit. J. Pharmacol. 2004, 141, 340-346 as being highly orexin-1 selective. WO2003/002561 discloses certain N-aroyl cyclic amine derivatives, encompassing benzimidazol-2-yl-methyl substituted pyrrolidine derivatives, as orexin receptor antagonists. Despite the great number of prior art compounds and their high structural variability, all compounds share a common structural feature, i.e. in position 2 of the saturated cyclic amide a linker group such as at least a methylene group (or longer groups such as —CH 2 —NH—CO—, —CH 2 —NH—, —CH 2 —O—, —CH 2 —S—, etc.) link the cyclic amide to the respective aromatic ring system substituent. It has now surprisingly been found that, despite the substantial conformational changes that may be expected from the removal of a linker between two rigid structural elements, the present compounds, that have a benzimidazole ring directly attached to a pyrrolidine amide in position 2, are potent orexin receptor antagonists. 
     The present invention, thus, provides novel benzimidazole-proline derivatives, which are non-peptide antagonists of human orexin receptors. These compounds are in particular of potential use in the treatment of disorders relating to orexinergic dysfunctions, comprising especially sleep disorders, anxiety disorders, addiction disorders, cognitive dysfunctions, mood disorders, or appetite disorders. 
     1) A first aspect of the invention relates to compounds of the formula (I) 
                         
wherein
 
Ar 1  represents
         phenyl or 5- or 6-membered heteroaryl, wherein said phenyl or 5- or 6-membered heteroaryl independently is mono-, di-, or tri-substituted; wherein
           one of said substituents is attached in ortho-position to the point of attachment of Ar 1  to the rest of the molecule; wherein said substituent is phenyl or 5- or 6-membered heteroaryl; wherein said phenyl or 5- or 6-membered heteroaryl substituent is independently unsubstituted, mono-, di-, or tri-substituted, wherein the substituents are independently selected from (C 1-4 )alkyl, (C 1-4 )alkoxy, halogen, cyano, (C 1-3 )fluoroalkyl, and (C 1-3 )fluoroalkoxy; or said ortho substituent is benzo[1,3]dioxolyl, or 2-(3-methoxy-phenyl)-ethynyl;   and the other of said substituents, if present, is/are independently selected from (C 1-4 )alkyl; (C 1-4 )alkoxy; (C 3-6 )cycloalkyl; halogen; cyano; (C 1-3 )fluoroalkyl; (C 1-3 )fluoroalkoxy; —NR 10 R 11 , wherein R 10  and R 11  independently represent hydrogen or (C 1-4 )alkyl, or R 10  and R 11  together with the nitrogen to which they are attached to form a pyrrolidine ring; unsubstituted pyridinyl; and phenyl which is unsubstituted, or mono- or di-substituted, wherein the substituents are independently selected from (C 1-4 )alkyl, (C 1-4 )alkoxy, cyano, and halogen;
 
one of R 2  and R 3  represents hydrogen, and the other represents hydrogen or (C 1-4 )alkyl (notably one of R 2  and R 3  represents hydrogen, and the other represents hydrogen or methyl); and
 
one of R 4a  and R 4b  represents hydrogen, and the other represents hydrogen, (C 1-4 )alkoxy (especially methoxy), or halogen (especially fluorine); or R 4a  and R 4b  together represent a group H 2 C═; or both R 4a  and R 4b  represent fluorine; wherein, in case R 3  is different from hydrogen, both R 4a  and R 4b  represent hydrogen;
 
R 1  represents hydrogen, (C 1-4 )alkyl (especially methyl or ethyl), (C 3-6 )cycloalkyl-(CH 2 )— (especially cyclopropyl-methyl), (C 2-3 )fluoroalkyl (especially 2-fluoro-ethyl), or (C 1-4 )alkoxy-(C 2-4 )alkyl (especially 2-methoxy-ethyl); and
 
(R 5 ) n  represents one to three optional substituents (i.e. n represents the integer 0, 1, 2, or 3) independently selected from (C 1-4 )alkyl, (C 1-4 )alkoxy (especially methoxy), halogen, (C 1-4 )alkyl-thio- (especially H 3 C—S—), (C 1-3 )fluoroalkyl (especially trifluoromethyl), (C 1-3 )fluoroalkoxy (especially trifluoromethoxy), (C 1-3 )fluoroalkyl-thio- (especially F 3 C—S—), hydroxy-(C 1-4 )alkyl- (especially HO—CH 2 —), (C 1-4 )alkoxy-carbonyl- (especially H 3 CO—CO—), nitro, hydroxy, and cyano; or (R 5 ) n  represents a group —O—CH 2 —CH 2 —O—; or (R 5 ) n  represents a fused phenyl group which, together with the benzimidazole moiety to which it is fused to, forms a 1H-naphtho[2,3-d]imidazol-2-yl group;
 
with the exception of
   
               [2-(1H-benzimidazol-2-yl)-1-pyrrolidinyl][2-(1H-pyrazol-1-yl)phenyl]-methanone (CAS Reg. No. 1293846-63-5);   [2-(1H-benzimidazol-2-yl)-1-pyrrolidinyl][5-(2,5-dimethyl-1H-pyrrol-1-yl)-1-methyl-1H-pyrazol-4-yl]-methanone (CAS Reg. No. 1288543-08-7);   [2-(1H-benzimidazol-2-yl)-1-pyrrolidinyl][1,1′-biphenyl]-2-yl-methanone (CAS Reg. No. 1277849-61-2);   [2-(6-methyl-1H-benzimidazol-2-yl)-pyrrolidin-1-yl][3-phenyl-isoxazol-4-yl]-methanone (CAS Reg. No. 1413410-98-6);   [2-(1H-imidazol-2-yl)phenyl][2-(6-methyl-1H-benzimidazol-2-yl)-pyrrolidin-1-yl]-methanone (CAS Reg. No. 1378205-71-0);   [2-(6-methyl-1H-benzimidazol-2-yl)-pyrrolidin-1-yl][3-(thien-2-yl)-1H-pyrazol-4-yl]-methanone (CAS Reg. No. 1377970-45-0);   [2-(6-methyl-1H-benzimidazol-2-yl)-pyrrolidin-1-yl][3-phenyl-1H-pyrazol-4-yl]-methanone (CAS Reg. No. 1377872-25-7);   [2-(1H-benzimidazol-2-yl)-pyrrolidin-1-yl][3-cyclopropyl-1-phenyl-1H-pyrazol-5-yl]-methanone (CAS Reg. No. 1331048-98-5); and   [2-(1H-benzimidazol-2-yl)-pyrrolidin-1-yl][1-(2-fluorophenyl)-5-(1H-pyrrol-1-yl)-1H-pyrazol-4-yl]-methanone (CAS Reg. No. 1290361-06-6).
 
2) A second aspect of the invention relates to compounds of the formula (I) according to embodiment 1), which are also compounds of the formula (II); wherein the absolute configuration is as depicted in formula (II):
   

                         
wherein
 
Ar 1  represents
         phenyl or 5- or 6-membered heteroaryl, wherein said phenyl or 5- or 6-membered heteroaryl independently is mono-, di-, or tri-substituted; wherein
           one of said substituents is attached in ortho-position to the point of attachment of Ar 1  to the rest of the molecule; wherein said substituent is phenyl or 5- or 6-membered heteroaryl; wherein said phenyl or 5- or 6-membered heteroaryl substituent is independently unsubstituted, mono-, di-, or tri-substituted, wherein the substituents are independently selected from (C 1-4 )alkyl, (C 1-4 )alkoxy, halogen, cyano, (C 1-3 )fluoroalkyl, and (C 1-3 )fluoroalkoxy; or said ortho substituent is benzo[1,3]dioxolyl, or 2-(3-methoxy-phenyl)-ethynyl;   and the other of said substituents, if present, is/are independently selected from (C 1-4 )alkyl; (C 1-4 )alkoxy; (C 3-6 )cycloalkyl; halogen; cyano; (C 1-3 )fluoroalkyl; (C 1-3 )fluoroalkoxy; —NR 10 R 11 , wherein R 10  and R 11  independently represent hydrogen or (C 1-4 )alkyl, or R 10  and R 11  together with the nitrogen to which they are attached to form a pyrrolidine ring; unsubstituted pyridinyl; and phenyl which is unsubstituted, or mono- or di-substituted, wherein the substituents are independently selected from (C 1-4 )alkyl, (C 1-4 )alkoxy, cyano, and halogen;
 
one of R 2  and R 3  represents hydrogen, and the other represents hydrogen or (C 1-4 )alkyl (notably one of R 2  and R 3  represents hydrogen, and the other represents hydrogen or methyl); and
 
one of R 4a  and R 4b  represents hydrogen, and the other represents hydrogen, (C 1-4 )alkoxy (especially methoxy), or halogen (especially fluorine); or R 4a  and R 4b  together represent a group H 2 C═; or both R 4a  and R 4b  represent fluorine; wherein, in case R 3  is different from hydrogen, both R 4a  and R 4b  represent hydrogen;
 
R 1  represents hydrogen, (C 1-4 )alkyl (especially methyl or ethyl), (C 3-6 )cycloalkyl-(CH 2 )— (especially cyclopropyl-methyl), (C 2-3 )fluoroalkyl (especially 2-fluoro-ethyl), or (C 1-4 )alkoxy-(C 2-4 )alkyl (especially 2-methoxy-ethyl); and
 
(R 5 ) n  represents one to three optional substituents (i.e. n represents the integer 0, 1, 2, or 3) independently selected from (C 1-4 )alkyl (especially methyl), (C 1-4 )alkoxy (especially methoxy), halogen (especially fluorine, chlorine or bromine), (C 1-4 )alkyl-thio- (especially H 3 C—S—), (C 1-3 )fluoroalkyl (especially trifluoromethyl), (C 1-3 )fluoroalkoxy (especially trifluoromethoxy), (C 1-3 )fluoroalkyl-thio- (especially F 3 C—S—), hydroxy-(C 1-4 )alkyl- (especially HO—CH 2 —), (C 1-4 )alkoxy-carbonyl- (especially H 3 CO—CO—), nitro, hydroxy, and cyano; or (R 5 ) n  represents a group —O—CH 2 —CH 2 —O—; or (R 5 ) n  represents a fused phenyl group which, together with the benzimidazole moiety to which it is fused to, forms a 1H-naphtho[2,3-d]imidazol-2-yl group;
 
with the exception of
   
               [(S)-2-(1H-benzimidazol-2-yl)-1-pyrrolidinyl][2-(1H-pyrazol-1-yl)phenyl]-methanone;   [(S)-2-(1H-benzimidazol-2-yl)-1-pyrrolidinyl][5-(2,5-dimethyl-1H-pyrrol-1-yl)-1-methyl-1H-pyrazol-4-yl]-methanone;   [(S)-2-(1H-benzimidazol-2-yl)-1-pyrrolidinyl][1,1′-biphenyl]-2-yl-methanone;   [(S)-2-(6-methyl-1H-benzimidazol-2-yl)-pyrrolidin-1-yl][3-phenyl-isoxazol-4-yl]-methanone;   [(S)-2-(1H-imidazol-2-yl)phenyl][2-(6-methyl-1H-benzimidazol-2-yl)-pyrrolidin-1-yl]-methanone;   [(S)-2-(6-methyl-1H-benzimidazol-2-yl)-pyrrolidin-1-yl][3-(thien-2-yl)-1H-pyrazol-4-yl]-methanone;   [(S)-2-(6-methyl-1H-benzimidazol-2-yl)-pyrrolidin-1-yl][3-phenyl-1H-pyrazol-4-yl]-methanone;   [(S)-2-(1H-benzimidazol-2-yl)-pyrrolidin-1-yl][3-cyclopropyl-1-phenyl-1H-pyrazol-5-yl]-methanone; and   [(S)-2-(1H-benzimidazol-2-yl)-pyrrolidin-1-yl][1-(2-fluorophenyl)-5-(1H-pyrrol-1-yl)-1H-pyrazol-4-yl]-methanone.
 
3) A third aspect of the invention relates to compounds of the formula (II) according to embodiment 2), which are also compounds of the formula (III); wherein the absolute configuration is as depicted in formula (III):
   

                         
wherein
 
Ar 1  represents
         phenyl or 5- or 6-membered heteroaryl, wherein said phenyl or 5- or 6-membered heteroaryl independently is mono-, di-, or tri-substituted; wherein
           one of said substituents is attached in ortho-position to the point of attachment of Ar 1  to the rest of the molecule; wherein said substituent is phenyl or 5- or 6-membered heteroaryl; wherein said phenyl or 5- or 6-membered heteroaryl substituent is independently unsubstituted, mono-, di-, or tri-substituted, wherein the substituents are independently selected from (C 1-4 )alkyl, (C 1-4 )alkoxy, halogen, cyano, (C 1-3 )fluoroalkyl, and (C 1-3 )fluoroalkoxy; or said ortho substituent is benzo[1,3]dioxolyl;   and the other of said substituents, if present, is/are independently selected from (C 1-4 )alkyl; (C 1-4 )alkoxy; (C 3-6 )cycloalkyl; halogen; cyano; (C 1-3 )fluoroalkyl; (C 1-3 )fluoroalkoxy; and —NR 10 R 11 , wherein R 10  and R 11  independently represent hydrogen or (C 1-4 )alkyl, or R 10  and R 11  together with the nitrogen to which they are attached to form a pyrrolidine ring;
 
one of R 2  and R 3  represents hydrogen, and the other represents hydrogen or (C 1-4 )alkyl (notably one of R 2  and R 3  represents hydrogen, and the other represents hydrogen or methyl); and
 
R 4a  and R 4b  independently represent hydrogen or halogen (especially fluorine); or R 4a  represents (C 1-4 )alkoxy (especially methoxy) and R 4b  represents hydrogen; or R 4a  and R 4b  together represent a group H 2 C═;
 
wherein, in case R 3  is different from hydrogen, both R 4a  and R 4b  represent hydrogen;
 
R 1  represents hydrogen, or (C 1-4 )alkyl (especially methyl or ethyl); and
 
R 14 , R 15 , R 16  and R 17  together represent one to three optional substituents (i.e. at least one of R 14 , R 15 , R 16  and R 17  is hydrogen) [notably R 14 , R 15 , R 16  and R 17  together represent one to three substituents (i.e. at least one of R 14 , R 15 , R 16  and R 17  is hydrogen and at least one of R 14 , R 15 , R 16  and R 17  is different from hydrogen)], wherein
   
           R 14  and R 17  independently represent hydrogen, (C 1-4 )alkyl, (C 1-4 )alkoxy (especially methoxy), (C 1-4 )alkyl-thio- (especially H 3 C—S—), halogen, (C 1-3 )fluoroalkyl (especially trifluoromethyl), (C 1-4 )alkoxy-carbonyl- (especially H 3 CO—CO—), hydroxy-(C 1-4 )alkyl-(especially HO—CH 2 —), hydroxy, or nitro; and   R 15  and R 16  independently represent hydrogen, (C 1-4 )alkyl, (C 1-4 )alkoxy (especially methoxy), (C 1-4 )alkyl-thio- (especially H 3 C—S—), halogen, (C 1-3 )fluoroalkyl (especially trifluoromethyl), (C 1-3 )fluoroalkoxy (especially trifluoromethoxy), (C 1-3 )fluoroalkyl-thio-(especially F 3 C—S—), hydroxy-(C 1-4 )alkyl- (especially HO—CH 2 —), or cyano;
 
or R 14  and R 15  together, or R 16  and R 17  together, represent a group —O—CH 2 —CH 2 —O—;
 
or R 15  and R 16  together represent a fused phenyl group which, together with the benzimidazole moiety to which it is fused to, forms a 1H-naphtho[2,3-d]imidazol-2-yl group;
 
with the exception of
       [(S)-2-(1H-benzimidazol-2-yl)-1-pyrrolidinyl][2-(1H-pyrazol-1-yl)phenyl]-methanone;   [(S)-2-(1H-benzimidazol-2-yl)-1-pyrrolidinyl][5-(2,5-dimethyl-1H-pyrrol-1-yl)-1-methyl-1H-pyrazol-4-yl]-methanone;   [(S)-2-(1H-benzimidazol-2-yl)-1-pyrrolidinyl][1,1′-biphenyl]-2-yl-methanone;
 
wherein, in a sub-embodiment, in addition to the above-listed three compounds also the following compounds are excluded from the scope of the compounds of embodiment 3):
   [(S)-2-(6-methyl-1H-benzimidazol-2-yl)-pyrrolidin-1-yl][3-phenyl-isoxazol-4-yl]-methanone;   [(S)-2-(1H-imidazol-2-yl)phenyl][2-(6-methyl-1H-benzimidazol-2-yl)-pyrrolidin-1-yl]-methanone;   [(S)-2-(6-methyl-1H-benzimidazol-2-yl)-pyrrolidin-1-yl][3-(thien-2-yl)-1H-pyrazol-4-yl]-methanone;   [(S)-2-(6-methyl-1H-benzimidazol-2-yl)-pyrrolidin-1-yl][3-phenyl-1H-pyrazol-4-yl]-methanone;   [(S)-2-(1H-benzimidazol-2-yl)-pyrrolidin-1-yl][3-cyclopropyl-1-phenyl-1H-pyrazol-5-yl]-methanone; and   [(S)-2-(1H-benzimidazol-2-yl)-pyrrolidin-1-yl][1-(2-fluorophenyl)-5-(1H-pyrrol-1-yl)-1H-pyrazol-4-yl]-methanone.   

     The compounds of formula (I) contain at least one stereogenic center which is situated in position 2 of the pyrrolidine moiety. Preferably, the absolute configuration of the pyrrolidine moiety of the present compounds, especially the absolute configuration of said chiral center in position 2 of the pyrrolidine moiety, is as depicted in formula (II) and (III) of embodiments 2) or 3); i.e. for example for R 2  being the substituent of lowest priority (e.g. when R 2  is hydrogen or methyl), said chiral center is preferably in absolute (S) configuration. In addition, the compounds of formulae (I), (II), (III), and the compounds of formulae (IV), (V), and (VI) below, may contain one or more further stereogenic or asymmetric centers, such as one or more asymmetric carbon atoms. The compounds of formulae (I), (II), (III), (IV), (V), and (VI) may thus be present as mixtures of stereoisomers or preferably as pure stereoisomers. Mixtures of stereoisomers may be separated in a manner known to a person skilled in the art. 
     In addition, it is well understood that, in case the benzimidazole moiety of the present compounds is unsubstituted on the ring nitrogen having a free valency (i.e. R 1  represents hydrogen) such benzimidazole moiety represents tautomeric forms. Thus, substituents (R 5 ) n  of the benzimidazole moiety may be attached in the position(s) ortho to the bridgehead atoms (i.e. attached in position(s) 4 and/or 7, corresponding to R 14  and/or R 17 ), and/or in the position(s) meta to the bridgehead atoms, (i.e. attached in position(s) 5 and/or 6, corresponding to R 15  and/or R 16 ). It is understood that the two ortho, and, respectively, the two meta positions are considered equivalent. For example, the group 4-methyl-1H-benzoimidazol-2-yl is understood to signify the same group as 7-methyl-1H-benzoimidazol-2-yl and 4-methyl-3H-benzoimidazol-2-yl and 7-methyl-3H-benzoimidazol-2-yl. 
     The present invention also includes isotopically labelled, especially  2 H (deuterium) labelled compounds of formulae (I), (II), (III), (IV), (V), and (VI), which compounds are identical to the compounds of formulae (I), (II), (III), (IV), (V), and (VI) except that one or more atoms have each been replaced by an atom having the same atomic number but an atomic mass different from the atomic mass usually found in nature. Isotopically labelled, especially  2 H (deuterium) labelled compounds of formulae (I), (II), (III), (IV), (V), and (VI) and salts thereof are within the scope of the present invention. Substitution of hydrogen with the heavier isotope  2 H (deuterium) may lead to greater metabolic stability, resulting e.g. in increased in-vivo half-life or reduced dosage requirements, or may lead to reduced inhibition of cytochrome P450 enzymes, resulting e.g. in an improved safety profile. In one embodiment of the invention, the compounds of formulae (I), (II), (III), (IV), (V), and (VI) are not isotopically labelled, or they are labelled only with one or more deuterium atoms. In a sub-embodiment, the compounds of formulae (I), (II), (III), (IV), (V), and (VI) are not isotopically labelled at all. Isotopically labelled compounds of formulae (I), (II), (III), (IV), (V), and (VI) be prepared in analogy to the methods described hereinafter, but using the appropriate isotopic variation of suitable reagents or starting materials. 
     In this patent application, a dotted line shows the point of attachment of the radical drawn. For example, the radical drawn below 
                         
represents a 2-(2-triazolyl)-phenyl group.
 
     Where the plural form is used for compounds, salts, pharmaceutical compositions, diseases and the like, this is intended to mean also a single compound, salt, or the like. 
     Any reference to compounds of formulae (I), (II), (III), (IV), (V), and (VI) according to any one of embodiments 1) to 57) is to be understood as referring also to the salts (and especially the pharmaceutically acceptable salts) of such compounds, as appropriate and expedient. 
     The term “pharmaceutically acceptable salts” refers to salts that retain the desired biological activity of the subject compound and exhibit minimal undesired toxicological effects. Such salts include inorganic or organic acid and/or base addition salts depending on the presence of basic and/or acidic groups in the subject compound. For reference see for example “Salt selection for basic drugs”,  Int. J. Pharm . (1986), 33, 201-217; “Handbook of Phramaceutical Salts. Properties, Selection and Use.”, P. Heinrich Stahl, Camille G. Wermuth (Eds.), Wiley-VCH, 2008; and “Pharmaceutical Salts and Co-crystals”, Johan Wouters and Luc Quéré (Eds.), RSC Publishing, 2012. 
     Definitions provided herein are intended to apply uniformly to the compounds of formulae (I), (II), (III), (IV), (V) and (VI) as defined in any one of embodiments 1) to 45), and, mutatis mutandis, throughout the description and the claims unless an otherwise expressly set out definition provides a broader or narrower definition. It is well understood that a definition or preferred definition of a term defines and may replace the respective term independently of (and in combination with) any definition or preferred definition of any or all other terms as defined herein. 
     The term “halogen” means fluorine, chlorine, or bromine, preferably fluorine or chlorine. 
     The term “alkyl”, used alone or in combination, refers to a saturated straight or branched chain alkyl group containing one to six carbon atoms. The term “(C x-y )alkyl” (x and y each being an integer), refers to an alkyl group as defined before, containing x to y carbon atoms. For example a (C 1-4 )alkyl group contains from one to four carbon atoms. Examples of alkyl groups are methyl, ethyl, propyl, isopropyl, n-butyl, isobutyl, sec.-butyl and tert.-butyl. Preferred are methyl and ethyl. Most preferred is methyl. 
     The term “alkoxy”, used alone or in combination, refers to an alkyl-O— group wherein the alkyl group is as defined before. The term “(C x-y )alkoxy” (x and y each being an integer) refers to an alkoxy group as defined before containing x to y carbon atoms. For example a (C 1-4 )alkoxy group means a group of the formula (C 1-4 )alkyl-O— in which the term “(C 1-4 )alkyl” has the previously given significance. Examples of alkoxy groups are methoxy, ethoxy, n-propoxy, isopropoxy, n-butoxy, isobutoxy, sec.-butoxy and tert.-butoxy. Preferred are ethoxy and especially methoxy. 
     The term “(C 1-4 )alkyl-thio-” used alone or in combination, refers to a group of the formula (C 1-4 )alkyl-S— in which the term “(C 1-4 )alkyl” has the previously given significance. An example is CH 3 —S—. 
     The term “fluoroalkyl” refers to an alkyl group as defined before containing one to three carbon atoms in which one or more (and possibly all) hydrogen atoms have been replaced with fluorine. The term “(C x-y )fluoroalkyl” (x and y each being an integer) refers to a fluoroalkyl group as defined before containing x to y carbon atoms. For example a (C 1-3 )fluoroalkyl group contains from one to three carbon atoms in which one to seven hydrogen atoms have been replaced with fluorine. Representative examples of fluoroalkyl groups include trifluoromethyl, 2-fluoroethyl, 2,2-difluoroethyl and 2,2,2-trifluoroethyl. Preferred are (C 1 )fluoroalkyl groups such as trifluoromethyl. 
     The term “fluoroalkoxy” refers to an alkoxy group as defined before containing one to three carbon atoms in which one or more (and possibly all) hydrogen atoms have been replaced with fluorine. The term “(C x-y )fluoroalkoxy” (x and y each being an integer) refers to a fluoroalkoxy group as defined before containing x to y carbon atoms. For example a (C 1-3 )fluoroalkoxy group contains from one to three carbon atoms in which one to seven hydrogen atoms have been replaced with fluorine. Representative examples of fluoroalkoxy groups include trifluoromethoxy, difluoromethoxy, 2-fluoroethoxy, 2,2-difluoroethoxy and 2,2,2-trifluoroethoxy. Preferred are (C 1 )fluoroalkoxy groups such as trifluoromethoxy and difluoromethoxy. 
     The term “(C 1-3 )fluoroalkyl-thio-” refers to (C 1-3 )fluoroalkyl group as defined before, which is linked to the rest of the molecule through a sulfur atom. An example is CF 3 —S—. 
     In case two of (R 5 ) n  together form a group —O—CH 2 —CH 2 —O—, such group together with the benzimidazole moiety especially forms a 7,8-dihydro-3H-6,9-dioxa-1,3-diaza-cyclopenta[a]naphthalen-2-yl group. 
     Particular examples of Ar 1  representing a phenyl group, wherein said phenyl is mono-, di-, or tri-substituted; wherein one of said substituents is attached in ortho-position to the point of attachment of Ar 1  to the rest of the molecule; are such that the other of said substituents, if present, is/are independently selected from (C 1-4 )alkyl; (C 1-4 )alkoxy; (C 3-6 )cycloalkyl; halogen; cyano; (C 1-3 )fluoroalkyl; (C 1-3 )fluoroalkoxy; unsubstituted pyridinyl; and phenyl which is unsubstituted, or mono- or di-substituted, wherein the substituents are independently selected from (C 1-4 )alkyl, (C 1-4 )alkoxy, cyano, and halogen [notably the other of said substituents, if present, is/are independently selected from (C 1-4 )alkyl, (C 1-4 )alkoxy, halogen, cyano, (C 1-3 )fluoroalkyl, and (C 1-3 )fluoroalkoxy; especially from (C 1-4 )alkyl, (C 1-4 )alkoxy, and halogen]. Particular examples of such phenyl groups which are further substituted in ortho position as used for the group Ar 1  are 1,2-phenylene, 4-methyl-1,2-phenylene, 5-methyl-1,2-phenylene, 6-methyl-1,2-phenylene, 4,5-dimethyl-1,2-phenylene, 5-fluoro-1,2-phenylene, 6-fluoro-1,2-phenylene, 5-chloro-1,2-phenylene, 5-cyano-1,2-phenylene, 5-methoxy-1,2-phenylene, 4,5-dimethoxy-1,2-phenylene, 5-trifluoromethyl-1,2-phenylene, 5-trifluoromethoxy-1,2-phenylene, 6-fluoro-5-methyl-1,2-phenylene, and 6-fluoro-5-methoxy-1,2-phenylene; and in addition to the above listed groups: 5-bromo-1,2-phenylene, 3,4-dimethyl-1,2-phenylene, 5-(pyridine-3-yl)-1,2-phenylene, and 5-(3-cyano-phenyl)-1,2-phenylene; wherein in the above groups the carbonyl group is attached in position 1. 
     Examples of the particular phenyl groups which are substituents of the group Ar 1  are especially phenyl groups which are unsubstituted, mono-, or di-substituted, wherein the substituents are independently selected from (C 1-4 )alkyl, (C 1-4 )alkoxy, halogen, cyano, (C 1-3 )fluoroalkyl, and (C 1-3 )fluoroalkoxy [notably from (C 1-4 )alkyl, (C 1-4 )alkoxy, halogen, and (C 1-3 )fluoroalkyl]. Particular examples are phenyl, 2-methyl-phenyl, 3-methyl-phenyl, 4-methyl-phenyl, 3,4-dimethyl-phenyl, 3-methoxy-phenyl, 2-fluoro-phenyl, 3-fluoro-phenyl, 4-fluoro-phenyl, 3,5-difluoro-phenyl, 4-fluoro-3-methyl-phenyl, 3-fluoro-4-methyl-phenyl, 3-chloro-phenyl, 4-chloro-phenyl, 2,3-dichloro-phenyl, 3,4-dichloro-phenyl, 4-bromo-phenyl, 3-trifluoromethyl-phenyl, 4-trifluoromethyl-phenyl; and in addition to the above-listed groups: 2-chloro-phenyl, 3,4-difluoro-phenyl, 2-methoxy-phenyl, 4-methoxy-phenyl, 3-cyano-phenyl, 4-cyano-phenyl, 3-trifluoromethoxy-phenyl, and 4-trifluoromethoxy-phenyl. 
     The term “heteroaryl”, if not explicitly stated otherwise, means a 5- to 10-membered monocyclic, or bicyclic, aromatic ring containing 1 to a maximum of 3 heteroatoms independently selected from oxygen, nitrogen and sulfur. Examples of such heteroaryl groups are 5-membered monocyclic heteroaryl groups such as furanyl, oxazolyl, isoxazolyl, oxadiazolyl, thienyl, thiazolyl, isothiazolyl, thiadiazolyl, pyrrolyl, imidazolyl, pyrazolyl, and triazolyl; 6-membered monocyclic heteroaryl such as pyridyl, pyrimidyl, pyridazinyl, and pyrazinyl; and 8- to 10-membered bicyclic heteroaryl such as indolyl, isoindolyl, benzofuranyl, isobenzofuranyl, benzothiophenyl, indazolyl, benzimidazolyl, benzoxazolyl (or benzooxazolyl), benzisoxazolyl, benzothiazolyl, benzoisothiazolyl, benzotriazolyl, benzoxadiazolyl, benzothiadiazolyl, quinolinyl, isoquinolinyl, naphthyridinyl, cinnolinyl, quinazolinyl, quinoxalinyl, phthalazinyl, pyrazolo[1,5-a]pyridyl, pyrazolo[1,5-a]pyrimidyl, imidazo[1,2-a]pyridyl, 1H-pyrrolo[3,2-b]pyridyl, 1H-pyrrolo[2,3-b]pyridyl, pyrrolo[3,2-d]pyrimidinyl, pyrrolo[2,3-d]pyrimidinyl, 4H-furo[3,2-b]pyrrolyl, pyrrolo[2,1-b]thiazolyl, imidazo[2,1-b]thiazolyl and purinyl. 
     Examples of the particular 5- or 6-membered heteroaryl groups which are further substituted in ortho position as used for the group Ar 1  are the above mentioned 5- or 6-membered heteroaryl groups, notably the 5-membered heteroaryl groups oxazolyl, isoxazolyl, thiophenyl, thiazolyl, isothiazolyl; and the 6-membered heteroaryl groups pyridyl, pyrimidyl and pyrazinyl. In a sub-embodiment, examples are oxazolyl (notably oxazol-4,5-diyl (in particular 2-methyl-oxazol-4,5-diyl), isoxazolyl (notably isoxazol-3,4-diyl, in particular 5-methyl-isoxazol-3,4-diyl), thiazolyl (notably thiazol-4,5-diyl, in particular 2-methyl-thiazol-4,5-diyl, 2-cyclopropyl-thiazol-4,5-diyl, 2-dimethylamino-thiazol-4,5-diyl, 2-(1-pyrrolidinyl)-thiazol-4,5-diyl) and thiophenyl (notably thiophen-2,3-diyl, in particular thiophen-2,3-diyl, 5-methyl-thiophen-2,3-diyl); as well as pyridyl (notably pyridin-2,3-diyl, in particular pyridin-2,3-diyl, 6-methyl-pyridin-2,3-diyl), pyrimidyl (notably pyrimidin-4,5-diyl, in particular pyrimidin-4,5-diyl, 2-methyl-pyrimidin-4,5-diyl), and pyrazinyl (notably pyrazin-2,3-diyl, in particular pyrazin-2,3-diyl). These groups are at least mono-substituted in ortho position, and preferably and independently carry no further substituent or one further substitutent as explicitly defined. In particular such optional further substituent may independently be selected from (C 1-4 )alkyl (especially methyl); (C 3-6 )cycloalkyl (especially cyclopropyl); —NR 10 R 11 , wherein R 10  and R 11  independently represent (C 1-4 )alkyl (especially methyl), or R 10  and R 11  together with the nitrogen to which they are attached to form a pyrrolidine ring; and phenyl which is unsubstituted, or mono- or di-substituted, wherein the substituents are independently selected from (C 1-4 )alkyl, (C 1-4 )alkoxy, cyano, and halogen. In a sub-embodiment, such optional further substituent may independently be selected from (C 1-4 )alkyl, (C 1-4 )alkoxy, (C 3-6 )cycloalkyl, halogen, cyano, (C 1-3 )fluoroalkyl, (C 1-3 )fluoroalkoxy, and —NR 10 R 11  [wherein especially oxazolyl groups carry no further substituent or one further substitutent selected from (C 1-4 )alkyl, (C 3-6 )cycloalkyl, —NR 10 R 11 ; thiazolyl groups carry no further substituent or one further substitutent selected from (C 1-4 )alkyl, (C 3-6 )cycloalkyl, —NR 10 R 11 , and phenyl which is unsubstituted, or mono- or di-substituted, wherein the substituents are independently selected from (C 1-4 )alkyl, (C 1-4 )alkoxy, cyano, and halogen (notably methyl, cyclopropyl, and phenyl which is unsubstituted, or mono- or di-substituted, wherein the substituents are independently selected from (C 1-4 )alkyl, (C 1-4 )alkoxy, cyano, and halogen; especially methyl and cyclopropyl); thiophenyl, pyridinyl and pyrimidinyl groups carry no further substituent or one further substitutent selected from (C 1-4 )alkyl (especially methyl); and pyrazinyl group carry no further substituent]. The above groups are preferably attached to the rest of the molecule (i.e. the carbonyl group) in position 4 of oxazolyl, isoxazolyl, or thiazolyl groups; in position 2 of pyridyl or pyrazinyl groups; in position 2 of thiophenyl groups; and in position 5 of pyrimidinyl groups. In a further sub-embodiment, particular examples of such groups are 2-methyl-thiazol-4,5-diyl, 2-cyclopropyl-thiazol-4,5-diyl, 2-dimethylamino-thiazol-4,5-diyl, thiophen-2,3-diyl; as well as 6-methyl-pyridin-2,3-diyl, 6-methyl-pyridin-3,4-diyl, 2-methyl-pyrimidin-4,5-diyl, pyrimidin-4,5-diyl, and pyrazin-2,3-diyl. Further particular examples are 2-(4-fluoro-2-methoxy-phenyl)-thiazol-4,5-diyl, 2-(2-methoxy-phenyl)-thiazol-4,5-diyl, 2-(3-methoxy-phenyl)-thiazol-4,5-diyl, 2-(4-methoxy-phenyl)-thiazol-4,5-diyl, 2-(3,4-dimethyl-phenyl)-thiazol-4,5-diyl, 2-(2,3-difluoro-phenyl)-thiazol-4,5-diyl, 2-(2,5-difluoro-phenyl)-thiazol-4,5-diyl, 2-(4-fluoro-2-methyl-phenyl)-thiazol-4,5-diyl, 2-(4-fluoro-3-methyl-phenyl)-thiazol-4,5-diyl, 2-(2-fluoro-4-methyl-phenyl)-thiazol-4,5-diyl, 2-(3-chloro-4-methyl-phenyl)-thiazol-4,5-diyl, 2-(3-cyano-phenyl)-thiazol-4,5-diyl, 2-(2-methyl-phenyl)-thiazol-4,5-diyl, 2-(3-methyl-phenyl)-thiazol-4,5-diyl, 2-(4-methyl-phenyl)-thiazol-4,5-diyl, 2-(2-fluoro-phenyl)-thiazol-4,5-diyl, 2-(3-fluoro-phenyl)-thiazol-4,5-diyl, 2-(4-fluoro-phenyl)-thiazol-4,5-diyl, 2-(2-chloro-phenyl)-thiazol-4,5-diyl, 2-(3-chloro-phenyl)-thiazol-4,5-diyl, and 2-phenyl)-thiazol-4,5-diyl. 
     Examples of the particular 5- or 6-membered heteroaryl groups which are substituents of the group Ar 1  are the above mentioned 5- or 6-membered heteroaryl groups; notably the 5-membered heteroaryl groups oxazolyl, isoxazolyl, oxadiazolyl, thienyl, thiazolyl, isothiazolyl, thiadiazolyl, imidazolyl, pyrazolyl, triazolyl, and the 6-membered heteroaryl groups pyridyl, pyrimidyl, pyrazinyl and pyridazinyl. In a sub-embodiment, such groups are especially pyrazolyl, triazolyl, pyridinyl and pyrimidinyl, notably pyrazol-1-yl, pyrimidin-2-yl, and [1,2,3]triazol-2-yl. The above mentioned groups may be unsubstituted or substituted as explicitly defined; wherein pyrazol-1-yl, and [1,2,3]triazol-2-yl groups are preferably unsubstituted. Particular examples are pyrazol-1-yl, [1,2,3]triazol-2-yl, 2-methyl-thiazol-4-yl, 3-methyl-[1,2,4]oxadiazol-5-yl, 6-methoxy-pyridin-3-yl, pyridin-2-yl, pyridin-3-yl, and pyrimidin-2-yl [notably the 5-membered heteroaryl group [1,2,3]triazol-2-yl; and the 6-membered heteroaryl group pyrimidin-2-yl]. 
     Further embodiments of the invention are presented hereinafter: 
     4) Another embodiment relates to compounds according to any one of embodiments 1) to 3), wherein one of R 2  and R 3  represents hydrogen, and the other represents hydrogen or methyl (wherein especially R 3  represents hydrogen and R 2  represents hydrogen or methyl).
 
5) Another embodiment relates to compounds according to any one of embodiments 1) to 4), wherein R 4a  and R 4b  represent hydrogen; or R 4a  represents methoxy or fluorine, and R 4b  represents hydrogen; or R 4a  and R 4b  together represent a group H 2 C═; wherein, in case R 3  is different from hydrogen, both R 4a  and R 4b  represent hydrogen.
 
6) Another embodiment relates to compounds according to any one of embodiments 1) to 3), wherein
         one of R 2  and R 3  represents hydrogen, and the other represents hydrogen or methyl (wherein especially R 3  represents hydrogen and R 2  represents hydrogen or methyl); and   R 4a  and R 4b  represent hydrogen; or R 4a  represents methoxy or fluorine, and R 4b  represents hydrogen; or R 4a  and R 4b  together represent a group H 2 C═; wherein, in case R 3  is methyl, both R 4a  and R 4b  represent hydrogen.
 
7) Another embodiment relates to compounds according to any one of embodiments 1) to 3), wherein
   R 3  represents hydrogen;   R 2  represents hydrogen or methyl; and   R 4a  and R 4b  represent hydrogen; or R 4a  represents methoxy or fluorine, and R 4b  represents hydrogen; or R 4a  and R 4b  together represent a group H 2 C═.
 
8) Another embodiment relates to compounds according to any one of embodiments 1) to 3), wherein R 2 , R 3 , R 4a  and R 4b  represent hydrogen.
 
9) Another embodiment relates to compounds according to any one of embodiments 1) to 3), wherein R 2  represents hydrogen or methyl; R 3  represents hydrogen; and R 4a  and R 4b  represent hydrogen, or R 4a  and R 4b  together represent a group H 2 C═.
 
10) Another embodiment relates to compounds according to any one of embodiments 1) to 3), wherein R 2  represents hydrogen or methyl (especially methyl); and R 3 , R 4a  and R 4b  represent hydrogen.
 
11) Another embodiment relates to compounds according to any one of embodiments 1) to 3), wherein R 2  represents hydrogen or methyl; R 3  represents hydrogen; and R 4a  and R 4b  together represent a group H 2 C═.
 
12) Another embodiment relates to compounds according to any one of embodiments 1) to 3), wherein R 2  represents hydrogen or methyl; R 3  represents hydrogen; R 4a  represents methoxy or fluorine (especially R 4a  represents methoxy); and R 4b  represents hydrogen.
 
13) Another embodiment relates to compounds according to any one of embodiments 1) to 3), wherein R 3  represents methyl and R 2 , R 4a  and R 4b  represent hydrogen.
 
14) Another embodiment relates to compounds according to any one of embodiments 1) to 3), wherein both R 4a  and R 4b  represent fluorine and R 2  and R 3  represent hydrogen.
 
15) Another embodiment relates to compounds of formula (I) or (II) according to any one of embodiments 1), 2), or 4) to 14), wherein (R 5 ) n  represents one or two optional substituents (i.e. n represents the integer 0, 1, or 2) (especially (R 5 ) n  represents one or two substituents; i.e. n represents the integer 1 or 2) independently selected from (C 1-4 )alkyl (especially methyl), (C 1-4 )alkoxy (especially methoxy), halogen (especially fluorine, chlorine or bromine), (C 1-4 )alkyl-thio- (especially H 3 C—S—), (C 1-3 )fluoroalkyl (especially trifluoromethyl), (C 1-3 )fluoroalkoxy (especially trifluoromethoxy), (C 1-3 )fluoroalkyl-thio- (especially F 3 C—S—), and cyano.
 
16) Another embodiment relates to compounds of formula (III) according to any one of embodiments 3) to 14); or to compounds of formula (I) or (II) according to any one of embodiments 1) to 14), wherein the fragment
       

                         
represents a fragment
 
                         
wherein
 
R 14 , R 15 , R 16  and R 17  together represent one or two optional substituents (i.e. at least two of R 14 , R 15 , R 16  and R 17  are hydrogen) [notably R 14 , R 15 , R 16  and R 17  together represent one or two substituents (i.e. at least two of R 14 , R 15 , R 16  and R 17  are hydrogen and at least one of R 14 , R 15 , R 16  and R 17  is different from hydrogen)], wherein
         R 14  and R 17  independently represent hydrogen, (C 1-4 )alkyl, (C 1-4 )alkoxy (especially methoxy), (C 1-4 )alkyl-thio- (especially H 3 C—S—), halogen, (C 1-3 )fluoroalkyl (especially trifluoromethyl), (C 1-4 )alkoxy-carbonyl- (especially H 3 CO—CO—), hydroxy-(C 1-4 )alkyl-(especially HO—CH 2 —), hydroxy, or nitro; and   R 15  and R 16  independently represent hydrogen, (C 1-4 )alkyl, (C 1-4 )alkoxy (especially methoxy), (C 1-4 )alkyl-thio- (especially H 3 C—S—), halogen, (C 1-3 )fluoroalkyl (especially trifluoromethyl), (C 1-3 )fluoroalkoxy (especially trifluoromethoxy), (C 1-3 )fluoroalkyl-thio-(especially F 3 C—S—), hydroxy-(C 1-4 )alkyl- (especially HO—CH 2 —), or cyano;
 
or R 14  and R 15  together, or R 16  and R 17  together, represent a group —O—CH 2 —CH 2 —O—; or R 15  and R 16  together represent a fused phenyl group which, together with the benzimidazole moiety to which it is fused to, forms a 1H-naphtho[2,3-d]imidazol-2-yl group.
 
17) Another embodiment relates to compounds of formula (III) according to any one of embodiments 3) to 14); or to compounds of formula (I) or (II) according to any one of embodiments 1) to 14), wherein the fragment
       

                         
represents a fragment
 
                         
wherein
 
R 14 , R 15 , R 16  and R 17  together represent one or two optional substituents [notably R 14 , R 15 , R 16  and R 17  together represent one or two substituents (i.e. at least two of R 14 , R 15 , R 16  and R 17  are hydrogen and at least one of R 14 , R 15 , R 16  and R 17  is different from hydrogen)], wherein
         R 14  and R 17  independently represent hydrogen, (C 1-4 )alkyl, (C 1-4 )alkoxy (especially methoxy), (C 1-4 )alkyl-thio- (especially H 3 C—S—), halogen, or (C 1-3 )fluoroalkyl (especially trifluoromethyl); and   R 15  and R 16  independently represent hydrogen, (C 1-4 )alkyl, (C 1-4 )alkoxy (especially methoxy), (C 1-4 )alkyl-thio- (especially H 3 C—S—), halogen, (C 1-3 )fluoroalkyl (especially trifluoromethyl), (C 1-3 )fluoroalkoxy (especially trifluoromethoxy), (C 1-3 )fluoroalkyl-thio-(especially F 3 C—S—), or cyano.
 
18) Another embodiment relates to compounds of formula (III) according to any one of embodiments 3) to 14); or to compounds of formula (I) or (II) according to any one of embodiments 1) to 14), wherein the fragment
       

                         
represents a fragment
 
                         
wherein
 
R 14 , R 15 , R 16  and R 17  together represent one or two substituents (i.e. at least two of R 14 , R 15 , R 16  and R 17  are hydrogen and at least one of R 14 , R 15 , R 16  and R 17  is different from hydrogen), wherein
         one of R 15  and R 16  represents (C 1-4 )alkyl, (C 1-4 )alkoxy (especially methoxy), (C 1-4 )alkyl-thio- (especially H 3 C—S—), halogen, (C 1-3 )fluoroalkyl (especially trifluoromethyl), (C 1-3 )fluoroalkoxy (especially trifluoromethoxy), or cyano;   or one of R 14  and R 17  represents (C 1-4 )alkyl, (C 1-4 )alkoxy (especially methoxy), (C 1-4 )alkyl-thio- (especially H 3 C—S—), halogen, or (C 1-3 )fluoroalkyl (especially trifluoromethyl);
 
and the remaining substituent, if present, is one of R 15  and R 16  representing (C 1-4 )alkyl, (C 1-4 )alkoxy (especially methoxy), or halogen.
 
19) Another embodiment relates to compounds according to any one of embodiments 1) to 18), wherein R 1  represents hydrogen.
 
20) Another embodiment relates to compounds according to any one of embodiments 1) to 18), wherein R 1  represents (C 1-4 )alkyl (especially methyl or ethyl, notably methyl).
 
21) Another embodiment relates to compounds according to any one of embodiments 1) to 20), wherein Ar 1  represents phenyl or 5- or 6-membered heteroaryl, wherein said phenyl or 5- or 6-membered heteroaryl independently is mono-, di-, or tri-substituted; wherein
   one of said substituents is attached in ortho-position to the point of attachment of Ar 1  to the rest of the molecule; wherein said substituent is phenyl or 5- or 6-membered heteroaryl; wherein said phenyl or 5- or 6-membered heteroaryl substituent is independently unsubstituted, mono-, di-, or tri-substituted (especially unsubstituted, mono-, or di-substituted), wherein the substituents are independently selected from (C 1-4 )alkyl, (C 1-4 )alkoxy, halogen, cyano, (C 1-3 )fluoroalkyl, and (C 1-3 )fluoroalkoxy; or said ortho substituent is benzo[1,3]dioxol-5-yl;   and the other of said substituents, if present, is/are independently selected from (C 1-4 )alkyl; (C 1-4 )alkoxy; (C 3-6 )cycloalkyl; halogen; cyano; (C 1-3 )fluoroalkyl; (C 1-3 )fluoroalkoxy; and —NR 10 R 11 , wherein R 10  and R 11  independently represent (C 1-4 )alkyl, or R 10  and R 11  together with the nitrogen to which they are attached to form a pyrrolidine ring.
 
22) Another embodiment relates to compounds of formula (I) or (II) according to any one of embodiments 1) to 20); or mutatis mutandis to compounds of formula (III) according to any one of embodiments 3) to 20); wherein Ar 1  represents phenyl or 5- or 6-membered heteroaryl, wherein said phenyl or 5- or 6-membered heteroaryl independently is mono-, di-, or tri-substituted; wherein
   one of said substituents is attached in ortho-position to the point of attachment of Ar 1  to the rest of the molecule; wherein said substituent is phenyl or 5- or 6-membered heteroaryl; wherein said phenyl or 5- or 6-membered heteroaryl substituent is independently unsubstituted, or mono-, or di-substituted, wherein the substituents are independently selected from (C 1-2 )alkyl, (C 1-2 )alkoxy, halogen, cyano, trifluoromethyl, and trifluoromethoxy;   or said ortho substituent is benzo[1,3]dioxolyl;   or said ortho substituent is 2-(3-methoxy-phenyl)-ethynyl   and the other of said substituents, if present, is/are independently selected from methyl; methoxy; cyclopropyl; halogen; cyano; trifluoromethyl; trifluoromethoxy; dimethylamino; pyrrolidin-1-yl; unsubstituted pyridinyl; and phenyl which is unsubstituted, or mono- or di-substituted, wherein the substituents are independently selected from methyl, methoxy, cyano, and halogen.
 
23) Another embodiment relates to compounds according to any one of embodiments 1) to 20), wherein
   Ar 1  represents 5-membered heteroaryl, wherein the 5-membered heteroaryl is mono- or di-substituted; wherein
           one of said substituents is attached in ortho-position to the point of attachment of Ar 1  to the rest of the molecule; wherein said ortho-substituent is phenyl, or 6-membered heteroaryl (especially pyridyl), which phenyl or 6-membered heteroaryl is independently unsubstituted, mono-, di-, or tri-substituted (especially unsubstituted, mono-, or di-substituted), wherein the substituents are independently selected from (C 1-4 )alkyl, (C 1-4 )alkoxy, halogen, cyano, (C 1-3 )fluoroalkyl, and (C 1-3 )fluoroalkoxy [wherein phenyl is especially unsubstituted, or mono-, or di-substituted with (C 1-4 )alkyl, (C 1-4 )alkoxy, halogen, (C 1-3 )fluoroalkyl, or (C 1-3 )fluoroalkoxy; and 6-membered heteroaryl is notably pyridyl which is mono-substituted with (C 1-4 )alkoxy];   and the other of said substituents, if present, is/are independently selected from (C 1-4 )alkyl (especially methyl); (C 3-6 )cycloalkyl (especially cyclopropyl); —NR 10 R 11 , wherein R 10  and R 11  independently represent (C 1-4 )alkyl (especially methyl), or R 10  and R 11  together with the nitrogen to which they are attached to form a pyrrolidine ring; and phenyl which is unsubstituted, or mono- or di-substituted, wherein the substituents are independently selected from (C 1-4 )alkyl, (C 1-4 )alkoxy, cyano, and halogen (especially the other of said substituents represents methyl or cyclopropyl);   
           or Ar 1  represents 6-membered heteroaryl, wherein the 6-membered heteroaryl is mono-, di-, or tri-substituted (especially mono- or di-substituted); wherein
           one of said substituents is attached in ortho-position to the point of attachment of Ar 1  to the rest of the molecule; wherein
               said ortho-substituent is unsubstituted 5-membered heteroaryl (notably pyrazol-1-yl or [1,2,3]triazol-2-yl, especially in case Ar 1  represents pyridyl);   or said ortho-substituent is phenyl which is unsubstituted, mono-, di-, or tri-substituted (especially unsubstituted, mono-, or di-substituted), wherein the substituents are independently selected from (C 1-4 )alkyl, (C 1-4 )alkoxy, halogen, cyano, (C 1-3 )fluoroalkyl, and (C 1-3 )fluoroalkoxy (especially (C 1-4 )alkyl, (C 1-4 )alkoxy, halogen and (C 1-3 )fluoroalkyl);   
               and the other of said substituents, if present, is/are independently selected from (C 1-4 )alkyl, (C 1-4 )alkoxy, halogen, and (C 1-3 )fluoroalkyl (especially (C 1-4 )alkyl, and halogen; notably methyl);   
           or Ar 1  represents phenyl which is mono-, di-, or tri-substituted; wherein
           one of said substituents is attached in ortho-position to the point of attachment of Ar 1  to the rest of the molecule; wherein
               said ortho-substituent is phenyl which is unsubstituted, mono-, di-, or tri-substituted (especially unsubstituted, mono-, or di-substituted), wherein the substituents are independently selected from (C 1-4 )alkyl, (C 1-4 )alkoxy, halogen, cyano, (C 1-3 )fluoroalkyl, and (C 1-3 )fluoroalkoxy;   or said ortho substituent is benzo[1,3]dioxol-5-yl;   or said ortho-substituent is 6-membered heteroaryl which is unsubstituted, mono-, or di-substituted (especially unsubstituted or mono-substituted), wherein the substituents are independently selected from (C 1-4 )alkyl, (C 1-4 )alkoxy, halogen, and (C 1-3 )fluoroalkyl (especially mono-substituted with (C 1-4 )alkyl, or (C 1-4 )alkoxy);   or said ortho-substituent is 5-membered heteroaryl which is unsubstituted, mono-, or di-substituted (especially unsubstituted or mono-substituted), wherein the substituents are independently selected from (C 1-4 )alkyl, (C 1-4 )alkoxy, halogen, and (C 1-3 )fluoroalkyl (especially (C 1-4 )alkyl, notably methyl);   or said ortho-substituent is 2-(3-methoxy-phenyl)-ethynyl;   
               
           and the other of said substituents, if present, is/are independently selected from (C 1-4 )alkyl; (C 1-4 )alkoxy; (C 3-6 )cycloalkyl; halogen; cyano; (C 1-3 )fluoroalkyl; (C 1-3 )fluoroalkoxy; unsubstituted pyridinyl; and phenyl which is unsubstituted, or mono- or di-substituted, wherein the substituents are independently selected from (C 1-4 )alkyl, (C 1-4 )alkoxy, cyano, and halogen [notably selected from (C 1-4 )alkyl, (C 1-4 )alkoxy, halogen, cyano, (C 1-3 )fluoroalkyl, and (C 1-3 )fluoroalkoxy; especially from (C 1-4 )alkyl, (C 1-4 )alkoxy, and halogen].
 
24) Another embodiment relates to compounds according to any one of embodiments 1) to 23), wherein one or both of the following characteristics are present:
   in case Ar 1  represents a 5-membered heteroaryl group, such group is an oxazolyl, thienyl, or thiazolyl group (especially a thiazolyl group); and/or   in case Ar 1  represents a 6-membered heteroaryl group, such group is a pyridinyl, pyrazinyl, or pyrimidinyl group (especially a pyridinyl group);
 
wherein said groups independently are substituted as defined in any one of the preceeding embodiments.
 
25) Another embodiment relates to compounds according to any one of embodiments 1) to 24), wherein one or both of the following characteristics are present:
   in case said ortho substituent of Ar 1  represents a 5-membered heteroaryl group, such group is a triazolyl (especially unsubstituted [1,2,3]triazol-2-yl), a pyrazolyl (especially unsubstituted pyrazol-1-yl), an oxadiazolyl (especially 3-methyl-[1,2,4]oxadiazol-5-yl), or a thiazolyl group (especially 2-methyl-thiazol-4-yl); [notably such group is [1,2,3]triazol-2-yl or pyrazol-1-yl]; and/or   in case said ortho substituent of Ar 1  represents a 6-membered heteroaryl group, such group is a pyridinyl or a pyrimidinyl group (especially 6-methoxy-pyridin-3-yl, pyridin-2-yl, pyridin-3-yl, or pyrimidin-2-yl; preferably 6-methoxy-pyridin-3-yl, pyridin-2-yl or pyrimidin-2-yl);
 
wherein said groups independently are unsubstituted or substituted as defined in any one of the preceeding embodiments, or as explicitly defined herein.
 
26) Another embodiment relates to compounds according to any one of the embodiments 1) to 20) wherein Ar 1  is a group independently selected from the following groups A, B, C, D, E, F, G, H, I, J, K, L, or M:
       

                                                                                                                                                                         
wherein the groups listed in A and L are preferred groups, and wherein each of the groups A to M forms a particular sub-embodiment.
 
27) Another embodiment relates to compounds of formula (III) according to any one of embodiments 3) to 14), or to compounds of formula (I) or (II) according to embodiment 16), wherein
         R 2 , R 3 , R 4a , R 4b  represent hydrogen; R 15  represents chlorine and R 14  represents methyl, or R 16  represents chlorine and R 17  represents methyl, and the remaining represent hydrogen;
 
and Ar 1  is as defined in any one of embodiments 21) to 26); wherein, in a sub-embodiment, a particular group for Ar 1  is:
       

                         
28) Another embodiment relates to compounds of formula (III) according to any one of embodiments 3) to 14), or to compounds of formula (I) or (II) according to embodiment 16), wherein R 2 , R 3 , R 4a , R 4b , R 14 , R 15 , R 16  and R 17  are characterized by one or more of the following characteristics:
         R 2 , R 3 , R 4a , R 4b , R 15 , and R 16  represent hydrogen; one of R 14  and R 17  represents —S—CH 3 , and the remaining represents hydrogen; or   R 2 , R 3 , R 4a , R 4b , R 14 , and R 17  represent hydrogen; one of R 15  and R 16  represents —O—CH 3  or —S—CH 3 , and the remaining represents hydrogen;
 
and Ar 1  is as defined in any one of embodiments 21) to 26); wherein, in a sub-embodiment, a particular group for Ar 1  is:
       

                         
29) Another embodiment relates to compounds of formula (III) according to any one of embodiments 3) to 14), or to compounds of formula (I) or (II) according to embodiment 16), wherein
         R 2 , R 3 , R 4a , R 4b , R 15 , and R 16  represent hydrogen; one of R 14  and R 17  represents —S—CH 3 , and the remaining represents hydrogen;
 
and Ar 1  is as defined in any one of embodiments 21) to 26); wherein, in a sub-embodiment, particular groups for Ar 1  are:
       

                         
30) Another embodiment relates to compounds of formula (III) according to any one of embodiments 3) to 14), or to compounds of formula (I) or (II) according to embodiment 16), wherein R 2 , R 3 , R 4a , R 4b , R 14 , R 15 , R 16  and R 17  are characterized by one, or more (in any combination), or all of the following characteristics:
         R 2 , R 3 , R 4a , R 4b , R 17 , and R 14  represent hydrogen, one of R 15  and R 16  represents —O—CH 3  or —S—CH 3 , and the remaining represents hydrogen; or   R 2  represents methyl; R 3 , R 4a , and R 4b  represent hydrogen; R 15  represents chlorine and R 14  represents methyl, or R 16  represents chlorine and R 17  represents methyl, and the remaining represent hydrogen; or   R 2  represents methyl; R 3 , R 4a , R 4b , R 14  and R 17  represent hydrogen; R 16  and R 15  both represent methyl;
 
and Ar 1  is as defined in any one of embodiments 21) to 26); wherein, in a sub-embodiment, particular groups for Ar 1  are:
       

                         
31) Another embodiment relates to compounds of formula (III) according to any one of embodiments 3) to 14), or to compounds of formula (I) or (II) according to embodiment 16), wherein
         R 2  represents methyl; R 3 , R 4a , R 4b , R 14  and R 17  represent hydrogen; R 15  and R 16  both represent methyl;
 
and Ar 1  is as defined in any one of embodiments 21) to 26); wherein, in a sub-embodiment, particular groups for Ar 1  are:
       

                         
32) Another embodiment relates to compounds according of formula (III) according to any one of embodiments 3) to 14), or to compounds of formula (I) or (II) according to embodiment 16), wherein
         R 2  represents methyl; R 3 , R 4a , R 4b , R 14  and R 17  represent hydrogen; R 15  and R 16  both represent methoxy;
 
and Ar 1  is as defined in any one of embodiments 21) to 26); wherein, in a sub-embodiment, particular groups for Ar 1  are:
       

                         
33) Another embodiment relates to compounds of formula (III) according to any one of embodiments 3) to 14), or to compounds of formula (I) or (II) according to embodiment 16), wherein R 2 , R 3 , R 4a , R 4b , R 14 , R 15 , R 16  and R 17  are characterized by one or more of the following characteristics:
         R 2  represents methyl; R 3 , R 4a , R 4b , R 14  and R 17  represent hydrogen; one of R 15  and R 16  represents trifluoromethyl, and the remaining represents hydrogen, chlorine or fluorine;   R 2  represents methyl; R 3 , R 4a , and R 4b  represent hydrogen; R 14  represents chorine and R 16  represents trifluoromethyl, or R 17  represents chorine and R 15  represents trifluoromethyl, and the remaining represent hydrogen;
 
and Ar 1  is as defined in any one of embodiments 21) to 26); wherein, in a sub-embodiment, a particular group for Ar 1  is:
       

                         
34) Another embodiment relates to compounds of formula (Ill) according to any one of embodiments 3) to 14), or to compounds of formula (I) or (II) according to embodiment 16), wherein R 2 , R 3 , R 4a , R 4b , R 14 , R 15 , R 16  and R 17  are characterized by one, or more (in any combination), or all of the following characteristics:
         R 3  represents methyl; R 2 , R 4a , and R 4b , represent hydrogen; R 14  represents methyl and R 15  represents chlorine, or R 17  represents methyl and R 16  represents chlorine, and the remaining represent hydrogen; or   R 3  represents methyl; R 2 , R 4a , R 4b , R 14  and R 17  represent hydrogen; one of R 15  and R 16  represents methyl, and the remaining represents chlorine; or   R 3  represents methyl; R 2 , R 4a , R 4b , R 14  and R 17  represent hydrogen; R 15  and R 16  both represent methyl; or   R 3  represents methyl; R 2 , R 4a , and R 4b  represent hydrogen; R 14  represents methyl and R 16  represents chlorine, or R 17  represents methyl and R 15  represents chlorine, and the remaining represent hydrogen; or   R 3  represents methyl; R 2 , R 4a , and R 4b  represent hydrogen; R 14  represents methyl and R 16  represents bromine, or R 17  represents methyl and R 15  represents bromine, and the remaining represent hydrogen; or   R 3  represents methyl; R 2 , R 4a , R 4b , R 14  and R 17  represent hydrogen; R 15  and R 16  both represent methoxy;
 
and Ar 1  is as defined in any one of embodiments 21) to 26); wherein, in a sub-embodiment, particular groups for Ar 1  are:
       

                         
35) Another embodiment relates to compounds of formula (Ill) according to any one of embodiments 3) to 14), or to compounds of formula (I) or (II) according to embodiment 16), wherein R 2 , R 3 , R 4a , R 4b , R 14 , R 15 , R 16  and R 17  are characterized by one, or more (in any combination), or all of the following characteristics:
         R 2 , R 3 , and R 4b  represent hydrogen; R 4a  represents methoxy; R 14  represents methyl and R 15  represents hydrogen or chlorine, or R 17  represents methyl and R 16  represents hydrogen or chlorine, and the remaining represent hydrogen; or   R 2 , R 3 , and R 4a  represent hydrogen; R 4b  represents methoxy; R 14  represents methyl and R 15  represents hydrogen or chlorine, or R 17  represents methyl and R 16  represents hydrogen or chlorine, and the remaining represents hydrogen; or   R 2 , R 3 , and R 4b  represent hydrogen; R 4a  represents fluorine; R 14  represents methyl and R 15  represents hydrogen or chlorine, or R 17  represents methyl and R 16  represents hydrogen or chlorine, and the remaining represents hydrogen; or   R 2 , R 3 , and R 4a  represent hydrogen; R 4b  represents fluorine; R 14  represents methyl and R 15  represents hydrogen or chlorine, or R 17  represents methyl and R 16  represents hydrogen or chlorine, and the remaining represents hydrogen; or   R 2  and R 3  represent hydrogen; R 4a  and R 4b  both represent fluorine; R 14  represents methyl and R 15  represents hydrogen or chlorine, or R 17  represents methyl and R 16  represents hydrogen or chlorine, and the remaining represents hydrogen;
 
and Ar 1  is as defined in any one of embodiments 21) to 26); wherein, in a sub-embodiment, particular groups for Ar 1  are:
       

                         
36) Another embodiment relates to compounds of formula (Ill) according to any one of embodiments 3) to 14), or to compounds of formula (I) or (II) according to embodiment 16), wherein
         R 2  and R 3  represent hydrogen, R 4a  and R 4b  together represent H 2 C═, and R 14 , R 15 , R 16  and R 17  together represent one or two substituents (i.e. two or three of R 14 , R 15 , R 16  and R 17  are hydrogen), wherein
           R 14  represents hydrogen or methoxy;   R 15  represents hydrogen, chlorine, methyl or methoxy;   R 16  represents hydrogen, methyl, chlorine, methoxy, trifluoromethoxy, tert.-butyl or —S—CH 3 ; and   R 17  represents hydrogen, methyl, methoxy, bromine or —S—CH 3 ;
 
and Ar 1  is as defined in any one of embodiments 21) to 26); wherein particular groups for Ar 1  are:
   
               

                         
37) Another embodiment relates to compounds according to any one of embodiments 27) to 36), wherein R 1  represents hydrogen.
 
38) Another embodiment relates to compounds according to any one of embodiments 27) to 36), wherein R 1  represents (C 1-4 )alkyl (especially methyl or ethyl, notably methyl).
 
39) Another embodiment relates to compounds of formula (I) according to any one of embodiments 1) to 26); wherein the fragment
 
                         
respectively the fragment
 
                         
represents a group independently selected from the following groups A, B, or C:
 
                                                                               
wherein it is understood that the benzimidazolyl moieties of groups A and B may be present in form of tautomers; and wherein the groups listed in group A are preferred groups.
 
40) Another embodiment relates to compounds of formula (I) according to any one of embodiments 1) to 14); wherein
         R 2  represents methyl; and R 3 , R 4a , and R 4b  represent hydrogen (in which case the present embodiment is a particular embodiment for the compounds of formula (V) below); or   R 3  represents methyl; and R 2 , R 4a , and R 4b  represent hydrogen (in which case the present embodiment is a particular embodiment for the compounds of formula (VI) below);   the fragment       

                         
represents a fragment
 
                         
wherein
         R 1  represents hydrogen; and   R 14 , R 15 , R 16  and R 17  together represent one or two substituents [i.e. at least two of R 14 , R 15 , R 16  and R 17  are hydrogen and at least one of R 14 , R 15 , R 16  and R 17  is different from hydrogen]; wherein
           one of R 15  and R 16  represents methyl, methoxy, fluorine, chlorine, bromine, trifluoromethyl, or trifluoromethoxy;   one of R 14  and R 17 , or the remaining of R 15  and R 16 , represents hydrogen, methyl, methoxy, fluorine, or chlorine;   and the remaining of R 14 , R 15 , R 16  and R 17  represent hydrogen;   
           wherein, in a sub-embodiment, particular benzimidazole fragments are independently selected from the following groups:       

     
       
         
         
             
             
         
       
         
         
           
             wherein it is understood that said benzimidazolyl moieties may be present in form of tautomers;
 
and
 
             Ar 1  is as defined in any one of embodiments 21) to 26); 
             wherein, in a sub-embodiment, particular groups Ar 1  are independently selected from the following groups A, B, C, D, or E: 
           
         
       
    
     
       
         
         
             
             
         
       
       
         
         
             
             
         
       
         
         
           
             wherein, in a further sub-embodiment, Ar 1  is group is especially selected from the groups listed in group A.
 
41) Another embodiment relates to compounds of formula (I) according to any one of embodiments 1) to 14); wherein
 
             R 2  represents methyl; and R 3 , R 4a , and R 4b  represent hydrogen (in which case the present embodiment is a particular embodiment for the compounds of formula (V) below); or 
             R 3  represents methyl; and R 2 , R 4a , and R 4b  represent hydrogen (in which case the present embodiment is a particular embodiment for the compounds of formula (VI) below); 
             the fragment 
           
         
       
    
                         
represents a fragment
 
                         
wherein
         R 1  represents hydrogen; and   R 14 , R 15 , R 16  and R 17  are as follows:
           R 15  represents chlorine and R 16  represents methyl, or R 16  represents chlorine and R 15  represents methyl, and R 14  and R 17  represent hydrogen;   or R 15  represents chlorine and R 14  represents methyl, or R 16  represents chlorine and R 17  represents methyl, and the remaining of R 14 , R 15 , R 16  and R 17  represent hydrogen;   or R 16  represents chlorine and R 14  represents methyl, or R 15  represents chlorine and R 17  represents methyl, and the remaining of R 14 , R 15 , R 16  and R 17  represent hydrogen;   R 15  represents bromine and R 16  represents fluorine, or R 16  represents bromine and R 15  represents fluorine, and R 14  and R 17  represent hydrogen;   or R 16  represents bromine and R 14  represents methyl, or R 15  represents bromine and R 17  represents methyl, and the remaining of R 14 , R 15 , R 16  and R 17  represent hydrogen;   or R 15  and R 16  both represent methoxy, and R 14  and R 17  represent hydrogen;   or one of R 15  and R 16  represents trifluoromethyl, the remaining of R 15  and R 16  represents hydrogen or chlorine; and R 14  and R 17  represent hydrogen;   or one of R 15  and R 16  represents trifluoromethoxy, and the remaining of R 15  and R 16 , and R 14  and R 17  represent hydrogen;   
           wherein, in a sub-embodiment, particular benzimidazole fragments are independently selected from the following groups:       

     
       
         
         
             
             
         
       
         
         
           
             wherein it is understood that said benzimidazolyl moieties may be present in form of tautomers;
 
and
 
             Ar 1  is as defined in any one of embodiments 21) to 26); 
             wherein, in a sub-embodiment, particular groups for Ar 1  are independently selected from the following groups A, B, C, D, or E: 
           
         
       
    
     
       
         
         
             
             
         
       
       
         
         
             
             
         
       
         
         
           
             wherein, in a further sub-embodiment, Ar 1  is group is especially selected from the groups listed in group A.
 
42) The invention, thus, relates to compounds of the formula (I) as defined in embodiment 1), compounds of the formula (II) as defined in embodiment 2), compounds of the formula (III) as defined in embodiment 3); or to such compounds further limited by the characteristics of any one of embodiments 6) to 41), under consideration of their respective dependencies; to pharmaceutically acceptable salts thereof; and to the use of such compounds as medicaments especially in the treatment of mental health disorders relating to orexinergic dysfunctions, which disorders are as defined below and which are especially selected from sleep disorders, anxiety disorders, addiction disorders, cognitive dysfunctions, mood disorders, or appetite disorders. For avoidance of any doubt, especially the following embodiments relating to the compounds of formula (I), (II), and (III) are thus possible and intended and herewith specifically disclosed in individualized form:
 
1, 6+1, 17+1, 17+6+1, 18+1, 18+6+1, 19+1, 19+6+1, 19+17+1, 19+17+6+1, 19+18+1, 19+18+6+1, 22+1, 22+6+1, 22+17+1, 22+17+6+1, 22+18+1, 22+18+6+1, 22+19+1, 22+19+6+1, 22+19+17+1, 22+19+17+6+1, 22+19+18+1, 22+19+18+6+1, 23+1, 23+6+1, 23+17+1, 23+17+6+1, 23+18+1, 23+18+6+1, 23+19+1, 23+19+6+1, 23+19+17+1, 23+19+17+6+1, 23+19+18+1, 23+19+18+6+1, 24+1, 24+6+1, 24+17+1, 24+17+6+1, 24+18+1, 24+18+6+1, 24+19+1, 24+19+6+1, 24+19+17+1, 24+19+17+6+1, 24+19+18+1, 24+19+18+6+1, 24+22+1, 24+22+6+1, 24+22+17+1, 24+22+17+6+1, 24+22+18+1, 24+22+18+6+1, 24+22+19+1, 24+22+19+6+1, 24+22+19+17+1, 24+22+19+17+6+1, 24+22+19+18+1, 24+22+19+18+6+1, 24+23+1, 24+23+6+1, 24+23+17+1, 24+23+17+6+1, 24+23+18+1, 24+23+18+6+1, 24+23+19+1, 24+23+19+6+1, 24+23+19+17+1, 24+23+19+17+6+1, 24+23+19+18+1, 24+23+19+18+6+1, 25+1, 25+6+1, 25+17+1, 25+17+6+1, 25+18+1, 25+18+6+1, 25+19+1, 25+19+6+1, 25+19+17+1, 25+19+17+6+1, 25+19+18+1, 25+19+18+6+1, 25+22+1, 25+22+6+1, 25+22+17+1, 25+22+17+6+1, 25+22+18+1, 25+22+18+6+1, 25+22+19+1, 25+22+19+6+1, 25+22+19+17+1, 25+22+19+17+6+1, 25+22+19+18+1, 25+22+19+18+6+1, 25+23+1, 25+23+6+1, 25+23+17+1, 25+23+17+6+1, 25+23+18+1, 25+23+18+6+1, 25+23+19+1, 25+23+19+6+1, 25+23+19+17+1, 25+23+19+17+6+1, 25+23+19+18+1, 25+23+19+18+6+1, 25+24+1, 25+24+6+1, 25+24+17+1, 25+24+17+6+1, 25+24+18+1, 25+24+18+6+1, 25+24+19+1, 25+24+19+6+1, 25+24+19+17+1, 25+24+19+17+6+1, 25+24+19+18+1, 25+24+19+18+6+1, 25+24+22+1, 25+24+22+6+1, 25+24+22+17+1, 25+24+22+17+6+1, 25+24+22+18+1, 25+24+22+18+6+1, 25+24+22+19+1, 25+24+22+19+6+1, 25+24+22+19+17+1, 25+24+22+19+17+6+1, 25+24+22+19+18+1, 25+24+22+19+18+6+1, 25+24+23+1, 25+24+23+6+1, 25+24+23+17+1, 25+24+23+17+6+1, 25+24+23+18+1, 25+24+23+18+6+1, 25+24+23+19+1, 25+24+23+19+6+1, 25+24+23+19+17+1, 25+24+23+19+17+6+1, 25+24+23+19+18+1, 25+24+23+19+18+6+1, 26+1, 26+6+1, 26+17+1, 26+17+6+1, 26+18+1, 26+18+6+1, 26+19+1, 26+19+6+1, 26+19+17+1, 26+19+17+6+1, 26+19+18+1, 26+19+18+6+1, 39+1, 39+6+1, 39+22+1, 39+22+6+1, 39+23+1, 39+23+6+1, 39+24+1, 39+24+6+1, 39+24+22+1, 39+24+22+6+1, 39+24+23+1, 39+24+23+6+1, 39+25+1, 39+25+6+1, 39+25+22+1, 39+25+22+6+1, 39+25+23+1, 39+25+23+6+1, 39+25+24+1, 39+25+24+6+1, 39+25+24+22+1, 39+25+24+22+6+1, 39+25+24+23+1, 39+25+24+23+6+1, 39+26+1, 39+26+6+1, 39+26+10+1, 39+26+13+1, 40+1, 41+1;
 
2, 6+2, 17+2, 17+6+2, 18+2, 18+6+2, 19+2, 19+6+2, 19+17+2, 19+17+6+2, 19+18+2, 19+18+6+2, 22+2, 22+6+2, 22+17+2, 22+17+6+2, 22+18+2, 22+18+6+2, 22+19+2, 22+19+6+2, 22+19+17+2, 22+19+17+6+2, 22+19+18+2, 22+19+18+6+2, 23+2, 23+6+2, 23+17+2, 23+17+6+2, 23+18+2, 23+18+6+2, 23+19+2, 23+19+6+2, 23+19+17+2, 23+19+17+6+2, 23+19+18+2, 23+19+18+6+2, 24+2, 24+6+2, 24+17+2, 24+17+6+2, 24+18+2, 24+18+6+2, 24+19+2, 24+19+6+2, 24+19+17+2, 24+19+17+6+2, 24+19+18+2, 24+19+18+6+2, 24+22+2, 24+22+6+2, 24+22+17+2, 24+22+17+6+2, 24+22+18+2, 24+22+18+6+2, 24+22+19+2, 24+22+19+6+2, 24+22+19+17+2, 24+22+19+17+6+2, 24+22+19+18+2, 24+22+19+18+6+2, 24+23+2, 24+23+6+2, 24+23+17+2, 24+23+17+6+2, 24+23+18+2, 24+23+18+6+2, 24+23+19+2, 24+23+19+6+2, 24+23+19+17+2, 24+23+19+17+6+2, 24+23+19+18+2, 24+23+19+18+6+2, 25+2, 25+6+2, 25+17+2, 25+17+6+2, 25+18+2, 25+18+6+2, 25+19+2, 25+19+6+2, 25+19+17+2, 25+19+17+6+2, 25+19+18+2, 25+19+18+6+2, 25+22+2, 25+22+6+2, 25+22+17+2, 25+22+17+6+2, 25+22+18+2, 25+22+18+6+2, 25+22+19+2, 25+22+19+6+2, 25+22+19+17+2, 25+22+19+17+6+2, 25+22+19+18+2, 25+22+19+18+6+2, 25+23+2, 25+23+6+2, 25+23+17+2, 25+23+17+6+2, 25+23+18+2, 25+23+18+6+2, 25+23+19+2, 25+23+19+6+2, 25+23+19+17+2, 25+23+19+17+6+2, 25+23+19+18+2, 25+23+19+18+6+2, 25+24+2, 25+24+6+2, 25+24+17+2, 25+24+17+6+2, 25+24+18+2, 25+24+18+6+2, 25+24+19+2, 25+24+19+6+2, 25+24+19+17+2, 25+24+19+17+6+2, 25+24+19+18+2, 25+24+19+18+6+2, 25+24+22+2, 25+24+22+6+2, 25+24+22+17+2, 25+24+22+17+6+2, 25+24+22+18+2, 25+24+22+18+6+2, 25+24+22+19+2, 25+24+22+19+6+2, 25+24+22+19+17+2, 25+24+22+19+17+6+2, 25+24+22+19+18+2, 25+24+22+19+18+6+2, 25+24+23+2, 25+24+23+6+2, 25+24+23+17+2, 25+24+23+17+6+2, 25+24+23+18+2, 25+24+23+18+6+2, 25+24+23+19+2, 25+24+23+19+6+2, 25+24+23+19+17+2, 25+24+23+19+17+6+2, 25+24+23+19+18+2, 25+24+23+19+18+6+2, 26+2, 26+6+2, 26+17+2, 26+17+6+2, 26+18+2, 26+18+6+2, 26+19+2, 26+19+6+2, 26+19+17+2, 26+19+17+6+2, 26+19+18+2, 26+19+18+6+2, 37+34+26+10+2, 37+34+26+13+2, 39+2, 39+6+2, 39+22+2, 39+22+6+2, 39+23+2, 39+23+6+2, 39+24+2, 39+24+6+2, 39+24+22+2, 39+24+22+6+2, 39+24+23+2, 39+24+23+6+2, 39+25+2, 39+25+6+2, 39+25+22+2, 39+25+22+6+2, 39+25+23+2, 39+25+23+6+2, 39+25+24+2, 39+25+24+6+2, 39+25+24+22+2, 39+25+24+22+6+2, 39+25+24+23+2, 39+25+24+23+6+2, 39+26+2, 39+26+6+2, 39+26+10+2, 39+26+13+2, 40+2, 41+2;
 
3, 24+23+3, 25+23+3, 25+24+3, 25+24+23+3, 37+34+25+24+23+3.
 
           
         
       
    
     In the list above the numbers refer to the embodiments according to their numbering provided hereinabove whereas “+” indicates the dependency from another embodiment. The different individualized embodiments are separated by commas. In other words, “39+26+6+2” for example refers to embodiment 39) depending on embodiment 26), depending on embodiment 6), depending on embodiment 2), i.e. embodiment “39+26+6+2” corresponds to the compounds of formula (II) according to embodiment 2) further limited by all the features of the embodiments 6), 26), and 39). 
     43) A further aspect of the invention relates to compounds of the formula (I) according to embodiment 1), which are also compounds of the formula (IV); wherein the absolute configuration is as depicted in formula (IV): 
                         
wherein
         Ar 1  represents 5-membered heteroaryl selected from oxazolyl, thienyl, and thiazolyl (especially thiazolyl), wherein said 5-membered heteroaryl is mono- or di-substituted; wherein
           one of said substituents is attached in ortho-position to the point of attachment of Ar 1  to the rest of the molecule; wherein said ortho-substituent is phenyl, or pyridyl, which phenyl or pyridyl is independently unsubstituted, mono-, or di-substituted, wherein the substituents are independently selected from (C 1-4 )alkyl, (C 1-4 )alkoxy, halogen, and (C 1-3 )fluoroalkyl, [wherein phenyl is especially unsubstituted, mono-, or di-substituted with methyl, ethyl, methoxy, halogen or trifluoromethyl; and pyridyl is mono-substituted with methoxy];   and the other of said substituents, if present, is independently selected from methyl; cyclopropyl; dimethylamino; pyrrolidin-1-yl; and phenyl which is unsubstituted, or mono- or di-substituted, wherein the substituents are independently selected from methyl, methoxy, cyano, and halogen (especially the other of said substituents represents methyl or cyclopropyl);   
           or Ar 1  represents 6-membered heteroaryl selected from pyridinyl, pyrazinyl, and pyrimidinyl (especially pyridinyl), wherein said 6-membered heteroaryl is mono- or di-substituted; wherein
           one of said substituents is attached in ortho-position to the point of attachment of Ar 1  to the rest of the molecule; wherein
               said ortho-substituent is pyrazol-1-yl or [1,2,3]triazol-2-yl;   or said ortho-substituent is phenyl which is unsubstituted, mono-, or di-substituted, wherein the substituents are independently selected from methyl, methoxy, halogen and trifluoromethyl;   
               and the other of said substituents, if present, is methyl;   
           or Ar 1  represents phenyl which is mono-, di-, or tri-substituted; wherein
           one of said substituents is attached in ortho-position to the point of attachment of Ar 1  to the rest of the molecule; wherein
               said ortho-substituent is phenyl which is unsubstituted, mono-, or di-substituted, wherein the substituents are independently selected from methyl, methoxy, halogen, cyano, trifluoromethyl, and trifluoromethoxy;   or said ortho substituent is benzo[1,3]dioxol-5-yl;   or said ortho substituent is 2-(3-methoxy-phenyl)-ethynyl   or said ortho-substituent is unsubstituted pyrimidinyl or pyridinyl;   or said ortho-substituent is unsubstituted pyrazol-1-yl or [1,2,3]triazol-2-yl; or oxadiazolyl or thiazolyl, optionally mono-substituted with methyl (especially unsubtituted pyrazol-1-yl or [1,2,3]triazol-2-yl);   
               and the other of said substituents, if present, is/are independently selected from methyl, methoxy, halogen, cyano, trifluoromethyl, trifluoromethoxy, unsubstituted pyridinyl, and phenyl optionally mono-substituted with cyano [especially methyl, methoxy, and halogen];
 
one of R 2  and R 3  represents hydrogen, the other of R 2  and R 3  represents hydrogen or methyl; and
 
R 4a  and R 4b  independently represent hydrogen or fluorine; or R 4a  represents methoxy and R 4b  represents hydrogen; or R 4a  and R 4b  together represent a group H 2 C═;
 
wherein, in case R 3  is different from hydrogen, both R 4a  and R 4b  represent hydrogen; (notably one of R 2  and R 3  represents hydrogen, the other of R 2  and R 3  represents methyl, and R 4a  and R 4b  both represent hydrogen)
 
R 1  represents hydrogen, methyl, ethyl, cyclopropyl-methyl, 2-fluoro-ethyl or 2-methoxy-ethyl (especially hydrogen); and
 
R 14 , R 15 , R 16  and R 17  together represent one to three optional substituents (i.e. at least one of R 14 , R 15 , R 16  and R 17  is hydrogen) [notably R 14 , R 15 , R 16  and R 17  together represent one to three substituents (i.e. at least one of R 14 , R 15 , R 16  and R 17  is hydrogen and at least one of R 14 , R 15 , R 16  and R 17  is different from hydrogen)], wherein
   
           R 14  and R 17  independently represent hydrogen, (C 1-4 )alkyl, (C 1-4 )alkoxy (especially methoxy), (C 1-4 )alkyl-thio- (especially H 3 C—S—), halogen, (C 1-3 )fluoroalkyl (especially trifluoromethyl), (C 1-4 )alkoxy-carbonyl- (especially H 3 CO—CO—), hydroxy-(C 1-4 )alkyl-(especially HO—CH 2 —), hydroxy, or nitro; and   R 15  and R 16  independently represent hydrogen, (C 1-4 )alkyl, (C 1-4 )alkoxy (especially methoxy), (C 1-4 )alkyl-thio- (especially H 3 C—S—), halogen, (C 1-3 )fluoroalkyl (especially trifluoromethyl), (C 1-3 )fluoroalkoxy (especially trifluoromethoxy), (C 1-3 )fluoroalkyl-thio-(especially F 3 C—S—), hydroxy-(C 1-4 )alkyl- (especially HO—CH 2 —), or cyano;
 
or R 14  and R 15  together, or R 16  and R 17  together, represent a group —O—CH 2 —CH 2 —O—;
 
or R 15  and R 16  together represent a fused phenyl group which, together with the benzimidazole moiety to which it is fused to, forms a 1H-naphtho[2,3-d]imidazol-2-yl group;
 
with the exception of
       [(S)-2-(1H-benzimidazol-2-yl)-1-pyrrolidinyl][2-(1H-pyrazol-1-yl)phenyl]-methanone; and   [(S)-2-(1H-benzimidazol-2-yl)-1-pyrrolidinyl][1,1′-biphenyl]-2-yl-methanone;
 
wherein all characteristics disclosed in embodiments 4) to 42) are intended to apply mutatis mutandis also to the compounds formula (IV) according to embodiment 43); wherein especially the following embodiments are thus possible and intended and herewith specifically disclosed in individualized form:
 
43, 10+43, 13+43, 18+10+43, 18+13+43, 18+43, 19+10+43, 19+13+43, 19+18+10+43, 19+18+13+43, 19+18+43, 19+43, 26+10+43, 26+13+43, 26+18+10+43, 26+18+13+43, 26+18+43, 26+19+10+43, 26+19+13+43, 26+19+18+10+43, 26+19+18+13+43, 26+19+18+43, 26+19+43, 26+43, 39+10+43, 39+13+43, 39+18+10+43, 39+18+13+43, 39+18+43, 39+19+10+43, 39+19+13+43, 39+19+18+10+43, 39+19+18+13+43, 39+19+18+43, 39+19+43, 39+26+10+43, 39+26+13+43, 39+26+18+10+43, 39+26+18+13+43, 39+26+18+43, 39+26+19+10+43, 39+26+19+13+43, 39+26+19+18+10+43, 39+26+19+18+13+43, 39+26+19+18+43, 39+26+19+43, 39+26+43, 39+43.
   

     In the list above the numbers refer to the embodiments according to their numbering provided hereinabove whereas “+” indicates the dependency from another embodiment as outlined above. 
     44) A preferred aspect of the invention relates to compounds of the formula (I) according to embodiment 1), which are also compounds of the formula (V); wherein the absolute configuration is as depicted in formula (V): 
                         
wherein
 
Ar 1  represents
         phenyl or 5- or 6-membered heteroaryl, wherein said phenyl or 5- or 6-membered heteroaryl independently is mono-, di-, or tri-substituted; wherein
           one of said substituents is attached in ortho-position to the point of attachment of Ar 1  to the rest of the molecule; wherein said substituent is phenyl or 5- or 6-membered heteroaryl; wherein said phenyl or 5- or 6-membered heteroaryl substituent is independently unsubstituted, mono-, di-, or tri-substituted, wherein the substituents are independently selected from (C 1-4 )alkyl, (C 1-4 )alkoxy, halogen, cyano, (C 1-3 )fluoroalkyl, and (C 1-3 )fluoroalkoxy; or said ortho substituent is benzo[1,3]dioxolyl;   and the other of said substituents, if present, is/are independently selected from (C 1-4 )alkyl; (C 1-4 )alkoxy; (C 3-6 )cycloalkyl; halogen; cyano; (C 1-3 )fluoroalkyl; (C 1-3 )fluoroalkoxy; —NR 10 R 11 , wherein R 10  and R 11  independently represent hydrogen or (C 1-4 )alkyl, or R 10  and R 11  together with the nitrogen to which they are attached to form a pyrrolidine ring; unsubstituted pyridinyl; and phenyl which is unsubstituted, or mono- or di-substituted, wherein the substituents are independently selected from (C 1-4 )alkyl, (C 1-4 )alkoxy, cyano, and halogen;
 
R 1  represents hydrogen, (C 1-4 )alkyl (especially methyl or ethyl), (C 3-6 )cycloalkyl-(CH 2 )— (especially cyclopropyl-methyl), (C 2-3 )fluoroalkyl (especially 2-fluoro-ethyl), or (C 1-4 )alkoxy-(C 2-4 )alkyl (especially 2-methoxy-ethyl); and
 
(R 5 ) n  represents one to three optional substituents (i.e. n represents the integer 0, 1, 2, or 3) independently selected from (C 1-4 )alkyl, (C 1-4 )alkoxy (especially methoxy), halogen, (C 1-4 )alkyl-thio- (especially H 3 C—S—), (C 1-3 )fluoroalkyl (especially trifluoromethyl), (C 1-3 )fluoroalkoxy (especially trifluoromethoxy), (C 1-3 )fluoroalkyl-thio- (especially F 3 C—S—), hydroxy-(C 1-4 )alkyl- (especially HO—CH 2 —), (C 1-4 )alkoxy-carbonyl- (especially H 3 CO—CO—), nitro, hydroxy, and cyano; or (R 5 ) n  represents a group —O—CH 2 —CH 2 —O—.
 
wherein all characteristics disclosed in embodiments 15) to 42) are intended to apply mutatis mutandis also to the compounds formula (V) according to embodiment 44); wherein especially the following embodiments are thus possible and intended and herewith specifically disclosed in individualized form:
 
44, 17+44, 18+44, 19+17+44, 19+18+44, 19+44, 22+17+44, 22+18+44, 22+19+17+44, 22+19+18+44, 22+19+44, 22+44, 23+17+44, 23+18+44, 23+19+17+44, 23+19+18+44, 23+19+44, 23+44, 24+17+44, 24+18+44, 24+19+17+44, 24+19+18+44, 24+19+44, 24+22+17+44, 24+22+18+44, 24+22+19+17+44, 24+22+19+18+44, 24+22+19+44, 24+22+44, 24+23+17+44, 24+23+18+44, 24+23+19+17+44, 24+23+19+18+44, 24+23+19+44, 24+23+44, 24+44, 25+17+44, 25+18+44, 25+19+17+44, 25+19+18+44, 25+19+44, 25+22+17+44, 25+22+18+44, 25+22+19+17+44, 25+22+19+18+44, 25+22+19+44, 25+22+44, 25+23+17+44, 25+23+18+44, 25+23+19+17+44, 25+23+19+18+44, 25+23+19+44, 25+23+44, 25+24+17+44, 25+24+18+44, 25+24+19+17+44, 25+24+19+18+44, 25+24+19+44, 25+24+22+17+44, 25+24+22+18+44, 25+24+22+19+17+44, 25+24+22+19+18+44, 25+24+22+19+44, 25+24+22+44, 25+24+23+17+44, 25+24+23+18+44, 25+24+23+19+17+44, 25+24+23+19+18+44, 25+24+23+19+44, 25+24+23+44, 25+24+44, 25+44, 26+17+44, 26+18+44, 26+19+17+44, 26+19+18+44, 26+19+44, 26+44, 39+22+44, 39+23+44, 39+24+22+44, 39+24+23+44, 39+24+44, 39+25+22+44, 39+25+23+44, 39+25+24+22+44, 39+25+24+23+44, 39+25+24+44, 39+25+44, 39+26+44, 39+44, 40+44, 41+44.
   
               

     In the list above the numbers refer to the embodiments according to their numbering provided hereinabove whereas “+” indicates the dependency from another embodiment as outlined above. 
     45) Another preferred aspect of the invention relates to compounds of the formula (I) according to embodiment 1), which are also compounds of the formula (VI); wherein the absolute configuration is as depicted in formula (VI): 
                         
wherein
 
Ar 1  represents
         phenyl or 5- or 6-membered heteroaryl, wherein said phenyl or 5- or 6-membered heteroaryl independently is mono-, di-, or tri-substituted; wherein
           one of said substituents is attached in ortho-position to the point of attachment of Ar 1  to the rest of the molecule; wherein said substituent is phenyl or 5- or 6-membered heteroaryl; wherein said phenyl or 5- or 6-membered heteroaryl substituent is independently unsubstituted, mono-, di-, or tri-substituted, wherein the substituents are independently selected from (C 1-4 )alkyl, (C 1-4 )alkoxy, halogen, cyano, (C 1-3 )fluoroalkyl, and (C 1-3 )fluoroalkoxy; or said ortho substituent is benzo[1,3]dioxolyl;   and the other of said substituents, if present, is/are independently selected from (C 1-4 )alkyl; (C 1-4 )alkoxy; (C 3-6 )cycloalkyl; halogen; cyano; (C 1-3 )fluoroalkyl; (C 1-3 )fluoroalkoxy; —NR 10 R 11 , wherein R 10  and R 11  independently represent hydrogen or (C 1-4 )alkyl, or R 10  and R 11  together with the nitrogen to which they are attached to form a pyrrolidine ring; unsubstituted pyridinyl; and phenyl which is unsubstituted, or mono- or di-substituted, wherein the substituents are independently selected from (C 1-4 )alkyl, (C 1-4 )alkoxy, cyano, and halogen;
 
R 1  represents hydrogen, (C 1-4 )alkyl (especially methyl or ethyl), (C 3-6 )cycloalkyl-(CH 2 )— (especially cyclopropyl-methyl), (C 2-3 )fluoroalkyl (especially 2-fluoro-ethyl), or (C 1-4 )alkoxy-(C 2-4 )alkyl (especially 2-methoxy-ethyl); and
 
(R 5 ) n  represents one to three optional substituents (i.e. n represents the integer 0, 1, 2, or 3) independently selected from (C 1-4 )alkyl, (C 1-4 )alkoxy (especially methoxy), halogen, (C 1-4 )alkyl-thio- (especially H 3 C—S—), (C 1-3 )fluoroalkyl (especially trifluoromethyl), (C 1-3 )fluoroalkoxy (especially trifluoromethoxy), (C 1-3 )fluoroalkyl-thio- (especially F 3 C—S—), hydroxy-(C 1-4 )alkyl- (especially HO—CH 2 —), (C 1-4 )alkoxy-carbonyl- (especially H 3 CO—CO—), nitro, hydroxy, and cyano; or (R 5 ) n  represents a group —O—CH 2 —CH 2 —O—.
 
wherein all characteristics disclosed in embodiments 15) to 42) are intended to apply mutatis mutandis also to the compounds formula (VI) according to embodiment 45); wherein especially the following embodiments are thus possible and intended and herewith specifically disclosed in individualized form:
 
45, 17+45, 18+45, 19+17+45, 19+18+45, 19+45, 22+17+45, 22+18+45, 22+19+17+45, 22+19+18+45, 22+19+45, 22+45, 23+17+45, 23+18+45, 23+19+17+45, 23+19+18+45, 23+19+45, 23+45, 24+17+45, 24+18+45, 24+19+17+45, 24+19+18+45, 24+19+45, 24+22+17+45, 24+22+18+45, 24+22+19+17+45, 24+22+19+18+45, 24+22+19+45, 24+22+45, 24+23+17+45, 24+23+18+45, 24+23+19+17+45, 24+23+19+18+45, 24+23+19+45, 24+23+45, 24+45, 25+17+45, 25+18+45, 25+19+17+45, 25+19+18+45, 25+19+45, 25+22+17+45, 25+22+18+45, 25+22+19+17+45, 25+22+19+18+45, 25+22+19+45, 25+22+45, 25+23+17+45, 25+23+18+45, 25+23+19+17+45, 25+23+19+18+45, 25+23+19+45, 25+23+45, 25+24+17+45, 25+24+18+45, 25+24+19+17+45, 25+24+19+18+45, 25+24+19+45, 25+24+22+17+45, 25+24+22+18+45, 25+24+22+19+17+45, 25+24+22+19+18+45, 25+24+22+19+45, 25+24+22+45, 25+24+23+17+45, 25+24+23+18+45, 25+24+23+19+17+45, 25+24+23+19+18+45, 25+24+23+19+45, 25+24+23+45, 25+24+45, 25+45, 26+17+45, 26+18+45, 26+19+17+45, 26+19+18+45, 26+19+45, 26+45, 39+22+45, 39+23+45, 39+24+22+45, 39+24+23+45, 39+24+45, 39+25+22+45, 39+25+23+45, 39+25+24+22+45, 39+25+24+23+45, 39+25+24+45, 39+25+45, 39+26+45, 39+45, 40+45, 41+45.
   
               

     In the list above the numbers refer to the embodiments according to their numbering provided hereinabove whereas “+” indicates the dependency from another embodiment as outlined above. 
     46) Another embodiment relates to compounds according to embodiment 1) selected from: 
     
         
         [2-(5-Chloro-6-methyl-1H-benzoimidazol-2-yl)-pyrrolidin-1-yl]-[5-(3-chloro-phenyl)-2-methyl-thiazol-4-yl]-methanone; 
         [5-(3-Chloro-phenyl)-2-methyl-thiazol-4-yl]-[2-(4,6-dimethyl-1H-benzoimidazol-2-yl)-pyrrolidin-1-yl]-methanone; 
         [2-(4-Bromo-1H-benzoimidazol-2-yl)-pyrrolidin-1-yl]-[5-(3-chloro-phenyl)-2-methyl-thiazol-4-yl]-methanone; 
         [2-(5-Bromo-7-methyl-1H-benzoimidazol-2-yl)-pyrrolidin-1-yl]-[5-(3-chloro-phenyl)-2-methyl-thiazol-4-yl]-methanone; 
         [2-(5-Chloro-4-methyl-1H-benzoimidazol-2-yl)-pyrrolidin-1-yl]-[5-(3-chloro-phenyl)-2-methyl-thiazol-4-yl]-methanone; 
         [5-(3-Chloro-phenyl)-2-methyl-thiazol-4-yl]-[2-(6-chloro-5-trifluoromethyl-1H-benzoimidazol-2-yl)-pyrrolidin-1-yl]-methanone; 
         [2-(4-Bromo-6-fluoro-1H-benzoimidazol-2-yl)-pyrrolidin-1-yl]-[5-(3-chloro-phenyl)-2-methyl-thiazol-4-yl]-methanone; 
         [5-(3-Chloro-phenyl)-2-methyl-thiazol-4-yl]-[2-(4,5-dimethyl-1H-benzoimidazol-2-yl)-pyrrolidin-1-yl]-methanone; 
         [2-(5,6-Dichloro-1H-benzoimidazol-2-yl)-pyrrolidin-1-yl]-(2-methyl-5-phenyl-thiazol-4-yl)-methanone; 
         [2-(5-Chloro-6-methyl-1H-benzoimidazol-2-yl)-pyrrolidin-1-yl]-(2-methyl-5-phenyl-thiazol-4-yl)-methanone; 
         [2-(4,6-Dimethyl-1H-benzoimidazol-2-yl)-pyrrolidin-1-yl]-(2-methyl-5-phenyl-thiazol-4-yl)-methanone; 
         [5-(3-Chloro-phenyl)-2-methyl-thiazol-4-yl]-[(S)-2-(7-methylsulfanyl-1H-benzoimidazol-2-yl)-pyrrolidin-1-yl]-methanone; 
         [2-(5-Chloro-4-methyl-1H-benzoimidazol-2-yl)-pyrrolidin-1-yl]-(2-methyl-5-phenyl-thiazol-4-yl)-methanone; 
         [2-(6-Chloro-5-trifluoromethyl-1H-benzoimidazol-2-yl)-pyrrolidin-1-yl]-(2-methyl-5-phenyl-thiazol-4-yl)-methanone; 
         [(S)-2-(4,6-Dimethyl-1H-benzoimidazol-2-yl)-pyrrolidin-1-yl]-(2-methyl-5-phenyl-thiazol-4-yl)-methanone; 
         [(S)-2-(5-Chloro-6-methyl-1H-benzoimidazol-2-yl)-pyrrolidin-1-yl]-(2-methyl-5-phenyl-thiazol-4-yl)-methanone; 
         [(S)-2-(6-Bromo-4-methyl-1H-benzoimidazol-2-yl)-pyrrolidin-1-yl]-(2-methyl-5-phenyl-thiazol-4-yl)-methanone; 
         [(S)-2-(5-Chloro-4-methyl-1H-benzoimidazol-2-yl)-pyrrolidin-1-yl]-(2-methyl-5-phenyl-thiazol-4-yl)-methanone; 
         [(S)-2-(5-Chloro-6-trifluoromethyl-1H-benzoimidazol-2-yl)-pyrrolidin-1-yl]-(2-methyl-5-phenyl-thiazol-4-yl)-methanone; 
         [(S)-2-(6-Methylsulfanyl-1H-benzoimidazol-2-yl)-pyrrolidin-1-yl]-(4-methyl-2-[1,2,3]triazol-2-yl-phenyl)-methanone; 
         (4,5-Dimethoxy-2-[1,2,3]triazol-2-yl-phenyl)-[(S)-2-(6-methylsulfanyl-1H-benzoimidazol-2-yl)-pyrrolidin-1-yl]-methanone; 
         (5-Methoxy-2-[1,2,3]triazol-2-yl-phenyl)-[(S)-2-(7-methylsulfanyl-1H-benzoimidazol-2-yl)-pyrrolidin-1-yl]-methanone; 
         (2-Fluoro-3-methoxy-6-[1,2,3]triazol-2-yl-phenyl)-[(S)-2-(7-methylsulfanyl-1H-benzoimidazol-2-yl)-pyrrolidin-1-yl]-methanone; 
         [(S)-2-(7-Methylsulfanyl-1H-benzoimidazol-2-yl)-pyrrolidin-1-yl]-(4-methyl-2-[1,2,3]triazol-2-yl-phenyl)-methanone; 
         [(S)-2-(6-Methylsulfanyl-1H-benzoimidazol-2-yl)-pyrrolidin-1-yl]-(2-methyl-5-p-tolyl-thiazol-4-yl)-methanone; 
         [(S)-2-(7-Methylsulfanyl-1H-benzoimidazol-2-yl)-pyrrolidin-1-yl]-(5-methyl-2-[1,2,3]triazol-2-yl-phenyl)-methanone; 
         [4-(3-Chloro-phenyl)-2-methyl-pyrimidin-5-yl]-[(S)-2-(6-methylsulfanyl-1H-benzoimidazol-2-yl)-pyrrolidin-1-yl]-methanone; 
         [4-(3,4-Dimethyl-phenyl)-2-methyl-pyrimidin-5-yl]-[(S)-2-(6-methylsulfanyl-1H-benzoimidazol-2-yl)-pyrrolidin-1-yl]-methanone; 
         (2-Methyl-4-phenyl-pyrimidin-5-yl)-[(S)-2-(6-methylsulfanyl-1H-benzoimidazol-2-yl)-pyrrolidin-1-yl]-methanone; 
         [4-(4-Bromo-3-chloro-phenyl)-2-methyl-pyrimidin-5-yl]-[(S)-2-(6-methylsulfanyl-1H-benzoimidazol-2-yl)-pyrrolidin-1-yl]-methanone; 
         (2-Cyclopropyl-5-phenyl-thiazol-4-yl)-[(S)-2-(7-methylsulfanyl-1H-benzoimidazol-2-yl)-pyrrolidin-1-yl]-methanone; 
         [5-(3-Methoxy-phenyl)-2-methyl-thiazol-4-yl]-[(S)-2-(7-methylsulfanyl-1H-benzoimidazol-2-yl)-pyrrolidin-1-yl]-methanone; 
         [(S)-2-(7-Methylsulfanyl-1H-benzoimidazol-2-yl)-pyrrolidin-1-yl]-[2-methyl-5-(3-trifluoromethyl-phenyl)-thiazol-4-yl]-methanone; 
         [(S)-2-(7-Methylsulfanyl-1H-benzoimidazol-2-yl)-pyrrolidin-1-yl]-(2-methyl-5-p-tolyl-thiazol-4-yl)-methanone; 
         (2-Cyclopropyl-5-p-tolyl-thiazol-4-yl)-[(S)-2-(7-methylsulfanyl-1H-benzoimidazol-2-yl)-pyrrolidin-1-yl]-methanone; 
         [2-Cyclopropyl-5-(4-fluoro-phenyl)-thiazol-4-yl]-[(S)-2-(7-methylsulfanyl-1H-benzoimidazol-2-yl)-pyrrolidin-1-yl]-methanone; 
         (3′,4′-Dimethyl-biphenyl-2-yl)-[(S)-2-(7-methylsulfanyl-1H-benzoimidazol-2-yl)-pyrrolidin-1-yl]-methanone; 
         [4-(3,4-Dichloro-phenyl)-2-methyl-pyrimidin-5-yl]-[(S)-2-(7-methylsulfanyl-1H-benzoimidazol-2-yl)-pyrrolidin-1-yl]-methanone; 
         [4-(3,4-Dichloro-phenyl)-pyrimidin-5-yl]-[(S)-2-(7-methylsulfanyl-1H-benzoimidazol-2-yl)-pyrrolidin-1-yl]-methanone; 
         [4-(3,4-Dimethyl-phenyl)-pyrimidin-5-yl]-[(S)-2-(7-methylsulfanyl-1H-benzoimidazol-2-yl)-pyrrolidin-1-yl]-methanone; 
         [4-(4-Bromo-3-chloro-phenyl)-pyrimidin-5-yl]-[(S)-2-(7-methylsulfanyl-1H-benzoimidazol-2-yl)-pyrrolidin-1-yl]-methanone; 
         [4-(3,4-Dimethyl-phenyl)-2-methyl-pyrimidin-5-yl]-[(S)-2-(7-methylsulfanyl-1H-benzoimidazol-2-yl)-pyrrolidin-1-yl]-methanone; 
         (2-Methyl-4-phenyl-pyrimidin-5-yl)-[(S)-2-(7-methylsulfanyl-1H-benzoimidazol-2-yl)-pyrrolidin-1-yl]-methanone; 
         [4-(4-Bromo-3-chloro-phenyl)-2-methyl-pyrimidin-5-yl]-[(S)-2-(7-methylsulfanyl-1H-benzoimidazol-2-yl)-pyrrolidin-1-yl]-methanone; 
         [4-(3,5-Dichloro-phenyl)-2-methyl-pyrimidin-5-yl]-[(S)-2-(7-methylsulfanyl-1H-benzoimidazol-2-yl)-pyrrolidin-1-yl]-methanone; 
         [5-(3-Chloro-phenyl)-2-methyl-thiazol-4-yl]-[2-(5,6-dichloro-1H-benzoimidazol-2-yl)-pyrrolidin-1-yl]-methanone; 
         [5-(3-Chloro-phenyl)-2-methyl-thiazol-4-yl]-[2-(5,6-dimethyl-1H-benzoimidazol-2-yl)-pyrrolidin-1-yl]-methanone; 
         [(2S,4R)-2-(5-Chloro-4-methyl-1H-benzoimidazol-2-yl)-4-fluoro-pyrrolidin-1-yl]-[5-(3-chloro-phenyl)-2-methyl-thiazol-4-yl]-methanone; 
         [(2S,4R)-2-(5-Chloro-4-methyl-1H-benzoimidazol-2-yl)-4-fluoro-pyrrolidin-1-yl]-(5-methyl-2-[1,2,3]triazol-2-yl-phenyl)-methanone; 
         [5-(3-Chloro-phenyl)-2-methyl-thiazol-4-yl]-[(2S,4R)-4-fluoro-2-(4-methyl-1H-benzoimidazol-2-yl)-pyrrolidin-1-yl]-methanone; 
         [(2S,4R)-2-(6-Chloro-7-methyl-1H-benzoimidazol-2-yl)-4-methoxy-pyrrolidin-1-yl]-(5-chloro-2-[1,2,3]triazol-2-yl-phenyl)-methanone; 
         [(2S,4R)-2-(6-Chloro-7-methyl-1H-benzoimidazol-2-yl)-4-methoxy-pyrrolidin-1-yl]-(2-fluoro-3-methoxy-6-[1,2,3]triazol-2-yl-phenyl)-methanone; 
         [(2S,4R)-2-(6-Chloro-7-methyl-1H-benzoimidazol-2-yl)-4-methoxy-pyrrolidin-1-yl]-(5-methoxy-2-[1,2,3]triazol-2-yl-phenyl)-methanone; 
         [(2S,4R)-2-(6-Chloro-7-methyl-1H-benzoimidazol-2-yl)-4-methoxy-pyrrolidin-1-yl]-(2-fluoro-3-methyl-6-[1,2,3]triazol-2-yl-phenyl)-methanone; 
         [(2S,4R)-2-(6-Chloro-7-methyl-1H-benzoimidazol-2-yl)-4-methoxy-pyrrolidin-1-yl]-(4,5-dimethyl-2-[1,2,3]triazol-2-yl-phenyl)-methanone; 
         [(2S,4R)-2-(5-Chloro-4-methyl-1H-benzoimidazol-2-yl)-4-methoxy-pyrrolidin-1-yl]-(5-methyl-2-[1,2,3]triazol-2-yl-phenyl)-methanone; 
         [(4R)-2-(5-Chloro-4-methyl-1H-benzoimidazol-2-yl)-4-methoxy-2-methyl-pyrrolidin-1-yl]-(2-methyl-5-phenyl-thiazol-4-yl)-methanone; 
         [(4R)-2-(5-Chloro-4-methyl-1H-benzoimidazol-2-yl)-4-methoxy-2-methyl-pyrrolidin-1-yl]-(5-methyl-2-[1,2,3]triazol-2-yl-phenyl)-methanone; 
         [(4R)-2-(5-Chloro-4-methyl-1H-benzoimidazol-2-yl)-4-methoxy-2-methyl-pyrrolidin-1-yl]-[5-(3-chloro-phenyl)-2-methyl-thiazol-4-yl]-methanone; 
         [5-(3-Chloro-phenyl)-2-methyl-thiazol-4-yl]-[(4R)-4-methoxy-2-methyl-2-(4-methyl-1H-benzoimidazol-2-yl)-pyrrolidin-1-yl]-methanone; 
         [(4R)-4-Methoxy-2-methyl-2-(4-methyl-1H-benzoimidazol-2-yl)-pyrrolidin-1-yl]-(2-methyl-5-phenyl-thiazol-4-yl)-methanone; 
         [(2S,4R)-2-(5-Chloro-4-methyl-1H-benzoimidazol-2-yl)-4-methoxy-2-methyl-pyrrolidin-1-yl]-(5-methyl-2-[1,2,3]triazol-2-yl-phenyl)-methanone; 
         [(2S,4R)-2-(5-Chloro-4-methyl-1H-benzoimidazol-2-yl)-4-methoxy-2-methyl-pyrrolidin-1-yl]-[5-(3-chloro-phenyl)-2-methyl-thiazol-4-yl]-methanone; 
         [(2S,4R)-2-(6-Chloro-7-methyl-1H-benzoimidazol-2-yl)-4-methoxy-pyrrolidin-1-yl]-(2-methyl-5-m-tolyl-thiazol-4-yl)-methanone; 
         [(2S,4R)-2-(6-Chloro-7-methyl-1H-benzoimidazol-2-yl)-4-methoxy-pyrrolidin-1-yl]-[2-dimethylamino-5-(3,4-dimethyl-phenyl)-thiazol-4-yl]-methanone; 
         [(2S,4R)-2-(6-Chloro-7-methyl-1H-benzoimidazol-2-yl)-4-methoxy-pyrrolidin-1-yl]-[5-(3,4-dimethyl-phenyl)-2-methyl-thiazol-4-yl]-methanone; 
         [(2S,4R)-2-(6-Chloro-7-methyl-1H-benzoimidazol-2-yl)-4-methoxy-pyrrolidin-1-yl]-[5-(4-chloro-phenyl)-2-methyl-thiazol-4-yl]-methanone; 
         [(2S,4R)-2-(6-Chloro-7-methyl-1H-benzoimidazol-2-yl)-4-methoxy-pyrrolidin-1-yl]-(2-methyl-5-p-tolyl-thiazol-4-yl)-methanone; 
         [(2S,4R)-2-(6-Chloro-7-methyl-1H-benzoimidazol-2-yl)-4-methoxy-pyrrolidin-1-yl]-[5-(4-methoxy-phenyl)-2-methyl-thiazol-4-yl]-methanone; 
         [(2S,4R)-2-(6-Chloro-7-methyl-1H-benzoimidazol-2-yl)-4-methoxy-pyrrolidin-1-yl]-(3′,4′-dimethyl-biphenyl-2-yl)-methanone; 
         [(2S,4R)-4-Methoxy-2-(4-methyl-1H-benzoimidazol-2-yl)-pyrrolidin-1-yl]-(2-methyl-5-phenyl-thiazol-4-yl)-methanone; 
         [(2S,4R)-2-(6-Chloro-7-methyl-1H-benzoimidazol-2-yl)-4-methoxy-pyrrolidin-1-yl]-(4′-fluoro-3′-methyl-biphenyl-2-yl)-methanone; 
         [(2S,4R)-2-(6-Chloro-7-methyl-1H-benzoimidazol-2-yl)-4-methoxy-pyrrolidin-1-yl]-[5-(3-chloro-phenyl)-2-dimethylamino-thiazol-4-yl]-methanone; 
         [(4R)-2-(5-Chloro-4-methyl-1H-benzoimidazol-2-yl)-4-methoxy-2-methyl-pyrrolidin-1-yl]-(5-fluoro-2-[1,2,3]triazol-2-yl-phenyl)-methanone; 
         [(4R)-2-(5-Chloro-4-methyl-1H-benzoimidazol-2-yl)-4-methoxy-2-methyl-pyrrolidin-1-yl]-(5-chloro-2-[1,2,3]triazol-2-yl-phenyl)-methanone; 
         [(4R)-2-(5-Chloro-4-methyl-1H-benzoimidazol-2-yl)-4-methoxy-2-methyl-pyrrolidin-1-yl]-(2-[1,2,3]triazol-2-yl-phenyl)-methanone; 
         [(4R)-2-(5-Chloro-4-methyl-1H-benzoimidazol-2-yl)-4-methoxy-2-methyl-pyrrolidin-1-yl]-(4,5-dimethyl-2-[1,2,3]triazol-2-yl-phenyl)-methanone; 
         [(4R)-2-(5-Chloro-4-methyl-1H-benzoimidazol-2-yl)-4-methoxy-2-methyl-pyrrolidin-1-yl]-(4-methyl-2-[1,2,3]triazol-2-yl-phenyl)-methanone; 
         [(4R)-2-(5-Chloro-4-methyl-1H-benzoimidazol-2-yl)-4-methoxy-2-methyl-pyrrolidin-1-yl]-(4,5-dimethoxy-2-[1,2,3]triazol-2-yl-phenyl)-methanone; 
         [(4R)-2-(5-Chloro-4-methyl-1H-benzoimidazol-2-yl)-4-methoxy-2-methyl-pyrrolidin-1-yl]-(5-methyl-2-pyrazol-1-yl-phenyl)-methanone; 
         [(4R)-2-(5-Chloro-4-methyl-1H-benzoimidazol-2-yl)-4-methoxy-2-methyl-pyrrolidin-1-yl]-(6-methyl-3-pyrazol-1-yl-pyridin-2-yl)-methanone; 
         [(4R)-2-(5-Chloro-4-methyl-1H-benzoimidazol-2-yl)-4-methoxy-2-methyl-pyrrolidin-1-yl]-(6-methyl-3-[1,2,3]triazol-2-yl-pyridin-2-yl)-methanone; 
         [(2S,4R)-2-(5-Chloro-4-methyl-1H-benzoimidazol-2-yl)-4-methoxy-pyrrolidin-1-yl]-(2-methyl-5-phenyl-thiazol-4-yl)-methanone; 
         [5-(3-Chloro-phenyl)-2-methyl-thiazol-4-yl]-[(2S,4R)-4-methoxy-2-(4-methyl-1H-benzoimidazol-2-yl)-pyrrolidin-1-yl]-methanone; 
         [(2S,4S)-2-(5-Chloro-4-methyl-1H-benzoimidazol-2-yl)-4-methoxy-pyrrolidin-1-yl]-[5-(3-chloro-phenyl)-2-methyl-thiazol-4-yl]-methanone; 
         [(2S,4R)-2-(5-Chloro-4-methyl-1H-benzoimidazol-2-yl)-4-methoxy-pyrrolidin-1-yl]-[5-(3-chloro-phenyl)-2-methyl-thiazol-4-yl]-methanone; 
         (5-Chloro-2-[1,2,3]triazol-2-yl-phenyl)-[(2S,3S)-2-(5,6-dimethoxy-1H-benzoimidazol-2-yl)-3-methyl-pyrrolidin-1-yl]-methanone; 
         [(2S,3S)-2-(5,6-Dimethoxy-1H-benzoimidazol-2-yl)-3-methyl-pyrrolidin-1-yl]-(4-methyl-2-[1,2,3]triazol-2-yl-phenyl)-methanone; 
         [(2S,3S)-2-(5-Chloro-4-methyl-1H-benzoimidazol-2-yl)-3-methyl-pyrrolidin-1-yl]-(4-methyl-2-[1,2,3]triazol-2-yl-phenyl)-methanone; 
         [(2S,3S)-2-(5-Chloro-4-methyl-1H-benzoimidazol-2-yl)-3-methyl-pyrrolidin-1-yl]-(5-methoxy-2-[1,2,3]triazol-2-yl-phenyl)-methanone; 
         [(2S,3S)-2-(5,6-Dimethyl-1H-benzoimidazol-2-yl)-3-methyl-pyrrolidin-1-yl]-(4-methyl-2-[1,2,3]triazol-2-yl-phenyl)-methanone; 
         [(2S,3S)-2-(5,6-Dimethyl-1H-benzoimidazol-2-yl)-3-methyl-pyrrolidin-1-yl]-(5-methoxy-2-[1,2,3]triazol-2-yl-phenyl)-methanone; 
         [(2S,3S)-2-(5,6-Dimethyl-1H-benzoimidazol-2-yl)-3-methyl-pyrrolidin-1-yl]-(2-[1,2,3]triazol-2-yl-phenyl)-methanone; 
         [(S)-2-Methyl-2-(4-methyl-1H-benzoimidazol-2-yl)-pyrrolidin-1-yl]-(2-methyl-5-phenyl-thiazol-4-yl)-methanone; 
         [(S)-2-(5,6-Dimethyl-1H-benzoimidazol-2-yl)-2-methyl-pyrrolidin-1-yl]-(5-methyl-2-[1,2,3]triazol-2-yl-phenyl)-methanone; 
         [(S)-2-(5,6-Dimethyl-1H-benzoimidazol-2-yl)-2-methyl-pyrrolidin-1-yl]-(4,4′-dimethyl-biphenyl-2-yl)-methanone; 
         [(S)-2-(5,6-Dimethyl-1H-benzoimidazol-2-yl)-2-methyl-pyrrolidin-1-yl]-(3′-fluoro-biphenyl-2-yl)-methanone; 
         [(S)-2-(5,6-Dimethyl-1H-benzoimidazol-2-yl)-2-methyl-pyrrolidin-1-yl]-(3′-methyl-biphenyl-2-yl)-methanone; 
         [(S)-2-(4,5-Dimethyl-1H-benzoimidazol-2-yl)-2-methyl-pyrrolidin-1-yl]-(3′-fluoro-4-methyl-biphenyl-2-yl)-methanone; 
         [(S)-2-(4,5-Dimethyl-1H-benzoimidazol-2-yl)-2-methyl-pyrrolidin-1-yl]-(3′-methoxy-4-methyl-biphenyl-2-yl)-methanone; 
         [(S)-2-(4,5-Dimethyl-1H-benzoimidazol-2-yl)-2-methyl-pyrrolidin-1-yl]-(4,3′-dimethyl-biphenyl-2-yl)-methanone; 
         [(S)-2-(4,5-Dimethyl-1H-benzoimidazol-2-yl)-2-methyl-pyrrolidin-1-yl]-(4′-methoxy-4-methyl-biphenyl-2-yl)-methanone; 
         [(S)-2-(4,5-Dimethyl-1H-benzoimidazol-2-yl)-2-methyl-pyrrolidin-1-yl]-(4,4′-dimethyl-biphenyl-2-yl)-methanone; 
         [(S)-2-(4,5-Dimethyl-1H-benzoimidazol-2-yl)-2-methyl-pyrrolidin-1-yl]-(2′-fluoro-4-methyl-biphenyl-2-yl)-methanone; 
         [(S)-2-(4,5-Dimethyl-1H-benzoimidazol-2-yl)-2-methyl-pyrrolidin-1-yl]-(4′-fluoro-4-methyl-biphenyl-2-yl)-methanone; 
         [(S)-2-(4,5-Dimethyl-1H-benzoimidazol-2-yl)-2-methyl-pyrrolidin-1-yl]-(3′-fluoro-biphenyl-2-yl)-methanone; 
         [(S)-2-(4,5-Dimethyl-1H-benzoimidazol-2-yl)-2-methyl-pyrrolidin-1-yl]-(3′-methyl-biphenyl-2-yl)-methanone; 
         [(S)-2-(4,5-Dimethyl-1H-benzoimidazol-2-yl)-2-methyl-pyrrolidin-1-yl]-(4-methoxy-biphenyl-2-yl)-methanone; 
         [(S)-2-(4,5-Dimethyl-1H-benzoimidazol-2-yl)-2-methyl-pyrrolidin-1-yl]-(4′-methyl-biphenyl-2-yl)-methanone; 
         [(S)-2-(6-Bromo-5-fluoro-1H-benzoimidazol-2-yl)-2-methyl-pyrrolidin-1-yl]-(4,5-dimethyl-2-[1,2,3]triazol-2-yl-phenyl)-methanone; 
         [(S)-2-(6-Bromo-5-fluoro-1H-benzoimidazol-2-yl)-2-methyl-pyrrolidin-1-yl]-(5-chloro-2-[1,2,3]triazol-2-yl-phenyl)-methanone; 
         [(S)-2-(5-tert-Butyl-1H-benzoimidazol-2-yl)-2-methyl-pyrrolidin-1-yl]-(5-methyl-2-[1,2,3]triazol-2-yl-phenyl)-methanone; 
         [(S)-2-(6-Bromo-5-fluoro-1H-benzoimidazol-2-yl)-2-methyl-pyrrolidin-1-yl]-(4-methyl-2-[1,2,3]triazol-2-yl-phenyl)-methanone; 
         [(S)-2-(6-Chloro-5-trifluoromethyl-1H-benzoimidazol-2-yl)-2-methyl-pyrrolidin-1-yl]-(2-fluoro-6-[1,2,3]triazol-2-yl-phenyl)-methanone; 
         [(S)-2-(6-Chloro-5-trifluoromethyl-1H-benzoimidazol-2-yl)-2-methyl-pyrrolidin-1-yl]-(2-fluoro-3-methyl-6-[1,2,3]triazol-2-yl-phenyl)-methanone; 
         [(S)-2-(6-Chloro-5-trifluoromethyl-1H-benzoimidazol-2-yl)-2-methyl-pyrrolidin-1-yl]-(4,5-dimethoxy-2-[1,2,3]triazol-2-yl-phenyl)-methanone; 
         [(S)-2-(6-Chloro-5-trifluoromethyl-1H-benzoimidazol-2-yl)-2-methyl-pyrrolidin-1-yl]-(5-fluoro-2-[1,2,3]triazol-2-yl-phenyl)-methanone; 
         [(S)-2-(6-Chloro-5-trifluoromethyl-1H-benzoimidazol-2-yl)-2-methyl-pyrrolidin-1-yl]-(4,5-dimethyl-2-[1,2,3]triazol-2-yl-phenyl)-methanone; 
         [(S)-2-(6-Chloro-5-trifluoromethyl-1H-benzoimidazol-2-yl)-2-methyl-pyrrolidin-1-yl]-(5-methyl-2-pyrazol-1-yl-phenyl)-methanone; 
         (5-Chloro-2-[1,2,3]triazol-2-yl-phenyl)-[(S)-2-(6-chloro-5-trifluoromethyl-1H-benzoimidazol-2-yl)-2-methyl-pyrrolidin-1-yl]-methanone; 
         [(S)-2-(4-Chloro-6-trifluoromethyl-1H-benzoimidazol-2-yl)-2-methyl-pyrrolidin-1-yl]-(5-methyl-2-[1,2,3]triazol-2-yl-phenyl)-methanone; 
         [(S)-2-(6-Chloro-5-trifluoromethyl-1H-benzoimidazol-2-yl)-2-methyl-pyrrolidin-1-yl]-(4-methyl-2-[1,2,3]triazol-2-yl-phenyl)-methanone; 
         [(S)-2-(6-Chloro-5-trifluoromethyl-1H-benzoimidazol-2-yl)-2-methyl-pyrrolidin-1-yl]-(2-[1,2,3]triazol-2-yl-phenyl)-methanone; 
         [(S)-2-(6-Chloro-5-trifluoromethyl-1H-benzoimidazol-2-yl)-2-methyl-pyrrolidin-1-yl]-(6-methyl-3-[1,2,3]triazol-2-yl-pyridin-2-yl)-methanone; 
         [(S)-2-(6-Chloro-5-trifluoromethyl-1H-benzoimidazol-2-yl)-2-methyl-pyrrol id in-1-yl]-(2-fluoro-3-methoxy-6-[1,2,3]triazol-2-yl-phenyl)-methanone; 
         [(S)-2-(6-Chloro-5-trifluoromethyl-1H-benzoimidazol-2-yl)-2-methyl-pyrrolidin-1-yl]-(3′-methoxy-4-methyl-biphenyl-2-yl)-methanone; 
         [(S)-2-(5-Chloro-6-methyl-1H-benzoimidazol-2-yl)-2-methyl-pyrrolidin-1-yl]-(5-methyl-2-[1,2,3]triazol-2-yl-phenyl)-methanone; 
         [(S)-2-(6-Chloro-5-trifluoromethyl-1H-benzoimidazol-2-yl)-2-methyl-pyrrolidin-1-yl]-(2′-fluoro-4-methyl-biphenyl-2-yl)-methanone; 
         [(S)-2-(6-Chloro-5-trifluoromethyl-1H-benzoimidazol-2-yl)-2-methyl-pyrrolidin-1-yl]-(4′-fluoro-4-methyl-biphenyl-2-yl)-methanone; 
         [(S)-2-(6-Chloro-5-trifluoromethyl-1H-benzoimidazol-2-yl)-2-methyl-pyrrolidin-1-yl]-(3′-fluoro-4-methyl-biphenyl-2-yl)-methanone; 
         2′-[(S)-2-(6-Chloro-5-trifluoromethyl-1H-benzoimidazol-2-yl)-2-methyl-pyrrolidine-1-carbonyl]-4′-methyl-biphenyl-3-carbonitrile; 
         [(S)-2-(4,6-Dimethyl-1H-benzoimidazol-2-yl)-2-methyl-pyrrolidin-1-yl]-(5-methyl-2-[1,2,3]triazol-2-yl-phenyl)-methanone; 
         (5-Chloro-2-[1,2,3]triazol-2-yl-phenyl)-[(S)-2-methyl-2-(5-trifluoromethyl-1H-benzoimidazol-2-yl)-pyrrolidin-1-yl]-methanone; 
         (4,5-Dimethyl-2-[1,2,3]triazol-2-yl-phenyl)-[(S)-2-methyl-2-(5-trifluoromethyl-1H-benzoimidazol-2-yl)-pyrrolidin-1-yl]-methanone; 
         (4-Methyl-2-[1,2,3]triazol-2-yl-phenyl)-[(S)-2-methyl-2-(5-trifluoromethyl-1H-benzoimidazol-2-yl)-pyrrolidin-1-yl]-methanone; 
         [(S)-2-(4-Bromo-1H-benzoimidazol-2-yl)-2-methyl-pyrrolidin-1-yl]-(5-methyl-2-[1,2,3]triazol-2-yl-phenyl)-methanone; 
         (3′-Fluoro-4-methyl-biphenyl-2-yl)-[(S)-2-methyl-2-(5-trifluoromethyl-1H-benzoimidazol-2-yl)-pyrrolidin-1-yl]-methanone; 
         (4,3′-Dimethyl-biphenyl-2-yl)-[(S)-2-methyl-2-(5-trifluoromethyl-1H-benzoimidazol-2-yl)-pyrrolidin-1-yl]-methanone; 
         [(S)-2-(5-Bromo-7-methyl-1H-benzoimidazol-2-yl)-2-methyl-pyrrolidin-1-yl]-(5-methyl-2-[1,2,3]triazol-2-yl-phenyl)-methanone; 
         (4′-Methoxy-4-methyl-biphenyl-2-yl)-[(S)-2-methyl-2-(5-trifluoromethyl-1H-benzoimidazol-2-yl)-pyrrolidin-1-yl]-methanone; 
         (4,4′-Dimethyl-biphenyl-2-yl)-[(S)-2-methyl-2-(5-trifluoromethyl-1H-benzoimidazol-2-yl)-pyrrolidin-1-yl]-methanone; 
         (2-Benzo[1,3]dioxol-5-yl-5-methyl-phenyl)-[(S)-2-methyl-2-(5-trifluoromethyl-1H-benzoimidazol-2-yl)-pyrrolidin-1-yl]-methanone; 
         [(S)-2-(5-Chloro-4-methyl-1H-benzoimidazol-2-yl)-2-methyl-pyrrolidin-1-yl]-(5-methyl-2-[1,2,3]triazol-2-yl-phenyl)-methanone; 
         [5-(3-Chloro-phenyl)-2-methyl-thiazol-4-yl]-[(S)-2-(4,5-difluoro-1H-benzoimidazol-2-yl)-2-methyl-pyrrolidin-1-yl]-methanone; 
         [(S)-2-(5,6-Dimethoxy-1H-benzoimidazol-2-yl)-2-methyl-pyrrolidin-1-yl]-(5-methyl-2-[1,2,3]triazol-2-yl-phenyl)-methanone; 
         [(S)-2-(4,5-Difluoro-1H-benzoimidazol-2-yl)-2-methyl-pyrrolidin-1-yl]-(2-methyl-5-m-tolyl-thiazol-4-yl)-methanone; 
         [(S)-2-(4,5-Difluoro-1H-benzoimidazol-2-yl)-2-methyl-pyrrolidin-1-yl]-[5-(3-methoxy-phenyl)-2-methyl-thiazol-4-yl]-methanone; 
         [(S)-2-(5-Chloro-4-methyl-1H-benzoimidazol-2-yl)-2-methyl-pyrrolidin-1-yl]-(5-methyl-2-pyrimidin-2-yl-phenyl)-methanone; 
         [(S)-2-(5-Chloro-4-methyl-1H-benzoimidazol-2-yl)-2-methyl-pyrrolidin-1-yl]-(5-methyl-2-pyridin-2-yl-phenyl)-methanone; 
         [(S)-2-(5-Chloro-4-methyl-1H-benzoimidazol-2-yl)-2-methyl-pyrrolidin-1-yl]-(5-methyl-2-pyridin-3-yl-phenyl)-methanone; 
         [(S)-2-(6-Bromo-5-fluoro-1H-benzoimidazol-2-yl)-2-methyl-pyrrolidin-1-yl]-(5-methyl-2-[1,2,3]triazol-2-yl-phenyl)-methanone; 
         [(S)-2-(6-Chloro-5-trifluoromethyl-1H-benzoimidazol-2-yl)-2-methyl-pyrrolidin-1-yl]-(5-methyl-2-[1,2,3]triazol-2-yl-phenyl)-methanone; 
         [(S)-2-(4-Bromo-6-fluoro-1H-benzoimidazol-2-yl)-2-methyl-pyrrolidin-1-yl]-(5-methyl-2-[1,2,3]triazol-2-yl-phenyl)-methanone; 
         [(S)-2-(4,5-Dimethyl-1H-benzoimidazol-2-yl)-2-methyl-pyrrolidin-1-yl]-(5-methyl-2-[1,2,3]triazol-2-yl-phenyl)-methanone; 
         [(S)-2-(4-Isopropyl-1H-benzoimidazol-2-yl)-2-methyl-pyrrolidin-1-yl]-(5-methyl-2-[1,2,3]triazol-2-yl-phenyl)-methanone; 
         [(S)-2-(5-Chloro-4-methyl-1H-benzoimidazol-2-yl)-2-methyl-pyrrolidin-1-yl]-(2-methyl-5-phenyl-thiazol-4-yl)-methanone; 
         [(S)-2-(7,8-Dihydro-3H-6,9-dioxa-1,3-diaza-cyclopenta[a]naphthalen-2-yl)-2-methyl-pyrrolidin-1-yl]-(5-methyl-2-[1,2,3]triazol-2-yl-phenyl)-methanone; 
         [(S)-2-(5-Chloro-4-methyl-1H-benzoimidazol-2-yl)-2-methyl-pyrrolidin-1-yl]-(5-chloro-2-[1,2,3]triazol-2-yl-phenyl)-methanone; 
         [(S)-2-(5-Chloro-4-methyl-1H-benzoimidazol-2-yl)-2-methyl-pyrrolidin-1-yl]-(5-methoxy-2-[1,2,3]triazol-2-yl-phenyl)-methanone; 
         [(S)-2-(5-Chloro-4-methyl-1H-benzoimidazol-2-yl)-2-methyl-pyrrolidin-1-yl]-(2-fluoro-3-methoxy-6-[1,2,3]triazol-2-yl-phenyl)-methanone; 
         [(S)-2-(5-Chloro-4-methyl-1H-benzoimidazol-2-yl)-2-methyl-pyrrolidin-1-yl]-(4-methyl-2-[1,2,3]triazol-2-yl-phenyl)-methanone; 
         [(S)-2-(5-Chloro-4-methyl-1H-benzoimidazol-2-yl)-2-methyl-pyrrolidin-1-yl]-(4,5-dimethoxy-2-[1,2,3]triazol-2-yl-phenyl)-methanone; 
         [5-(3-Chloro-phenyl)-2-methyl-thiazol-4-yl]-[(S)-2-methyl-2-(4-methyl-1H-benzoimidazol-2-yl)-pyrrolidin-1-yl]-methanone; 
         [(S)-2-(5-Chloro-4-methyl-1H-benzoimidazol-2-yl)-2-methyl-pyrrolidin-1-yl]-(4,5-dimethyl-2-[1,2,3]triazol-2-yl-phenyl)-methanone; 
         [(S)-2-(5-Chloro-4-methyl-1H-benzoimidazol-2-yl)-2-methyl-pyrrolidin-1-yl]-(5-methyl-2-pyrazol-1-yl-phenyl)-methanone; 
         [(S)-2-(5-Chloro-4-methyl-1H-benzoimidazol-2-yl)-2-methyl-pyrrolidin-1-yl]-(6-methyl-3-pyrazol-1-yl-pyridin-2-yl)-methanone; 
         [(S)-2-(5-Chloro-4-methyl-1H-benzoimidazol-2-yl)-2-methyl-pyrrolidin-1-yl]-(5-fluoro-2-[1,2,3]triazol-2-yl-phenyl)-methanone; 
         [(S)-2-(5-Chloro-4-methyl-1H-benzoimidazol-2-yl)-2-methyl-pyrrolidin-1-yl]-(2-[1,2,3]triazol-2-yl-phenyl)-methanone; 
         [(S)-2-(5-Chloro-4-methyl-1H-benzoimidazol-2-yl)-2-methyl-pyrrolidin-1-yl]-(6-methyl-3-[1,2,3]triazol-2-yl-pyridin-2-yl)-methanone; 
         [(S)-2-(5-Chloro-4-methyl-1H-benzoimidazol-2-yl)-2-methyl-pyrrolidin-1-yl]-(2-fluoro-6-[1,2,3]triazol-2-yl-phenyl)-methanone; 
         [(S)-2-(5-Chloro-4-methyl-1H-benzoimidazol-2-yl)-2-methyl-pyrrolidin-1-yl]-[5-(3-chloro-phenyl)-2-methyl-thiazol-4-yl]-methanone; 
         (4,5-Dimethyl-2-[1,2,3]triazol-2-yl-phenyl)-[(S)-2-methyl-2-(4-methyl-1H-benzoimidazol-2-yl)-pyrrolidin-1-yl]-methanone; 
         (5-Chloro-2-[1,2,3]triazol-2-yl-phenyl)-[(S)-2-(5,6-dimethyl-1H-benzoimidazol-2-yl)-2-methyl-pyrrolidin-1-yl]-methanone; 
         [(S)-2-(5,6-Dimethyl-1H-benzoimidazol-2-yl)-2-methyl-pyrrolidin-1-yl]-(5-methoxy-2-[1,2,3]triazol-2-yl-phenyl)-methanone; 
         [(S)-2-(5,6-Dimethyl-1H-benzoimidazol-2-yl)-2-methyl-pyrrolidin-1-yl]-(4-methyl-2-[1,2,3]triazol-2-yl-phenyl)-methanone; 
         [(S)-2-(5,6-Dimethyl-1H-benzoimidazol-2-yl)-2-methyl-pyrrolidin-1-yl]-(4,5-dimethyl-2-[1,2,3]triazol-2-yl-phenyl)-methanone; 
         (5-Chloro-2-[1,2,3]triazol-2-yl-phenyl)-[(S)-2-(5,6-dimethoxy-1H-benzoimidazol-2-yl)-2-methyl-pyrrolidin-1-yl]-methanone; 
         [(S)-2-(5,6-Dimethoxy-1H-benzoimidazol-2-yl)-2-methyl-pyrrolidin-1-yl]-(5-methoxy-2-[1,2,3]triazol-2-yl-phenyl)-methanone; 
         [(S)-2-(5,6-Dichloro-1H-benzoimidazol-2-yl)-2-methyl-pyrrolidin-1-yl]-(5-methyl-2-[1,2,3]triazol-2-yl-phenyl)-methanone; 
         [(S)-2-(5,6-Dimethoxy-1H-benzoimidazol-2-yl)-2-methyl-pyrrolidin-1-yl]-(2-[1,2,3]triazol-2-yl-5-trifluoromethyl-phenyl)-methanone; 
         [(S)-2-(5,6-Dimethoxy-1H-benzoimidazol-2-yl)-2-methyl-pyrrolidin-1-yl]-(4,5-dimethyl-2-[1,2,3]triazol-2-yl-phenyl)-methanone; 
         [(S)-2-(5,6-Dimethoxy-1H-benzoimidazol-2-yl)-2-methyl-pyrrolidin-1-yl]-(5-methyl-2-pyrazol-1-yl-phenyl)-methanone; 
         [(S)-2-(5,6-Dimethyl-1H-benzoimidazol-2-yl)-2-methyl-pyrrolidin-1-yl]-(3′-methoxy-4-methyl-biphenyl-2-yl)-methanone; 
         [(S)-2-(5,6-Dimethyl-1H-benzoimidazol-2-yl)-2-methyl-pyrrolidin-1-yl]-(4′-methoxy-4-methyl-biphenyl-2-yl)-methanone; 
         [(S)-2-(5,6-Dimethyl-1H-benzoimidazol-2-yl)-2-methyl-pyrrolidin-1-yl]-(2′-fluoro-4-methyl-biphenyl-2-yl)-methanone; 
         [(S)-2-(5,6-Dimethyl-1H-benzoimidazol-2-yl)-2-methyl-pyrrolidin-1-yl]-(4′-fluoro-4-methyl-biphenyl-2-yl)-methanone; 
         [(S)-2-(5,6-Dimethyl-1H-benzoimidazol-2-yl)-2-methyl-pyrrolidin-1-yl]-(3′-fluoro-4-methyl-biphenyl-2-yl)-methanone; 
         [(S)-2-(5,6-Dimethyl-1H-benzoimidazol-2-yl)-2-methyl-pyrrolidin-1-yl]-(4,3′-dimethyl-biphenyl-2-yl)-methanone; 
         [5-(4-Bromo-phenyl)-2-methyl-thiazol-4-yl]-[(S)-2-(7-methyl-1H-benzoimidazol-2-yl)-4-methylene-pyrrolidin-1-yl]-methanone; 
         [(S)-2-(7-Methyl-1H-benzoimidazol-2-yl)-4-methylene-pyrrolidin-1-yl]-(2-methyl-5-m-tolyl-thiazol-4-yl)-methanone; 
         [5-(3-Bromo-phenyl)-2-methyl-thiazol-4-yl]-[(S)-2-(7-methyl-1H-benzoimidazol-2-yl)-4-methylene-pyrrolidin-1-yl]-methanone; 
         [5-(3,5-Dimethyl-phenyl)-2-methyl-thiazol-4-yl]-[(S)-2-(7-methyl-1H-benzoimidazol-2-yl)-4-methylene-pyrrolidin-1-yl]-methanone; 
         [5-(3-Bromo-4-fluoro-phenyl)-2-methyl-thiazol-4-yl]-[(S)-2-(7-methyl-1H-benzoimidazol-2-yl)-4-methylene-pyrrolidin-1-yl]-methanone; 
         [(S)-2-(7-Methyl-1H-benzoimidazol-2-yl)-4-methylene-pyrrolidin-1-yl]-[2-methyl-5-(3-trifluoromethyl-phenyl)-thiazol-4-yl]-methanone; 
         [5-(3,4-Dichloro-phenyl)-2-methyl-thiazol-4-yl]-[(S)-2-(7-methyl-1H-benzoimidazol-2-yl)-4-methylene-pyrrolidin-1-yl]-methanone; 
         [5-(3-Methoxy-phenyl)-2-methyl-thiazol-4-yl]-[(S)-2-(7-methyl-1H-benzoimidazol-2-yl)-4-methylene-pyrrolidin-1-yl]-methanone; 
         [5-(4-Bromo-phenyl)-2-methyl-thiazol-4-yl]-[(S)-2-(6-chloro-7-methyl-1H-benzoimidazol-2-yl)-4-methylene-pyrrolidin-1-yl]-methanone; 
         [(S)-2-(6-Chloro-7-methyl-1H-benzoimidazol-2-yl)-4-methylene-pyrrolidin-1-yl]-[5-(6-methoxy-pyridin-3-yl)-2-methyl-thiazol-4-yl]-methanone; 
         [(S)-2-(6-Chloro-7-methyl-1H-benzoimidazol-2-yl)-4-methylene-pyrrolidin-1-yl]-[5-(4-fluoro-phenyl)-2-methyl-thiazol-4-yl]-methanone; 
         [(S)-2-(6-Chloro-7-methyl-1H-benzoimidazol-2-yl)-4-methylene-pyrrolidin-1-yl]-[5-(4-chloro-phenyl)-2-methyl-thiazol-4-yl]-methanone; 
         [(S)-2-(6-Chloro-7-methyl-1H-benzoimidazol-2-yl)-4-methylene-pyrrolidin-1-yl]-[2-methyl-5-(3-trifluoromethyl-phenyl)-thiazol-4-yl]-methanone; 
         [(S)-2-(6-Chloro-7-methyl-1H-benzoimidazol-2-yl)-4-methylene-pyrrolidin-1-yl]-[5-(3-methoxy-phenyl)-2-methyl-thiazol-4-yl]-methanone; 
         [(S)-2-(6-Chloro-7-methyl-1H-benzoimidazol-2-yl)-4-methylene-pyrrolidin-1-yl]-(2-methyl-5-m-tolyl-thiazol-4-yl)-methanone; 
         [5-(3-Bromo-phenyl)-2-methyl-thiazol-4-yl]-[(S)-2-(6-chloro-7-methyl-1H-benzoimidazol-2-yl)-4-methylene-pyrrolidin-1-yl]-methanone; 
         [(S)-2-(6-Chloro-7-methyl-1H-benzoimidazol-2-yl)-4-methylene-pyrrolidin-1-yl]-[5-(3,5-dimethyl-phenyl)-2-methyl-thiazol-4-yl]-methanone; 
         [5-(3-Bromo-4-fluoro-phenyl)-2-methyl-thiazol-4-yl]-[(S)-2-(6-chloro-7-methyl-1H-benzoimidazol-2-yl)-4-methylene-pyrrolidin-1-yl]-methanone; 
         [(S)-2-(6-Chloro-7-methyl-1H-benzoimidazol-2-yl)-4-methylene-pyrrolidin-1-yl]-[5-(3,4-dichloro-phenyl)-2-methyl-thiazol-4-yl]-methanone; 
         [(S)-2-(6-Chloro-7-methyl-1H-benzoimidazol-2-yl)-4-methylene-pyrrolidin-1-yl]-(6-methyl-3-[1,2,3]triazol-2-yl-pyridin-2-yl)-methanone; 
         [(S)-2-(6-Chloro-7-methyl-1H-benzoimidazol-2-yl)-4-methylene-pyrrolidin-1-yl]-(5-chloro-2-[1,2,3]triazol-2-yl-phenyl)-methanone; 
         [(S)-2-(6-Chloro-7-methyl-1H-benzoimidazol-2-yl)-4-methylene-pyrrolidin-1-yl]-(4,5-dimethyl-2-[1,2,3]triazol-2-yl-phenyl)-methanone; 
         [(S)-2-(6-Chloro-7-methyl-1H-benzoimidazol-2-yl)-4-methylene-pyrrolidin-1-yl]-(5-methoxy-2-[1,2,3]triazol-2-yl-phenyl)-methanone; 
         [(S)-2-(6-Chloro-7-methyl-1H-benzoimidazol-2-yl)-4-methylene-pyrrolidin-1-yl]-(2-fluoro-3-methyl-6-[1,2,3]triazol-2-yl-phenyl)-methanone; 
         [(S)-2-(6-Chloro-7-methyl-1H-benzoimidazol-2-yl)-4-methylene-pyrrolidin-1-yl]-(2-fluoro-3-methoxy-6-[1,2,3]triazol-2-yl-phenyl)-methanone; 
         [(S)-2-(6-Chloro-5-trifluoromethyl-1H-benzoimidazol-2-yl)-4-methylene-pyrrolidin-1-yl]-[5-(3,4-dimethyl-phenyl)-2-methyl-thiazol-4-yl]-methanone; 
         [2-(5-Methoxy-1H-benzoimidazol-2-yl)-2-methyl-4-methylene-pyrrolidin-1-yl]-(2-methyl-5-m-tolyl-thiazol-4-yl)-methanone; 
         [2-Dimethylamino-5-(3,4-dimethyl-phenyl)-thiazol-4-yl]-[2-(5-methoxy-1H-benzoimidazol-2-yl)-2-methyl-4-methylene-pyrrolidin-1-yl]-methanone; 
         [5-(3,4-Dimethyl-phenyl)-2-methyl-thiazol-4-yl]-[2-(5-methoxy-1H-benzoimidazol-2-yl)-2-methyl-4-methylene-pyrrolidin-1-yl]-methanone; 
         [5-(4-Chloro-phenyl)-2-methyl-thiazol-4-yl]-[2-(5-methoxy-1H-benzoimidazol-2-yl)-2-methyl-4-methylene-pyrrolidin-1-yl]-methanone; 
         [2-(5-Methoxy-1H-benzoimidazol-2-yl)-2-methyl-4-methylene-pyrrolidin-1-yl]-[5-(4-methoxy-phenyl)-2-methyl-thiazol-4-yl]-methanone; 
         [2-(5-Methoxy-1H-benzoimidazol-2-yl)-2-methyl-4-methylene-pyrrolidin-1-yl]-(2-methyl-5-p-tolyl-thiazol-4-yl)-methanone; 
         [5-(3-Chloro-phenyl)-2-dimethylamino-thiazol-4-yl]-[2-(5-methoxy-1H-benzoimidazol-2-yl)-2-methyl-4-methylene-pyrrolidin-1-yl]-methanone; 
         [5-(3-Chloro-phenyl)-2-methyl-thiazol-4-yl]-[2-(5-methoxy-1H-benzoimidazol-2-yl)-2-methyl-4-methylene-pyrrolidin-1-yl]-methanone; 
         [2-(5-Methoxy-1H-benzoimidazol-2-yl)-2-methyl-4-methylene-pyrrolidin-1-yl]-(5-methyl-2-[1,2,3]triazol-2-yl-phenyl)-methanone; 
         (5-Chloro-2-[1,2,3]triazol-2-yl-phenyl)-[2-(5-methoxy-1H-benzoimidazol-2-yl)-2-methyl-4-methylene-pyrrolidin-1-yl]-methanone; 
         (4,5-Dimethyl-2-[1,2,3]triazol-2-yl-phenyl)-[2-(5-methoxy-1H-benzoimidazol-2-yl)-2-methyl-4-methylene-pyrrolidin-1-yl]-methanone; 
         [(S)-2-(5-tert-Butyl-1H-benzoimidazol-2-yl)-4-methylene-pyrrolidin-1-yl]-(4,5-dimethyl-2-[1,2,3]triazol-2-yl-phenyl)-methanone; 
         [(S)-2-(5-tert-Butyl-1H-benzoimidazol-2-yl)-4-methylene-pyrrolidin-1-yl]-(4-methyl-2-[1,2,3]triazol-2-yl-phenyl)-methanone; 
         [(S)-2-(5-tert-Butyl-1H-benzoimidazol-2-yl)-4-methylene-pyrrolidin-1-yl]-(4,5-dimethoxy-2-[1,2,3]triazol-2-yl-phenyl)-methanone; 
         [(S)-2-(5-Chloro-6-trifluoromethyl-1H-benzoimidazol-2-yl)-4-methylene-pyrrolidin-1-yl]-(2-fluoro-6-[1,2,3]triazol-2-yl-phenyl)-methanone; 
         [(S)-2-(5-Chloro-6-trifluoromethyl-1H-benzoimidazol-2-yl)-4-methylene-pyrrolidin-1-yl]-(5-fluoro-2-[1,2,3]triazol-2-yl-phenyl)-methanone; 
         (5-Chloro-2-[1,2,3]triazol-2-yl-phenyl)-[(S)-2-(5-chloro-6-trifluoromethyl-1H-benzoimidazol-2-yl)-4-methylene-pyrrolidin-1-yl]-methanone; 
         [(S)-2-(5-Chloro-6-trifluoromethyl-1H-benzoimidazol-2-yl)-4-methylene-pyrrolidin-1-yl]-(2-[1,2,3]triazol-2-yl-phenyl)-methanone; 
         [(S)-2-(5-Chloro-6-trifluoromethyl-1H-benzoimidazol-2-yl)-4-methylene-pyrrol id in-1-yl]-(2-fluoro-3-methoxy-6-[1,2,3]triazol-2-yl-phenyl)-methanone; 
         [(S)-2-(5-Chloro-6-trifluoromethyl-1H-benzoimidazol-2-yl)-4-methylene-pyrrolidin-1-yl]-(2-fluoro-3-methyl-6-[1,2,3]triazol-2-yl-phenyl)-methanone; 
         [(S)-2-(5-Chloro-6-trifluoromethyl-1H-benzoimidazol-2-yl)-4-methylene-pyrrolidin-1-yl]-(4,5-dimethyl-2-[1,2,3]triazol-2-yl-phenyl)-methanone; 
         [(S)-2-(5-Chloro-6-trifluoromethyl-1H-benzoimidazol-2-yl)-4-methylene-pyrrolidin-1-yl]-(4-methyl-2-[1,2,3]triazol-2-yl-phenyl)-methanone; 
         [(S)-2-(5-Chloro-6-trifluoromethyl-1H-benzoimidazol-2-yl)-4-methylene-pyrrolidin-1-yl]-(4,5-dimethoxy-2-[1,2,3]triazol-2-yl-phenyl)-methanone; 
         [(S)-2-(5-Chloro-6-trifluoromethyl-1H-benzoimidazol-2-yl)-4-methylene-pyrrolidin-1-yl]-(5-methyl-2-pyrazol-1-yl-phenyl)-methanone; 
         [(S)-2-(5-Chloro-6-trifluoromethyl-1H-benzoimidazol-2-yl)-4-methylene-pyrrolidin-1-yl]-(6-methyl-3-pyrazol-1-yl-pyridin-2-yl)-methanone; 
         [(S)-2-(5-Chloro-6-trifluoromethyl-1H-benzoimidazol-2-yl)-4-methylene-pyrrolidin-1-yl]-(6-methyl-3-[1,2,3]triazol-2-yl-pyridin-2-yl)-methanone; 
         [(S)-2-(5,6-Dimethyl-1H-benzoimidazol-2-yl)-4-methylene-pyrrolidin-1-yl]-(5-fluoro-2-[1,2,3]triazol-2-yl-phenyl)-methanone; 
         (5-Chloro-2-[1,2,3]triazol-2-yl-phenyl)-[(S)-2-(5,6-dimethyl-1H-benzoimidazol-2-yl)-4-methylene-pyrrolidin-1-yl]-methanone; 
         [(S)-2-(5,6-Dimethyl-1H-benzoimidazol-2-yl)-4-methylene-pyrrolidin-1-yl]-(2-[1,2,3]triazol-2-yl-phenyl)-methanone; 
         [(S)-2-(5,6-Dimethyl-1H-benzoimidazol-2-yl)-4-methylene-pyrrolidin-1-yl]-(2-fluoro-3-methoxy-6-[1,2,3]triazol-2-yl-phenyl)-methanone; 
         [(S)-2-(5,6-Dimethyl-1H-benzoimidazol-2-yl)-4-methylene-pyrrolidin-1-yl]-(2-fluoro-3-methyl-6-[1,2,3]triazol-2-yl-phenyl)-methanone; 
         [(S)-2-(5,6-Dimethyl-1H-benzoimidazol-2-yl)-4-methylene-pyrrolidin-1-yl]-(4,5-dimethyl-2-[1,2,3]triazol-2-yl-phenyl)-methanone; 
         [5-(3-Bromo-4-fluoro-phenyl)-2-methyl-thiazol-4-yl]-[(S)-2-(5-methoxy-1H-benzoimidazol-2-yl)-4-methylene-pyrrolidin-1-yl]-methanone; 
         (2-Cyclopropyl-5-m-tolyl-thiazol-4-yl)-[(S)-2-(5-methoxy-1H-benzoimidazol-2-yl)-4-methylene-pyrrolidin-1-yl]-methanone; 
         [2-Dimethylamino-5-(3,4-dimethyl-phenyl)-thiazol-4-yl]-[(S)-2-(5-methoxy-1H-benzoimidazol-2-yl)-4-methylene-pyrrolidin-1-yl]-methanone; 
         [5-(3-Bromo-phenyl)-2-cyclopropyl-thiazol-4-yl]-[(S)-2-(5-methoxy-1H-benzoimidazol-2-yl)-4-methylene-pyrrolidin-1-yl]-methanone; 
         [2-Cyclopropyl-5-(3-methoxy-phenyl)-thiazol-4-yl]-[(S)-2-(5-methoxy-1H-benzoimidazol-2-yl)-4-methylene-pyrrolidin-1-yl]-methanone; 
         [2-(3,4-Dimethyl-phenyl)-5-methyl-thiophen-3-yl]-[(S)-2-(5-methoxy-1H-benzoimidazol-2-yl)-4-methylene-pyrrolidin-1-yl]-methanone; 
         [(S)-2-(5-Chloro-4-methyl-1H-benzoimidazol-2-yl)-4-methylene-pyrrolidin-1-yl]-(2-methyl-5-phenyl-thiazol-4-yl)-methanone; 
         [(S)-2-(5-Chloro-4-methyl-1H-benzoimidazol-2-yl)-4-methylene-pyrrolidin-1-yl]-(5-methyl-2-[1,2,3]triazol-2-yl-phenyl)-methanone; 
         [5-(3-Chloro-phenyl)-2-methyl-thiazol-4-yl]-[(S)-2-(4-methyl-1H-benzoimidazol-2-yl)-4-methylene-pyrrolidin-1-yl]-methanone; 
         [(S)-2-(5-Chloro-4-methyl-1H-benzoimidazol-2-yl)-4-methylene-pyrrolidin-1-yl]-[5-(3-chloro-phenyl)-2-methyl-thiazol-4-yl]-methanone; 
         [5-(3,4-Dimethyl-phenyl)-2-methyl-thiazol-4-yl]-[(S)-2-(6-methoxy-1H-benzoimidazol-2-yl)-4-methylene-pyrrolidin-1-yl]-methanone; 
         [(S)-2-(4,5-Dimethyl-1H-benzoimidazol-2-yl)-4-methylene-pyrrolidin-1-yl]-[5-(3,4-dimethyl-phenyl)-2-methyl-thiazol-4-yl]-methanone; 
         [(S)-2-(4,7-Dimethoxy-1H-benzoimidazol-2-yl)-4-methylene-pyrrolidin-1-yl]-[5-(3,4-dimethyl-phenyl)-2-methyl-thiazol-4-yl]-methanone; 
         [5-(3,4-Dimethyl-phenyl)-2-methyl-thiazol-4-yl]-[(S)-4-methylene-2-(4-methylsulfanyl-1H-benzoimidazol-2-yl)-pyrrolidin-1-yl]-methanone; 
         [(S)-2-(4-Bromo-1H-benzoimidazol-2-yl)-4-methylene-pyrrolidin-1-yl]-[5-(3,4-dimethyl-phenyl)-2-methyl-thiazol-4-yl]-methanone; 
         [(S)-2-(4-Chloro-1H-benzoimidazol-2-yl)-4-methylene-pyrrolidin-1-yl]-[5-(3,4-dimethyl-phenyl)-2-methyl-thiazol-4-yl]-methanone; 
         [5-(3,4-Dimethyl-phenyl)-2-methyl-thiazol-4-yl]-[(S)-4-methylene-2-(5-methylsulfanyl-1H-benzoimidazol-2-yl)-pyrrolidin-1-yl]-methanone; 
         [5-(3,4-Dimethyl-phenyl)-2-methyl-thiazol-4-yl]-[(S)-2-(4-methyl-1H-benzoimidazol-2-yl)-4-methylene-pyrrolidin-1-yl]-methanone; 
         [(S)-2-(5-Chloro-4-methyl-1H-benzoimidazol-2-yl)-4-methylene-pyrrolidin-1-yl]-[5-(3,4-dimethyl-phenyl)-2-methyl-thiazol-4-yl]-methanone; 
         [(S)-2-(5-Chloro-6-methyl-1H-benzoimidazol-2-yl)-4-methylene-pyrrolidin-1-yl]-[5-(3,4-dimethyl-phenyl)-2-methyl-thiazol-4-yl]-methanone; 
         [(S)-2-(5,6-Dimethyl-1H-benzoimidazol-2-yl)-4-methylene-pyrrolidin-1-yl]-[5-(3,4-dimethyl-phenyl)-2-methyl-thiazol-4-yl]-methanone; 
         [(S)-2-(5-tert-Butyl-1H-benzoimidazol-2-yl)-4-methylene-pyrrolidin-1-yl]-[5-(3,4-dimethyl-phenyl)-2-methyl-thiazol-4-yl]-methanone; 
         [(S)-2-(4,6-Dimethyl-1H-benzoimidazol-2-yl)-4-methylene-pyrrolidin-1-yl]-[5-(3,4-dimethyl-phenyl)-2-methyl-thiazol-4-yl]-methanone; 
         [(S)-2-(5,6-Dimethyl-1H-benzoimidazol-2-yl)-4-methylene-pyrrolidin-1-yl]-(5-methyl-2-[1,2,3]triazol-2-yl-phenyl)-methanone; 
         [(S)-2-(4,6-Dimethyl-1H-benzoimidazol-2-yl)-4-methylene-pyrrolidin-1-yl]-(5-methyl-2-[1,2,3]triazol-2-yl-phenyl)-methanone; 
         [(S)-2-(5-Chloro-6-methyl-1H-benzoimidazol-2-yl)-4-methylene-pyrrolidin-1-yl]-(5-methyl-2-[1,2,3]triazol-2-yl-phenyl)-methanone; 
         [(S)-2-(5-Chloro-6-trifluoromethyl-1H-benzoimidazol-2-yl)-4-methylene-pyrrolidin-1-yl]-(5-methyl-2-[1,2,3]triazol-2-yl-phenyl)-methanone; 
         [(S)-2-(5-Methoxy-1H-benzoimidazol-2-yl)-4-methylene-pyrrolidin-1-yl]-(2-methyl-5-m-tolyl-thiazol-4-yl)-methanone; 
         [2-(3,4-Dimethyl-phenyl)-5-methyl-thiophen-3-yl]-[2-(5-methoxy-1H-benzoimidazol-2-yl)-4-methylene-pyrrolidin-1-yl]-methanone; 
         [2-(3,4-Dimethyl-phenyl)-5-methyl-thiophen-3-yl]-[4-methylene-2-(7-methylsulfanyl-1H-benzoimidazol-2-yl)-pyrrolidin-1-yl]-methanone; 
         [2-(3,4-Dimethyl-phenyl)-5-methyl-thiophen-3-yl]-[4-methylene-2-(5-methylsulfanyl-1H-benzoimidazol-2-yl)-pyrrolidin-1-yl]-methanone; 
         [2-(5-Chloro-4-methyl-1H-benzoimidazol-2-yl)-4-methylene-pyrrolidin-1-yl]-[2-(3,4-dimethyl-phenyl)-5-methyl-thiophen-3-yl]-methanone; 
         [2-(5,6-Dimethyl-1H-benzoimidazol-2-yl)-4-methylene-pyrrolidin-1-yl]-[2-(3,4-dimethyl-phenyl)-5-methyl-thiophen-3-yl]-methanone; 
         [2-(4,6-Dimethyl-1H-benzoimidazol-2-yl)-4-methylene-pyrrolidin-1-yl]-[2-(3,4-dimethyl-phenyl)-5-methyl-thiophen-3-yl]-methanone; 
         [2-(4,5-Dimethyl-1H-benzoimidazol-2-yl)-4-methylene-pyrrolidin-1-yl]-[2-(3,4-dimethyl-phenyl)-5-methyl-thiophen-3-yl]-methanone; 
         [2-(4-Bromo-1H-benzoimidazol-2-yl)-4-methylene-pyrrolidin-1-yl]-[2-(3,4-dimethyl-phenyl)-5-methyl-thiophen-3-yl]-methanone; 
         [2-(3,4-Dimethyl-phenyl)-5-methyl-thiophen-3-yl]-[2-(4-methyl-1H-benzoimidazol-2-yl)-4-methylene-pyrrolidin-1-yl]-methanone; 
         [5-(3-Chloro-phenyl)-2-methyl-thiazol-4-yl]-[(S)-2-(5-methoxy-1H-benzoimidazol-2-yl)-4-methylene-pyrrolidin-1-yl]-methanone; 
         [2-(5-Chloro-6-methyl-1H-benzoimidazol-2-yl)-4-methylene-pyrrolidin-1-yl]-[2-(3,4-dimethyl-phenyl)-5-methyl-thiophen-3-yl]-methanone; 
         [2-(5-tert-Butyl-1H-benzoimidazol-2-yl)-4-methylene-pyrrolidin-1-yl]-[2-(3,4-dimethyl-phenyl)-5-methyl-thiophen-3-yl]-methanone; 
         [2-(4,7-Dimethoxy-1H-benzoimidazol-2-yl)-4-methylene-pyrrolidin-1-yl]-[2-(3,4-dimethyl-phenyl)-5-methyl-thiophen-3-yl]-methanone; 
         [2-(7-Chloro-1H-benzoimidazol-2-yl)-4-methylene-pyrrolidin-1-yl]-[2-(3,4-dimethyl-phenyl)-5-methyl-thiophen-3-yl]-methanone; 
         (2-Cyclopropyl-5-m-tolyl-thiazol-4-yl)-[2-(5-methoxy-1H-benzoimidazol-2-yl)-4-methylene-pyrrolidin-1-yl]-methanone; 
         (2-Cyclopropyl-5-m-tolyl-thiazol-4-yl)-[4-methylene-2-(7-methylsulfanyl-1H-benzoimidazol-2-yl)-pyrrolidin-1-yl]-methanone; 
         (2-Cyclopropyl-5-m-tolyl-thiazol-4-yl)-[4-methylene-2-(5-methylsulfanyl-1H-benzoimidazol-2-yl)-pyrrolidin-1-yl]-methanone; 
         [2-(5-Chloro-4-methyl-1H-benzoimidazol-2-yl)-4-methylene-pyrrolidin-1-yl]-(2-cyclopropyl-5-m-tolyl-thiazol-4-yl)-methanone; 
         [5-(3,4-Dimethyl-phenyl)-2-methyl-thiazol-4-yl]-[(S)-2-(5-methoxy-1H-benzoimidazol-2-yl)-4-methylene-pyrrolidin-1-yl]-methanone; 
         (2-Cyclopropyl-5-m-tolyl-thiazol-4-yl)-[2-(5,6-dimethyl-1H-benzoimidazol-2-yl)-4-methylene-pyrrolidin-1-yl]-methanone; 
         (2-Cyclopropyl-5-m-tolyl-thiazol-4-yl)-[2-(4,6-dimethyl-1H-benzoimidazol-2-yl)-4-methylene-pyrrolidin-1-yl]-methanone; 
         (2-Cyclopropyl-5-m-tolyl-thiazol-4-yl)-[2-(4,5-dimethyl-1H-benzoimidazol-2-yl)-4-methylene-pyrrolidin-1-yl]-methanone; 
         [2-(4-Bromo-1H-benzoimidazol-2-yl)-4-methylene-pyrrolidin-1-yl]-(2-cyclopropyl-5-m-tolyl-thiazol-4-yl)-methanone; 
         (2-Cyclopropyl-5-m-tolyl-thiazol-4-yl)-[2-(4-methyl-1H-benzoimidazol-2-yl)-4-methylene-pyrrolidin-1-yl]-methanone; 
         [2-(5-Chloro-6-methyl-1H-benzoimidazol-2-yl)-4-methylene-pyrrolidin-1-yl]-(2-cyclopropyl-5-m-tolyl-thiazol-4-yl)-methanone; 
         [2-(5-Chloro-6-trifluoromethyl-1H-benzoimidazol-2-yl)-4-methylene-pyrrolidin-1-yl]-(2-cyclopropyl-5-m-tolyl-thiazol-4-yl)-methanone; 
         (2-Cyclopropyl-5-m-tolyl-thiazol-4-yl)-[2-(4,7-dimethoxy-1H-benzoimidazol-2-yl)-4-methylene-pyrrolidin-1-yl]-methanone; 
         [2-(7-Chloro-1H-benzoimidazol-2-yl)-4-methylene-pyrrolidin-1-yl]-(2-cyclopropyl-5-m-tolyl-thiazol-4-yl)-methanone; 
         [(S)-2-(5-Chloro-1,4-dimethyl-1H-benzoimidazol-2-yl)-2-methyl-pyrrolidin-1-yl]-(5-methyl-2-[1,2,3]triazol-2-yl-phenyl)-methanone; 
         [(S)-2-(6-Chloro-1,7-dimethyl-1H-benzoimidazol-2-yl)-2-methyl-pyrrolidin-1-yl]-(5-methyl-2-[1,2,3]triazol-2-yl-phenyl)-methanone; 
         [(S)-2-(5-Bromo-1,7-dimethyl-1H-benzoimidazol-2-yl)-2-methyl-pyrrolidin-1-yl]-(5-methyl-2-[1,2,3]triazol-2-yl-phenyl)-methanone; 
         [(S)-2-(6-Bromo-1,4-dimethyl-1H-benzoimidazol-2-yl)-2-methyl-pyrrolidin-1-yl]-(5-methyl-2-[1,2,3]triazol-2-yl-phenyl)-methanone; 
         (S)-(5-(3-chlorophenyl)-2-methylthiazol-4-yl)(2-(1,4-dimethyl-1H-benzo[d]imidazol-2-yl)-2-methylpyrrolidin-1-yl)methanone; 
         (S)-(5-(3-chlorophenyl)-2-methylthiazol-4-yl)(2-(1,7-dimethyl-1H-benzo[d]imidazol-2-yl)-2-methylpyrrolidin-1-yl)methanone; 
         (S)-(5-(3-chlorophenyl)-2-methylthiazol-4-yl)(2-(1-ethyl-4-methyl-1H-benzo[d]imidazol-2-yl)-2-methylpyrrolidin-1-yl)methanone; 
         (S)-(5-(3-chlorophenyl)-2-methylthiazol-4-yl)(2-(1-ethyl-7-methyl-1H-benzo[d]imidazol-2-yl)-2-methylpyrrolidin-1-yl)methanone; 
         (S)-(2-(5-chloro-1,4-dimethyl-1H-benzo[d]imidazol-2-yl)-2-methylpyrrolidin-1-yl)(2-methyl-5-phenylthiazol-4-yl)methanone; 
         (S)-(2-(6-chloro-1,7-dimethyl-1H-benzo[d]imidazol-2-yl)-2-methylpyrrolidin-1-yl)(2-methyl-5-phenylthiazol-4-yl)methanone; 
         (S)-(2-(5-chloro-1-ethyl-4-methyl-1H-benzo[d]imidazol-2-yl)-2-methylpyrrolidin-1-yl)(2-methyl-5-phenylthiazol-4-yl)methanone; and 
         (S)-(2-(6-chloro-1-ethyl-7-methyl-1H-benzo[d]imidazol-2-yl)-2-methylpyrrolidin-1-yl)(2-methyl-5-phenylthiazol-4-yl)methanone.
 
47) In addition to the above-listed compounds, further compounds according to embodiment 1) are selected from:
 
         [5-(3-Chloro-phenyl)-2-methyl-thiazol-4-yl]-[2-(4-chloro-6-trifluoromethyl-1H-benzoimidazol-2-yl)-pyrrolidin-1-yl]-methanone; 
         [4-(3-Chloro-phenyl)-2-methyl-pyrimidin-5-yl]-[(S)-2-(7-methylsulfanyl-1H-benzoimidazol-2-yl)-pyrrolidin-1-yl]-methanone; 
         [(2S,3S)-3-Methyl-2-(4-methyl-1H-benzoimidazol-2-yl)-pyrrolidin-1-yl]-(5-methyl-2-[1,2,3]triazol-2-yl-phenyl)-methanone; 
         [5-(3-Chloro-phenyl)-2-methyl-thiazol-4-yl]-[(2S,3S)-2-(5,6-dimethyl-1H-benzoimidazol-2-yl)-3-methyl-pyrrolidin-1-yl]-methanone; 
         [(2S,3S)-2-(6-Chloro-4-methyl-1H-benzoimidazol-2-yl)-3-methyl-pyrrolidin-1-yl]-[5-(4-fluoro-phenyl)-2-methyl-thiazol-4-yl]-methanone; 
         [(2S,3S)-2-(6-Chloro-4-methyl-1H-benzoimidazol-2-yl)-3-methyl-pyrrolidin-1-yl]-(2-[1,2,3]triazol-2-yl-phenyl)-methanone; 
         [(2S,3S)-2-(5-Chloro-1H-benzoimidazol-2-yl)-3-methyl-pyrrolidin-1-yl]-[5-(3-chloro-phenyl)-2-methyl-thiazol-4-yl]-methanone; 
         [5-(3-Chloro-phenyl)-2-methyl-thiazol-4-yl]-[(2S,3S)-2-(5,6-difluoro-1H-benzoimidazol-2-yl)-3-methyl-pyrrolidin-1-yl]-methanone; 
         2-{(2S,3S)-1-[5-(3-Chloro-phenyl)-2-methyl-thiazole-4-carbonyl]-3-methyl-pyrrolidin-2-yl}-1H-benzoimidazole-4-carboxylic acid methyl ester; 
         [5-(3-Chloro-phenyl)-2-methyl-thiazol-4-yl]-[(2S,3S)-2-(4-methoxy-1H-benzoimidazol-2-yl)-3-methyl-pyrrolidin-1-yl]-methanone; 
         [(2S,3S)-2-(5-Chloro-6-methyl-1H-benzoimidazol-2-yl)-3-methyl-pyrrolidin-1-yl]-[5-(3-chloro-phenyl)-2-methyl-thiazol-4-yl]-methanone; 
         [5-(3-Chloro-phenyl)-2-methyl-thiazol-4-yl]-[(2S,3S)-2-(4,6-dimethyl-1H-benzoimidazol-2-yl)-3-methyl-pyrrolidin-1-yl]-methanone; 
         [5-(3-Chloro-phenyl)-2-methyl-thiazol-4-yl]-[(2S,3S)-2-(4-hydroxymethyl-1H-benzoimidazol-2-yl)-3-methyl-pyrrolidin-1-yl]-methanone; 
         [5-(3-Chloro-phenyl)-2-methyl-thiazol-4-yl]-[(2S,3S)-3-methyl-2-(4-trifluoromethyl-1H-benzoimidazol-2-yl)-pyrrolidin-1-yl]-methanone; 
         [5-(3-Chloro-phenyl)-2-methyl-thiazol-4-yl]-[(2S,3S)-2-(5-fluoro-1H-benzoimidazol-2-yl)-3-methyl-pyrrolidin-1-yl]-methanone; 
         [(2S,3S)-2-(5-Chloro-4-methyl-1H-benzoimidazol-2-yl)-3-methyl-pyrrolidin-1-yl]-[5-(3-chloro-phenyl)-2-methyl-thiazol-4-yl]-methanone; 
         [(2S,3S)-2-(4-Chloro-1H-benzoimidazol-2-yl)-3-methyl-pyrrolidin-1-yl]-[5-(3-chloro-phenyl)-2-methyl-thiazol-4-yl]-methanone; 
         [5-(3-Chloro-phenyl)-2-methyl-thiazol-4-yl]-[(2S,3S)-2-(4,5-difluoro-1H-benzoimidazol-2-yl)-3-methyl-pyrrolidin-1-yl]-methanone; 
         [5-(3-Chloro-phenyl)-2-methyl-thiazol-4-yl]-[(2S,3S)-2-(4,5-dimethyl-1H-benzoimidazol-2-yl)-3-methyl-pyrrolidin-1-yl]-methanone; 
         [5-(3-Chloro-phenyl)-2-methyl-thiazol-4-yl]-[(2S,3S)-2-(4-isopropyl-1H-benzoimidazol-2-yl)-3-methyl-pyrrolidin-1-yl]-methanone; 
         [5-(3-Chloro-phenyl)-2-methyl-thiazol-4-yl]-[(2S,3S)-2-(5-methoxy-1H-benzoimidazol-2-yl)-3-methyl-pyrrolidin-1-yl]-methanone; 
         [(2S,3S)-2-(5-Chloro-7-methyl-1H-benzoimidazol-2-yl)-3-methyl-pyrrolidin-1-yl]-[5-(3-chloro-phenyl)-2-methyl-thiazol-4-yl]-methanone; 
         (5-Methyl-2-[1,2,3]triazol-2-yl-phenyl)-[(2S,3S)-3-methyl-2-(5-trifluoromethyl-1H-benzoimidazol-2-yl)-pyrrolidin-1-yl]-methanone; 
         [5-(3-Chloro-phenyl)-2-methyl-thiazol-4-yl]-[(2S,3S)-3-methyl-2-(5-methyl-1H-benzoimidazol-2-yl)-pyrrolidin-1-yl]-methanone; 
         [(2S,3S)-2-(5,6-Dimethyl-1H-benzoimidazol-2-yl)-3-methyl-pyrrolidin-1-yl]-(5-methyl-2-[1,2,3]triazol-2-yl-phenyl)-methanone; 
         [(2S,3S)-2-(5-Chloro-6-methyl-1H-benzoimidazol-2-yl)-3-methyl-pyrrolidin-1-yl]-(5-methyl-2-[1,2,3]triazol-2-yl-phenyl)-methanone; 
         [(2S,3S)-2-(4,6-Dimethyl-1H-benzoimidazol-2-yl)-3-methyl-pyrrolidin-1-yl]-(5-methyl-2-[1,2,3]triazol-2-yl-phenyl)-methanone; 
         [(2S,3S)-2-(5-Chloro-4-methyl-1H-benzoimidazol-2-yl)-3-methyl-pyrrolidin-1-yl]-(5-methyl-2-[1,2,3]triazol-2-yl-phenyl)-methanone; 
         [(2S,3S)-2-(4,5-Dimethyl-1H-benzoimidazol-2-yl)-3-methyl-pyrrolidin-1-yl]-(5-methyl-2-[1,2,3]triazol-2-yl-phenyl)-methanone; 
         [(2S,3S)-2-(5-Chloro-7-methyl-1H-benzoimidazol-2-yl)-3-methyl-pyrrolidin-1-yl]-(5-methyl-2-[1,2,3]triazol-2-yl-phenyl)-methanone; 
         [(2S,3S)-3-Methyl-2-(4-methyl-1H-benzoimidazol-2-yl)-pyrrolidin-1-yl]-(2-methyl-5-phenyl-thiazol-4-yl)-methanone; 
         [(2S,3S)-3-Methyl-2-(5-methyl-1H-benzoimidazol-2-yl)-pyrrolidin-1-yl]-(2-methyl-5-phenyl-thiazol-4-yl)-methanone; 
         [5-(3,5-Difluoro-phenyl)-2-methyl-thiazol-4-yl]-[(2S,3S)-2-(5,6-dimethoxy-1H-benzoimidazol-2-yl)-3-methyl-pyrrolidin-1-yl]-methanone; 
         [(2S,3S)-2-(5,6-Dimethoxy-1H-benzoimidazol-2-yl)-3-methyl-pyrrolidin-1-yl]-[5-(4-fluoro-phenyl)-2-methyl-thiazol-4-yl]-methanone; 
         [(2S,3S)-2-(5-Chloro-4-methyl-1H-benzoimidazol-2-yl)-3-methyl-pyrrolidin-1-yl]-(2-[1,2,3]triazol-2-yl-phenyl)-methanone; 
         [(2S,3S)-2-(1H-Benzoimidazol-2-yl)-3-methyl-pyrrolidin-1-yl]-[5-(3-chloro-phenyl)-2-methyl-thiazol-4-yl]-methanone; 
         [(2S,3S)-2-(5-Chloro-4-methyl-1H-benzoimidazol-2-yl)-3-methyl-pyrrolidin-1-yl]-(5-chloro-2-[1,2,3]triazol-2-yl-phenyl)-methanone; 
         [(2S,3S)-2-(5-Chloro-4-methyl-1H-benzoimidazol-2-yl)-3-methyl-pyrrolidin-1-yl]-(4′-methyl-biphenyl-2-yl)-methanone; 
         [(2S,3S)-2-(5-Chloro-4-methyl-1H-benzoimidazol-2-yl)-3-methyl-pyrrolidin-1-yl]-[5-(4-chloro-phenyl)-2-methyl-thiazol-4-yl]-methanone; 
         [(2S,3S)-2-(5-Chloro-4-methyl-1H-benzoimidazol-2-yl)-3-methyl-pyrrolidin-1-yl]-(5-methyl-2-pyrazol-1-yl-phenyl)-methanone; 
         [(2S,3S)-2-(5-Chloro-4-methyl-1H-benzoimidazol-2-yl)-3-methyl-pyrrolidin-1-yl]-(2-methyl-4-p-tolyl-thiazol-5-yl)-methanone; 
         [(2S,3S)-2-(5-Chloro-4-methyl-1H-benzoimidazol-2-yl)-3-methyl-pyrrolidin-1-yl]-[5-(3,5-difluoro-phenyl)-2-methyl-thiazol-4-yl]-methanone; 
         [(2S,3S)-2-(5-Chloro-4-methyl-1H-benzoimidazol-2-yl)-3-methyl-pyrrolidin-1-yl]-(2-fluoro-3-methyl-6-[1,2,3]triazol-2-yl-phenyl)-methanone; 
         [(2S,3S)-2-(5-Chloro-4-methyl-1H-benzoimidazol-2-yl)-3-methyl-pyrrolidin-1-yl]-[5-(6-methoxy-pyridin-3-yl)-2-methyl-thiazol-4-yl]-methanone; 
         [5-(3-Chloro-phenyl)-2-methyl-thiazol-4-yl]-[(2S,3S)-3-methyl-2-(4-methyl-1H-benzoimidazol-2-yl)-pyrrolidin-1-yl]-methanone; 
         [(2S,3S)-2-(5-Chloro-4-methyl-1H-benzoimidazol-2-yl)-3-methyl-pyrrolidin-1-yl]-[5-(4-fluoro-phenyl)-2-methyl-thiazol-4-yl]-methanone; 
         [(2S,3S)-2-(5-Chloro-6-methyl-1H-benzoimidazol-2-yl)-3-methyl-pyrrolidin-1-yl]-(5-chloro-2-[1,2,3]triazol-2-yl-phenyl)-methanone; 
         [(2S,3S)-2-(5-Chloro-6-methyl-1H-benzoimidazol-2-yl)-3-methyl-pyrrolidin-1-yl]-(4-methyl-2-[1,2,3]triazol-2-yl-phenyl)-methanone; 
         [(2S,3S)-2-(5-Chloro-6-methyl-1H-benzoimidazol-2-yl)-3-methyl-pyrrolidin-1-yl]-(5-methyl-2-pyrazol-1-yl-phenyl)-methanone; 
         [(2S,3S)-2-(5-Chloro-6-methyl-1H-benzoimidazol-2-yl)-3-methyl-pyrrolidin-1-yl]-(5-methoxy-2-[1,2,3]triazol-2-yl-phenyl)-methanone; 
         [(2S,3S)-2-(5-Chloro-6-methyl-1H-benzoimidazol-2-yl)-3-methyl-pyrrolidin-1-yl]-(2-fluoro-3-methyl-6-[1,2,3]triazol-2-yl-phenyl)-methanone; 
         [(2S,3S)-2-(5-Chloro-6-methyl-1H-benzoimidazol-2-yl)-3-methyl-pyrrolidin-1-yl]-(2-[1,2,3]triazol-2-yl-phenyl)-methanone; 
         [(2S,3S)-2-(5-Chloro-6-methyl-1H-benzoimidazol-2-yl)-3-methyl-pyrrolidin-1-yl]-(4′-methyl-biphenyl-2-yl)-methanone; 
         [(2S,3S)-2-(5-Chloro-6-methyl-1H-benzoimidazol-2-yl)-3-methyl-pyrrolidin-1-yl]-[5-(4-chloro-phenyl)-2-methyl-thiazol-4-yl]-methanone; 
         [(2S,3S)-2-(5-Chloro-6-methyl-1H-benzoimidazol-2-yl)-3-methyl-pyrrolidin-1-yl]-(2-methyl-4-p-tolyl-thiazol-5-yl)-methanone; 
         [(2S,3S)-2-(5-Chloro-6-methyl-1H-benzoimidazol-2-yl)-3-methyl-pyrrolidin-1-yl]-[5-(3,5-difluoro-phenyl)-2-methyl-thiazol-4-yl]-methanone; 
         (5-Chloro-2-[1,2,3]triazol-2-yl-phenyl)-[(2S,3S)-2-(5,6-dimethyl-1H-benzoimidazol-2-yl)-3-methyl-pyrrolidin-1-yl]-methanone; 
         [(2S,3S)-2-(5,6-Dimethyl-1H-benzoimidazol-2-yl)-3-methyl-pyrrolidin-1-yl]-(5-methyl-2-pyrazol-1-yl-phenyl)-methanone; 
         [(2S,3S)-2-(5,6-Dimethyl-1H-benzoimidazol-2-yl)-3-methyl-pyrrolidin-1-yl]-(4′-methyl-biphenyl-2-yl)-methanone; 
         [5-(4-Chloro-phenyl)-2-methyl-thiazol-4-yl]-[(2S,3S)-2-(5,6-dimethyl-1H-benzoimidazol-2-yl)-3-methyl-pyrrolidin-1-yl]-methanone; 
         [(2S,3S)-2-(5,6-Dimethyl-1H-benzoimidazol-2-yl)-3-methyl-pyrrolidin-1-yl]-(2-methyl-4-p-tolyl-thiazol-5-yl)-methanone; 
         [5-(3,5-Difluoro-phenyl)-2-methyl-thiazol-4-yl]-[(2S,3S)-2-(5,6-dimethyl-1H-benzoimidazol-2-yl)-3-methyl-pyrrolidin-1-yl]-methanone; 
         [5-(3-Chloro-phenyl)-2-methyl-thiazol-4-yl]-[(2S,3S)-3-methyl-2-(5-trifluoromethyl-1H-benzoimidazol-2-yl)-pyrrolidin-1-yl]-methanone; 
         [(2S,3S)-2-(5,6-Dimethyl-1H-benzoimidazol-2-yl)-3-methyl-pyrrolidin-1-yl]-[5-(4-fluoro-phenyl)-2-methyl-thiazol-4-yl]-methanone; 
         [(2S,3S)-2-(6-Chloro-4-methyl-1H-benzoimidazol-2-yl)-3-methyl-pyrrolidin-1-yl]-(5-chloro-2-[1,2,3]triazol-2-yl-phenyl)-methanone; 
         [(2S,3S)-2-(6-Chloro-4-methyl-1H-benzoimidazol-2-yl)-3-methyl-pyrrolidin-1-yl]-(4′-methyl-biphenyl-2-yl)-methanone; 
         [(2S,3S)-2-(6-Chloro-4-methyl-1H-benzoimidazol-2-yl)-3-methyl-pyrrolidin-1-yl]-(4-methyl-2-[1,2,3]triazol-2-yl-phenyl)-methanone; 
         [(2S,3S)-2-(6-Chloro-4-methyl-1H-benzoimidazol-2-yl)-3-methyl-pyrrolidin-1-yl]-[5-(4-chloro-phenyl)-2-methyl-thiazol-4-yl]-methanone; 
         [(2S,3S)-2-(6-Chloro-4-methyl-1H-benzoimidazol-2-yl)-3-methyl-pyrrolidin-1-yl]-(5-methyl-2-pyrazol-1-yl-phenyl)-methanone; 
         [(2S,3S)-2-(6-Chloro-4-methyl-1H-benzoimidazol-2-yl)-3-methyl-pyrrolidin-1-yl]-(2-methyl-4-p-tolyl-thiazol-5-yl)-methanone; 
         [(2S,3S)-2-(6-Chloro-4-methyl-1H-benzoimidazol-2-yl)-3-methyl-pyrrolidin-1-yl]-(5-methoxy-2-[1,2,3]triazol-2-yl-phenyl)-methanone; 
         [(2S,3S)-2-(6-Chloro-4-methyl-1H-benzoimidazol-2-yl)-3-methyl-pyrrolidin-1-yl]-[5-(3,5-difluoro-phenyl)-2-methyl-thiazol-4-yl]-methanone; 
         [(2S,3S)-2-(6-Chloro-4-methyl-1H-benzoimidazol-2-yl)-3-methyl-pyrrolidin-1-yl]-(2-fluoro-3-methyl-6-[1,2,3]triazol-2-yl-phenyl)-methanone; 
         [(S)-2-(5-Chloro-1H-benzoimidazol-2-yl)-2-methyl-pyrrolidin-1-yl]-(5-methyl-2-[1,2,3]triazol-2-yl-phenyl)-methanone; 
         [(S)-2-(6-Chloro-5-fluoro-1H-benzoimidazol-2-yl)-2-methyl-pyrrolidin-1-yl]-(5-methyl-2-[1,2,3]triazol-2-yl-phenyl)-methanone; 
         [(S)-2-(6-Bromo-5-fluoro-1H-benzoimidazol-2-yl)-2-methyl-pyrrolidin-1-yl]-(5-methyl-2-pyrazol-1-yl-phenyl)-methanone; 
         [(S)-2-(6-Bromo-5-fluoro-1H-benzoimidazol-2-yl)-2-methyl-pyrrolidin-1-yl]-(6-methyl-3-[1,2,3]triazol-2-yl-pyridin-2-yl)-methanone; 
         [(S)-2-(6-Chloro-5-trifluoromethyl-1H-benzoimidazol-2-yl)-2-methyl-pyrrolidin-1-yl]-(2-pyrazol-1-yl-phenyl)-methanone; 
         [(S)-2-(6-Chloro-5-trifluoromethyl-1H-benzoimidazol-2-yl)-2-methyl-pyrrolidin-1-yl]-(6-methyl-3-pyrazol-1-yl-pyridin-2-yl)-methanone; 
         [(S)-2-(6-Chloro-5-trifluoromethyl-1H-benzoimidazol-2-yl)-2-methyl-pyrrolidin-1-yl]-(2-[1,2,3]triazol-2-yl-5-trifluoromethyl-phenyl)-methanone; 
         [(S)-2-(6-Chloro-5-trifluoromethyl-1H-benzoimidazol-2-yl)-2-methyl-pyrrolidin-1-yl]-(2-[1,2,3]triazol-2-yl-5-trifluoromethoxy-phenyl)-methanone; 
         (5-Methyl-2-[1,2,3]triazol-2-yl-phenyl)-[(S)-2-methyl-2-(4-trifluoromethyl-1H-benzoimidazol-2-yl)-pyrrolidin-1-yl]-methanone; 
         (5-Methyl-2-pyrazol-1-yl-phenyl)-[(S)-2-methyl-2-(5-trifluoromethyl-1H-benzoimidazol-2-yl)-pyrrolidin-1-yl]-methanone; 
         (6-Methyl-3-[1,2,3]triazol-2-yl-pyridin-2-yl)-[(S)-2-methyl-2-(5-trifluoromethyl-1H-benzoimidazol-2-yl)-pyrrolidin-1-yl]-methanone; 
         (3′-Methoxy-4-methyl-biphenyl-2-yl)-[(S)-2-methyl-2-(5-trifluoromethyl-1H-benzoimidazol-2-yl)-pyrrolidin-1-yl]-methanone; 
         4′-Methyl-2′-[(S)-2-methyl-2-(5-trifluoromethyl-1H-benzoimidazol-2-yl)-pyrrolidine-1-carbonyl]-biphenyl-4-carbonitrile; 
         (2′-Fluoro-4-methyl-biphenyl-2-yl)-[(S)-2-methyl-2-(5-trifluoromethyl-1H-benzoimidazol-2-yl)-pyrrolidin-1-yl]-methanone; 
         (4′-Fluoro-4-methyl-biphenyl-2-yl)-[(S)-2-methyl-2-(5-trifluoromethyl-1H-benzoimidazol-2-yl)-pyrrolidin-1-yl]-methanone; 
         [(S)-2-(4,5-Difluoro-1H-benzoimidazol-2-yl)-2-methyl-pyrrolidin-1-yl]-(4,5-dimethyl-2-[1,2,3]triazol-2-yl-phenyl)-methanone; 
         (5-Methyl-2-[1,2,3]triazol-2-yl-phenyl)-[(S)-2-methyl-2-(5-trifluoromethoxy-1H-benzoimidazol-2-yl)-pyrrolidin-1-yl]-methanone; 
         [(S)-2-(4,5-Difluoro-1H-benzoimidazol-2-yl)-2-methyl-pyrrolidin-1-yl]-(2-methyl-5-phenyl-thiazol-4-yl)-methanone; 
         [(S)-2-(4,5-Difluoro-1H-benzoimidazol-2-yl)-2-methyl-pyrrolidin-1-yl]-(2-methyl-5-p-tolyl-thiazol-4-yl)-methanone; 
         [5-(4-Chloro-phenyl)-2-methyl-thiazol-4-yl]-[(S)-2-(4,5-difluoro-1H-benzoimidazol-2-yl)-2-methyl-pyrrolidin-1-yl]-methanone; 
         [(S)-2-(4,5-Difluoro-1H-benzoimidazol-2-yl)-2-methyl-pyrrolidin-1-yl]-[5-(3-fluoro-phenyl)-2-methyl-thiazol-4-yl]-methanone; 
         [(S)-2-(6-Fluoro-5-trifluoromethyl-1H-benzoimidazol-2-yl)-2-methyl-pyrrolidin-1-yl]-(5-methyl-2-[1,2,3]triazol-2-yl-phenyl)-methanone; 
         [(S)-2-(5-Bromo-1H-benzoimidazol-2-yl)-2-methyl-pyrrolidin-1-yl]-(5-methyl-2-[1,2,3]triazol-2-yl-phenyl)-methanone; 
         (5-Methyl-2-[1,2,3]triazol-2-yl-phenyl)-[(S)-2-methyl-2-(5-trifluoromethyl-1H-benzoimidazol-2-yl)-pyrrolidin-1-yl]-methanone; 
         [(2S,4R)-2-(6-Chloro-1,7-dimethyl-1H-benzoimidazol-2-yl)-4-methoxy-pyrrolidin-1-yl]-(5-methoxy-2-[1,2,3]triazol-2-yl-phenyl)-methanone; and 
         [(2S,4R)-2-(5-Chloro-1,4-dimethyl-1H-benzoimidazol-2-yl)-4-methoxy-pyrrolidin-1-yl]-(5-methoxy-2-[1,2,3]triazol-2-yl-phenyl)-methanone.
 
48) In addition to the above-listed compounds, further compounds according to embodiment 1) are selected from:
 
         [2-(5,6-Dimethoxy-1H-benzoimidazol-2-yl)-pyrrolidin-1-yl]-(2-methyl-5-phenyl-thiazol-4-yl)-methanone; 
         [2-(4,5-Dimethyl-1H-benzoimidazol-2-yl)-pyrrolidin-1-yl]-(2-methyl-5-phenyl-thiazol-4-yl)-methanone; 
         [2-(5-Methoxy-1H-benzoimidazol-2-yl)-pyrrolidin-1-yl]-(5-methyl-2-[1,2,3]triazol-2-yl-phenyl)-methanone; 
         (5-Fluoro-2-[1,2,3]triazol-2-yl-phenyl)-[(S)-2-(6-methylsulfanyl-1H-benzoimidazol-2-yl)-pyrrolidin-1-yl]-methanone; 
         (5-Chloro-2-[1,2,3]triazol-2-yl-phenyl)-[(S)-2-(6-methylsulfanyl-1H-benzoimidazol-2-yl)-pyrrolidin-1-yl]-methanone; 
         (5-Methoxy-2-[1,2,3]triazol-2-yl-phenyl)-[(S)-2-(6-methylsulfanyl-1H-benzoimidazol-2-yl)-pyrrolidin-1-yl]-methanone; 
         3-[(S)-2-(6-Methylsulfanyl-1H-benzoimidazol-2-yl)-pyrrolidine-1-carbonyl]-4-[1,2,3]triazol-2-yl-benzonitrile; 
         [(S)-2-(6-Methylsulfanyl-1H-benzoimidazol-2-yl)-pyrrolidin-1-yl]-(2-methyl-6-[1,2,3]triazol-2-yl-phenyl)-methanone; 
         (5-Fluoro-2-[1,2,3]triazol-2-yl-phenyl)-[(S)-2-(6-methoxy-1H-benzoimidazol-2-yl)-pyrrolidin-1-yl]-methanone; 
         (5-Chloro-2-[1,2,3]triazol-2-yl-phenyl)-[(S)-2-(6-methoxy-1H-benzoimidazol-2-yl)-pyrrolidin-1-yl]-methanone; 
         [(S)-2-(6-Methoxy-1H-benzoimidazol-2-yl)-pyrrolidin-1-yl]-(5-methoxy-2-[1,2,3]triazol-2-yl-phenyl)-methanone; 
         3-[(S)-2-(6-Methoxy-1H-benzoimidazol-2-yl)-pyrrolidine-1-carbonyl]-4-[1,2,3]triazol-2-yl-benzonitrile; 
         [(S)-2-(6-Methoxy-1H-benzoimidazol-2-yl)-pyrrolidin-1-yl]-(5-methyl-2-[1,2,3]triazol-2-yl-phenyl)-methanone; 
         [(S)-2-(6-Methoxy-1H-benzoimidazol-2-yl)-pyrrolidin-1-yl]-(4-methyl-2-[1,2,3]triazol-2-yl-phenyl)-methanone; 
         [(S)-2-(6-Methoxy-1H-benzoimidazol-2-yl)-pyrrolidin-1-yl]-(2-methyl-6-[1,2,3]triazol-2-yl-phenyl)-methanone; 
         (4,5-Dimethoxy-2-[1,2,3]triazol-2-yl-phenyl)-[(S)-2-(6-methoxy-1H-benzoimidazol-2-yl)-pyrrolidin-1-yl]-methanone; 
         (5-Fluoro-2-[1,2,3]triazol-2-yl-phenyl)-[(S)-2-(7-methylsulfanyl-1H-benzoimidazol-2-yl)-pyrrolidin-1-yl]-methanone; 
         (2-Fluoro-6-[1,2,3]triazol-2-yl-phenyl)-[(S)-2-(7-methylsulfanyl-1H-benzoimidazol-2-yl)-pyrrolidin-1-yl]-methanone; 
         (5-Chloro-2-[1,2,3]triazol-2-yl-phenyl)-[(S)-2-(7-methylsulfanyl-1H-benzoimidazol-2-yl)-pyrrolidin-1-yl]-methanone; 
         3-[(S)-2-(7-Methylsulfanyl-1H-benzoimidazol-2-yl)-pyrrolidine-1-carbonyl]-4-[1,2,3]triazol-2-yl-benzonitrile; 
         [(S)-2-(6-Methylsulfanyl-1H-benzoimidazol-2-yl)-pyrrolidin-1-yl]-(5-methyl-2-[1,2,3]triazol-2-yl-phenyl)-methanone; 
         [(S)-2-(7-Methylsulfanyl-1H-benzoimidazol-2-yl)-pyrrolidin-1-yl]-(2-methyl-6-[1,2,3]triazol-2-yl-phenyl)-methanone; 
         (2-Fluoro-3-methyl-6-[1,2,3]triazol-2-yl-phenyl)-[(S)-2-(5-methoxy-1H-benzoimidazol-2-yl)-pyrrolidin-1-yl]-methanone; 
         (5-Methyl-2-pyrazol-1-yl-phenyl)-[(S)-2-(5-methylsulfanyl-1H-benzoimidazol-2-yl)-pyrrolidin-1-yl]-methanone; 
         (2-Fluoro-3-methyl-6-[1,2,3]triazol-2-yl-phenyl)-[(S)-2-(5-methylsulfanyl-1H-benzoimidazol-2-yl)-pyrrolidin-1-yl]-methanone; 
         [(S)-2-(5-Methoxy-1H-benzoimidazol-2-yl)-pyrrolidin-1-yl]-(5-methyl-2-[1,2,3]triazol-2-yl-phenyl)-methanone; 
         (3′,4-Dimethyl-biphenyl-2-yl)-[(S)-2-(6-methoxy-1H-benzoimidazol-2-yl)-pyrrolidin-1-yl]-methanone; 
         [5-(2,3-Dichloro-phenyl)-2-methyl-thiazol-4-yl]-[(S)-2-(6-methylsulfanyl-1H-benzoimidazol-2-yl)-pyrrolidin-1-yl]-methanone; 
         [(S)-2-(7-Methoxy-1H-benzoimidazol-2-yl)-pyrrolidin-1-yl]-(5-methyl-2-[1,2,3]triazol-2-yl-phenyl)-methanone; 
         (3′,4-Dimethyl-biphenyl-2-yl)-[(S)-2-(6-methylsulfanyl-1H-benzoimidazol-2-yl)-pyrrolidin-1-yl]-methanone; 
         [(S)-2-(6-Methylsulfanyl-1H-benzoimidazol-2-yl)-pyrrolidin-1-yl]-(2-[1,2,3]triazol-2-yl-phenyl)-methanone; 
         [(S)-2-(5-Methylsulfanyl-1H-benzoimidazol-2-yl)-pyrrolidin-1-yl]-(5-methyl-2-[1,2,3]triazol-2-yl-phenyl)-methanone; 
         [(S)-2-(7-Methylsulfanyl-1H-benzoimidazol-2-yl)-pyrrolidin-1-yl]-(2-[1,2,3]triazol-2-yl-phenyl)-methanone; 
         [(2S,4R)-2-(6-Chloro-7-methyl-1H-benzoimidazol-2-yl)-4-methoxy-pyrrolidin-1-yl]-(2-methyl-6-[1,2,3]triazol-2-yl-phenyl)-methanone; 
         [(2S,4R)-2-(6-Chloro-7-methyl-1H-benzoimidazol-2-yl)-4-methoxy-pyrrolidin-1-yl]-(4-methyl-2-[1,2,3]triazol-2-yl-phenyl)-methanone; 
         [(2S,4R)-2-(6-Chloro-7-methyl-1H-benzoimidazol-2-yl)-4-methoxy-pyrrolidin-1-yl]-(5-fluoro-2-[1,2,3]triazol-2-yl-phenyl)-methanone; 
         (5-Chloro-2-[1,2,3]triazol-2-yl-phenyl)-[(2S,4R)-4-methoxy-2-(6-methoxy-1H-benzoimidazol-2-yl)-pyrrolidin-1-yl]-methanone; 
         (4,5-Dimethyl-2-[1,2,3]triazol-2-yl-phenyl)-[(2S,4R)-4-methoxy-2-(6-methoxy-1H-benzoimidazol-2-yl)-pyrrolidin-1-yl]-methanone; 
         [(S)-2-(5,6-Dimethyl-1H-benzoimidazol-2-yl)-2-methyl-pyrrolidin-1-yl]-(2-[1,2,3]triazol-2-yl-phenyl)-methanone; 
         [5-(6-Methoxy-pyridin-3-yl)-2-methyl-thiazol-4-yl]-[(S)-2-(7-methyl-1H-benzoimidazol-2-yl)-4-methylene-pyrrolidin-1-yl]-methanone; 
         [5-(4-Fluoro-phenyl)-2-methyl-thiazol-4-yl]-[(S)-2-(7-methyl-1H-benzoimidazol-2-yl)-4-methylene-pyrrolidin-1-yl]-methanone; 
         (4,5-Dimethyl-2-[1,2,3]triazol-2-yl-phenyl)-[(S)-2-(7-methyl-1H-benzoimidazol-2-yl)-4-methylene-pyrrolidin-1-yl]-methanone; 
         [5-(4-Chloro-phenyl)-2-methyl-thiazol-4-yl]-[(S)-2-(7-methyl-1H-benzoimidazol-2-yl)-4-methylene-pyrrolidin-1-yl]-methanone; 
         (5-Methoxy-2-[1,2,3]triazol-2-yl-phenyl)-[(S)-2-(7-methyl-1H-benzoimidazol-2-yl)-4-methylene-pyrrolidin-1-yl]-methanone; 
         [(S)-2-(7-Methyl-1H-benzoimidazol-2-yl)-4-methylene-pyrrolidin-1-yl]-(6-methyl-3-[1,2,3]triazol-2-yl-pyridin-2-yl)-methanone; 
         [(S)-2-(5-Methoxy-1H-benzoimidazol-2-yl)-4-methylene-pyrrolidin-1-yl]-(5-methyl-2-[1,2,3]triazol-2-yl-phenyl)-methanone; 
         [(S)-2-(5-Methoxy-1H-benzoimidazol-2-yl)-4-methylene-pyrrolidin-1-yl]-(2-[1,2,3]triazol-2-yl-phenyl)-methanone; 
         [(S)-2-(6-Chloro-7-methyl-1H-benzoimidazol-2-yl)-4-methylene-pyrrolidin-1-yl]-(5-methyl-2-pyrazol-1-yl-phenyl)-methanone; 
         [(S)-2-(6-Chloro-7-methyl-1H-benzoimidazol-2-yl)-4-methylene-pyrrolidin-1-yl]-(6-methyl-3-pyrazol-1-yl-pyridin-2-yl)-methanone; 
         (5-Chloro-2-[1,2,3]triazol-2-yl-phenyl)-[(S)-2-(6-methoxy-1H-benzoimidazol-2-yl)-4-methylene-pyrrolidin-1-yl]-methanone; 
         [(S)-2-(6-Methoxy-1H-benzoimidazol-2-yl)-4-methylene-pyrrolidin-1-yl]-(5-methyl-2-pyrazol-1-yl-phenyl)-methanone; 
         (4,5-Dimethyl-2-[1,2,3]triazol-2-yl-phenyl)-[(S)-2-(6-methoxy-1H-benzoimidazol-2-yl)-4-methylene-pyrrolidin-1-yl]-methanone; 
         [(S)-2-(5-Methoxy-1H-benzoimidazol-2-yl)-4-methylene-pyrrolidin-1-yl]-(3′-methyl-biphenyl-2-yl)-methanone; 
         [(S)-2-(6-Methoxy-1H-benzoimidazol-2-yl)-4-methylene-pyrrolidin-1-yl]-(5-methoxy-2-[1,2,3]triazol-2-yl-phenyl)-methanone; 
         (2-Fluoro-3-methyl-6-[1,2,3]triazol-2-yl-phenyl)-[(S)-2-(6-methoxy-1H-benzoimidazol-2-yl)-4-methylene-pyrrolidin-1-yl]-methanone; 
         [(S)-2-(5-tert-Butyl-1H-benzoimidazol-2-yl)-4-methylene-pyrrolidin-1-yl]-(5-fluoro-2-[1,2,3]triazol-2-yl-phenyl)-methanone; 
         [(S)-2-(5-tert-Butyl-1H-benzoimidazol-2-yl)-4-methylene-pyrrolidin-1-yl]-(5-chloro-2-[1,2,3]triazol-2-yl-phenyl)-methanone; 
         [(S)-2-(5-tert-Butyl-1H-benzoimidazol-2-yl)-4-methylene-pyrrolidin-1-yl]-(2-[1,2,3]triazol-2-yl-phenyl)-methanone; 
         [(S)-2-(5-tert-Butyl-1H-benzoimidazol-2-yl)-4-methylene-pyrrolidin-1-yl]-(2-fluoro-3-methyl-6-[1,2,3]triazol-2-yl-phenyl)-methanone; 
         [(S)-2-(5-tert-Butyl-1H-benzoimidazol-2-yl)-4-methylene-pyrrolidin-1-yl]-(2-methyl-6-[1,2,3]triazol-2-yl-phenyl)-methanone; 
         [(S)-2-(5-tert-Butyl-1H-benzoimidazol-2-yl)-4-methylene-pyrrolidin-1-yl]-(5-methyl-2-pyrazol-1-yl-phenyl)-methanone; 
         [(S)-2-(5-tert-Butyl-1H-benzoimidazol-2-yl)-4-methylene-pyrrolidin-1-yl]-(6-methyl-3-[1,2,3]triazol-2-yl-pyridin-2-yl)-methanone; 
         (5-Fluoro-2-[1,2,3]triazol-2-yl-phenyl)-[(S)-2-(5-methoxy-1H-benzoimidazol-2-yl)-4-methylene-pyrrolidin-1-yl]-methanone; 
         [(S)-2-(5-Chloro-6-trifluoromethyl-1H-benzoimidazol-2-yl)-4-methylene-pyrrolidin-1-yl]-(2-methyl-6-[1,2,3]triazol-2-yl-phenyl)-methanone; 
         [(S)-2-(5,6-Dimethyl-1H-benzoimidazol-2-yl)-4-methylene-pyrrolidin-1-yl]-(2-fluoro-6-[1,2,3]triazol-2-yl-phenyl)-methanone; 
         [(S)-2-(5-Methoxy-1H-benzoimidazol-2-yl)-4-methylene-pyrrolidin-1-yl]-[5-(4-methoxy-phenyl)-2-methyl-thiazol-4-yl]-methanone; 
         [5-(4-Bromo-phenyl)-2-methyl-thiazol-4-yl]-[(S)-2-(5-methoxy-1H-benzoimidazol-2-yl)-4-methylene-pyrrolidin-1-yl]-methanone; 
         [(S)-2-(5-Methoxy-1H-benzoimidazol-2-yl)-4-methylene-pyrrolidin-1-yl]-(2-methyl-5-phenyl-thiazol-4-yl)-methanone; 
         [5-(3-Fluoro-phenyl)-2-methyl-thiazol-4-yl]-[(S)-2-(5-methoxy-1H-benzoimidazol-2-yl)-4-methylene-pyrrolidin-1-yl]-methanone; 
         [(S)-2-(5-Methoxy-1H-benzoimidazol-2-yl)-4-methylene-pyrrolidin-1-yl]-(2-m-tolyl-thiophen-3-yl)-methanone; 
         [2-(3,4-Dimethyl-phenyl)-thiophen-3-yl]-[(S)-2-(5-methoxy-1H-benzoimidazol-2-yl)-4-methylene-pyrrolidin-1-yl]-methanone; 
         [(S)-2-(4-Methyl-1H-benzoimidazol-2-yl)-4-methylene-pyrrolidin-1-yl]-(2-methyl-5-phenyl-thiazol-4-yl)-methanone; 
         [5-(4-Chloro-phenyl)-2-methyl-thiazol-4-yl]-[(S)-2-(5-methoxy-1H-benzoimidazol-2-yl)-4-methylene-pyrrolidin-1-yl]-methanone; 
         [(S)-4-Methylene-2-(7-methylsulfanyl-1H-benzoimidazol-2-yl)-pyrrolidin-1-yl]-(5-methyl-2-[1,2,3]triazol-2-yl-phenyl)-methanone; 
         [(S)-4-Methylene-2-(5-methylsulfanyl-1H-benzoimidazol-2-yl)-pyrrolidin-1-yl]-(5-methyl-2-[1,2,3]triazol-2-yl-phenyl)-methanone; 
         [(S)-2-(4,5-Dimethyl-1H-benzoimidazol-2-yl)-4-methylene-pyrrolidin-1-yl]-(5-methyl-2-[1,2,3]triazol-2-yl-phenyl)-methanone; and 
         [(S)-2-(5-tert-Butyl-1H-benzoimidazol-2-yl)-4-methylene-pyrrolidin-1-yl]-(5-methyl-2-[1,2,3]triazol-2-yl-phenyl)-methanone.
 
49) In addition to the above-listed compounds, further compounds according to embodiment 1) are selected from:
 
         [(2S,3S)-2-(4-Chloro-1H-benzoimidazol-2-yl)-3-methyl-pyrrolidin-1-yl]-[2-(3,4-dimethyl-phenyl)-thiophen-3-yl]-methanone; 
         [5-(3,4-Dimethyl-phenyl)-2-methyl-thiazol-4-yl]-[(2S,3S)-3-methyl-2-(4-trifluoromethyl-1H-benzoimidazol-2-yl)-pyrrolidin-1-yl]-methanone; 
         [2-(3,4-Dimethyl-phenyl)-thiophen-3-yl]-[(2S,3S)-3-methyl-2-(4-trifluoromethyl-1H-benzoimidazol-2-yl)-pyrrolidin-1-yl]-methanone; 
         [(2S,3S)-2-(5,6-Dimethoxy-1H-benzoimidazol-2-yl)-3-methyl-pyrrolidin-1-yl]-(5-methyl-2-pyrimidin-2-yl-phenyl)-methanone; 
         [(S)-2-(5-Chloro-4-methyl-1H-benzoimidazol-2-yl)-2-methyl-pyrrolidin-1-yl]-(4-fluoro-biphenyl-2-yl)-methanone; 
         [(S)-2-(5-Chloro-4-methyl-1H-benzoimidazol-2-yl)-2-methyl-pyrrolidin-1-yl]-(5-fluoro-2-pyridin-2-yl-phenyl)-methanone; 
         [(S)-2-(5-Chloro-4-methyl-1H-benzoimidazol-2-yl)-2-methyl-pyrrolidin-1-yl]-(2-fluoro-6-pyridin-2-yl-phenyl)-methanone; 
         [(S)-2-(5-Chloro-4-methyl-1H-benzoimidazol-2-yl)-2-methyl-pyrrolidin-1-yl]-(2-fluoro-6-pyrimidin-2-yl-phenyl)-methanone; 
         [(S)-2-(5-Chloro-4-methyl-1H-benzoimidazol-2-yl)-2-methyl-pyrrolidin-1-yl]-(4-methyl-biphenyl-2-yl)-methanone; 
         [(S)-2-(5-Chloro-4-methyl-1H-benzoimidazol-2-yl)-2-methyl-pyrrolidin-1-yl]-(5-fluoro-2-pyrimidin-2-yl-phenyl)-methanone; 
         [(S)-2-(5-Chloro-4-methyl-1H-benzoimidazol-2-yl)-2-methyl-pyrrolidin-1-yl]-(3-fluoro-biphenyl-2-yl)-methanone; 
         (4,5-Dimethyl-2-[1,2,3]triazol-2-yl-phenyl)-[(S)-2-methyl-2-(5-trifluoromethoxy-1H-benzoimidazol-2-yl)-pyrrolidin-1-yl]-methanone; 
         (4-Methyl-2-[1,2,3]triazol-2-yl-phenyl)-[(S)-2-methyl-2-(5-trifluoromethoxy-1H-benzoimidazol-2-yl)-pyrrolidin-1-yl]-methanone; 
         [5-(3,4-Dimethyl-phenyl)-2-methyl-thiazol-4-yl]-[(S)-2-methyl-2-(5-trifluoromethoxy-1H-benzoimidazol-2-yl)-pyrrolidin-1-yl]-methanone; 
         [(S)-2-(5-Chloro-4-methyl-1H-benzoimidazol-2-yl)-2-methyl-pyrrolidin-1-yl]-(2-methyl-5-phenyl-pyridin-4-yl)-methanone; 
         [(S)-2-Methyl-2-(5-trifluoromethyl-1H-benzoimidazol-2-yl)-pyrrolidin-1-yl]-(4-pyridin-3-yl-biphenyl-2-yl)-methanone; 
         [(S)-2-(6-Bromo-4,5-dimethyl-1H-benzoimidazol-2-yl)-2-methyl-pyrrolidin-1-yl]-(5-methyl-2-[1,2,3]triazol-2-yl-phenyl)-methanone; 
         [(S)-2-(6-Bromo-4,5-dimethyl-1H-benzoimidazol-2-yl)-2-methyl-pyrrolidin-1-yl]-(2-fluoro-6-[1,2,3]triazol-2-yl-phenyl)-methanone; 
         Biphenyl-2-yl-[(S)-2-(6-bromo-4,5-dimethyl-1H-benzoimidazol-2-yl)-2-methyl-pyrrolidin-1-yl]-methanone; 
         [(S)-2-(6-Bromo-4,5-dimethyl-1H-benzoimidazol-2-yl)-2-methyl-pyrrolidin-1-yl]-(4-methyl-biphenyl-2-yl)-methanone; 
         [(S)-2-(6-Bromo-4,5-dimethyl-1H-benzoimidazol-2-yl)-2-methyl-pyrrolidin-1-yl]-(2-methyl-5-o-tolyl-thiazol-4-yl)-methanone; 
         [(S)-2-(6-Bromo-4,5-dimethyl-1H-benzoimidazol-2-yl)-2-methyl-pyrrolidin-1-yl]-[5-(2,3-dichloro-phenyl)-2-methyl-thiazol-4-yl]-methanone; 
         [(S)-2-(6-Bromo-4,5-dimethyl-1H-benzoimidazol-2-yl)-2-methyl-pyrrolidin-1-yl]-[5-(3,4-dimethyl-phenyl)-2-methyl-thiazol-4-yl]-methanone; 
         [(S)-2-(6-Bromo-4,5-dimethyl-1H-benzoimidazol-2-yl)-2-methyl-pyrrolidin-1-yl]-[5-(3,5-difluoro-phenyl)-2-methyl-thiazol-4-yl]-methanone; 
         [(S)-2-(6-Bromo-4,5-dimethyl-1H-benzoimidazol-2-yl)-2-methyl-pyrrolidin-1-yl]-[5-(3-methoxy-phenyl)-2-methyl-thiazol-4-yl]-methanone; 
         [(S)-2-(6-Bromo-4,5-dimethyl-1H-benzoimidazol-2-yl)-2-methyl-pyrrolidin-1-yl]-[5-(4-fluoro-phenyl)-2-methyl-thiazol-4-yl]-methanone; 
         [(S)-2-(5-Bromo-7-methyl-1H-benzoimidazol-2-yl)-2-methyl-pyrrolidin-1-yl]-(5-methyl-2-pyrimidin-2-yl-phenyl)-methanone; 
         [(S)-2-Methyl-2-(7-methyl-1H-benzoimidazol-2-yl)-pyrrolidin-1-yl]-(5-methyl-2-pyrimidin-2-yl-phenyl)-methanone; 
         [(S)-2-(6-Chloro-5-trifluoromethyl-1H-benzoimidazol-2-yl)-2-methyl-pyrrolidin-1-yl]-(5-methyl-2-pyrimidin-2-yl-phenyl)-methanone; 
         [(S)-2-(5,6-Dimethoxy-1H-benzoimidazol-2-yl)-2-methyl-pyrrolidin-1-yl]-(5-methyl-2-pyrimidin-2-yl-phenyl)-methanone; 
         [(S)-2-(5,6-Dimethyl-1H-benzoimidazol-2-yl)-2-methyl-pyrrolidin-1-yl]-(5-methyl-2-pyrimidin-2-yl-phenyl)-methanone; 
         [(S)-2-(5-Chloro-4-methyl-1H-benzoimidazol-2-yl)-2-methyl-pyrrolidin-1-yl]-(3-fluoro-4,3′-dimethoxy-biphenyl-2-yl)-methanone; 
         [(S)-2-(5-Chloro-4-methyl-1H-benzoimidazol-2-yl)-2-methyl-pyrrolidin-1-yl]-(3,2′-difluoro-4-methoxy-biphenyl-2-yl)-methanone; 
         [(S)-2-(5-Chloro-4-methyl-1H-benzoimidazol-2-yl)-2-methyl-pyrrolidin-1-yl]-(3,4′-difluoro-4-methoxy-biphenyl-2-yl)-methanone; 
         [(S)-2-(5-Chloro-4-methyl-1H-benzoimidazol-2-yl)-2-methyl-pyrrolidin-1-yl]-(3,3′-difluoro-4-methoxy-biphenyl-2-yl)-methanone; 
         [(S)-2-(5-Chloro-4-methyl-1H-benzoimidazol-2-yl)-2-methyl-pyrrolidin-1-yl]-(3-fluoro-4-methoxy-3′-methyl-biphenyl-2-yl)-methanone; 
         [(S)-2-(5-Chloro-4-methyl-1H-benzoimidazol-2-yl)-2-methyl-pyrrolidin-1-yl]-(3-fluoro-4-methoxy-4′-methyl-biphenyl-2-yl)-methanone; 
         [(S)-2-(5-Chloro-4-methyl-1H-benzoimidazol-2-yl)-2-methyl-pyrrolidin-1-yl]-(3-fluoro-4-methoxy-3′-trifluoromethyl-biphenyl-2-yl)-methanone; 
         (6-Benzo[1,3]dioxol-5-yl-2-fluoro-3-methoxy-phenyl)-[(S)-2-(5-chloro-4-methyl-1H-benzoimidazol-2-yl)-2-methyl-pyrrolidin-1-yl]-methanone; 
         2′-[(S)-2-(5-Chloro-4-methyl-1H-benzoimidazol-2-yl)-2-methyl-pyrrolidine-1-carbonyl]-3′-fluoro-4′-methoxy-biphenyl-3-carbonitrile; 
         [(S)-2-(5-Chloro-4-methyl-1H-benzoimidazol-2-yl)-2-methyl-pyrrolidin-1-yl]-(3-fluoro-4-methoxy-3′-trifluoromethoxy-biphenyl-2-yl)-methanone; 
         [(S)-2-(5,6-Dimethyl-1H-benzoimidazol-2-yl)-4-methylene-pyrrolidin-1-yl]-(4-methyl-2-[1,2,3]triazol-2-yl-phenyl)-methanone; 
         (4,5-Dimethoxy-2-[1,2,3]triazol-2-yl-phenyl)-[(S)-2-(5,6-dimethyl-1H-benzoimidazol-2-yl)-4-methylene-pyrrolidin-1-yl]-methanone; 
         (4-Methyl-2-[1,2,3]triazol-2-yl-phenyl)-[(S)-2-methyl-2-(1,5,6-trimethyl-1H-benzoimidazol-2-yl)-pyrrolidin-1-yl]-methanone; 
         [(S)-2-(1-Ethyl-5,6-dimethyl-1H-benzoimidazol-2-yl)-2-methyl-pyrrolidin-1-yl]-(4-methyl-2-[1,2,3]triazol-2-yl-phenyl)-methanone; 
         [(S)-2-(5,6-Dimethoxy-1-methyl-1H-benzoimidazol-2-yl)-2-methyl-pyrrolidin-1-yl]-(4,5-dimethyl-2-[1,2,3]triazol-2-yl-phenyl)-methanone; 
         (4,5-Dimethyl-2-[1,2,3]triazol-2-yl-phenyl)-[(S)-2-(1-ethyl-5,6-dimethoxy-1H-benzoimidazol-2-yl)-2-methyl-pyrrolidin-1-yl]-methanone; 
         (4′-Fluoro-4-methyl-biphenyl-2-yl)-[(S)-2-methyl-2-(1,5,6-trimethyl-1H-benzoimidazol-2-yl)-pyrrolidin-1-yl]-methanone; 
         [(S)-2-(1-Ethyl-5,6-dimethyl-1H-benzoimidazol-2-yl)-2-methyl-pyrrolidin-1-yl]-(4′-fluoro-4-methyl-biphenyl-2-yl)-methanone; 
         (4,5-Dimethyl-2-[1,2,3]triazol-2-yl-phenyl)-[(S)-2-methyl-2-(1,5,6-trimethyl-1H-benzoimidazol-2-yl)-pyrrolidin-1-yl]-methanone; 
         [(S)-2-(5-Chloro-1,4-dimethyl-1H-benzoimidazol-2-yl)-2-methyl-pyrrolidin-1-yl]-(6-methyl-3-[1,2,3]triazol-2-yl-pyridin-2-yl)-methanone; 
         [(S)-2-(5-Chloro-1,4-dimethyl-1H-benzoimidazol-2-yl)-2-methyl-pyrrolidin-1-yl]-(2-[1,2,3]triazol-2-yl-phenyl)-methanone; 
         [(S)-2-(6-Chloro-1-methyl-5-trifluoromethyl-1H-benzoimidazol-2-yl)-2-methyl-pyrrolidin-1-yl]-(5-methyl-2-[1,2,3]triazol-2-yl-phenyl)-methanone; 
         [(S)-2-(5-Chloro-1-ethyl-4-methyl-1H-benzoimidazol-2-yl)-2-methyl-pyrrolidin-1-yl]-(5-methyl-2-[1,2,3]triazol-2-yl-phenyl)-methanone; 
         [(S)-2-(5-Chloro-1,4-dimethyl-1H-benzoimidazol-2-yl)-2-methyl-pyrrolidin-1-yl]-(5-chloro-2-[1,2,3]triazol-2-yl-phenyl)-methanone; 
         [(S)-2-(5-Chloro-1,4-dimethyl-1H-benzoimidazol-2-yl)-2-methyl-pyrrolidin-1-yl]-(5-methoxy-2-[1,2,3]triazol-2-yl-phenyl)-methanone; 
         (4,3′-Dimethyl-biphenyl-2-yl)-[(S)-2-methyl-2-(1,5,6-trimethyl-1H-benzoimidazol-2-yl)-pyrrolidin-1-yl]-methanone; 
         (4,3′-Dimethyl-biphenyl-2-yl)-[(S)-2-(1-ethyl-5,6-dimethyl-1H-benzoimidazol-2-yl)-2-methyl-pyrrolidin-1-yl]-methanone; 
         (4,3′-Dimethyl-biphenyl-2-yl)-{(S)-2-[1-(2-fluoro-ethyl)-5,6-dimethyl-1H-benzoimidazol-2-yl]-2-methyl-pyrrolidin-1-yl}-methanone; 
         (4,3′-Dimethyl-biphenyl-2-yl)-{(S)-2-[1-(2-methoxy-ethyl)-5,6-dimethyl-1H-benzoimidazol-2-yl]-2-methyl-pyrrolidin-1-yl}-methanone; 
         (3′-Fluoro-4-methyl-biphenyl-2-yl)-[(S)-2-methyl-2-(1,5,6-trimethyl-1H-benzoimidazol-2-yl)-pyrrolidin-1-yl]-methanone; 
         [(S)-2-(1-Ethyl-5,6-dimethyl-1H-benzoimidazol-2-yl)-2-methyl-pyrrolidin-1-yl]-(3′-fluoro-4-methyl-biphenyl-2-yl)-methanone; 
         [(S)-2-(5-Chloro-1,4-dimethyl-1H-benzoimidazol-2-yl)-2-methyl-pyrrolidin-1-yl]-[5-(3-chloro-phenyl)-2-methyl-thiazol-4-yl]-methanone; 
         [(S)-2-(1-Cyclopropylmethyl-5,6-dimethyl-1H-benzoimidazol-2-yl)-2-methyl-pyrrolidin-1-yl]-(3′-fluoro-4-methyl-biphenyl-2-yl)-methanone; 
         {(S)-2-[1-(2-Fluoro-ethyl)-5,6-dimethyl-1H-benzoimidazol-2-yl]-2-methyl-pyrrolidin-1-yl}-(3-fluoro-4-methyl-biphenyl-2-yl)-methanone; 
         (4,4′-Dimethyl-biphenyl-2-yl)-[(S)-2-methyl-2-(1,5,6-trimethyl-1H-benzoimidazol-2-yl)-pyrrolidin-1-yl]-methanone; 
         (4,4′-Dimethyl-biphenyl-2-yl)-[(S)-2-(1-ethyl-5,6-dimethyl-1H-benzoimidazol-2-yl)-2-methyl-pyrrolidin-1-yl]-methanone; 
         (4,4′-Dimethyl-biphenyl-2-yl)-{(S)-2-[1-(2-fluoro-ethyl)-5,6-dimethyl-1H-benzoimidazol-2-yl]-2-methyl-pyrrolidin-1-yl}-methanone; 
         (3′-Methoxy-4-methyl-biphenyl-2-yl)-[(S)-2-methyl-2-(1,5,6-trimethyl-1H-benzoimidazol-2-yl)-pyrrolidin-1-yl]-methanone; 
         (2′-Fluoro-4-methyl-biphenyl-2-yl)-[(S)-2-methyl-2-(1,5,6-trimethyl-1H-benzoimidazol-2-yl)-pyrrolidin-1-yl]-methanone; 
         [(S)-2-(1-Ethyl-5,6-dimethyl-1H-benzoimidazol-2-yl)-2-methyl-pyrrolidin-1-yl]-(3′-methoxy-4-methyl-biphenyl-2-yl)-methanone; 
         {(S)-2-[1-(2-Fluoro-ethyl)-5,6-dimethyl-1H-benzoimidazol-2-yl]-2-methyl-pyrrolidin-1-yl}-(3′-methoxy-4-methyl-biphenyl-2-yl)-methanone; 
         {(S)-2-[1-(2-Fluoro-ethyl)-5,6-dimethyl-1H-benzoimidazol-2-yl]-2-methyl-pyrrolidin-1-yl}-(2′-fluoro-4-methyl-biphenyl-2-yl)-methanone; and 
         [(S)-2-(5,6-Dimethoxy-1-methyl-1H-benzoimidazol-2-yl)-2-methyl-pyrrolidin-1-yl]-(5-methyl-2-[1,2,3]triazol-2-yl-phenyl)-methanone.
 
50) In addition to the above-listed compounds, further compounds according to embodiment 1) are selected from:
 
         [(2S,3S)-2-(5-Chloro-6-methyl-1H-benzoimidazol-2-yl)-3-methyl-pyrrolidin-1-yl]-(5-methyl-2-pyridin-2-yl-phenyl)-methanone; 
         (4-Chloro-biphenyl-2-yl)-[(2S,3S)-2-(5-chloro-6-methyl-1H-benzoimidazol-2-yl)-3-methyl-pyrrolidin-1-yl]-methanone; 
         [(2S,3S)-2-(5-Chloro-6-methyl-1H-benzoimidazol-2-yl)-3-methyl-pyrrolidin-1-yl]-(5-methyl-2-pyridin-3-yl-phenyl)-methanone; 
         [(2S,3S)-2-(5-Chloro-6-methyl-1H-benzoimidazol-2-yl)-3-methyl-pyrrolidin-1-yl]-(4-fluoro-biphenyl-2-yl)-methanone; 
         [(2S,3S)-2-(5-Chloro-6-methyl-1H-benzoimidazol-2-yl)-3-methyl-pyrrolidin-1-yl]-(5-fluoro-2-pyridin-2-yl-phenyl)-methanone; 
         2-[(2S,3S)-2-(5-Chloro-6-methyl-1H-benzoimidazol-2-yl)-3-methyl-pyrrolidine-1-carbonyl]-biphenyl-4-carbonitrile; 
         [(2S,3S)-2-(5-Chloro-6-methyl-1H-benzoimidazol-2-yl)-3-methyl-pyrrolidin-1-yl]-(4-methyl-2-pyridin-2-yl-phenyl)-methanone; 
         [(2S,3S)-2-(5-Chloro-6-methyl-1H-benzoimidazol-2-yl)-3-methyl-pyrrolidin-1-yl]-(4-methyl-2-pyridin-3-yl-phenyl)-methanone; 
         [(2S,3S)-2-(5-Chloro-6-methyl-1H-benzoimidazol-2-yl)-3-methyl-pyrrolidin-1-yl]-(5-methyl-biphenyl-2-yl)-methanone; 
         [(2S,3S)-2-(5-Chloro-6-methyl-1H-benzoimidazol-2-yl)-3-methyl-pyrrolidin-1-yl]-(3-fluoro-biphenyl-2-yl)-methanone; 
         [(2S,3S)-2-(5-Chloro-6-methyl-1H-benzoimidazol-2-yl)-3-methyl-pyrrolidin-1-yl]-(2-fluoro-3-methyl-6-pyridin-2-yl-phenyl)-methanone; 
         [(2S,3S)-2-(5-Chloro-6-methyl-1H-benzoimidazol-2-yl)-3-methyl-pyrrolidin-1-yl]-(3-fluoro-4-methyl-biphenyl-2-yl)-methanone; 
         [(2S,3S)-2-(5-Chloro-6-methyl-1H-benzoimidazol-2-yl)-3-methyl-pyrrolidin-1-yl]-(4-methyl-biphenyl-2-yl)-methanone; 
         [(2S,3S)-2-(5-Chloro-6-methyl-1H-benzoimidazol-2-yl)-3-methyl-pyrrolidin-1-yl]-(2-fluoro-3-methyl-6-pyridin-3-yl-phenyl)-methanone; 
         [(2S,3S)-2-(4-Chloro-1H-benzoimidazol-2-yl)-3-methyl-pyrrolidin-1-yl]-[5-(3,5-difluoro-phenyl)-2-methyl-thiazol-4-yl]-methanone; 
         [(2S,3S)-2-(4-Chloro-1H-benzoimidazol-2-yl)-3-methyl-pyrrolidin-1-yl]-[5-(4-chloro-phenyl)-2-methyl-thiazol-4-yl]-methanone; 
         [(2S,3S)-2-(4-Chloro-1H-benzoimidazol-2-yl)-3-methyl-pyrrolidin-1-yl]-[5-(3-methoxy-phenyl)-2-methyl-thiazol-4-yl]-methanone; 
         [(2S,3S)-2-(4-Chloro-1H-benzoimidazol-2-yl)-3-methyl-pyrrolidin-1-yl]-(2-methyl-5-m-tolyl-thiazol-4-yl)-methanone; 
         [5-(4-Bromo-phenyl)-2-methyl-thiazol-4-yl]-[(2S,3S)-2-(4-chloro-1H-benzoimidazol-2-yl)-3-methyl-pyrrolidin-1-yl]-methanone; 
         [(2S,3S)-2-(4-Chloro-1H-benzoimidazol-2-yl)-3-methyl-pyrrolidin-1-yl]-(2-methyl-5-p-tolyl-thiazol-4-yl)-methanone; 
         [(2S,3S)-2-(4-Chloro-1H-benzoimidazol-2-yl)-3-methyl-pyrrolidin-1-yl]-[5-(3,4-dimethyl-phenyl)-2-methyl-thiazol-4-yl]-methanone; 
         [(2S,3S)-2-(4-Chloro-1H-benzoimidazol-2-yl)-3-methyl-pyrrolidin-1-yl]-[2-dimethylamino-5-(3,4-dimethyl-phenyl)-thiazol-4-yl]-methanone; 
         [(2S,3S)-2-(5-Chloro-6-methyl-1H-benzoimidazol-2-yl)-3-methyl-pyrrolidin-1-yl]-(4-methyl-2-pyrimidin-2-yl-phenyl)-methanone; 
         [(2S,3S)-2-(5-Chloro-6-methyl-1H-benzoimidazol-2-yl)-3-methyl-pyrrolidin-1-yl]-(5-fluoro-2-pyrimidin-2-yl-phenyl)-methanone; 
         [(2S,3S)-2-(5-Chloro-6-methyl-1H-benzoimidazol-2-yl)-3-methyl-pyrrolidin-1-yl]-(2-fluoro-6-pyrimidin-2-yl-phenyl)-methanone; 
         [(2S,3S)-2-(5-Chloro-4-methyl-1H-benzoimidazol-2-yl)-3-methyl-pyrrolidin-1-yl]-[2-(3-methoxy-phenylethynyl)-phenyl]-methanone; 
         [(2S,3S)-2-(5-Chloro-6-methyl-1H-benzoimidazol-2-yl)-3-methyl-pyrrolidin-1-yl]-[2-(3-methoxy-phenylethynyl)-phenyl]-methanone; 
         [5-(4-Fluoro-phenyl)-2-methyl-thiazol-4-yl]-[(2S,3S)-3-methyl-2-(5-trifluoromethyl-1H-benzoimidazol-2-yl)-pyrrolidin-1-yl]-methanone; 
         [5-(3-Methoxy-phenyl)-2-methyl-thiazol-4-yl]-[(2S,3S)-3-methyl-2-(5-trifluoromethyl-1H-benzoimidazol-2-yl)-pyrrolidin-1-yl]-methanone; 
         (2-Methyl-5-m-tolyl-thiazol-4-yl)-[(2S,3S)-3-methyl-2-(5-trifluoromethyl-1H-benzoimidazol-2-yl)-pyrrolidin-1-yl]-methanone; 
         [5-(4-Chloro-phenyl)-2-methyl-thiazol-4-yl]-[(2S,3S)-3-methyl-2-(5-trifluoromethyl-1H-benzoimidazol-2-yl)-pyrrolidin-1-yl]-methanone; 
         (2-Methyl-5-p-tolyl-thiazol-4-yl)-[(2S,3S)-3-methyl-2-(5-trifluoromethyl-1H-benzoimidazol-2-yl)-pyrrolidin-1-yl]-methanone; 
         [5-(4-Methoxy-phenyl)-2-methyl-thiazol-4-yl]-[(2S,3S)-3-methyl-2-(5-trifluoromethyl-1H-benzoimidazol-2-yl)-pyrrolidin-1-yl]-methanone; 
         [5-(4-Bromo-phenyl)-2-methyl-thiazol-4-yl]-[(2S,3S)-3-methyl-2-(5-trifluoromethyl-1H-benzoimidazol-2-yl)-pyrrolidin-1-yl]-methanone; 
         [5-(3,4-Difluoro-phenyl)-2-methyl-thiazol-4-yl]-[(2S,3S)-3-methyl-2-(5-trifluoromethyl-1H-benzoimidazol-2-yl)-pyrrolidin-1-yl]-methanone; 
         [2-(3,4-Dimethyl-phenyl)-thiophen-3-yl]-[(2S,3S)-3-methyl-2-(5-trifluoromethyl-1H-benzoimidazol-2-yl)-pyrrolidin-1-yl]-methanone; 
         [5-(3,4-Dimethyl-phenyl)-2-methyl-thiazol-4-yl]-[(2S,3S)-3-methyl-2-(5-trifluoromethyl-1H-benzoimidazol-2-yl)-pyrrolidin-1-yl]-methanone; 
         [5-(2-Chloro-phenyl)-2-methyl-thiazol-4-yl]-[(2S,3S)-3-methyl-2-(5-trifluoromethyl-1H-benzoimidazol-2-yl)-pyrrolidin-1-yl]-methanone; 
         [5-(2-Methoxy-phenyl)-2-methyl-thiazol-4-yl]-[(2S,3S)-3-methyl-2-(5-trifluoromethyl-1H-benzoimidazol-2-yl)-pyrrolidin-1-yl]-methanone; 
         [5-(3,5-Difluoro-phenyl)-2-methyl-thiazol-4-yl]-[(2S,3S)-3-methyl-2-(5-trifluoromethyl-1H-benzoimidazol-2-yl)-pyrrolidin-1-yl]-methanone; 
         [5-(4-Fluoro-phenyl)-2-methyl-thiazol-4-yl]-[(2S,3S)-3-methyl-2-(4-trifluoromethyl-1H-benzoimidazol-2-yl)-pyrrolidin-1-yl]-methanone; 
         [5-(4-Chloro-phenyl)-2-methyl-thiazol-4-yl]-[(2S,3S)-3-methyl-2-(4-trifluoromethyl-1H-benzoimidazol-2-yl)-pyrrolidin-1-yl]-methanone; 
         [5-(4-Bromo-phenyl)-2-methyl-thiazol-4-yl]-[(2S,3S)-3-methyl-2-(4-trifluoromethyl-1H-benzoimidazol-2-yl)-pyrrolidin-1-yl]-methanone; 
         (2-Methyl-5-p-tolyl-thiazol-4-yl)-[(2S,3S)-3-methyl-2-(4-trifluoromethyl-1H-benzoimidazol-2-yl)-pyrrolidin-1-yl]-methanone; 
         [5-(3,4-Difluoro-phenyl)-2-methyl-thiazol-4-yl]-[(2S,3S)-3-methyl-2-(4-trifluoromethyl-1H-benzoimidazol-2-yl)-pyrrolidin-1-yl]-methanone; 
         [5-(2-Methoxy-phenyl)-2-methyl-thiazol-4-yl]-[(2S,3S)-3-methyl-2-(4-trifluoromethyl-1H-benzoimidazol-2-yl)-pyrrolidin-1-yl]-methanone; 
         [5-(3,5-Difluoro-phenyl)-2-methyl-thiazol-4-yl]-[(2S,3S)-3-methyl-2-(4-trifluoromethyl-1H-benzoimidazol-2-yl)-pyrrolidin-1-yl]-methanone; 
         (2-Methyl-5-m-tolyl-thiazol-4-yl)-[(2S,3S)-3-methyl-2-(4-trifluoromethyl-1H-benzoimidazol-2-yl)-pyrrolidin-1-yl]-methanone; 
         [5-(4-Methoxy-phenyl)-2-methyl-thiazol-4-yl]-[(2S,3S)-3-methyl-2-(4-trifluoromethyl-1H-benzoimidazol-2-yl)-pyrrolidin-1-yl]-methanone; 
         [(2S,3S)-2-(5-Chloro-4-methyl-1H-benzoimidazol-2-yl)-3-methyl-pyrrolidin-1-yl]-(5-methyl-2-pyridin-2-yl-phenyl)-methanone; 
         (4-Chloro-biphenyl-2-yl)-[(2S,3S)-2-(5-chloro-4-methyl-1H-benzoimidazol-2-yl)-3-methyl-pyrrolidin-1-yl]-methanone; 
         [(2S,3S)-2-(5-Chloro-4-methyl-1H-benzoimidazol-2-yl)-3-methyl-pyrrolidin-1-yl]-(5-methyl-2-pyridin-3-yl-phenyl)-methanone; 
         [(2S,3S)-2-(5-Chloro-4-methyl-1H-benzoimidazol-2-yl)-3-methyl-pyrrolidin-1-yl]-(4-fluoro-biphenyl-2-yl)-methanone; 
         [(2S,3S)-2-(5-Chloro-4-methyl-1H-benzoimidazol-2-yl)-3-methyl-pyrrolidin-1-yl]-(5-fluoro-2-pyridin-2-yl-phenyl)-methanone; 
         2-[(2S,3S)-2-(5-Chloro-4-methyl-1H-benzoimidazol-2-yl)-3-methyl-pyrrolidine-1-carbonyl]-biphenyl-4-carbonitrile; 
         [(2S,3S)-2-(5-Chloro-4-methyl-1H-benzoimidazol-2-yl)-3-methyl-pyrrolidin-1-yl]-(4-methyl-2-pyridin-2-yl-phenyl)-methanone; 
         [(2S,3S)-2-(5-Chloro-4-methyl-1H-benzoimidazol-2-yl)-3-methyl-pyrrolidin-1-yl]-(5-methyl-biphenyl-2-yl)-methanone; 
         [(2S,3S)-2-(5-Chloro-4-methyl-1H-benzoimidazol-2-yl)-3-methyl-pyrrolidin-1-yl]-(3-fluoro-biphenyl-2-yl)-methanone; 
         [(2S,3S)-2-(5-Chloro-4-methyl-1H-benzoimidazol-2-yl)-3-methyl-pyrrolidin-1-yl]-(4-trifluoromethyl-biphenyl-2-yl)-methanone; 
         [(2S,3S)-2-(5-Chloro-4-methyl-1H-benzoimidazol-2-yl)-3-methyl-pyrrolidin-1-yl]-(3-fluoro-4-methyl-biphenyl-2-yl)-methanone; 
         [(2S,3S)-2-(5-Chloro-4-methyl-1H-benzoimidazol-2-yl)-3-methyl-pyrrolidin-1-yl]-(4-methyl-biphenyl-2-yl)-methanone; 
         [(2S,3S)-2-(5-Chloro-4-methyl-1H-benzoimidazol-2-yl)-3-methyl-pyrrolidin-1-yl]-(2-fluoro-3-methyl-6-pyridin-3-yl-phenyl)-methanone; 
         [(2S,3S)-2-(5-Chloro-4-methyl-1H-benzoimidazol-2-yl)-3-methyl-pyrrolidin-1-yl]-(4-methyl-2-pyrimidin-2-yl-phenyl)-methanone; 
         [(2S,3S)-2-(5-Chloro-4-methyl-1H-benzoimidazol-2-yl)-3-methyl-pyrrolidin-1-yl]-(5-fluoro-2-pyrimidin-2-yl-phenyl)-methanone; 
         [(2S,3S)-2-(5-Chloro-4-methyl-1H-benzoimidazol-2-yl)-3-methyl-pyrrolidin-1-yl]-(2-fluoro-3-methyl-6-pyrimidin-2-yl-phenyl)-methanone; 
         [(2S,3S)-2-(5-Chloro-4-methyl-1H-benzoimidazol-2-yl)-3-methyl-pyrrolidin-1-yl]-(2-fluoro-6-pyrimidin-2-yl-phenyl)-methanone; 
         [(2S,3S)-2-(5-Chloro-4-methyl-1H-benzoimidazol-2-yl)-3-methyl-pyrrolidin-1-yl]-(5-methyl-2-pyrimidin-2-yl-phenyl)-methanone; 
         [(2S,3S)-2-(5-Chloro-6-methyl-1H-benzoimidazol-2-yl)-3-methyl-pyrrolidin-1-yl]-(5-methyl-2-pyrimidin-2-yl-phenyl)-methanone; 
         [(2S,3S)-2-(6-Chloro-7-methyl-1H-benzoimidazol-2-yl)-3-methyl-pyrrolidin-1-yl]-(5-methyl-2-pyrimidin-2-yl-phenyl)-methanone; 
         [(2S,3S)-2-(5-Chloro-7-methyl-1H-benzoimidazol-2-yl)-3-methyl-pyrrolidin-1-yl]-(5-methyl-2-pyrimidin-2-yl-phenyl)-methanone; 
         [(S)-2-(5-Chloro-4-methyl-1H-benzoimidazol-2-yl)-2-methyl-pyrrolidin-1-yl]-[5-(4-fluoro-phenyl)-2-phenyl-thiazol-4-yl]-methanone; 
         [2,5-Bis-(4-fluoro-phenyl)-thiazol-4-yl]-[(S)-2-(5-chloro-4-methyl-1H-benzoimidazol-2-yl)-2-methyl-pyrrolidin-1-yl]-methanone; 
         [(S)-2-(5-Chloro-4-methyl-1H-benzoimidazol-2-yl)-2-methyl-pyrrolidin-1-yl]-[5-(4-fluoro-phenyl)-2-m-tolyl-thiazol-4-yl]-methanone; 
         [(S)-2-(5-Chloro-4-methyl-1H-benzoimidazol-2-yl)-2-methyl-pyrrolidin-1-yl]-[5-(4-fluoro-phenyl)-2-(3-methoxy-phenyl)-thiazol-4-yl]-methanone; 
         [(S)-2-(5-Chloro-4-methyl-1H-benzoimidazol-2-yl)-2-methyl-pyrrolidin-1-yl]-[5-(4-fluoro-phenyl)-2-p-tolyl-thiazol-4-yl]-methanone; 
         [(S)-2-(5-Chloro-4-methyl-1H-benzoimidazol-2-yl)-2-methyl-pyrrolidin-1-yl]-[5-(4-fluoro-phenyl)-2-(2-fluoro-phenyl)-thiazol-4-yl]-methanone; 
         [(S)-2-(5-Chloro-4-methyl-1H-benzoimidazol-2-yl)-2-methyl-pyrrolidin-1-yl]-[5-(4-fluoro-phenyl)-2-(3-fluoro-phenyl)-thiazol-4-yl]-methanone; 
         (4-Methyl-biphenyl-2-yl)-[(S)-2-methyl-2-(5-trifluoromethoxy-1H-benzoimidazol-2-yl)-pyrrolidin-1-yl]-methanone; 
         [5-(3,5-Difluoro-phenyl)-2-methyl-thiazol-4-yl]-[(S)-2-methyl-2-(5-trifluoromethoxy-1H-benzoimidazol-2-yl)-pyrrolidin-1-yl]-methanone; 
         [5-(3-Methoxy-phenyl)-2-methyl-thiazol-4-yl]-[(S)-2-methyl-2-(5-trifluoromethoxy-1H-benzoimidazol-2-yl)-pyrrolidin-1-yl]-methanone; 
         [5-(4-Fluoro-phenyl)-2-methyl-thiazol-4-yl]-[(S)-2-methyl-2-(5-trifluoromethoxy-1H-benzoimidazol-2-yl)-pyrrolidin-1-yl]-methanone; 
         [(S)-2-(5-Chloro-4-methyl-1H-benzoimidazol-2-yl)-2-methyl-pyrrolidin-1-yl]-[2-(2,3-difluoro-phenyl)-5-(4-fluoro-phenyl)-thiazol-4-yl]-methanone; 
         [(S)-2-(5-Chloro-4-methyl-1H-benzoimidazol-2-yl)-2-methyl-pyrrolidin-1-yl]-[2-(4-fluoro-3-methyl-phenyl)-5-(4-fluoro-phenyl)-thiazol-4-yl]-methanone; 
         [(S)-2-(5-Chloro-4-methyl-1H-benzoimidazol-2-yl)-2-methyl-pyrrolidin-1-yl]-[2-(2-fluoro-4-methyl-phenyl)-5-(4-fluoro-phenyl)-thiazol-4-yl]-methanone; 
         3-[4-[(S)-2-(5-Chloro-4-methyl-1H-benzoimidazol-2-yl)-2-methyl-pyrrolidine-1-carbonyl]-5-(4-fluoro-phenyl)-thiazol-2-yl]-benzonitrile; 
         [(S)-2-(5-Chloro-4-methyl-1H-benzoimidazol-2-yl)-2-methyl-pyrrolidin-1-yl]-[2-(2-chloro-phenyl)-5-(4-fluoro-phenyl)-thiazol-4-yl]-methanone; 
         [(S)-2-(5-Chloro-4-methyl-1H-benzoimidazol-2-yl)-2-methyl-pyrrolidin-1-yl]-[2-(3-chloro-phenyl)-5-(4-fluoro-phenyl)-thiazol-4-yl]-methanone; 
         [(S)-2-(5-Chloro-4-methyl-1H-benzoimidazol-2-yl)-2-methyl-pyrrolidin-1-yl]-[2-(4-fluoro-2-methyl-phenyl)-5-(4-fluoro-phenyl)-thiazol-4-yl]-methanone; 
         [(S)-2-(5-Chloro-4-methyl-1H-benzoimidazol-2-yl)-2-methyl-pyrrolidin-1-yl]-[2-(4-fluoro-2-methoxy-phenyl)-5-(4-fluoro-phenyl)-thiazol-4-yl]-methanone; 
         [(S)-2-(5-Chloro-4-methyl-1H-benzoimidazol-2-yl)-2-methyl-pyrrolidin-1-yl]-[2-(2,5-difluoro-phenyl)-5-(4-fluoro-phenyl)-thiazol-4-yl]-methanone; 
         [(S)-2-(6-Bromo-4,5-dimethyl-1H-benzoimidazol-2-yl)-2-methyl-pyrrolidin-1-yl]-(3,4-dimethyl-2-[1,2,3]triazol-2-yl-phenyl)-methanone; 
         3′-[(S)-2-Methyl-2-(5-trifluoromethyl-1H-benzoimidazol-2-yl)-pyrrolidine-1-carbonyl]-4′-[1,2,3]triazol-2-yl-biphenyl-3-carbonitrile; 
         2′-[(S)-2-(5-Chloro-4-methyl-1H-benzoimidazol-2-yl)-2-methyl-pyrrolidine-1-carbonyl]-3′-fluoro-4′-methoxy-biphenyl-4-carbonitrile; 
         [(S)-2-(6-Bromo-5-fluoro-1-methyl-1H-benzoimidazol-2-yl)-2-methyl-pyrrolidin-1-yl]-(5-methyl-2-[1,2,3]triazol-2-yl-phenyl)-methanone; 
         (3′-Fluoro-4-methyl-biphenyl-2-yl)-{(S)-2-[1-(2-methoxy-ethyl)-5,6-dimethyl-1H-benzoimidazol-2-yl]-2-methyl-pyrrolidin-1-yl}-methanone; and 
         [(2S,3S)-2-(5-Chloro-6-methyl-1H-benzoimidazol-2-yl)-3-methyl-pyrrolidin-1-yl]-(2-fluoro-3-methyl-6-pyrimidin-2-yl-phenyl)-methanone.
 
51) In addition to the above-listed compounds, further compounds according to embodiment 1) are selected from:
 
         (4-Bromo-biphenyl-2-yl)-[(S)-2-methyl-2-(5-trifluoromethyl-1H-benzoimidazol-2-yl)-pyrrolidin-1-yl]-methanone; 
         [(S)-2-(5,6-Dimethyl-1H-benzoimidazol-2-yl)-4-methylene-pyrrolidin-1-yl]-(2-methyl-6-[1,2,3]triazol-2-yl-phenyl)-methanone; 
         [(S)-2-(5,6-Dimethyl-1H-benzoimidazol-2-yl)-4-methylene-pyrrolidin-1-yl]-(5-methyl-2-pyrazol-1-yl-phenyl)-methanone; and 
         [(S)-2-(5,6-Dimethyl-1H-benzoimidazol-2-yl)-4-methylene-pyrrolidin-1-yl]-(6-methyl-3-[1,2,3]triazol-2-yl-pyridin-2-yl)-methanone.
 
52) In another embodiment, preferred compounds according to embodiment 1) are selected from:
 
         [(2S,3S)-2-(5-Chloro-4-methyl-1H-benzoimidazol-2-yl)-3-methyl-pyrrolidin-1-yl]-(2-fluoro-6-pyrimidin-2-yl-phenyl)-methanone; 
         [(2S,3S)-2-(5-Chloro-4-methyl-1H-benzoimidazol-2-yl)-3-methyl-pyrrolidin-1-yl]-(2-fluoro-3-methyl-6-pyrimidin-2-yl-phenyl)-methanone; 
         [(2S,3S)-2-(5-Chloro-6-methyl-1H-benzoimidazol-2-yl)-3-methyl-pyrrolidin-1-yl]-(2-fluoro-3-methyl-6-pyrimidin-2-yl-phenyl)-methanone; 
         [(2S,3S)-2-(5-Chloro-4-methyl-1H-benzoimidazol-2-yl)-3-methyl-pyrrolidin-1-yl]-(5-chloro-2-[1,2,3]triazol-2-yl-phenyl)-methanone; 
         [(2S,3S)-2-(5-Chloro-4-methyl-1H-benzoimidazol-2-yl)-3-methyl-pyrrolidin-1-yl]-(2-fluoro-3-methyl-6-[1,2,3]triazol-2-yl-phenyl)-methanone; 
         3′-[(S)-2-Methyl-2-(5-trifluoromethyl-1H-benzoimidazol-2-yl)-pyrrolidine-1-carbonyl]-4′-[1,2,3]triazol-2-yl-biphenyl-3-carbonitrile; and 
         [(S)-2-(5-Chloro-4-methyl-1H-benzoimidazol-2-yl)-2-methyl-pyrrolidin-1-yl]-[5-(4-fluoro-phenyl)-2-phenyl-thiazol-4-yl]-methanone.
 
53) In another embodiment, preferred compounds according to embodiment 1) are selected from:
 
         (5-Methyl-2-[1,2,3]triazol-2-yl-phenyl)-[(S)-2-methyl-2-(5-trifluoromethyl-1H-benzoimidazol-2-yl)-pyrrolidin-1-yl]-methanone; 
         (5-Methyl-2-[1,2,3]triazol-2-yl-phenyl)-[(S)-2-methyl-2-(5-trifluoromethoxy-1H-benzoimidazol-2-yl)-pyrrolidin-1-yl]-methanone; 
         [(S)-2-(5,6-Dimethoxy-1H-benzoimidazol-2-yl)-2-methyl-pyrrolidin-1-yl]-(5-methyl-2-[1,2,3]triazol-2-yl-phenyl)-methanone; 
         [(S)-2-(6-Bromo-5-fluoro-1H-benzoimidazol-2-yl)-2-methyl-pyrrolidin-1-yl]-(5-methyl-2-[1,2,3]triazol-2-yl-phenyl)-methanone; 
         [(S)-2-(6-Chloro-5-trifluoromethyl-1H-benzoimidazol-2-yl)-2-methyl-pyrrolidin-1-yl]-(5-methyl-2-[1,2,3]triazol-2-yl-phenyl)-methanone; 
         [(S)-2-(5-Chloro-4-methyl-1H-benzoimidazol-2-yl)-2-methyl-pyrrolidin-1-yl]-(5-chloro-2-[1,2,3]triazol-2-yl-phenyl)-methanone; 
         [(S)-2-(5-Chloro-4-methyl-1H-benzoimidazol-2-yl)-2-methyl-pyrrolidin-1-yl]-(2-fluoro-3-methoxy-6-[1,2,3]triazol-2-yl-phenyl)-methanone; 
         [(S)-2-(5-Chloro-4-methyl-1H-benzoimidazol-2-yl)-2-methyl-pyrrolidin-1-yl]-(4-methyl-2-[1,2,3]triazol-2-yl-phenyl)-methanone; 
         [(S)-2-(5-Chloro-4-methyl-1H-benzoimidazol-2-yl)-2-methyl-pyrrolidin-1-yl]-(5-methyl-2-pyrazol-1-yl-phenyl)-methanone; 
         [(S)-2-(5-Chloro-4-methyl-1H-benzoimidazol-2-yl)-2-methyl-pyrrolidin-1-yl]-(6-methyl-3-pyrazol-1-yl-pyridin-2-yl)-methanone; 
         [(S)-2-(5-Chloro-4-methyl-1H-benzoimidazol-2-yl)-2-methyl-pyrrolidin-1-yl]-(5-fluoro-2-[1,2,3]triazol-2-yl-phenyl)-methanone; 
         [(S)-2-(5-Chloro-4-methyl-1H-benzoimidazol-2-yl)-2-methyl-pyrrolidin-1-yl]-(2-[1,2,3]triazol-2-yl-phenyl)-methanone; 
         (5-Chloro-2-[1,2,3]triazol-2-yl-phenyl)-[(S)-2-(5,6-dimethoxy-1H-benzoimidazol-2-yl)-2-methyl-pyrrolidin-1-yl]-methanone; 
         [(S)-2-(5,6-Dimethoxy-1H-benzoimidazol-2-yl)-2-methyl-pyrrolidin-1-yl]-(5-methoxy-2-[1,2,3]triazol-2-yl-phenyl)-methanone; 
         [(S)-2-(5,6-Dimethoxy-1H-benzoimidazol-2-yl)-2-methyl-pyrrolidin-1-yl]-(5-methyl-2-pyrazol-1-yl-phenyl)-methanone; 
         [(S)-2-(6-Chloro-5-trifluoromethyl-1H-benzoimidazol-2-yl)-2-methyl-pyrrolidin-1-yl]-(4,5-dimethyl-2-[1,2,3]triazol-2-yl-phenyl)-methanone; and 
         (4,5-Dimethyl-2-[1,2,3]triazol-2-yl-phenyl)-[(S)-2-methyl-2-(5-trifluoromethyl-1H-benzoimidazol-2-yl)-pyrrolidin-1-yl]-methanone.
 
54) In another embodiment, further preferred compounds according to embodiment 1) are:
 
         [(S)-2-(5-Chloro-4-methyl-1H-benzoimidazol-2-yl)-2-methyl-pyrrolidin-1-yl]-(6-methyl-3-[1,2,3]triazol-2-yl-pyridin-2-yl)-methanone; and 
         [(S)-2-(5-Chloro-4-methyl-1H-benzoimidazol-2-yl)-2-methyl-pyrrolidin-1-yl]-(5-methyl-2-pyrimidin-2-yl-phenyl)-methanone.
 
55) A particularly preferred compound according to embodiment 1) is:
 
         [(S)-2-(5-Bromo-7-methyl-1H-benzoimidazol-2-yl)-2-methyl-pyrrolidin-1-yl]-(5-methyl-2-[1,2,3]triazol-2-yl-phenyl)-methanone.
 
56) Another particularly preferred compound according to embodiment 1) is:
 
         [(S)-2-(5-Bromo-7-methyl-1H-benzoimidazol-2-yl)-2-methyl-pyrrolidin-1-yl]-(5-methyl-2-pyrimidin-2-yl-phenyl)-methanone.
 
57) Another particularly preferred compound according to embodiment 1) is:
 
         [(S)-2-(5-Chloro-4-methyl-1H-benzoimidazol-2-yl)-2-methyl-pyrrolidin-1-yl]-(5-methoxy-2-[1,2,3]triazol-2-yl-phenyl)-methanone. 
       
    
     The compounds of formulae (I), (II), (Ill), (IV), (V), and (VI) according to any one of embodiments 1) to 57) and their pharmaceutically acceptable salts can be used as medicaments, e.g. in the form of pharmaceutical compositions for enteral (such especially oral) or parenteral administration (including topical application or inhalation). 
     The production of the pharmaceutical compositions can be effected in a manner which will be familiar to any person skilled in the art (see for example Remington,  The Science and Practice of Pharmacy,  21st Edition (2005), Part 5, “Pharmaceutical Manufacturing” [published by Lippincott Williams &amp; Wilkins]) by bringing the described compounds of formulae (I), (II) and (III) or their pharmaceutically acceptable salts, optionally in combination with other therapeutically valuable substances, into a galenical administration form together with suitable, non-toxic, inert, therapeutically compatible solid or liquid carrier materials and, if desired, usual pharmaceutical adjuvants. 
     The present invention also relates to a method for the prevention or treatment of a disease or disorder mentioned herein comprising administering to a subject a pharmaceutically active amount of a compound of formulae (I), (II), (III), (IV), (V), and (VI) according to any one of embodiments 1) to 57). 
     In a preferred embodiment of the invention, the administered amount of such a compound of formulae (I), (II), (III), (IV), (V), and (VI) according to any one of embodiments 1) to 57) is comprised between 1 mg and 1000 mg per day, particularly between 5 mg and 500 mg per day, more particularly between 25 mg and 400 mg per day, especially between 50 mg and 200 mg per day. 
     For avoidance of any doubt, if compounds are described as useful for the prevention or treatment of certain diseases, such compounds are likewise suitable for use in the preparation of a medicament for the prevention or treatment of said diseases. 
     The compounds according to formulae (I), (II), (III), (IV), (V), and (VI) according to any one of embodiments 1) to 57) are useful for the prevention or treatment of disorders relating to orexinergic dysfunctions. 
     Such disorders relating to orexinergic dysfunctions are diseases or disorders where an antagonist of a human orexin receptor is required, notably mental health disorders relating to orexinergic dysfunctions. The above mentioned disorders may in particular be defined as comprising sleep disorders, anxiety disorders, addiction disorders, cognitive dysfunctions, mood disorders, or appetite disorders. In one sub-embodiment, the above mentioned disorders comprise especially anxiety disorders, addiction disorders and mood disorders, notably anxiety disorders and addiction disorders. In another sub-embodiment, the above mentioned disorders comprise especially sleep disorders. 
     In addition, further disorders relating to orexinergic dysfunctions are selected from treating, controlling, ameliorating or reducing the risk of epilepsy, including absence epilepsy; treating or controlling pain, including neuropathic pain; treating or controlling Parkinson&#39;s disease; treating or controlling psychosis including acute mania and bipolar disorder; treating or controlling stroke, particularly ischemic or haemorrhagic stroke; blocking an emetic response i.e. nausea and vomiting; and treating or controlling agitation, in isolation or co-morbid with another medical condition. 
     Anxiety disorders can be distinguished by the primary object or specificity of threat, ranging from rather diffuse as in generalized anxiety disorder, to circumscribed as encountered in phobic anxieties (PHOBs) or post-traumatic stress disorders (PTSDs). Anxiety disorders may, thus, be defined as comprising generalized anxiety disorders (GAD), obsessive compulsive disorders (OCDs), acute stress disorders, posttraumatic stress disorders (PTSDs), panic anxiety disorders (PADs) including panic attacks, phobic anxieties (PHOBs), specific phobia, social phobia (social anxiety disorder), avoidance, somatoform disorders including hypochondriasis, separation anxiety disorder, anxiety disorders due to a general medical condition, and substance induced anxiety disorders. In a sub-embodiment, particular examples of circumscribed threat induced anxiety disorders are phobic anxieties or post-traumatic stress disorders. Anxiety disorders especially include post-traumatic stress disorders, obsessive compulsive disorders, panic attacks, phobic anxieties, and avoidance. 
     Addiction disorders may be defined as addictions to one or more rewarding stimuli, notably to one rewarding stimulus. Such rewarding stimuli may be of either natural or synthetic origin. Examples of such rewarding stimuli are substances/drugs {of either natural or synthetic origin; such as cocaine, amphetamines, opiates [of natural or (semi-)synthetic origin such as morphine or heroin],  cannabis , ethanol, mescaline, nicotine, and the like}, which substances/drugs may be consumed alone or in combination; or other rewarding stimuli {of either natural origin (such as food, sweet, fat, or sex, and the like), or synthetic origin [such as gambling, or internet/IT (such as immoderate gaming, or inappropriate involvement in online social networking sites or blogging), and the like]}. In a sub-embodiment, addiction disorders relating to psychoactive substance use, abuse, seeking and reinstatement are defined as all types of psychological or physical addictions and their related tolerance and dependence components. Substance-related addiction disorders especially include substance use disorders such as substance dependence, substance craving and substance abuse; substance-induced disorders such as substance intoxication, substance withdrawal, and substance-induced delirium. The expression “prevention or treatment of addictions” (i.e. preventive or curative treatment of patients who have been diagnosed as having an addiction, or as being at risk of developing addictions) refers to diminishing addictions, notably diminishing the onset of addictions, to weakening their maintenance, to facilitating withdrawal, to facilitating abstinence, or to attenuating, decreasing or preventing the occurrence of reinstatement of addiction (especially to diminishing the onset of addictions, to facilitating withdrawal, or to attenuating, decreasing or preventing the occurrence of reinstatement of addiction). 
     Mood disorders include major depressive episode, manic episode, mixed episode and hypomanic episode; depressive disorders including major depressive disorder, dysthymic disorders; bipolar disorders including bipolar I disorder, bipolar II disorder (recurrent major depressive episodes with hypomanic episodes), cyclothymic disorder; mood disorders including mood disorder due to a general medical condition (including the subtypes with depressive features, with major depressive-like episode, with manic features, and with mixed features), substance-induced mood disorder (including the subtypes with depressive features, with manic features, and with mixed features). Such mood disorders are especially major depressive episode, major depressive disorder, mood disorder due to a general medical condition; and substance-induced mood disorder. 
     Appetite disorders comprise eating disorders and drinking disorders. Eating disorders may be defined as comprising eating disorders associated with excessive food intake and complications associated therewith; anorexias; compulsive eating disorders; obesity (due to any cause, whether genetic or environmental); obesity-related disorders including overeating and obesity observed in Type 2 (non-insulin-dependent) diabetes patients; bulimias including bulimia nervosa; cachexia; and binge eating disorder. Particular eating disorders comprise metabolic dysfunction; dysregulated appetite control; compulsive obesities; bulimia or anorexia nervosa. In a sub-embodiment, eating disorders may be defined as especially comprising anorexia nervosa, bulimia, cachexia, binge eating disorder, or compulsive obesities. Drinking disorders include polydipsias in psychiatric disorders and all other types of excessive fluid intake. Pathologically modified food intake may result from disturbed appetite (attraction or aversion for food); altered energy balance (intake vs. expenditure); disturbed perception of food quality (high fat or carbohydrates, high palatability); disturbed food availability (unrestricted diet or deprivation) or disrupted water balance. 
     Cognitive dysfunctions include deficits in attention, learning and especially memory functions occurring transiently or chronically in psychiatric, neurologic, neurodegenerative, cardiovascular and immune disorders, and also occurring transiently or chronically in the normal, healthy, young, adult, or especially aging population. Cognitive dysfunctions especially relate to the enhancement or maintenance of memory in patients who have been diagnosed as having, or being at risk of developing, diseases or disorders in which diminished memory (notably declarative or procedural) is a symptom [in particular dementias such as frontotemporal dementia, or dementia with Lewy bodies, or (especially) Alzheimer&#39;s disease]. Especially, the term “prevention or treatment of cognitive dysfunctions” relates to the enhancement or maintenance of memory in patients who have a clinical manifestation of a cognitive dysfunction, especially expressed as a deficit of declarative memory, linked to dementias such as frontotemporal dementia, or dementia with Lewy bodies, or (especially) Alzheimer&#39;s disease. Furthermore, the term “prevention or treatment of cognitive dysfunctions” also relates to improving memory consolidation in any of the above mentioned patient populations. 
     Sleep disorders comprise dyssomnias, parasomnias, sleep disorders associated with a general medical condition and substance-induced sleep disorders. In particular, dyssomnias include intrinsic sleep disorders (especially insomnias, breathing-related sleep disorders, periodic limb movement disorder, and restless leg syndrome), extrinsic sleep disorders, and circadian-rhythm sleep disorders. Dyssomnias notably include insomnia, primary insomnia, idiopathic insomnia, insomnias associated with depression, emotional/mood disorders, aging, Alzheimer&#39;s disease or cognitive impairment; REM sleep interruptions; breathing-related sleep disorders; sleep apnea; periodic limb movement disorder (nocturnal myoclonus), restless leg syndrome, circadian rhythm sleep disorder; shift work sleep disorder; and jet-lag syndrome. Parasomnias include arousal disorders and sleep-wake transition disorders; notably parasomnias include nightmare disorder, sleep terror disorder, and sleepwalking disorder. Sleep disorders associated with a general medical condition are in particular sleep disorders associated with diseases such as mental disorders, neurological disorders, neuropathic pain, and heart and lung diseases. Substance-induced sleep disorders include especially the subtypes insomnia type, parasomnia type and mixed type, and notably include conditions due to drugs which cause reductions in REM sleep as a side effect. Sleep disorders especially include all types of insomnias, sleep-related dystonias; restless leg syndrome; sleep apneas; jet-lag syndrome; shift work sleep disorder, delayed or advanced sleep phase syndrome, or insomnias related to psychiatric disorders. In addition, sleep disorders further include sleep disorders associated with aging; intermittent treatment of chronic insomnia; situational transient insomnia (new environment, noise) or short-term insomnia due to stress; grief; pain or illness. 
     In the context of the present invention, it is to be understood that, in case certain environmental conditions such as stress or fear (wherein stress may be of social origin (e.g. social stress) or of physical origin (e.g. physical stress), including stress caused by fear) facilitate or precipitate any of the disorders or diseases as defined before, the present compounds may be particularly useful for the treatment of such environmentally conditioned disorder or disease. 
     Preparation of Compounds of Formula (I): 
     The compounds of formulae (I), (II), (Ill), (IV), (V), and (VI) can be prepared by the methods given below, by the methods given in the experimental part below or by analogous methods. Optimum reaction conditions may vary with the particular reactants or solvents used, but such conditions can be determined by a person skilled in the art by routine optimisation procedures. In some cases the final product may be further modified, for example, by manipulation of substituents to give a new final product. These manipulations may include, but are not limited to, reduction, oxidation, alkylation, acylation, and hydrolysis reactions which are commonly known to those skilled in the art. In some cases the order of carrying out the following reaction schemes, and/or reaction steps, may be varied to facilitate the reaction or to avoid unwanted reaction products. 
     Compounds of formulae (I), (II), (Ill), (IV), (V), and (VI) of the present invention can be prepared according to the general sequence of reactions outlined below wherein Ar 1 , R 1 , R 2 , R 3 , R 4a , R 4b  and (R 5 ) n  are as defined for formula (I). 
     The synthesis of compound of formulae (I), wherein R 1  represents hydrogen, starts from proline-derivatives (a) which are commercially available or prepared as described below. 
     There are two general synthetic approaches of equal importance towards compounds of formulae (I). 
     Synthetic approach 1 starts with a Boc-protection of the respective proline derivative a under standard conditions by for example dissolving the proline a in a solvent such as DCM or THF and adding a base to the solution, for example DIPEA, TEA or aqueous Na 2 CO 3  followed by the addition of Boc 2 O. The reaction is performed at room temperature and is usually complete within a few hours and results in the Boc-protected proline derivative b which is then coupled with the appropriate phenylene-diamine- or pyridine-diamine derivative in solvents such as THF, DCM or DMF in the presence of a coupling agent such as HBTU or TBTU or the like and a base, for example DIPEA or TEA to give compound c. To obtain the benzimidazole derivative d the precursor c is dissolved in AcOH and heated to 100° C. for 1 h. Compound d is Boc-deprotected under acidic conditions such as 4M HCl in dioxane (preferred method) or TFA in DCM to give precursor e which is converted into final compound f by an amide coupling reaction with Ar 1 —COOH in a solvent such as THF, DMF or DCM in the presence of a coupling agent such as TBTU, HBTU, HATU, EDC or the like and a base such as DIPEA, TEA or N-methylmorpholine. 
     
       
         
         
             
             
         
       
     
     Synthetic approach 2 starts with an esterification (usually methyl ester formation) of the proline derivative a by dissolving the starting material in THF and adding 5 equivalents of the respective alcohol (usually MeOH) followed by the addition of EDC and DMAP. The reaction is run at RT and is usually complete within a few hours. The methyl-ester derivative g is acylated with Ar 1 —COOH under conditions described above to result in intermediate h. Esterhydrolysis under standard conditions by dissolving the ester derivative h in THF/MeOH=1/1 followed by the addition of 2 equivalents of aq. 1M NaOH solution. The reaction runs at RT and is usually complete after a few hours to result in the carboxylic acid derivative i. The final compounds f are obtained via precursor j by applying the same conditions as described for the amide-coupling and the cyclization in synthetic approach 1. 
     The following scheme depicts the methodology to prepare N-methylated benzimidazolo-derivatives of formula (I), wherein R 1  represents methyl: 
     
       
         
         
             
             
         
       
     
     Final compounds g1 and g2 are prepared by simple alkylation of compounds f (compounds of formula (I) wherein R 1  is H) with an alkyl halide (for example MeI) in the presence of a carbonate base (e.g. Cs 2 CO 3 ) in a polar, aprotic solvent (e.g. DMF) at RT. In case the phenylring of the benzimidazole-system is unsymmetrically substituted with respect to R 14 , R 15 , R 16 , and R 17  the alkylation (methylation) reaction results in two isomeric products g1 and g2 as depicted above. 
     The following proline derivatives are commercially available and were purchased and used as starting materials according to the methods described herein: 
     
       
         
         
             
             
         
       
     
     The following proline derivatives may be prepared according to the procedures outlined in the following scheme: 
     
       
         
         
             
             
         
       
     
     The diastereomeric 4-hydroxy-proline derivatives k and n are commercially available starting points. Both compounds may be fully deprotonated with NaH in DMF followed by the addition of an excess of MeI to give the 4-methoxy-proline-methylester derivatives l and o which can be transformed into the carboxylic acid derivatives m and p by standard ester hydrolysis (e.g. 1M NaOH, MeOH, THF, rt). 
     Whenever the compounds of formulae (I), (II), (Ill), (IV), (V), or (VI) are obtained in the form of mixtures of stereoisomers such as especially enantiomers, the stereoisomers can be separated using methods known to one skilled in the art: e.g. by formation and separation of diastereomeric salts or by HPLC over a chiral stationary phase such as a Daicel ChiralPak AD-H (5 μm) column, a Daicel ChiralCel OD-H (5 μm) column, a Daicel ChiralCel OD (10 μm) column, a Daicel ChiralPak IA (5 μm) column, a Daicel ChiralPak IB (5 μm) column, a Daicel ChiralPak IC (5 μm) column, or a (R,R)-Whelk-01 (5 μm) column. Typical conditions of chiral HPLC are an isocratic mixture of eluent A (EtOH, in presence or absence of a base like TEA and/or diethylamine or of an acid like TFA) and eluent B (heptane). 
     The following examples are provided to illustrate the invention. These examples are illustrative only and should not be construed as limiting the invention in any way. 
    
    
     EXPERIMENTAL PART 
     I. Chemistry 
     All temperatures are stated in ° C. Commercially available starting materials were used as received without further purification. Unless otherwise specified, all reactions were carried out in oven-dried glassware under an atmosphere of nitrogen. Compounds were purified by flash column chromatography on silica gel or by preparative HPLC. Compounds described in the invention are characterised by LC-MS data (retention time t R  is given in min; molecular weight obtained from the mass spectrum is given in g/mol) using the conditions listed below. In cases where compounds of the present invention appear as a mixture of conformational isomers, particularly visible in their LC-MS spectra, the retention time of the most abundant conformer is given. Racemates can be separated into their enantiomers by preparative HPLC (column: ChiralPaK IC 250×4.6 mm, 5 μm, 45% ethanol in heptane). 
     LC-MS with Acidic Conditions 
     Method A: Agilent 1100 series with mass spectrometry detection (MS: Finnigan single quadrupole). Column: Zorbax SB-aq (3.5 μm, 4.6×50 mm). Conditions: MeCN [eluent A]; water+0.04% TFA [eluent B]. Gradient: 95% B→5% B over 1.5 min (flow: 4.5 mL/min). Detection: UV/Vis+MS. 
     Method B: Agilent 1100 series with mass spectrometry detection (MS: Finnigan single quadrupole). Column: Waters XBridge C18 (2.5 μm, 4.6×30 mm). Conditions: MeCN [eluent A]; water+0.04% TFA [eluent B]. Gradient: 95% B→5% B over 1.5 min (flow: 4.5 mL/min). Detection: UV/Vis+MS. 
     LC-MS with Basic Conditions 
     Method C: Agilent 1100 series with mass spectrometry detection (MS: Finnigan single quadrupole). Column: Zorbax Extend C18 (5 μm, 4.6×50 mm). Conditions: MeCN [eluent A]; 13 mmol/L NH 3  in water [eluent B]. Gradient: 95% B→5% B over 1.5 min (flow: 4.5 mL/min). Detection: UV/Vis+MS. 
     Method D: Agilent 1100 series with mass spectrometry detection (MS: Finnigan single quadrupole). Column: Waters XBridge C18 (5 m, 4.6×50 mm). Conditions: MeCN [eluent A]; 13 mmol/L NH 3  in water [eluent B]. Gradient: 95% B→5% B over 1.5 min (flow: 4.5 mL/min). Detection: UV/Vis+MS. 
     Preparative HPLC with Acidic Conditions 
     Method E: Column: Waters XBridge (10 m, 75×30 mm). Conditions: MeCN [eluent A]; water+0.5% HCOOH [eluent B]; Gradient: 90% B→5% B over 6.4 min (flow: 75 mL/min). Detection: UV/Vis+MS. 
     Preparative HPLC with Basic Conditions 
     Method F: Column: Waters XBridge (10 m, 75×30 mm). Conditions: MeCN [eluent A]; water+0.5% NH 4 OH (25% aq.) [eluent B]; Gradient: 90% B→5% B over 6.5 min (flow: 75 mL/min). Detection: UV/Vis+MS 
     Abbreviations (as Used Hereinbefore or Hereinafter) 
     Abbreviations (as used herein and in the description above): 
     Ac Acetyl (such as in OAc=acetate, AcOH=acetic acid) 
     AcOH Acetic acid 
     anh. Anhydrous 
     aq. aqueous 
     atm Atmosphere 
     tBME tert-Butylmethylether 
     Boc tert-Butoxycarbonyl 
     Boc 2 O di-tert-Butyl dicarbonate 
     BSA Bovine serum albumine 
     Bu Butyl such as in tBu=tert-butyl=tertiary butyl 
     CC Column Chromatography on silica gel 
     CHO Chinese Hamster Ovary 
     conc. Concentrated 
     DCE 1,2-Dichloroethane 
     DCM Dichloromethane 
     DEA Diethylamine 
     DIPEA Diisopropylethylamine 
     DMF N,N-Dimethylformamide 
     DMSO Dimethyl sulfoxide 
     EDC 
     ELSD Evaporative Light-Scattering Detection 
     eq Equivalent(s) 
     ES Electron spray 
     Et Ethyl 
     Et 2 O Diethyl ether 
     EtOAc Ethyl acetate 
     EtOH Ethanol 
     Ex. Example 
     FC Flash Chromatography on silica gel 
     FCS Foatal calf serum 
     FLIPR Fluorescent imaging plate reader 
     h Hour(s) 
     HATU 
     HBSS Hank&#39;s balanced salt solution 
     HBTU 
     HEPES 4-(2-Hydroxyethyl)-piperazine-1-ethanesulfonic acid 
       1 H-NMR Nuclear magnetic resonance of the proton 
     HPLC High performance liquid chromatography 
     LC-MS Liquid chromatography-Mass Spectroscopy 
     Lit. Literature 
     M Exact mass (as used for LC-MS) 
     Me Methyl 
     MeCN Acetonitrile 
     MeOH Methanol 
     MeI Methyl iodide 
     MHz Megahertz 
     μl microliter 
     min Minute(s) 
     MS Mass spectroscopy 
     N Normality 
     Pd(OAc) 2  Palladium diacetate 
     Pd(PPh 3 ) 4  Tetrakis(triphenylphosphine)palladium(0) 
     PL-HCO 3  Polymer supported hydrogen carbonate 
     Ph Phenyl 
     PPh 3  Triphenylphosphine 
     prep. Preparative 
     RT Room temperature 
     sat. Saturated 
     TBTU O-(Benzotriazol-1-yl)-N,N,N′,N′-tetramethyluronium tetrafluoroborate 
     TEA Triethylamine 
     TFA trifluoroacetic acid 
     Tf Trifluoromethansulfonyl 
     THF Tetrahydrofuran 
     t R  Retention time 
     UV Ultra violet 
     I-Chemistry 
     All temperatures are stated in ° C. The commercially available starting materials were used as received without further purification. Compounds are purified by flash column chromatography on silica gel (FC) or by preparative HPLC. Compounds described in the invention are characterized by LC-MS (retention time t R  is given in min.; molecular weight obtained from the mass spectrum is given in g/mol, using the conditions listed below). If the mass is not detectable the compounds are also characterized by  1 H-NMR (400 MHz: Bruker; chemical shifts are given in ppm relative to the solvent used; multiplicities: s=singlet, d=doublet, t=triplet; p=pentuplet, hex=hexet, hept=heptet, m=multiplet, br=broad, coupling constants are given in Hz). 
     LC-MS with Acidic Conditions (Conditions A) 
     Apparatus: Agilent 1100 series with mass spectroscopy detection (MS: Finnigan single quadrupole). Column: Waters XBridge C18 (2.5 m, 4.6×30 mm). Conditions: MeCN [eluent A]; water+0.04% TFA [eluent B]. Gradient: 95% B→5% B over 1.5 min. (flow: 4.5 ml/min.). Detection: UV/Vis+MS. 
     LC-MS with Basic Conditions (Conditions B) 
     Apparatus: Agilent 1100 series with mass spectroscopy detection (MS: Finnigan single quadrupole). Column: Waters XBridge C18 (5 m, 4.6×50 mm). Conditions: MeCN [eluent A]; 13 mmol/l NH 3  in water [eluent B]. Gradient: 95% B→5% B over 1.5 min. (flow: 4.5 ml/min.). Detection: UV/Vis+MS. 
     Preparative HPLC for Purification of Compounds (Conditions C) 
     Column: Waters XBridge (10 m, 75×30 mm). Conditions: MeCN [eluent A]; water+0.5% NH 4 OH (25% aq.) [eluent B]; Gradient: 90% B→5% B over 6.5 min. (flow: 75 ml/min.). Detection: UV+ELSD. 
     Preparative HPLC for Purification of Compounds (Conditions D) 
     Column: Waters Atlantis T3 OBD (10 m, 75×30 mm). Conditions: MeCN [eluent A]; water+0.5% HCOOH [eluent B]; Gradient: 90% B→5% B over 6.4 min. (flow: 75 ml/min.). Detection: UV+ELSD. 
     LC-MS with Basic Conditions (Conditions E) 
     Apparatus: Agilent 1100 series with mass spectroscopy detection (MS: Finnigan single quadrupole). Column: Agilent Zorbax Extend-C18 (5 um, 4.6×50 mm). Conditions: MeCN [eluent A]; 13 mmol/l NH 3  in water [eluent B]. Gradient: 95% B→5% B over 1.5 min. (flow: 4.5 ml/min.). Detection: UV+MS. 
     LC-MS with Acidic Conditions (Conditions F) 
     Apparatus: Agilent 1100 series with mass spectroscopy detection (MS: Finnigan single quadrupole). Column: Agilent Zorbax SB-Aq, (3.5 um, 4.6×50 mm). Conditions: MeCN [eluent A]; water+0.04% TFA [eluent B]. Gradient: 95% B→5% B over 1.5 min. (flow: 4.5 ml/min.). Detection: UV+MS. 
     The following examples illustrate the preparation of compounds of the invention but do not at all limit the scope thereof. 
     Preparation of Precursors and Intermediates: 
     A Preparation of Building Blocks of Formula Ar 1 —CO—OH: 
     The preparation of these acids is described in detail for example in the following documents: WO 2008/020405; WO 2008/038251; WO 2008/081399; WO 2008/139416. All other carboxylic acids used in the experimental part which are not described in the following section are either commercially available or fully described in the literature listed above and in the introduction part. 
     In addition to commercially available building blocks, further particular building blocks of formula Ar 1 —CO—OH are prepared as follows: 
     
       
         
         
             
             
         
       
       
         
         
             
             
         
       
     
     A.1 2-Fluoro-3-methyl-6-(2H-1,2,3-triazol-2-yl)benzoic Acid 39 
     2-Fluoro-3-methyl-6-(2H-1,2,3-triazol-2-yl)benzoic acid 39 is synthesized in analogy to procedures reported in WO2008/069997. 
     In a dry Schlenk Tube at RT under nitrogen are successively charged 2-fluoro-6-iodo-3-methyl-benzoic acid (1.786 mmol, 1 eq), CuI (0.089 mmol, 0.05 eq), 1H-1,2,3-triazole (3.571 mmol, 2 eq), Cs 2 CO 3  (3.571 mmol, 2 eq) and DMF (2.5 mL). The resulting blue suspension is stirred at 80° C. overnight. The obtained reaction mixture is taken up in 1 M aq. HCl and extracted twice with EtOAc. The combined organic layers are dried over Na 2 SO 4 , filtered and concentrated under reduced pressure. Purification is achieved by preparative HPLC (conditions D) to give the titled compound (246 mg) as a pale yellow solid. LC-MS (conditions A): t R =0.55 min, [M+1] + =222.19. 
     A.2 5-Methoxy-2-(2H-1,2,3-triazol-2-yl)benzoic Acid 40 
     The title compound is prepared in analogy to compound 39 starting from 2-iodo-5-methoxybenzoic acid (1.798 mmol, 1 eq). 40 (313 mg) is obtained as a yellow solid. LC-MS (conditions A): t R =0.49 min, [M+1] + =220.07. 
     A.3 2-Fluoro-3-methoxy-6-(2H-1,2,3-triazol-2-yl)benzoic Acid 41 
     The title compound is prepared in analogy to compound 39 starting from 2-fluoro-6-iodo-3-methoxy-benzoic acid (1.689 mmol, 1 eq). 41 (221 mg) is obtained as a pale yellow solid. LC-MS (conditions A): t R =0.48 min, [M+1] + =238.18. 
     A.4 2-(2H-1,2,3-Triazol-2-yl)-5-(trifluoromethyl)benzoic Acid 42 
     The title compound is prepared in analogy to compound 39 starting from 2-iodo-5-trifluorobenzoic acid (1.582 mmol, 1 eq). 42 (268 mg, 66%) is obtained as a white solid. LC-MS (conditions A): t R =0.64 min, [M+1] + =257.91. 
     A.5 2-(2H-1,2,3-Triazol-2-yl)-5-(trifluoromethoxy)benzoic Acid 43 
     The title compound is prepared in analogy to compound 39 starting from 2-iodo-5-(trifluoromethoxy)benzoic acid (1.506 mmol, 1 eq). 43 (243 mg) is obtained as an off-white solid. LC-MS (conditions A): t R =0.66 min, [M+1] + =273.69. 
     A.6 5-Cyano-2-(2H-1,2,3-triazol-2-yl)benzoic Acid 44 
     The title compound is prepared in analogy to compound 39 starting from 5-cyano-2-iodobenzoic acid (1.831 mmol, 1 eq). 44 (214 mg) is obtained as a grey solid. LC-MS (conditions A): t R =0.46 min, [M+1] + =not detectable.  1 H NMR (D 6 -DMSO): □□13.49 (m, 1H), 8.21 (m, 1H), 8.18 (m, 2H), 8.15 (m, 1H), 8.03 (m, 1H). 
     A.7 5-Methyl-2-(pyridin-2-yl)benzoic Acid 45 
     a) In a dry Schlenk Tube at RT under nitrogen are successively charged 2-iodo-5-methylbenzoic acid methyl ester (13.765 mmol, 1 eq), CuI (2.753 mmol, 0.2 eq), CsF (27.529 mmol, 2 eq), 2-tributylstannylpyridine (20.647 mmol, 1.5 eq), Pd(PPh 3 ) 4  (1.376 mmol, 0.1 eq) and DMF (60 mL). The resulting suspension is stirred at 90° C. overnight. The obtained reaction mixture is diluted with EtOAc and filtered through a short pad of Celite®. A solution of sat. aq. NaHCO 3  is then added to the filtrate and the aq. phase extracted with EtOAc (3 times). The combined organic layers are washed with H 2 O and brine, dried over Na 2 SO 4 , filtered and concentrated under reduced pressure. Purification is achieved by FC (EtOAc/Heptane 1:4 to 3:7) to give methyl 5-methyl-2-(pyridin-2-yl)benzoate (2.64 g) as a brown oil. LC-MS (conditions A): t R =0.67 min, [M+1] + =228.07. 
     b) To a solution of methyl 5-methyl-2-(pyridin-2-yl)benzoate (11.617 mmol, 1 eq) in MeOH (15 mL) and THF (17 mL) is added 1 M NaOH (23.233 mL, 2 eq). The resulting mixture is stirred at RT overnight. The volatiles are evaporated under reduced pressure and the remaining aq. phase is acidified with 2 M HCl to pH=1-2 and extracted with DCM (3 times). The combined organic layers are dried over Na 2 SO 4 , filtered and concentrated under reduced pressure to give 5-methyl-2-(pyridin-2-yl)benzoic acid 45 (2.65 g) as a pale brown foam. LC-MS (conditions A): t R =0.39 min, [M+1] + =214.25. 
     A.8 2-Fluoro-3-methyl-6-(1H-pyrazol-1-yl)benzoic Acid 46 
     The title compound is prepared in analogy to compound 39 replacing the 1H-1,2,3-triazole with 1H-pyrazole (25 mmol, 2 eq). 46 (1.86 g) is obtained as a light yellow solid. LC-MS (conditions F): t R =0.63 min, [M+1] + =221.16. 
     A.9 2-Fluoro-3-methyl-6-(pyridin-2-yl)benzoic Acid 47 
     a) In a dry Schlenk Tube at RT under nitrogen are successively charged methyl 2-fluoro-6-iodo-3-methylbenzoate (9.18 mmol, 1 eq), CuI (1.84 mmol, 0.2 eq), CsF (18.4 mmol, 2 eq), 2-tributylstannylpyridine (9.18 mmol, 1 eq), Pd(PPh 3 ) 4 (0.918 mmol, 0.1 eq) and DMF (40 mL). The resulting suspension is stirred at 90° C. overnight. The obtained reaction mixture is diluted with EtOAc and filtered through a short pad of Celite®. A solution of sat. aq. NaHCO 3  is then added to the filtrate and the aq. phase extracted with EtOAc (3 times). The combined organic layers are washed with H 2 O and brine, dried over Na 2 SO 4 , filtered and concentrated under reduced pressure. Purification is achieved by FC (Teledyne Isco Combiflash Rf, SiO 2  cartridge 120 g; Heptane to EtOAc/Heptane 3:7) to give methyl 2-fluoro-3-methyl-6-(pyridin-2-yl)benzoate as a brown oil. LC-MS (conditions F): t R =0.74 min, [M+1] + =246.15. 
     b) To a solution of methyl 2-fluoro-3-methyl-6-(pyridin-2-yl)benzoate (6.36 mmol, 1 eq) in MeOH (11.3 mL) is added NaOH 32% (6.27 mL). The resulting mixture is stirred at 60° C. for 1 hour. The volatiles are evaporated under reduced pressure and the remaining aq. phase is acidified with 7 M HCl to pH=1-2. The pink suspension is concentrated under reduced pressure and the obtained solid is purified by preparative HPLC (conditions D) to give 2-fluoro-3-methyl-6-(pyridin-2-yl)benzoic acid 47 (1.14 g) as a light pink solid. LC-MS (conditions F): t R =0.47 min, [M+1] + =232.17. 
     A.10 3-fluoro-4-methyl-[1,1′-biphenyl]-2-carboxylic Acid 48 
     a) In a dry Schlenk Tube at RT under nitrogen are successively charged methyl 2-fluoro-6-iodo-3-methylbenzoate (23.5 mmol, 1 eq), Pd(PPh 3 ) 4  (1.17 mmol, 0.05 eq) and toluene (60 mL). The resulting mixture is stirred at RT for 15 minutes before a solution of phenyloronic acid (25.8 mmol, 1.1 eq) in EtOH (26 mL) and 2 M Na 2 CO 3  (54 mL) are successively added. The resulting mixture is stirred at reflux overnight. The obtained reaction mixture is diluted with Et 2 O and the solvents are removed under reduced pressure. The residue is purified by FC (Teledyne Isco Combiflash Rf, SiO 2  cartridge 120 g; heptane to EtOAc/heptane 3:97) to give methyl 3-fluoro-4-methyl-[1,1′-biphenyl]-2-carboxylate as a light yellow oil. LC-MS (conditions F): t R =0.94 min, [M+1] + =245.19. 
     b) To a solution of methyl 3-fluoro-4-methyl-[1,1′-biphenyl]-2-carboxylate (23 mmol, 1 eq) in MeOH (42 mL) is added NaOH 32% (24 mL). The resulting mixture is stirred at 65° C. for 2 hour. The volatiles are evaporated under reduced pressure and the remaining aq. phase is acidified with 7 M HCl to pH=1-2. The resulting suspension is filtered under vacuum and the obtained solid dried under hight vacuum. 3-Fluoro-4-methyl-[1,1′-biphenyl]-2-carboxylic acid 48 (4.35 g) is obtained as a white solid. LC-MS (conditions F): t R =0.81 min, [M+1] + =not detectable. 
     5-Aryl-2-methyl-thiazole-4-carboxylic Acids 
     These acids were prepared by a three-step sequence depicted in the scheme below, e.g. Darzens condensation of 4-fluoro-benzaldehyde 49 with methyl dichloroacetate to give the methyl keto-ester 50 (Hamamoto H. et al  Tetrahedron Asymmetry  2000, 11, 4485-4497) which is converted to the desired 5-(4-fluoro-phenyl)-2-methyl-4-carboxylic acid 51 by reaction with thioamide (U.S. Pat. No. 3,282,927) followed by ester hydrolysis under basic conditions. 
     
       
         
         
             
             
         
       
     
     The following compounds were prepared according to the same sequence: 
     
       
         
         
             
             
         
       
       
         
         
             
             
         
       
     
     PREPARATION OF THE EXAMPLES 
     Synthesis of Example 1.1 
     
       
         
         
             
             
         
       
     
     Step 1: 5-Methyl-2-(2H-1,2,3-triazol-2-yl)benzoic acid (2; 12.27 g, 60.4 mmol) and L-proline methylester hydrochloride (1; 10.20 g, 60.4 mmol) are dissolved in DCM (250 ml) followed by the addition of DIPEA (23.42 g, 31 ml, 181 mmol) and HATU (22.95 g, 60.4 mmol). Stirring at room temperature is continued for 1 h, the DCM is evaporated under reduced pressure and EtOAc (750 ml) is added. The reaction mixture is extracted with brine (3×300 ml). The organic layer is dried with MgSO 4 , filtered and the solvent is evaporated under reduced pressure to give (S)-methyl 1-(5-methyl-2-(2H-1,2,3-triazol-2-yl)benzoyl)pyrrolidine-2-carboxylate (3) which is used in the next step without further purification. LC-MS: t R =0.66 min; [M+H] + =315.09. 
     Step 2: (S)-Methyl 1-(5-methyl-2-(2H-1,2,3-triazol-2-yl)benzoyl)pyrrolidine-2-carboxylate (3, 18.81 g, 60.4 mmol) is dissolved in a mixture of MeOH (180 ml) and THF (210 ml) followed by the addition of aq. NaOH solution (1 M; 150 ml). Stirring is continued for 1 h. The reaction mixture is concentrated (removal of the organic solvents) under reduced pressure and acidified to pH 1 by the addition of aq. HCl (1M). The product is extracted with EtOAc (3×250 ml). The combined organic layers are dried with MgSO 4 , filtered and the solvent is evaporated under reduced pressure to give 17.14 g (87%) (S)-1-(5-methyl-2-(2H-1,2,3-triazol-2-yl)benzoyl)pyrrolidine-2-carboxylic acid (4). LC-MS: t R =0.57 min; [M+H] + =301.17. 
     Step 3: (S)-1-(5-Methyl-2-(2H-1,2,3-triazol-2-yl)benzoyl)pyrrolidine-2-carboxylic acid (4; 17.11 g, 51.3 mmol) is dissolved in DCM (250 ml) at RT followed by the addition of 3,4-diaminoanisole dihydrochlodride (5; 10.83 g, 51.3 mmol). To this reaction mixture DIPEA (23.2 g, 180 mmol) is then slowly added followed by the addition of HATU (19.7 g, 51.8 mmol). Stirring is continued for 1 h at RT. The reaction mixture is concentrated under reduced pressure. The residue is taken up in EtOAc (750 ml) and washed with brine (2×500 ml). The organic layer is dried with MgSO 4 , filtered and concentrated under reduced pressure. The crude product is purified by flash master chromatography (Silicagel; EtOAc/MeOH=95/5) to give (S)—N-(2-amino-4-methoxyphenyl)-1-(5-methyl-2-(2H-1,2,3-triazol-2-yl)benzoyl)pyrrolidine-2-carboxamide (6). LC-MS: t R =0.64 min; [M+H] + =421.17. 
     Step 4: (S)—N-(2-amino-4-methoxyphenyl)-1-(5-methyl-2-(2H-1,2,3-triazol-2-yl)benzoyl) pyrrolidine-2-carboxamide (6; 21.57 g, 51.3 mmol) is dissolved in pure AcOH (390 ml) and heated to 100° C. for 30 minutes. The reaction mixture is cooled to rt and the acetic acid is removed under reduced pressure. The residual material is carefully diluted with sat. aq. NaHCO 3  solution (600 ml). The product precipitated and is filtered off and purified by flash master chromatography (Silicagel, DCM/MeOH=98/2) to give (S)-(2-(6-methoxy-1H-benzo[d]imidazol-2-yl)pyrrolidin-1-yl)(5-methyl-2-(2H-1,2,3-triazol-2-yl)phenyl)methanone (Example 1.1) as a colorless powder. LC-MS: t R =0.55 min; [M+H] + =403.16. 
     Synthesis of Example 2.1 
     
       
         
         
             
             
         
       
     
     Step 1: (2S,4S)-1-(tert-Butoxycarbonyl)-4-fluoropyrrolidine-2-carboxylic acid (7; 144.27 mg, 0.6 mmol) is dissolved in a 1/1 mixture of DMF/DCM (1.2 ml) followed by the addition of DIPEA (0.44 ml, 2.52 mmol) and 4-chloro-3-methylbenzene-1,2-diamine (8; 121.95 mg, 0.6 mmol) dissolved in a 1/1 mixture of DMF/DCM (1.2 ml) and finally by the addition of HATU (240 mg, 0.63 mmol) dissolved in DMF (1 ml). The reaction mixture is stirred at RT for 15 h then passed through PL-HCO 3  packed filter syringe (1 g) with a 1/1-mixture of DMF/DCM (4 ml). The solvent is removed under reduced pressure to give (2S,4S)-tert-butyl 2-((2-amino-4-chloro-3-methylphenyl)carbamoyl)-4-fluoropyrrolidine-1-carboxylate (9) which is used in the next step without further purification. LC-MS: t R =0.79 min; [M+H] + =372.26. 
     Step 2: (2S,4S)-tert-Butyl 2-((2-amino-4-chloro-3-methylphenyl)carbamoyl)-4-fluoropyrrolidine-1-carboxylate (9; 220 mg, 0.6 mmol) is dissolved in 100% AcOH (3 ml, 52.5 mmol) and heated to 60° C. for 3 h. Toluene (3 ml) is added to the reaction mixture and the solvents are removed under reduced pressure to give (2S,4S)-tert-butyl 2-(6-chloro-7-methyl-1H-benzo[d]imidazol-2-yl)-4-fluoropyrrolidine-1-carboxylate (10), which is used in the next step without further purification. LC-MS: t R =0.8 min; [M+H] + =354.25. 
     Step 3: (2S,4S)-tert-Butyl 2-(6-chloro-7-methyl-1H-benzo[d]imidazol-2-yl)-4-fluoropyrrolidine-1-carboxylate (10; 210 mg, 0.6 mmol) is dissolved in dioxane (0.5 ml) and a solution of HCl in dioxane (4M, 3 ml, 12 mmol) is carefully added. The reaction mixture turns into a suspension. To solubilize the reaction mixture MeOH (1 ml) is added. Stirring is continued for 2 h. The solvents are removed under reduced pressure to give 6-chloro-2-((2S,4S)-4-fluoropyrrolidin-2-yl)-7-methyl-1H-benzo[d]imidazole hydrochloride (11) which is used in the next step without further purification. LC-MS: t R =0.61 min; [M+H] + =254.14. 
     Step 4: 6-Chloro-2-((2S,4S)-4-fluoropyrrolidin-2-yl)-7-methyl-1H-benzo[d]imidazole hydrochloride (11; 30 mg, 0.1 mmol) is dissolved in DCM (0.2 ml) and DIPEA (0.072 ml, 0.42 mmol) is added, followed by the addition of a solution of 5-methyl-2-(2H-1,2,3-triazol-2-yl)benzoic acid (2; 20.3 mg, 0.1 mmol), HATU (40 mg, 0.105 mmol) and DIPEA (80 mg, 0.62 mmol) in 0.5 ml DMF. Stirring is continued at room temperature for 16 h. The reaction mixture is diluted with DCM/MeOH=1/1 (1 ml) followed by the addition of PL-HCO 3 -resin (213 mg, 0.4 mmol) and stirring is continued for 2 h. The resin is filtered off, the solvent is evaporated under reduced pressure and the product is purified by preparative HPLC to give ((2S,4S)-2-(6-chloro-7-methyl-1H-benzo[d]imidazol-2-yl)-4-fluoropyrrolidin-1-yl)(5-methyl-2-(2H-1,2,3-triazol-2-yl)phenyl)methanone (Example 2.1) as a colorless powder. LC-MS: t R =1.14 min; [M+H] + =439.25. 
     Synthesis of Example 3.1 
     
       
         
         
             
             
         
       
     
     Step 1: (2S,4S)-1-(tert-Butoxycarbonyl)-4-hydroxypyrrolidine-2-carboxylic acid (12, 1.503 g, 6.5 mmol) is dissolved in DMF (9.06 ml) and added to a suspension of NaH (60% dispersion in mineral oil, 676 mg, 16.9 mmol) in DMF (9.06 ml) in an argon atmosphere at RT and stirring is continued for 30 minutes followed by the addition of MeI (3.14 g, 22.14 mmol). Stirring is continued for 23 h. An aq., sat. solution of KH 2 PO 4  (30 ml) is added followed by the addition of solid KH 2 PO 4  (400 mg) and another portion of an aq., sat. solution of KH 2 PO 4  (10 ml). The product is extracted with Et 2 O (3×40 ml). The combined organic layers are dried with MgSO 4 , filtered and the solvent is removed under reduced pressure to give the 3-methoxy-proline methylester-intermediate, which is dissolved in MeOH (4.5 ml) followed by the addition of an aq. NaOH solution (3M, 3.76 ml, 11.3 mmol). Stirring is continued for 12 h. The reaction mixture is neutralized to pH=9, by the addition of a sat. solution of KH 2 PO 4  and extracted with Et 2 O (3×8 ml). The combined ether layers are discarded and the aq. layer is acidified to pH=4.5 with aq. HCl. The product is extracted with EtOAc (3×40 ml). The combined organic layers are dried with MgSO 4 , filtered and the solvent is removed under reduced pressure to give (2S,4S)-1-(tert-butoxycarbonyl)-4-methoxypyrrolidine-2-carboxylic acid (13). 
     Step 2: (2S,4S)-1-(tert-Butoxycarbonyl)-4-methoxypyrrolidine-2-carboxylic acid (13; 147.1 mg, 0.6 mmol) is dissolved in a 1/1 mixture of DMF/DCM (1.2 ml) followed by the addition of DIPEA (0.44 ml, 2.52 mmol) and 4-chloro-3-methylbenzene-1,2-diamine (8; 121.95 mg, 0.6 mmol) dissolved in a 1/1 mixture of DMF/DCM (1.2 ml) and finally by the addition of HATU (240 mg, 0.63 mmol) dissolved in DMF (1 ml). The reaction mixture is stirred at RT for 15 h then passed through PL-HCO 3  packed filter syringe (1 g) with a 1/1-mixture of DMF/DCM (4 ml). The solvent is removed under reduced pressure to give (2S,4S)-tert-butyl 2-((2-amino-4-chloro-3-methylphenyl)carbamoyl)-4-methoxypyrrolidine-1-carboxylate (14) which is used in the next step without further purification. LC-MS: t R =0.8 min; [M+H] + =384.28. 
     Step 3: (2S,4S)-tert-Butyl 2-((2-amino-4-chloro-3-methylphenyl)carbamoyl)-4-methoxypyrrolidine-1-carboxylate (14; 230 mg, 0.6 mmol) is dissolved in 100% AcOH (3 ml, 52.5 mmol) and heated to 60° C. for 3 h. Toluene (3 ml) is added to the reaction mixture and the solvents are removed under reduced pressure to give (2S,4S)-tert-butyl 2-(6-chloro-7-methyl-1H-benzo[d]imidazol-2-yl)-4-methoxypyrrolidine-1-carboxylate (15), which is used in the next step without further purification. LC-MS: t R =0.80 min; [M+H] + =366.27. 
     Step 4: (2S,4S)-tert-Butyl 2-(6-chloro-7-methyl-1H-benzo[d]imidazol-2-yl)-4-methoxypyrrolidine-1-carboxylate (15; 220 mg, 0.6 mmol) is dissolved in dioxane (0.5 ml) and a solution of HCl in dioxane (4M, 3 ml, 12 mmol) is carefully added. The reaction mixture turns into a suspension. To solubilize the reaction mixture MeOH (1 ml) is added. Stirring is continued for 2 h. The solvents are removed under reduced pressure to give 6-chloro-2-((2S,4S)-4-methoxypyrrolidin-2-yl)-7-methyl-1H-benzo[d]imidazole hydrochloride (16) which is used in the next step without further purification. LC-MS: t R =0.61 min; [M+H] + =266.16. 
     Step 5: 6-Chloro-2-((2S,4S)-4-methoxypyrrolidin-2-yl)-7-methyl-1H-benzo[d]imidazole (16; 30 mg, 0.1 mmol) is dissolved in DCM (0.2 ml) and DIPEA (0.072 ml, 0.42 mmol) is added, followed by the addition of a solution of 5-methyl-2-(2H-1,2,3-triazol-2-yl)benzoic acid (2; 20.3 mg, 0.1 mmol), HATU (40 mg, 0.105 mmol) and DIPEA (80 mg, 0.62 mmol) in 0.5 ml DMF. Stirring is continued at room temperature for 16 h. The reaction mixture is diluted with DCM/MeOH=1/1 (1 ml) followed by the addition of PL-HCO 3 -resin (213 mg, 0.4 mmol) and stirring is continued for 2 h. The resin is filtered off, the solvent is evaporated under reduced pressure and the product is purified by preparative HPLC to give ((2S,4S)-2-(6-chloro-7-methyl-1H-benzo[d]imidazol-2-yl)-4-methoxypyrrolidin-1-yl)(5-methyl-2-(2H-1,2,3-triazol-2-yl)phenyl)methanone (Ex. 3.1) as a colorless powder. LC-MS: tR=1.16 min; [M+H] + =451.29. 
     Synthesis of Example 4.1 
     
       
         
         
             
             
         
       
     
     Step 1: (2S,3S)-3-Methylpyrrolidine-2-carboxylic acid (17; 2.45 g, 19 mmol) is dissolved in a 1/1-mixture of MeCN/water (66.5 ml) and TEA (13.6 ml; 69.9 mmol) is added followed by the addition of Boc 2 O (6.22 g, 28.5 mmol) dissolved in MeCN (14.25 ml). The reaction mixture is stirred at RT for 90 minutes. The organic solvents are evaporated under reduced pressure and water (24 ml) is added to the residue followed by the addition of aq. NaOH solution (1M, 28.5 ml, 28.5 mmol). The product is extracted with Et 2 O (5×60 ml). The combined organic layers are dried with MgSO 4 , filtered and the solvent is evaporated under reduced pressure to give (2S,3S)-1-(tert-butoxycarbonyl)-3-methylpyrrolidine-2-carboxylic acid (18). LC-MS: t R =0.64 min; [M+H] + =230.16. 
     Step 2: (2S,3S)-1-(tert-Butoxycarbonyl)-3-methylpyrrolidine-2-carboxylic acid (18; 69 mg, 0.3 mmol) is dissolved in a 1/1 mixture of DMF/DCM (0.6 ml) followed by the addition of DIPEA (0.22 ml, 1.26 mmol) and 3-methylbenzene-1,2-diamine (19; 36.9 mg, 0.3 mmol) dissolved in a 1/1 mixture of DMF/DCM (0.6 ml) and finally by the addition of HATU (120 mg, 0.315 mmol) dissolved in DMF (0.63 ml). The reaction mixture is stirred at RT for 17 h then passed through PL-HCO 3  packed filter syringe (640 mg) with a 1/1-mixture of DMF/DCM (6 ml). The solvent is removed under reduced pressure to give (2S,3S)-tert-butyl 2-((2-amino-3-methylphenyl)carbamoyl)-3-methylpyrrolidine-1-carboxylate (20) which is used in the next step without further purification. LC-MS: t R =0.75 min; [M+H] + =334.11. 
     Step 3: (2S,3S)-tert-Butyl 2-((2-amino-3-methylphenyl)carbamoyl)-3-methylpyrrolidine-1-carboxylate (20; 100 mg, 0.3 mmol) is dissolved in 100% AcOH (3 ml, 52.5 mmol) and heated to 60° C. for 3 h. Toluene (3 ml) is added to the reaction mixture and the solvents are removed under reduced pressure to give (2S,3S)-tert-butyl 3-methyl-2-(7-methyl-1H-benzo[d]imidazol-2-yl)pyrrolidine-1-carboxylate (21), which is used in the next step without further purification. LC-MS: t R =0.75 min; [M+H] + =316.11. 
     Step 4: (2S,3S)-tert-Butyl 3-methyl-2-(7-methyl-1H-benzo[d]imidazol-2-yl)pyrrolidine-1-carboxylate (21; 94.5 mg, 0.3 mmol) is dissolved in methanol (0.75 ml) and a solution of HCl in dioxane (4M, 1.5 ml, 6 mmol) is carefully added. Stirring is continued for 2 h. The solvents are removed under reduced pressure to give 7-methyl-2-((2S,3S)-3-methylpyrrolidin-2-yl)-1H-benzo[d]imidazole hydrochloride (22) which is used in the next step without further purification. LC-MS: t R =0.58 min; [M+H] + =216.14. 
     Step 5: 7-Methyl-2-((2S,3S)-3-methylpyrrolidin-2-yl)-1H-benzo[d]imidazole hydrochloride (22; 25.2 mg, 0.1 mmol) is dissolved in DCM (0.2 ml) and DIPEA (0.072 ml, 0.42 mmol) is added, followed by the addition of a solution of 5-methyl-2-(2H-1,2,3-triazol-2-yl)benzoic acid (2; 20.3 mg, 0.1 mmol), HATU (40 mg, 0.105 mmol) and DIPEA (80 mg, 0.62 mmol) in 0.5 ml DMF. Stirring is continued at room temperature for 16 h. The reaction mixture is diluted with DCM/MeOH=1/1 (1 ml) followed by the addition of PL-HCO 3 -resin (213 mg, 0.4 mmol) and stirring is continued for 2 h. The resin is filtered off, the solvent is evaporated under reduced pressure and the product is purified by preparative HPLC to give (5-methyl-2-(2H-1,2,3-triazol-2-yl)phenyl)((2S,3S)-3-methyl-2-(7-methyl-1H-benzo[d]imidazol-2-yl)pyrrolidin-1-yl)methanone (Ex. 4.1) as a colorless powder. LC-MS: t R =0.96 min; [M+H] + =401.16. 
     Synthesis of Example 5.1 
     
       
         
         
             
             
         
       
     
     Step 1: (S)-2-Methylpyrrolidine-2-carboxylic acid hydrochloride (23; 82.5 g, 498 mmol) is dissolved in a 1/1-mixture of MeCN/water (1000 ml) and TEA (210 ml; 1490 mmol) is added followed by the addition of Boc 2 O (120 g, 548 mmol) dissolved in MeCN (200 ml). The reaction mixture is stirred at RT for 3 hours. The organic solvents are evaporated under reduced pressure and 2M aqueous sodium hydroxide (300 ml) is added to the residue The aqueous phase is extracted with Et 2 O (400 ml). and cooled to 10° C. followed by slow addition of 25% aqueous hydrochloric acid until the pH=5-6 followed by careful addition of aqueous 1M hydrochloric acid to pH=2. The product precipitates and is filtered off, washed with water (300 ml) and dried at high vacuum to give 90.7 g of (S)-1-(tert-butoxycarbonyl)-2-methylpyrrolidine-2-carboxylic acid (24) as a slightly grey solid. LC-MS: t R =0.63 min; [M+H] + =230.24. 
     Step 2: (S)-1-(tert-Butoxycarbonyl)-2-methylpyrrolidine-2-carboxylic acid (24; 137.6 mg, 0.6 mmol) is dissolved in a 1/1 mixture of DMF/DCM (1.2 ml) followed by the addition of DIPEA (0.44 ml, 2.52 mmol) and 3-methylbenzene-1,2-diamine (19; 73.8 mg, 0.6 mmol) dissolved in a 1/1 mixture of DMF/DCM (1.2 ml) and finally by the addition of HATU (240 mg, 0.63 mmol) dissolved in DMF (1.26 ml). The reaction mixture is stirred at RT for 17 h then passed through PL-HCO 3  packed filter syringe (1 g) with a 1/1-mixture of DMF/DCM (6 ml). The solvent is removed under reduced pressure to give (S)-tert-butyl 2-((2-amino-3-methylphenyl)carbamoyl)-2-methylpyrrolidine-1-carboxylate (25) which is used in the next step without further purification. LC-MS: t R =0.78 min; [M+H] + =334.3. 
     Step 3: (S)-tert-Butyl 2-((2-amino-3-methylphenyl)carbamoyl)-2-methylpyrrolidine-1-carboxylate (25; 200 mg, 0.6 mmol) is dissolved in 100% AcOH (3 ml, 52.5 mmol) and heated to 60° C. for 3 h. Toluene (3 ml) is added to the reaction mixture and the solvents are removed under reduced pressure to give (S)-tert-butyl 2-methyl-2-(7-methyl-1H-benzo[d]imidazol-2-yl)pyrrolidine-1-carboxylate (26), which is used in the next step without further purification. LC-MS: t R =0.76 min; [M+H] + =316.24. 
     Step 4: (S)-tert-Butyl 2-methyl-2-(7-methyl-1H-benzo[d]imidazol-2-yl)pyrrolidine-1-carboxylate (26; 189.7 mg, 0.6 mmol) is dissolved in MeOH (1.5 ml) and a solution of HCl in dioxane (4M, 3 ml, 12 mmol) is carefully added. Stirring is continued for 2 h. The solvents are removed under reduced pressure to give (S)-7-methyl-2-(2-methylpyrrolidin-2-yl)-1H-benzo[d]imidazole hydrochloride (27) which is used in the next step without further purification. LC-MS: t R =0.57 min; [M+H] + =216.31. 
     Step 5: (S)-7-Methyl-2-(2-methylpyrrolidin-2-yl)-1H-benzo[d]imidazole hydrochloride (27; 25.2 mg, 0.1 mmol) is dissolved in DCM (0.2 ml) and DIPEA (0.072 ml, 0.42 mmol) is added, followed by the addition of a solution of 2-methyl-5-phenylthiazole-4-carboxylic acid (28; 22 mg, 0.1 mmol), HATU (40 mg, 0.105 mmol) and DIPEA (80 mg, 0.62 mmol) in 0.5 ml DMF. Stirring is continued at RT for 16 h. The reaction mixture is diluted with DCM/MeOH=1/1 (1 ml) followed by the addition of PL-HCO 3 -resin (213 mg, 0.4 mmol) and stirring is continued for 2 h. The resin is filtered off, the solvent is evaporated under reduced pressure and the product is purified by preparative HPLC to give (S)-(2-methyl-2-(7-methyl-1H-benzo[d]imidazol-2-yl)pyrrolidin-1-yl)(2-methyl-5-phenylthiazol-4-yl)methanone (Ex. 5.1) as a colorless powder. LC-MS: t R =1.19 min; [M+H] + =417.31. 
     Synthesis of Example 6.1 
     
       
         
         
             
             
         
       
     
     Step 1: (S)-1-(tert-Butoxycarbonyl)-4-methylenepyrrolidine-2-carboxylic acid (29; 1.0 g, 4.4 mmol) and HATU (1.84 g, 4.84 mmol) is suspended in DCM (30 ml) followed by the addition of DIPEA (3.8 ml, 22 mmol) and 4-methoxybenzene-1,2-diamine hydrochloride (5; 960 mg, 4.4 mmol). The reaction mixture is stirred at RT for 16 h. The mixture is then poured onto brine (100 ml) and extracted with DCM (2×100 ml). The combined organic layers are dried over MgSO 4 , filtered and the solvent is removed under reduced pressure. The crude product is purified by FC (ethyl acetate) to give (S)-tert-butyl 2-((2-amino-4-methoxyphenyl)carbamoyl)-4-methylenepyrrolidine-1-carboxylate (30) as a slightly yellow amorphous solid. LC-MS: t R =0.65 min; [M+H] + =348.03. 
     Step 2: (S)-tert-Butyl 2-((2-amino-4-methoxyphenyl)carbamoyl)-4-methylenepyrrolidine-1-carboxylate (30; 1.52 g, 4.38 mmol) is dissolved in 100% AcOH (43.8 ml, 766 mmol) and heated to 100° C. for 30 minutes. The reaction mixture is concentrated under reduced pressure followed by the addition of DCM (150 ml) to the residue. The organic layer is washed with sat. aq. NaHCO 3  solution (150 ml) and brine (150 ml) and dried over MgSO 4 , filtered and the solvent is evaporated to give (S)-tert-butyl 2-(6-methoxy-1H-benzo[d]imidazol-2-yl)-4-methylenepyrrolidine-1-carboxylate (31) as a slightly yellow, amorphous solid. LC-MS: t R =0.55 min; [M+H] + =330.22. 
     Step 3: (S)-tert-Butyl 2-(6-methoxy-1H-benzo[d]imidazol-2-yl)-4-methylenepyrrolidine-1-carboxylate (31; 1.21 g, 3.67 mmol) is dissolved in dioxane (19 ml) and a solution of HCl in dioxane (4M, 19 ml, 73.5 mmol) is carefully added. Stirring is continued for 2 h. The solvents are removed under reduced pressure and the product is dried at HV to give (S)-6-methoxy-2-(4-methylenepyrrolidin-2-yl)-1H-benzo[d]imidazole hydrochloride (32), as a slightly beige solid. LC-MS: t R =0.37 min; [M+H] + =230.22. 
     Step 4: 5-(4-Fluorophenyl)-2-methylthiazole-4-carboxylic acid (33; 12.4 mg, 0.207 mmol) is dissolved in MeCN (1 ml) and TBTU (66.5 mg, 0.207 mmol) and DIPEA (0.161 ml, 122 mg, 0.941 mmol) are added, followed by the addition of a solution of (S)-6-methoxy-2-(4-methylenepyrrolidin-2-yl)-1H-benzo[d]imidazole hydrochloride (32; 50 mg, 0.188 mmol) and DIPEA (8 mg, 0.6 mmol, 0.05 ml) in 0.5 ml MeCN. Stirring is continued at RT for 16 h. The product is directly purified by preparative HPLC to give (S)-(5-(4-fluorophenyl)-2-methylthiazol-4-yl)(2-(6-methoxy-1H-benzo[d]imidazol-2-yl)-4-methylenepyrrolidin-1-yl)methanone (Ex. 6.1) as a colorless powder. LC-MS: t R =0.63 min; [M+H] + =448.97. 
     Synthesis of Example 7.4 
                         
(S)-(2-(5-bromo-7-methyl-1H-benzo[d]imidazol-2-yl)-2-methylpyrrolidin-1-yl)(5-methyl-2-(2H-1,2,3-triazol-2-yl)phenyl)methanone (34; 157 mg, 0.329 mmol) is dissolved in DMF (2 ml) and Cs 2 CO 3  (161 mg, 0.493 mmol) is added followed by the slow addition of a solution of MeI (58.3 mg, 0.411 mmol) in DMF (1 ml) at 0° C. Stirring is continued for 60 min at 0° C. The reaction mixture is poured onto water (100 ml). The precipitated product is filtered off, washed with water (10 ml), dried at HV to give an isomeric mixture of Ex. 7.4 consisting of (S)-(2-(5-bromo-1,7-dimethyl-1H-benzo[d]imidazol-2-yl)-2-methylpyrrolidin-1-yl)(5-methyl-2-(2H-1,2,3-triazol-2-yl)phenyl)methanone (35a) and (S)-(2-(6-bromo-1,4-dimethyl-1H-benzo[d]imidazol-2-yl)-2-methylpyrrolidin-1-yl)(5-methyl-2-(2H-1,2,3-triazol-2-benzo[d]imidazol-2-yl)-2-methylpyrrolidin-1-yl)(5-methyl-2-(2H-1,2,3-triazol-2-yl)phenyl)methanone (35b) as a slightly grey powder. LC-MS: t R =0.79 min; [M+H] + =495.11.
 
     According to the procedures described herein before, the following examples are prepared: 
                                 Example   Compound name. LC-MS data                                        1.1   (5-Methyl-2-[1,2,3]triazol-2-yl-phenyl)-[(S)-2-(4-nitro-1H-benzoimidazol-2-yl)-pyrrolidin-1-yl]-           methanone. LC-MS: t R  = 0.84; [M + H] +  = 418.2       1.2   [(S)-2-(5-Methoxy-1H-benzoimidazol-2-yl)-pyrrolidin-1-yl]-(5-methyl-2-[1,2,3]triazol-2-yl-phenyl)-           methanone. LC-MS: t R  = 0.63; [M + H] +  = 403.2       1.3   [(S)-2-(5-Chloro-1H-benzoimidazol-2-yl)-pyrrolidin-1-yl]-(5-methyl-2-[1,2,3]triazol-2-yl-phenyl)-           methanone. LC-MS: t R  = 0.71; [M + H] +  = 407.1       1.4   [(S)-2-(7-Methoxy-1H-benzoimidazol-2-yl)-pyrrolidin-1-yl]-(5-methyl-2-[1,2,3]triazol-2-yl-phenyl)-           methanone. LC-MS: t R  = 0.64; [M + H] +  = 403.2       1.5   [(S)-2-(7-Methylsulfanyl-1H-benzoimidazol-2-yl)-pyrrolidin-1-yl]-(5-methyl-2-[1,2,3]triazol-2-yl-phenyl)-           methanone. LC-MS: t R  = 0.68; [M + H] +  = 419.2       1.6   [(S)-2-(7-Chloro-1H-benzoimidazol-2-yl)-pyrrolidin-1-yl]-(5-methyl-2-[1,2,3]triazol-2-yl-phenyl)-           methanone. LC-MS: t R  = 0.74; [M + H] +  = 407.2       1.7   [(S)-2-(5-Methylsulfanyl-1H-benzoimidazol-2-yl)-pyrrolidin-1-yl]-(5-methyl-2-[1,2,3]triazol-2-yl-phenyl)-           methanone. LC-MS: t R  = 0.68; [M + H] +  = 419.2       1.9   [5-(3-Chloro-phenyl)-2-methyl-thiazol-4-yl]-[(S)-2-(5-methoxy-1H-benzoimidazol-2-yl)-pyrrolidin-1-yl]-           methanone. LC-MS: t R  = 0.76; [M + H] +  = 453.2       1.10   [(S)-2-(5-Chloro-1H-benzoimidazol-2-yl)-pyrrolidin-1-yl]-[5-(3-chloro-phenyl)-2-methyl-thiazol-4-yl]-           methanone. LC-MS: t R  = 0.84; [M + H] +  = 457.1       1.11   [5-(3-Chloro-phenyl)-2-methyl-thiazol-4-yl]-[(S)-2-(7-methoxy-1H-benzoimidazol-2-yl)-pyrrolidin-1-yl]-           methanone. LC-MS: t R  = 0.77; [M + H] +  = 453.1       1.12   [5-(3-Chloro-phenyl)-2-methyl-thiazol-4-yl]-[(S)-2-(4-hydroxy-1H-benzoimidazol-2-yl)-pyrrolidin-1-yl]-           methanone. LC-MS: t R  = 0.71; [M + H] +  = 439.1       1.13   [5-(3-Chloro-phenyl)-2-methyl-thiazol-4-yl]-[(S)-2-(7-methylsulfanyl-1H-benzoimidazol-2-yl)-pyrrolidin-           1-yl]-methanone. LC-MS: t R  = 0.82; [M + H] +  = 469.1       1.14   [(S)-2-(7-Chloro-1H-benzoimidazol-2-yl)-pyrrolidin-1-yl]-[5-(3-chloro-phenyl)-2-methyl-thiazol-4-yl]-           methanone. LC-MS: t R  = 0.87; [M + H] +  = 457.1       1.15   [5-(3-Chloro-phenyl)-2-methyl-thiazol-4-yl]-[(S)-2-(5-methylsulfanyl-1H-benzoimidazol-2-yl)-pyrrolidin-           1-yl]-methanone. LC-MS: t R  = 0.81; [M + H] +  = 469.1       1.16   [(S)-2-(6-Methoxy-1H-benzoimidazol-2-yl)-pyrrolidin-1-yl]-(5-methyl-2-[1,2,3]triazol-2-yl-phenyl)-           methanone. LC-MS: t R  = 0.63; [M + H] +  = 403.2       1.17   [(S)-2-(6-Methylsulfanyl-1H-benzoimidazol-2-yl)-pyrrolidin-1-yl]-(5-methyl-2-[1,2,3]triazol-2-yl-phenyl)-           methanone. LC-MS: t R  = 0.69; [M + H] +  = 419.2       1.18   [5-(4-Bromo-phenyl)-2-methyl-thiazol-4-yl]-[(S)-2-(6-methoxy-1H-benzoimidazol-2-yl)-pyrrolidin-1-yl]-           methanone. LC-MS: t R  = 0.77; [M + H] +  = 497.1       1.19   [5-(2,3-Dichloro-phenyl)-2-methyl-thiazol-4-yl]-[(S)-2-(6-methoxy-1H-benzoimidazol-2-yl)-pyrrolidin-1-           yl]-methanone. LC-MS: t R  = 0.81; [M + H] +  = 487.1       1.20   [(S)-2-(6-Methoxy-1H-benzoimidazol-2-yl)-pyrrolidin-1-yl]-[5-(3-methoxy-phenyl)-2-methyl-thiazol-4-           yl]-methanone. LC-MS: t R  = 0.70; [M + H] +  = 449.2       1.21   [5-(3-Fluoro-phenyl)-2-methyl-thiazol-4-yl]-[(S)-2-(6-methoxy-1H-benzoimidazol-2-yl)-pyrrolidin-1-yl]-           methanone. LC-MS: t R  = 0.71; [M + H] +  = 437.2       1.22   [(S)-2-(6-Methoxy-1H-benzoimidazol-2-yl)-pyrrolidin-1-yl]-(2-methyl-5-p-tolyl-thiazol-4-yl)-methanone.           LC-MS: t R  = 0.75; [M + H] +  = 433.2       1.23   (2-Cyclopropyl-5-p-tolyl-thiazol-4-yl)-[(S)-2-(6-methoxy-1H-benzoimidazol-2-yl)-pyrrolidin-1-yl]-           methanone. LC-MS: t R  = 0.83; [M + H] +  = 459.3       1.24   [5-(4-Ethyl-phenyl)-2-methyl-thiazol-4-yl]-[(S)-2-(6-methoxy-1H-benzoimidazol-2-yl)-pyrrolidin-1-yl]-           methanone. LC-MS: t R  = 0.81; [M + H] +  = 447.2       1.25   [5-(3-Chloro-phenyl)-2-methyl-thiazol-4-yl]-[(S)-2-(6-methoxy-1H-benzoimidazol-2-yl)-pyrrolidin-1-yl]-           methanone. LC-MS: t R  = 0.76; [M + H] +  = 453.2       1.26   (3′,4′-Dimethyl-biphenyl-2-yl)-[(S)-2-(6-methoxy-1H-benzoimidazol-2-yl)-pyrrolidin-1-yl]-methanone.           LC-MS: t R  = 0.80; [M + H] +  = 426.3       1.27   [(S)-2-(6-Methoxy-1H-benzoimidazol-2-yl)-pyrrolidin-1-yl]-(2-[1,2,3]triazol-2-yl-phenyl)-methanone.           LC-MS: t R  = 0.58; [M + H] +  = 389.2       1.28   [4-(3,4-Dichloro-phenyl)-2-methyl-pyrimidin-5-yl]-[(S)-2-(6-methoxy-1H-benzoimidazol-2-yl)-           pyrrolidin-1-yl]-methanone. LC-MS: t R  = 0.76; [M + H] +  = 482.2       1.29   [4-(3-Chloro-phenyl)-2-methyl-pyrimidin-5-yl]-[(S)-2-(6-methoxy-1H-benzoimidazol-2-yl)-pyrrolidin-1-           yl]-methanone. LC-MS: t R  = 0.68; [M + H] +  = 448.2       1.30   [4-(4-Bromo-3-chloro-phenyl)-pyrimidin-5-yl]-[(S)-2-(6-methoxy-1H-benzoimidazol-2-yl)-pyrrolidin-1-           yl]-methanone. LC-MS: t R  = 0.73; [M + H] +  = 512.11       1.31   [4-(3,4-Dimethyl-phenyl)-2-methyl-pyrimidin-5-yl]-[(S)-2-(6-methoxy-1H-benzoimidazol-2-yl)-           pyrrolidin-1-yl]-methanone. LC-MS: t R  = 0.69; [M + H] +  = 442.3       1.32   [(S)-2-(6-Methoxy-1H-benzoimidazol-2-yl)-pyrrolidin-1-yl]-(2-methyl-4-phenyl-pyrimidin-5-yl)-           methanone. LC-MS: t R  = 0.59; [M + H] +  = 414.2       1.33   [4-(4-Bromo-3-chloro-phenyl)-2-methyl-pyrimidin-5-yl]-[(S)-2-(6-methoxy-1H-benzoimidazol-2-yl)-           pyrrolidin-1-yl]-methanone. LC-MS: t R  = 0.77; [M + H] +  = 526.1       1.34   [5-(4-Bromo-phenyl)-2-methyl-thiazol-4-yl]-[(S)-2-(6-methylsulfanyl-1H-benzoimidazol-2-yl)-pyrrolidin-           1-yl]-methanone. LC-MS: t R  = 0.83; [M + H] +  = 513.1       1.35   (2-Cyclopropyl-5-phenyl-thiazol-4-yl)-[(S)-2-(6-methylsulfanyl-1H-benzoimidazol-2-yl)-pyrrolidin-1-yl]-           methanone. LC-MS: t R  = 0.82; [M + H] +  = 461.2       1.36   [5-(2,3-Dichloro-phenyl)-2-methyl-thiazol-4-yl]-[(S)-2-(6-methylsulfanyl-1H-benzoimidazol-2-yl)-           pyrrolidin-1-yl]-methanone. LC-MS: t R  = 0.86; [M + H] +  = 503.1       1.37   [5-(3-Methoxy-phenyl)-2-methyl-thiazol-4-yl]-[(S)-2-(6-methylsulfanyl-1H-benzoimidazol-2-yl)-           pyrrolidin-1-yl]-methanone. LC-MS: t R  = 0.75; [M + H] +  = 465.2       1.38   [(S)-2-(6-Methylsulfanyl-1H-benzoimidazol-2-yl)-pyrrolidin-1-yl]-[2-methyl-5-(3-trifluoromethyl-           phenyl)-thiazol-4-yl]-methanone. LC-MS: t R  = 0.85; [M + H] +  = 503.2       1.39   [5-(3-Fluoro-phenyl)-2-methyl-thiazol-4-yl]-[(S)-2-(6-methylsulfanyl-1H-benzoimidazol-2-yl)-pyrrolidin-           1-yl]-methanone. LC-MS: t R  = 0.76; [M + H] +  = 453.2       1.40   [(S)-2-(6-Methylsulfanyl-1H-benzoimidazol-2-yl)-pyrrolidin-1-yl]-(2-methyl-5-p-tolyl-thiazol-4-yl)-           methanone. LC-MS: t R  = 0.80; [M + H] +  = 449.2       1.41   (2-Cyclopropyl-5-p-tolyl-thiazol-4-yl)-[(S)-2-(6-methylsulfanyl-1H-benzoimidazol-2-yl)-pyrrolidin-1-yl]-           methanone. LC-MS: t R  = 0.87; [M + H] +  = 475.3       1.42   [5-(4-Ethyl-phenyl)-2-methyl-thiazol-4-yl]-[(S)-2-(6-methylsulfanyl-1H-benzoimidazol-2-yl)-pyrrolidin-           1-yl]-methanone. LC-MS: t R  = 0.85; [M + H] +  = 463.2       1.43   [5-(3-Chloro-phenyl)-2-methyl-thiazol-4-yl]-[(S)-2-(6-methylsulfanyl-1H-benzoimidazol-2-yl)-pyrrolidin-           1-yl]-methanone. LC-MS: t R  = 0.81; [M + H] +  = 469.2       1.44   [5-(3,5-Difluoro-phenyl)-2-methyl-thiazol-4-yl]-[(S)-2-(6-methylsulfanyl-1H-benzoimidazol-2-yl)-           pyrrolidin-1-yl]-methanone. LC-MS: t R  = 0.79; [M + H] +  = 471.2       1.45   [3-(3-Fluoro-5-methyl-phenyl)-pyrazin-2-yl]-[(S)-2-(6-methylsulfanyl-1H-benzoimidazol-2-yl)-           pyrrolidin-1-yl]-methanone. LC-MS: t R  = 0.73; [M + H] +  = 448.2       1.46   (3′,4′-Dimethyl-biphenyl-2-yl)-[(S)-2-(6-methylsulfanyl-1H-benzoimidazol-2-yl)-pyrrolidin-1-yl]-           methanone. LC-MS: t R  = 0.85; [M + H] +  = 442.2       1.47   [(S)-2-(6-Methylsulfanyl-1H-benzoimidazol-2-yl)-pyrrolidin-1-yl]-(2-[1,2,3]triazol-2-yl-phenyl)-           methanone. LC-MS: t R  = 0.63; [M + H] +  = 405.2       1.49   [4-(3,4-Dichloro-phenyl)-2-methyl-pyrimidin-5-yl]-[(S)-2-(6-methylsulfanyl-1H-benzoimidazol-2-yl)-           pyrrolidin-1-yl]-methanone. LC-MS: t R  = 0.82; [M + H] +  = 498.1       1.50   [4-(4-Fluoro-phenyl)-2-methyl-pyrimidin-5-yl]-[(S)-2-(6-methylsulfanyl-1H-benzoimidazol-2-yl)-           pyrrolidin-1-yl]-methanone. LC-MS: t R  = 0.69; [M + H] +  = 448.2       1.51   [4-(3-Chloro-phenyl)-2-methyl-pyrimidin-5-yl]-[(S)-2-(6-methylsulfanyl-1H-benzoimidazol-2-yl)-           pyrrolidin-1-yl]-methanone. LC-MS: t R  = 0.74; [M + H] +  = 464.2       1.52   [4-(3,4-Dichloro-phenyl)-pyrimidin-5-yl]-[(S)-2-(6-methylsulfanyl-1H-benzoimidazol-2-yl)-pyrrolidin-1-           yl]-methanone. LC-MS: t R  = 0.78; [M + H] +  = 484.1       1.53   4-(3,4-Dimethyl-phenyl)-pyrimidin-5-yl]-[(S)-2-(6-methylsulfanyl-1H-benzoimidazol-2-yl)-pyrrolidin-1-           yl]-methanone. LC-MS: t R  = 0.72; [M + H] +  = 444.2       1.54   [4-(4-Bromo-3-chloro-phenyl)-pyrimidin-5-yl]-[(S)-2-(6-methylsulfanyl-1H-benzoimidazol-2-yl)-           pyrrolidin-1-yl]-methanone. LC-MS: t R  = 0.79; [M + H] +  = 528.1       1.55   [4-(3,4-Dimethyl-phenyl)-2-methyl-pyrimidin-5-yl]-[(S)-2-(6-methylsulfanyl-1H-benzoimidazol-2-yl)-           pyrrolidin-1-yl]-methanone. LC-MS: t R  = 0.75; [M + H] +  = 458.3       1.56   [4-(3-Methoxy-phenyl)-2-methyl-pyrimidin-5-yl]-[(S)-2-(6-methylsulfanyl-1H-benzoimidazol-2-yl)-           pyrrolidin-1-yl]-methanone. LC-MS: t R  = 0.67; [M + H] +  = 460.3       1.57   (2-Methyl-4-phenyl-pyrimidin-5-yl)-[(S)-2-(6-methylsulfanyl-1H-benzoimidazol-2-yl)-pyrrolidin-1-yl]-           methanone. LC-MS: t R  = 0.66; [M + H] +  = 430.2       1.58   [4-(4-Bromo-3-chloro-phenyl)-2-methyl-pyrimidin-5-yl]-[(S)-2-(6-methylsulfanyl-1H-benzoimidazol-2-           yl)-pyrrolidin-1-yl]-methanone. LC-MS: t R  = 0.83; [M + H] +  = 542.0       1.59   [4-(3,5-Dichloro-phenyl)-2-methyl-pyrimidin-5-yl]-[(S)-2-(6-methylsulfanyl-1H-benzoimidazol-2-yl)-           pyrrolidin-1-yl]-methanone. LC-MS: t R  = 0.82; [M + H] +  = 498.2       1.60   [5-(4-Bromo-phenyl)-2-methyl-thiazol-4-yl]-[(S)-2-(7-methylsulfanyl-1H-benzoimidazol-2-yl)-pyrrolidin-           1-yl]-methanone. LC-MS: t R  = 0.84; [M + H] +  = 513.1       1.61   (2-Cyclopropyl-5-phenyl-thiazol-4-yl)-[(S)-2-(7-methylsulfanyl-1H-benzoimidazol-2-yl)-pyrrolidin-1-yl]-           methanone. LC-MS: t R  = 0.83; [M + H] +  = 461.2       1.62   [5-(2,3-Dichloro-phenyl)-2-methyl-thiazol-4-yl]-[(S)-2-(7-methylsulfanyl-1H-benzoimidazol-2-yl)-           pyrrolidin-1-yl]-methanone. LC-MS: t R  = 0.86; [M + H] +  = 503.1       1.63   [5-(3-Methoxy-phenyl)-2-methyl-thiazol-4-yl]-[(S)-2-(7-methylsulfanyl-1H-benzoimidazol-2-yl)-           pyrrolidin-1-yl]-methanone. LC-MS: t R  = 0.76; [M + H] +  = 465.2       1.64   [(S)-2-(7-Methylsulfanyl-1H-benzoimidazol-2-yl)-pyrrolidin-1-yl]-[2-methyl-5-(3-trifluoromethyl-           phenyl)-thiazol-4-yl]-methanone. LC-MS: t R  = 0.86; [M + H] +  = 503.2       1.65   [5-(3-Fluoro-phenyl)-2-methyl-thiazol-4-yl]-[(S)-2-(7-methylsulfanyl-1H-benzoimidazol-2-yl)-pyrrolidin-           1-yl]-methanone. LC-MS: t R  = 0.77; [M + H] +  = 453.2       1.66   [(S)-2-(7-Methylsulfanyl-1H-benzoimidazol-2-yl)-pyrrolidin-1-yl]-(2-methyl-5-p-tolyl-thiazol-4-yl)-           methanone. LC-MS: t R  = 0.80; [M + H] +  = 449.2       1.67   [5-(3,4-Difluoro-phenyl)-2-methyl-thiazol-4-yl]-[(S)-2-(7-methylsulfanyl-1H-benzoimidazol-2-yl)-           pyrrolidin-1-yl]-methanone. LC-MS: t R  = 0.80; [M + H] +  = 471.1       1.68   (2-Cyclopropyl-5-p-tolyl-thiazol-4-yl)-[(S)-2-(7-methylsulfanyl-1H-benzoimidazol-2-yl)-pyrrolidin-1-yl]-           methanone. LC-MS: t R  = 0.88; [M + H] +  = 475.3       1.69   [5-(4-Ethyl-phenyl)-2-methyl-thiazol-4-yl]-[(S)-2-(7-methylsulfanyl-1H-benzoimidazol-2-yl)-pyrrolidin-           1-yl]-methanone. LC-MS: t R  = 0.86; [M + H] +  = 463.2       1.70   [2-Cyclopropyl-5-(4-fluoro-phenyl)-thiazol-4-yl]-[(S)-2-(7-methylsulfanyl-1H-benzoimidazol-2-yl)-           pyrrolidin-1-yl]-methanone. LC-MS: t R  = 0.84; [M + H] +  = 479.2       1.71   [5-(3,5-Difluoro-phenyl)-2-methyl-thiazol-4-yl]-[(S)-2-(7-methylsulfanyl-1H-benzoimidazol-2-yl)-           pyrrolidin-1-yl]-methanone. LC-MS: t R  = 0.79; [M + H] +  = 471.2       1.72   [3-(4-Methoxy-phenyl)-pyrazin-2-yl]-[(S)-2-(7-methylsulfanyl-1H-benzoimidazol-2-yl)-pyrrolidin-1-yl]-           methanone. LC-MS: t R  = 0.68; [M + H] +  = 446.2       1.73   [(S)-2-(7-Methylsulfanyl-1H-benzoimidazol-2-yl)-pyrrolidin-1-yl]-[3-(3-trifluoromethyl-phenyl)-pyrazin-           2-yl]-methanone. LC-MS: t R  = 0.80; [M + H] +  = 484.2       1.74   [3-(3-Fluoro-5-methyl-phenyl)-pyrazin-2-yl]-[(S)-2-(7-methylsulfanyl-1H-benzoimidazol-2-yl)-           pyrrolidin-1-yl]-methanone. LC-MS: t R  = 0.74; [M + H] +  = 448.2       1.75   (3′,4′-Dimethyl-biphenyl-2-yl)-[(S)-2-(7-methylsulfanyl-1H-benzoimidazol-2-yl)-pyrrolidin-1-yl]-           methanone. LC-MS: t R  = 0.87; [M + H] +  = 442.2       1.76   [(S)-2-(7-Methylsulfanyl-1H-benzoimidazol-2-yl)-pyrrolidin-1-yl]-(2-[1,2,3]triazol-2-yl-phenyl)-           methanone. LC-MS: t R  = 0.63; [M + H] +  = 405.2       1.78   [(S)-2-(7-Methylsulfanyl-1H-benzoimidazol-2-yl)-pyrrolidin-1-yl]-(4-p-tolyl-pyrimidin-5-yl)-methanone.           LC-MS: t R  = 0.70; [M + H] +  = 430.2       1.79   [4-(3,4-Dichloro-phenyl)-2-methyl-pyrimidin-5-yl]-[(S)-2-(7-methylsulfanyl-1H-benzoimidazol-2-yl)-           pyrrolidin-1-yl]-methanone. LC-MS: t R  = 0.86; [M + H] +  = 498.2       1.80   [4-(4-Fluoro-phenyl)-2-methyl-pyrimidin-5-yl]-[(S)-2-(7-methylsulfanyl-1H-benzoimidazol-2-yl)-           pyrrolidin-1-yl]-methanone. LC-MS: t R  = 0.71; [M + H] +  = 448.2       1.81   [4-(3-Chloro-phenyl)-2-methyl-pyrimidin-5-yl]-[(S)-2-(7-methylsulfanyl-1H-benzoimidazol-2-yl)-           pyrrolidin-1-yl]-methanone. LC-MS: t R  = 0.77; [M + H] +  = 464.2       1.82   [4-(3,4-Dichloro-phenyl)-pyrimidin-5-yl]-[(S)-2-(7-methylsulfanyl-1H-benzoimidazol-2-yl)-pyrrolidin-1-           yl]-methanone. LC-MS: t R  = 0.74; [M + H] +  = 444.3       1.83   [4-(3,4-Dimethyl-phenyl)-pyrimidin-5-yl]-[(S)-2-(7-methylsulfanyl-1H-benzoimidazol-2-yl)-pyrrolidin-1-           yl]-methanone. LC-MS: t R  = 0.83; [M + H] +  = 528.0       1.84   [4-(4-Bromo-3-chloro-phenyl)-pyrimidin-5-yl]-[(S)-2-(7-methylsulfanyl-1H-benzoimidazol-2-yl)-           pyrrolidin-1-yl]-methanone. LC-MS: t R  = 0.77; [M + H] +  = 458.2       1.85   [4-(3,4-Dimethyl-phenyl)-2-methyl-pyrimidin-5-yl]-[(S)-2-(7-methylsulfanyl-1H-benzoimidazol-2-yl)-           pyrrolidin-1-yl]-methanone. LC-MS: t R  = 0.68; [M + H] +  = 460.2       1.86   [4-(3-Methoxy-phenyl)-2-methyl-pyrimidin-5-yl]-[(S)-2-(7-methylsulfanyl-1H-benzoimidazol-2-yl)-           pyrrolidin-1-yl]-methanone. LC-MS: t R  = 0.67; [M + H] +  = 430.2       1.87   (2-Methyl-4-phenyl-pyrimidin-5-yl)-[(S)-2-(7-methylsulfanyl-1H-benzoimidazol-2-yl)-pyrrolidin-1-yl]-           methanone. LC-MS: t R  = 0.70; [M + H] +  = 430.2       1.88   [(S)-2-(7-Methylsulfanyl-1H-benzoimidazol-2-yl)-pyrrolidin-1-yl]-(4-m-tolyl-pyrimidin-5-yl)-methanone.           LC-MS: t R  = 0.82; [M + H] +  = 484.1       1.89   [4-(3,5-Dichloro-phenyl)-pyrimidin-5-yl]-[(S)-2-(7-methylsulfanyl-1H-benzoimidazol-2-yl)-pyrrolidin-1-           yl]-methanone. LC-MS: t R  = 0.87; [M + H] +  = 542.1       1.90   [4-(4-Bromo-3-chloro-phenyl)-2-methyl-pyrimidin-5-yl]-[(S)-2-(7-methylsulfanyl-1H-benzoimidazol-2-           yl)-pyrrolidin-1-yl]-methanone. LC-MS: t R  = 0.86; [M + H] +  = 498.2       1.91   [4-(3,5-Dichloro-phenyl)-2-methyl-pyrimidin-5-yl]-[(S)-2-(7-methylsulfanyl-1H-benzoimidazol-2-yl)-           pyrrolidin-1-yl]-methanone. LC-MS: t R  = 0.99; [M + H] +  = 491.1       1.92   rac-[5-(3-Chloro-phenyl)-2-methyl-thiazol-4-yl]-[2-(5,6-dichloro-1H-benzoimidazol-2-yl)-pyrrolidin-1-           yl]-methanone. LC-MS: t R  = 0.86; [M + H] +  = 501.1       1.93   rac-[2-(5-Bromo-1H-benzoimidazol-2-yl)-pyrrolidin-1-yl]-[5-(3-chloro-phenyl)-2-methyl-thiazol-4-yl]-           methanone. LC-MS: t R  = 0.94; [M + H] +  = 491.1       1.94   rac-[5-(3-Chloro-phenyl)-2-methyl-thiazol-4-yl]-[2-(5-trifluoromethyl-1H-benzoimidazol-2-yl)-pyrrolidin-           1-yl]-methanone. LC-MS: t R  = 0.82; [M + H] +  = 451.2       1.95   rac-[5-(3-Chloro-phenyl)-2-methyl-thiazol-4-yl]-[2-(5,6-dimethyl-1H-benzoimidazol-2-yl)-pyrrolidin-1-           yl]-methanone. LC-MS: t R  = 0.78; [M + H] +  = 437.1       1.96   rac-[5-(3-Chloro-phenyl)-2-methyl-thiazol-4-yl]-[2-(4-methyl-1H-benzoimidazol-2-yl)-pyrrolidin-1-yl]-           methanone. LC-MS: t R  = 0.84; [M + H] +  = 457.1       1.97   rac-[2-(5-Chloro-1H-benzoimidazol-2-yl)-pyrrolidin-1-yl]-[5-(3-chloro-phenyl)-2-methyl-thiazol-4-yl]-           methanone. LC-MS: t R  = 0.92; [M + H] +  = 475.2       1.98   rac-[2-(6-Chloro-5-fluoro-1H-benzoimidazol-2-yl)-pyrrolidin-1-yl]-[5-(3-chloro-phenyl)-2-methyl-           thiazol-4-yl]-methanone. LC-MS: t R  = 0.91; [M + H] +  = 479.2       1.99   rac-[2-(5-tert-Butyl-1H-benzoimidazol-2-yl)-pyrrolidin-1-yl]-[5-(3-chloro-phenyl)-2-methyl-thiazol-4-yl]-           methanone. LC-MS: t R  = 1.12; [M + H] +  = 525.1       1.100   rac-[5-(3-Chloro-phenyl)-2-methyl-thiazol-4-yl]-[2-(4-chloro-6-trifluoromethyl-1H-benzoimidazol-2-yl)-           pyrrolidin-1-yl]-methanone. LC-MS: t R  = 0.86; [M + H] +  = 471.1       1.101   rac-[2-(5-Chloro-6-methyl-1H-benzoimidazol-2-yl)-pyrrolidin-1-yl]-[5-(3-chloro-phenyl)-2-methyl-           thiazol-4-yl]-methanone. LC-MS: t R  = 0.83; [M + H] +  = 451.2       1.102   rac-[5-(3-Chloro-phenyl)-2-methyl-thiazol-4-yl]-[2-(4,6-dimethyl-1H-benzoimidazol-2-yl)-pyrrolidin-1-           yl]-methanone. LC-MS: t R  = 0.71; [M + H] +  = 453.2       1.103   rac-[5-(3-Chloro-phenyl)-2-methyl-thiazol-4-yl]-[2-(4-hydroxymethyl-1H-benzoimidazol-2-yl)-           pyrrolidin-1-yl]-methanone. LC-MS: t R  = 0.84; [M + H] +  = 441.1       1.104   rac-[5-(3-Chloro-phenyl)-2-methyl-thiazol-4-yl]-[2-(4-fluoro-1H-benzoimidazol-2-yl)-pyrrolidin-1-yl]-           methanone. LC-MS: t R  = 0.97; [M + H] +  = 491.2       1.105   rac-[5-(3-Chloro-phenyl)-2-methyl-thiazol-4-yl]-[2-(4-trifluoromethyl-1H-benzoimidazol-2-yl)-pyrrolidin-           1-yl]-methanone. LC-MS: t R  = 0.89; [M + H] +  = 501.1       1.106   rac-[2-(4-Bromo-1H-benzoimidazol-2-yl)-pyrrolidin-1-yl]-[5-(3-chloro-phenyl)-2-methyl-thiazol-4-yl]-           methanone. LC-MS: t R  = 0.89; [M + H] +  = 515.2       1.107   rac-[2-(5-Bromo-7-methyl-1H-benzoimidazol-2-yl)-pyrrolidin-1-yl]-[5-(3-chloro-phenyl)-2-methyl-           thiazol-4-yl]-methanone. LC-MS: t R  = 0.92; [M + H] +  = 507.2       1.108   rac-[5-(3-Chloro-phenyl)-2-methyl-thiazol-4-yl]-[2-(5-trifluoromethoxy-1H-benzoimidazol-2-yl)-           pyrrolidin-1-yl]-methanone. LC-MS: t R  = 0.87; [M + H] +  = 471.2       1.109   rac-[2-(5-Chloro-4-methyl-1H-benzoimidazol-2-yl)-pyrrolidin-1-yl]-[5-(3-chloro-phenyl)-2-methyl-           thiazol-4-yl]-methanone. LC-MS: t R  = 0.73; [M + H] +  = 483.2       1.110   rac-[5-(3-Chloro-phenyl)-2-methyl-thiazol-4-yl]-[2-(5,6-dimethoxy-1H-benzoimidazol-2-yl)-pyrrolidin-1-           yl]-methanone. LC-MS: t R  = 1.02; [M + H] +  = 509.1       1.111   rac-[5-(3-Chloro-phenyl)-2-methyl-thiazol-4-yl]-[2-(6-fluoro-5-trifluoromethyl-1H-benzoimidazol-2-yl)-           pyrrolidin-1-yl]-methanone. LC-MS: t R  = 0.93; [M + H] +  = 519.1       1.112   rac-[2-(6-Bromo-5-fluoro-1H-benzoimidazol-2-yl)-pyrrolidin-1-yl]-[5-(3-chloro-phenyl)-2-methyl-           thiazol-4-yl]-methanone. LC-MS: t R  = 1.08; [M + H] +  = 525.3       1.113   rac-[5-(3-Chloro-phenyl)-2-methyl-thiazol-4-yl]-[2-(6-chloro-5-trifluoromethyl-1H-benzoimidazol-2-yl)-           pyrrolidin-1-yl]-methanone. LC-MS: t R  = 0.99; [M + H] +  = 519.1       1.114   rac-[2-(4-Bromo-6-fluoro-1H-benzoimidazol-2-yl)-pyrrolidin-1-yl]-[5-(3-chloro-phenyl)-2-methyl-           thiazol-4-yl]-methanone. LC-MS: t R  = 0.82; [M + H] +  = 451.2       1.115   rac-[5-(3-Chloro-phenyl)-2-methyl-thiazol-4-yl]-[2-(4,5-dimethyl-1H-benzoimidazol-2-yl)-pyrrolidin-1-           yl]-methanone. LC-MS: t R  = 0.87; [M + H] +  = 465.2       1.116   rac-[5-(3-Chloro-phenyl)-2-methyl-thiazol-4-yl]-[2-(4-isopropyl-1H-benzoimidazol-2-yl)-pyrrolidin-1-yl]-           methanone. LC-MS: t R  = 0.75; [M + H] +  = 481.2       1.117   rac-[5-(3-Chloro-phenyl)-2-methyl-thiazol-4-yl]-[2-(7,8-dihydro-3H-6,9-dioxa-1,3-diaza-           cyclopenta[    ]naphthalen-2-yl)-pyrrolidin-1-yl]-methanone. LC-MS: t R  = 1.12; [M + H] +  = 525.1       1.118   rac-[2-(4,6-Bis-trifluoromethyl-1H-benzoimidazol-2-yl)-pyrrolidin-1-yl]-(2-methyl-5-phenyl-thiazol-4-yl)-           methanone. LC-MS: t R  = 0.92; [M + H] +  = 457.1       1.119   rac-[2-(5,6-Dichloro-1H-benzoimidazol-2-yl)-pyrrolidin-1-yl]-(2-methyl-5-phenyl-thiazol-4-yl)-           methanone. LC-MS: t R  = 0.79; [M + H] +  = 467.1       1.120   rac-[2-(5-Bromo-1H-benzoimidazol-2-yl)-pyrrolidin-1-yl]-(2-methyl-5-phenyl-thiazol-4-yl)-methanone.           LC-MS: t R  = 0.87; [M + H] +  = 457.2       1.121   rac-(2-Methyl-5-phenyl-thiazol-4-yl)-[2-(5-trifluoromethyl-1H-benzoimidazol-2-yl)-pyrrolidin-1-yl]-           methanone. LC-MS: t R  = 0.76; [M + H] +  = 417.2       1.122   rac-[2-(5,6-Dimethyl-1H-benzoimidazol-2-yl)-pyrrolidin-1-yl]-(2-methyl-5-phenyl-thiazol-4-yl)-           methanone. LC-MS: t R  = 0.71; [M + H] +  = 403.2       1.123   rac-[2-(4-Methyl-1H-benzoimidazol-2-yl)-pyrrolidin-1-yl]-(2-methyl-5-phenyl-thiazol-4-yl)-methanone.           LC-MS: t R  = 0.85; [M + H] +  = 445.3       1.124   rac-[2-(5-tert-Butyl-1H-benzoimidazol-2-yl)-pyrrolidin-1-yl]-(2-methyl-5-phenyl-thiazol-4-yl)-           methanone. LC-MS: t R  = 1.06; [M + H] +  = 491.1       1.125   rac-[2-(4-Chloro-6-trifluoromethyl-1H-benzoimidazol-2-yl)-pyrrolidin-1-yl]-(2-methyl-5-phenyl-thiazol-           4-yl)-methanone. LC-MS: t R  = 0.80; [M + H] +  = 437.2       1.126   rac-[2-(5-Chloro-6-methyl-1H-benzoimidazol-2-yl)-pyrrolidin-1-yl]-(2-methyl-5-phenyl-thiazol-4-yl)-           methanone. LC-MS: t R  = 0.76; [M + H] +  = 417.2       1.127   rac-[2-(4,6-Dimethyl-1H-benzoimidazol-2-yl)-pyrrolidin-1-yl]-(2-methyl-5-phenyl-thiazol-4-yl)-           methanone. LC-MS: t R  = 0.63; [M + H] +  = 419.1       1.128   rac-[2-(4-Hydroxymethyl-1H-benzoimidazol-2-yl)-pyrrolidin-1-yl]-(2-methyl-5-phenyl-thiazol-4-yl)-           methanone. LC-MS: t R  = 0.90; [M + H] +  = 457.2       1.129   rac-(2-Methyl-5-phenyl-thiazol-4-yl)-[2-(4-trifluoromethyl-1H-benzoimidazol-2-yl)-pyrrolidin-1-yl]-           methanone. LC-MS: t R  = 0.81; [M + H] +  = 467.1       1.130   rac-[2-(4-Bromo-1H-benzoimidazol-2-yl)-pyrrolidin-1-yl]-(2-methyl-5-phenyl-thiazol-4-yl)-methanone.           LC-MS: t R  = 0.82; [M + H] +  = 481.1       1.131   rac-[2-(5-Bromo-7-methyl-1H-benzoimidazol-2-yl)-pyrrolidin-1-yl]-(2-methyl-5-phenyl-thiazol-4-yl)-           methanone. LC-MS: t R  = 0.86; [M + H] +  = 473.2       1.132   rac-(2-Methyl-5-phenyl-thiazol-4-yl)-[2-(5-trifluoromethoxy-1H-benzoimidazol-2-yl)-pyrrolidin-1-yl]-           methanone. LC-MS: t R  = 0.81; [M + H] +  = 437.2       1.133   rac-[2-(5-Chloro-4-methyl-1H-benzoimidazol-2-yl)-pyrrolidin-1-yl]-(2-methyl-5-phenyl-thiazol-4-yl)-           methanone. LC-MS: t R  = 0.67; [M + H] +  = 449.2       1.134   rac-[2-(5,6-Dimethoxy-1H-benzoimidazol-2-yl)-pyrrolidin-1-yl]-(2-methyl-5-phenyl-thiazol-4-yl)-           methanone. LC-MS: t R  = 0.96; [M + H] +  = 475.2       1.135   rac-[2-(6-Fluoro-5-trifluoromethyl-1H-benzoimidazol-2-yl)-pyrrolidin-1-yl]-(2-methyl-5-phenyl-thiazol-           4-yl)-methanone. LC-MS: t R  = 0.86; [M + H] +  = 485.1       1.136   rac-[2-(6-Bromo-5-fluoro-1H-benzoimidazol-2-yl)-pyrrolidin-1-yl]-(2-methyl-5-phenyl-thiazol-4-yl)-           methanone. LC-MS: t R  = 1.01; [M + H] +  = 491.2       1.137   rac-[2-(6-Chloro-5-trifluoromethyl-1H-benzoimidazol-2-yl)-pyrrolidin-1-yl]-(2-methyl-5-phenyl-thiazol-           4-yl)-methanone. LC-MS: t R  = 0.92; [M + H] +  = 485.1       1.138   rac-[2-(4-Bromo-6-fluoro-1H-benzoimidazol-2-yl)-pyrrolidin-1-yl]-(2-methyl-5-phenyl-thiazol-4-yl)-           methanone. LC-MS: t R  = 0.75; [M + H] +  = 417.2       1.139   rac-[2-(4,5-Dimethyl-1H-benzoimidazol-2-yl)-pyrrolidin-1-yl]-(2-methyl-5-phenyl-thiazol-4-yl)-           methanone. LC-MS: t R  = 0.69; [M + H] +  = 447.2       1.140   rac-[2-(7,8-Dihydro-3H-6,9-dioxa-1,3-diaza-cyclopenta[    ]naphthalen-2-yl)-pyrrolidin-1-yl]-(2-methyl-5-           phenyl-thiazol-4-yl)-methanone. LC-MS: t R  = 0.63; [M + H] +  = 403.2       1.141   rac-[2-(5-Methoxy-1H-benzoimidazol-2-yl)-pyrrolidin-1-yl]-(5-methyl-2-[1,2,3]triazol-2-yl-phenyl)-           methanone. LC-MS: t R  = 0.76; [M + H] +  = 417.2       1.142   [(S)-2-(4,6-Dimethyl-1H-benzoimidazol-2-yl)-pyrrolidin-1-yl]-(2-methyl-5-phenyl-thiazol-4-yl)-           methanone. LC-MS: t R  = 0.80; [M + H] +  = 437.2       1.143   [(S)-2-(5-Chloro-6-methyl-1H-benzoimidazol-2-yl)-pyrrolidin-1-yl]-(2-methyl-5-phenyl-thiazol-4-yl)-           methanone. LC-MS: t R  = 0.82; [M + H] +  = 481.1       1.144   [(S)-2-(6-Bromo-4-methyl-1H-benzoimidazol-2-yl)-pyrrolidin-1-yl]-(2-methyl-5-phenyl-thiazol-4-yl)-           methanone. LC-MS: t R  = 0.81; [M + H] +  = 437.1       1.145   [(S)-2-(5-Chloro-4-methyl-1H-benzoimidazol-2-yl)-pyrrolidin-1-yl]-(2-methyl-5-phenyl-thiazol-4-yl)-           methanone. LC-MS: t R  = 1.02; [M + H] +  = 491.1       1.146   [(S)-2-(5-Chloro-6-trifluoromethyl-1H-benzoimidazol-2-yl)-pyrrolidin-1-yl]-(2-methyl-5-phenyl-thiazol-           4-yl)-methanone. LC-MS: t R  = 0.67; [M + H] +  = 423.2       1.147   (5-Fluoro-2-[1,2,3]triazol-2-yl-phenyl)-[(S)-2-(6-methylsulfanyl-1H-benzoimidazol-2-yl)-pyrrolidin-1-yl]-           methanone. LC-MS: t R  = 0.65; [M + H] +  = 423.2       1.148   (2-Fluoro-6-[1,2,3]triazol-2-yl-phenyl)-[(S)-2-(6-methylsulfanyl-1H-benzoimidazol-2-yl)-pyrrolidin-1-yl]-           methanone. LC-MS: t R  = 0.72; [M + H] +  = 439.2       1.149   (5-Chloro-2-[1,2,3]triazol-2-yl-phenyl)-[(S)-2-(6-methylsulfanyl-1H-benzoimidazol-2-yl)-pyrrolidin-1-yl]-           methanone. LC-MS: t R  = 0.66; [M + H] +  = 435.2       1.150   (5-Methoxy-2-[1,2,3]triazol-2-yl-phenyl)-[(S)-2-(6-methylsulfanyl-1H-benzoimidazol-2-yl)-pyrrolidin-1-           yl]-methanone. LC-MS: t R  = 0.77; [M + H] +  = 473.2       1.151   [(S)-2-(6-Methylsulfanyl-1H-benzoimidazol-2-yl)-pyrrolidin-1-yl]-(2-[1,2,3]triazol-2-yl-5-trifluoromethyl-           phenyl)-methanone. LC-MS: t R  = 0.65; [M + H] +  = 430.2       1.152   3-[(S)-2-(6-Methylsulfanyl-1H-benzoimidazol-2-yl)-pyrrolidine-1-carbonyl]-4-[1,2,3]triazol-2-yl-           benzonitrile. LC-MS: t R  = 0.69; [M + H] +  = 419.2       1.153   [(S)-2-(6-Methylsulfanyl-1H-benzoimidazol-2-yl)-pyrrolidin-1-yl]-(4-methyl-2-[1,2,3]triazol-2-yl-phenyl)-           methanone. LC-MS: t R  = 0.69; [M + H] +  = 419.2       1.154   [(S)-2-(6-Methylsulfanyl-1H-benzoimidazol-2-yl)-pyrrolidin-1-yl]-(2-methyl-6-[1,2,3]triazol-2-yl-phenyl)-           methanone. LC-MS: t R  = 0.63; [M + H] +  = 465.2       1.155   (4,5-Dimethoxy-2-[1,2,3]triazol-2-yl-phenyl)-[(S)-2-(6-methylsulfanyl-1H-benzoimidazol-2-yl)-           pyrrolidin-1-yl]-methanone. LC-MS: t R  = 0.61; [M + H] +  = 407.2       1.156   (5-Fluoro-2-[1,2,3]triazol-2-yl-phenyl)-[(S)-2-(6-methoxy-1H-benzoimidazol-2-yl)-pyrrolidin-1-yl]-           methanone. LC-MS: t R  = 0.66; [M + H] +  = 423.1       1.157   (5-Chloro-2-[1,2,3]triazol-2-yl-phenyl)-[(S)-2-(6-methoxy-1H-benzoimidazol-2-yl)-pyrrolidin-1-yl]-           methanone. LC-MS: t R  = 0.61; [M + H] +  = 419.2       1.158   [(S)-2-(6-Methoxy-1H-benzoimidazol-2-yl)-pyrrolidin-1-yl]-(5-methoxy-2-[1,2,3]triazol-2-yl-phenyl)-           methanone. LC-MS: t R  = 0.59; [M + H] +  = 414.2       1.159   3-[(S)-2-(6-Methoxy-1H-benzoimidazol-2-yl)-pyrrolidine-1-carbonyl]-4-[1,2,3]triazol-2-yl-benzonitrile.           LC-MS: t R  = 0.64; [M + H] +  = 403.2       1.160   [(S)-2-(6-Methoxy-1H-benzoimidazol-2-yl)-pyrrolidin-1-yl]-(4-methyl-2-[1,2,3]triazol-2-yl-phenyl)-           methanone. LC-MS: t R  = 0.63; [M + H] +  = 403.2       1.161   [(S)-2-(6-Methoxy-1H-benzoimidazol-2-yl)-pyrrolidin-1-yl]-(2-methyl-6-[1,2,3]triazol-2-yl-phenyl)-           methanone. LC-MS: t R  = 0.58; [M + H] +  = 449.2       1.162   (4,5-Dimethoxy-2-[1,2,3]triazol-2-yl-phenyl)-[(S)-2-(6-methoxy-1H-benzoimidazol-2-yl)-pyrrolidin-1-           yl]-methanone. LC-MS: t R  = 0.67; [M + H] +  = 423.2       1.163   (5-Fluoro-2-[1,2,3]triazol-2-yl-phenyl)-[(S)-2-(7-methylsulfanyl-1H-benzoimidazol-2-yl)-pyrrolidin-1-yl]-           methanone. LC-MS: t R  = 0.66; [M + H] +  = 423.2       1.164   (2-Fluoro-6-[1,2,3]triazol-2-yl-phenyl)-[(S)-2-(7-methylsulfanyl-1H-benzoimidazol-2-yl)-pyrrolidin-1-yl]-           methanone. LC-MS: t R  = 0.73; [M + H] +  = 439.1       1.165   (5-Chloro-2-[1,2,3]triazol-2-yl-phenyl)-[(S)-2-(7-methylsulfanyl-1H-benzoimidazol-2-yl)-pyrrolidin-1-yl]-           methanone. LC-MS: t R  = 0.66; [M + H] +  = 435.2       1.166   (5-Methoxy-2-[1,2,3]triazol-2-yl-phenyl)-[(S)-2-(7-methylsulfanyl-1H-benzoimidazol-2-yl)-pyrrolidin-1-           yl]-methanone. LC-MS: t R  = 0.66; [M + H] +  = 430.1       1.167   3-[(S)-2-(7-Methylsulfanyl-1H-benzoimidazol-2-yl)-pyrrolidine-1-carbonyl]-4-[1,2,3]triazol-2-yl-           benzonitrile. LC-MS: t R  = 0.68; [M + H] +  = 453.2       1.168   (2-Fluoro-3-methoxy-6-[1,2,3]triazol-2-yl-phenyl)-[(S)-2-(7-methylsulfanyl-1H-benzoimidazol-2-yl)-           pyrrolidin-1-yl]-methanone. LC-MS: t R  = 0.69; [M + H] +  = 419.2       1.169   [(S)-2-(7-Methylsulfanyl-1H-benzoimidazol-2-yl)-pyrrolidin-1-yl]-(4-methyl-2-[1,2,3]triazol-2-yl-phenyl)-           methanone. LC-MS: t R  = 0.70; [M + H] +  = 419.3       1.170   [(S)-2-(7-Methylsulfanyl-1H-benzoimidazol-2-yl)-pyrrolidin-1-yl]-(2-methyl-6-[1,2,3]triazol-2-yl-phenyl)-           methanone. LC-MS: t R  = 0.63; [M + H] +  = 402.2       1.171   [(S)-2-(5-Methoxy-1H-benzoimidazol-2-yl)-pyrrolidin-1-yl]-(5-methyl-2-pyrazol-1-yl-phenyl)-           methanone. LC-MS: t R  = 0.65; [M + H] +  = 421.2       1.172   (2-Fluoro-3-methyl-6-[1,2,3]triazol-2-yl-phenyl)-[(S)-2-(5-methoxy-1H-benzoimidazol-2-yl)-pyrrolidin-           1-yl]-methanone. LC-MS: t R  = 0.59; [M + H] +  = 404.2       1.173   [(S)-2-(5-Methoxy-1H-benzoimidazol-2-yl)-pyrrolidin-1-yl]-(6-methyl-3-[1,2,3]triazol-2-yl-pyridin-2-yl)-           methanone. LC-MS: t R  = 0.71; [M + H] +  = 437.2       1.174   (2-Fluoro-3-methyl-6-[1,2,3]triazol-2-yl-phenyl)-[(S)-2-(4-methylsulfanyl-1H-benzoimidazol-2-yl)-           pyrrolidin-1-yl]-methanone. LC-MS: t R  = 0.64; [M + H] +  = 420.2       1.175   [(S)-2-(4-Methylsulfanyl-1H-benzoimidazol-2-yl)-pyrrolidin-1-yl]-(6-methyl-3-[1,2,3]triazol-2-yl-pyridin-           2-yl)-methanone. LC-MS: t R  = 0.64; [M + H] +  = 404.2       1.176   [(S)-2-(5-Methylsulfanyl-1H-benzoimidazol-2-yl)-pyrrolidin-1-yl]-(2-pyrazol-1-yl-phenyl)-methanone.           LC-MS: t R  = 0.69; [M + H] +  = 418.2       1.177   (5-Methyl-2-pyrazol-1-yl-phenyl)-[(S)-2-(5-methylsulfanyl-1H-benzoimidazol-2-yl)-pyrrolidin-1-yl]-           methanone. LC-MS: t R  = 0.64; [M + H] +  = 419.2       1.178   (6-Methyl-3-pyrazol-1-yl-pyridin-2-yl)-[(S)-2-(5-methylsulfanyl-1H-benzoimidazol-2-yl)-pyrrolidin-1-yl]-           methanone. LC-MS: t R  = 0.71; [M + H] +  = 437.2       1.179   (2-Fluoro-3-methyl-6-[1,2,3]triazol-2-yl-phenyl)-[(S)-2-(5-methylsulfanyl-1H-benzoimidazol-2-yl)-           pyrrolidin-1-yl]-methanone. LC-MS: t R  = 0.65; [M + H] +  = 420.2       1.180   [(S)-2-(5-Methylsulfanyl-1H-benzoimidazol-2-yl)-pyrrolidin-1-yl]-(6-methyl-3-[1,2,3]triazol-2-yl-pyridin-           2-yl)-methanone. LC-MS: t R  = 0.72; [M + H] +  = 421.2       2.1   [(2S,4S)-2-(5-Chloro-4-methyl-1H-benzoimidazol-2-yl)-4-fluoro-pyrrolidin-1-yl]-(5-methyl-2-           [1,2,3]triazol-2-yl-phenyl)-methanone. LC-MS: t R  = 0.75; [M + H] +  = 439.2       2.2   [(2S,4S)-4-Fluoro-2-(4-methyl-1H-benzoimidazol-2-yl)-pyrrolidin-1-yl]-(2-methyl-5-phenyl-thiazol-4-           yl)-methanone. LC-MS: t R  = 0.72; [M + H] +  = 421.2       2.3   [(2S,4R)-4-Fluoro-2-(4-methyl-1H-benzoimidazol-2-yl)-pyrrolidin-1-yl]-(2-methyl-5-phenyl-thiazol-4-           yl)-methanone. LC-MS: t R  = 0.73; [M + H] +  = 421.2       2.4   [(S)-4,4-Difluoro-2-(4-methyl-1H-benzoimidazol-2-yl)-pyrrolidin-1-yl]-(2-methyl-5-phenyl-thiazol-4-yl)-           methanone. LC-MS: t R  = 0.78; [M + H] +  = 439.2       2.5   [(2S,4R)-2-(5-Chloro-4-methyl-1H-benzoimidazol-2-yl)-4-fluoro-pyrrolidin-1-yl]-(5-methyl-2-           [1,2,3]triazol-2-yl-phenyl)-methanone. LC-MS: t R  = 0.76; [M + H] +  = 439.2       2.6   [(S)-2-(5-Chloro-4-methyl-1H-benzoimidazol-2-yl)-4,4-difluoro-pyrrolidin-1-yl]-(5-methyl-2-           [1,2,3]triazol-2-yl-phenyl)-methanone. LC-MS: t R  = 0.88; [M + H] +  = 457.2       2.7   [(2S,4S)-2-(5-Chloro-4-methyl-1H-benzoimidazol-2-yl)-4-fluoro-pyrrolidin-1-yl]-(2-methyl-5-phenyl-           thiazol-4-yl)-methanone. LC-MS: t R  = 0.81; [M + H] +  = 455.2       2.8   [(S)-2-(5-Chloro-4-methyl-1H-benzoimidazol-2-yl)-4,4-difluoro-pyrrolidin-1-yl]-(2-methyl-5-phenyl-           thiazol-4-yl)-methanone. LC-MS: t R  = 0.94; [M + H] +  = 473.2       2.9   [5-(3-Chloro-phenyl)-2-methyl-thiazol-4-yl]-[(2S,4R)-4-fluoro-2-(4-methyl-1H-benzoimidazol-2-yl)-           pyrrolidin-1-yl]-methanone. LC-MS: t R  = 0.80; [M + H] +  = 455.2       2.10   [(2S,4R)-2-(5-Chloro-4-methyl-1H-benzoimidazol-2-yl)-4-fluoro-pyrrolidin-1-yl]-[5-(3-chloro-phenyl)-2-           methyl-thiazol-4-yl]-methanone. LC-MS: t R  = 0.91; [M + H] +  = 489.1       2.11   [(2S,4R)-4-Fluoro-2-(4-methyl-1H-benzoimidazol-2-yl)-pyrrolidin-1-yl]-(5-methyl-2-[1,2,3]triazol-2-yl-           phenyl)-methanone. LC-MS: t R  = 0.63; [M + H] +  = 405.2       3.1   [(2S,4S)-2-(5-Chloro-4-methyl-1H-benzoimidazol-2-yl)-4-methoxy-pyrrolidin-1-yl]-(5-methyl-2-           [1,2,3]triazol-2-yl-phenyl)-methanone. LC-MS: t R  = 0.75; [M + H] +  = 451.2       3.2   [(2S,4R)-2-(5-Chloro-4-methyl-1H-benzoimidazol-2-yl)-4-methoxy-pyrrolidin-1-yl]-(5-methyl-2-           [1,2,3]triazol-2-yl-phenyl)-methanone. LC-MS: t R  = 0.74; [M + H] +  = 451.3       3.3   [(2S,4S)-4-Methoxy-2-(4-methyl-1H-benzoimidazol-2-yl)-pyrrolidin-1-yl]-(2-methyl-5-phenyl-thiazol-4-           yl)-methanone. LC-MS: t R  = 0.73; [M + H] +  = 433.2       3.4   [(2S,4R)-4-Methoxy-2-(4-methyl-1H-benzoimidazol-2-yl)-pyrrolidin-1-yl]-(2-methyl-5-phenyl-thiazol-4-           yl)-methanone. LC-MS: t R  = 0.73; [M + H] +  = 433.2       3.5   [(2S,4S)-2-(5-Chloro-4-methyl-1H-benzoimidazol-2-yl)-4-methoxy-pyrrolidin-1-yl]-(2-methyl-5-phenyl-           thiazol-4-yl)-methanone. LC-MS: t R  = 0.82; [M + H] +  = 467.2       3.6   [(2S,4R)-2-(5-Chloro-4-methyl-1H-benzoimidazol-2-yl)-4-methoxy-pyrrolidin-1-yl]-(2-methyl-5-phenyl-           thiazol-4-yl)-methanone. LC-MS: t R  = 0.82; [M + H] +  = 467.2       3.7   [5-(3-Chloro-phenyl)-2-methyl-thiazol-4-yl]-[(2S,4R)-4-methoxy-2-(4-methyl-1H-benzoimidazol-2-yl)-           pyrrolidin-1-yl]-methanone. LC-MS: t R  = 0.80; [M + H] +  = 467.2       3.8   [(2S,4S)-2-(5-Chloro-4-methyl-1H-benzoimidazol-2-yl)-4-methoxy-pyrrolidin-1-yl]-[5-(3-chloro-           phenyl)-2-methyl-thiazol-4-yl]-methanone. LC-MS: t R  = 0.88; [M + H] +  = 501.2       3.9   [(2S,4R)-2-(5-Chloro-4-methyl-1H-benzoimidazol-2-yl)-4-methoxy-pyrrolidin-1-yl]-[5-(3-chloro-           phenyl)-2-methyl-thiazol-4-yl]-methanone. LC-MS: t R  = 0.89; [M + H] +  = 501.1       3.10   [(2S,4R)-2-(6-Chloro-7-methyl-1H-benzoimidazol-2-yl)-4-methoxy-pyrrolidin-1-yl]-(5-chloro-2-           [1,2,3]triazol-2-yl-phenyl)-methanone. LC-MS: t R  = 0.79; [M + H] +  = 471.2       3.11   [(2S,4R)-2-(6-Chloro-7-methyl-1H-benzoimidazol-2-yl)-4-methoxy-pyrrolidin-1-yl]-(2-fluoro-3-           methoxy-6-[1,2,3]triazol-2-yl-phenyl)-methanone. LC-MS: t R  = 0.74; [M + H] +  = 485.2       3.12   [(2S,4R)-2-(6-Chloro-7-methyl-1H-benzoimidazol-2-yl)-4-methoxy-pyrrolidin-1-yl]-(5-methoxy-2-           [1,2,3]triazol-2-yl-phenyl)-methanone. LC-MS: t R  = 0.72; [M + H] +  = 467.2       3.13   [(2S,4R)-2-(6-Chloro-7-methyl-1H-benzoimidazol-2-yl)-4-methoxy-pyrrolidin-1-yl]-(2-fluoro-3-methyl-           6-[1,2,3]triazol-2-yl-phenyl)-methanone. LC-MS: t R  = 0.72; [M + H] +  = 469.3       3.14   [(2S,4R)-2-(6-Chloro-7-methyl-1H-benzoimidazol-2-yl)-4-methoxy-pyrrolidin-1-yl]-(2-methyl-6-           [1,2,3]triazol-2-yl-phenyl)-methanone. LC-MS: t R  = 0.75; [M + H] +  = 451.2       3.15   [(2S,4R)-2-(6-Chloro-7-methyl-1H-benzoimidazol-2-yl)-4-methoxy-pyrrolidin-1-yl]-(4-methyl-2-           [1,2,3]triazol-2-yl-phenyl)-methanone. LC-MS: t R  = 07.5; [M + H] +  = 451.2       3.16   [(2S,4R)-2-(6-Chloro-7-methyl-1H-benzoimidazol-2-yl)-4-methoxy-pyrrolidin-1-yl]-(4,5-dimethyl-2-           [1,2,3]triazol-2-yl-phenyl)-methanone. LC-MS: t R  = 0.77; [M + H] +  = 465.2       3.17   [(2S,4R)-2-(6-Chloro-7-methyl-1H-benzoimidazol-2-yl)-4-methoxy-pyrrolidin-1-yl]-(2-[1,2,3]triazol-2-           yl-5-trifluoromethyl-phenyl)-methanone. LC-MS: t R  = 0.84; [M + H] +  = 505.2       3.18   [(2S,4R)-2-(6-Chloro-7-methyl-1H-benzoimidazol-2-yl)-4-methoxy-pyrrolidin-1-yl]-(5-fluoro-2-           [1,2,3]triazol-2-yl-phenyl)-methanone. LC-MS: t R  = 0.74; [M + H] +  = 455.2       3.19   (5-Chloro-2-[1,2,3]triazol-2-yl-phenyl)-[(2S,4R)-4-methoxy-2-(6-methoxy-1H-benzoimidazol-2-yl)-           pyrrolidin-1-yl]-methanone. LC-MS: t R  = 0.66; [M + H] +  = 453.2       3.20   [(2S,4R)-4-Methoxy-2-(6-methoxy-1H-benzoimidazol-2-yl)-pyrrolidin-1-yl]-(5-methoxy-2-[1,2,3]triazol-           2-yl-phenyl)-methanone. LC-MS: t R  = 0.60; [M + H] +  = 449.2       3.21   [(2S,4R)-4-Methoxy-2-(6-methoxy-1H-benzoimidazol-2-yl)-pyrrolidin-1-yl]-(4-methyl-2-[1,2,3]triazol-2-           yl-phenyl)-methanone. LC-MS: t R  = 0.63; [M + H] +  = 433.3       3.22   (4,5-Dimethyl-2-[1,2,3]triazol-2-yl-phenyl)-[(2S,4R)-4-methoxy-2-(6-methoxy-1H-benzoimidazol-2-yl)-           pyrrolidin-1-yl]-methanone. LC-MS: t R  = 0.67; [M + H] +  = 447.2       3.23   (5-Fluoro-2-[1,2,3]triazol-2-yl-phenyl)-[(2S,4R)-4-methoxy-2-(6-methoxy-1H-benzoimidazol-2-yl)-           pyrrolidin-1-yl]-methanone. LC-MS: t R  = 0.61; [M + H] +  = 437.2       3.24   [(2RS)-(4R)-2-(5-Chloro-4-methyl-1H-benzoimidazol-2-yl)-4-methoxy-2-methyl-pyrrolidin-1-yl]-(2-           methyl-5-phenyl-thiazol-4-yl)-methanone. LC-MS: t R  = 0.84; [M + H] +  = 481.2       3.25   [(2RS)-(4R)-2-(5-Chloro-4-methyl-1H-benzoimidazol-2-yl)-4-methoxy-2-methyl-pyrrolidin-1-yl]-(5-           methyl-2-[1,2,3]triazol-2-yl-phenyl)-methanone. LC-MS: t R  = 0.79; [M + H] +  = 465.2       3.26   [(2RS)-(4R)-4-Methoxy-2-methyl-2-(4-methyl-1H-benzoimidazol-2-yl)-pyrrolidin-1-yl]-(5-methyl-2-           [1,2,3]triazol-2-yl-phenyl)-methanone. LC-MS: t R  = 0.72; [M + H] +  = 431.2       3.27   [(2RS)-(4R)-2-(5-Chloro-4-methyl-1H-benzoimidazol-2-yl)-4-methoxy-2-methyl-pyrrolidin-1-yl]-[5-(3-           chloro-phenyl)-2-methyl-thiazol-4-yl]-methanone. LC-MS: t R  = 0.90; [M + H] +  = 515.2       3.28   [5-(3-Chloro-phenyl)-2-methyl-thiazol-4-yl]-[(2RS)-(4R)-4-methoxy-2-methyl-2-(4-methyl-1H-           benzoimidazol-2-yl)-pyrrolidin-1-yl]-methanone. LC-MS: t R  = 0.82; [M + H] +  = 481.2       3.29   [(2RS)-(4R)-4-Methoxy-2-methyl-2-(4-methyl-1H-benzoimidazol-2-yl)-pyrrolidin-1-yl]-(2-methyl-5-           phenyl-thiazol-4-yl)-methanone. LC-MS: t R  = 0.76; [M + H] +  = 447.2       3.30   [(2S,4R)-2-(5-Chloro-4-methyl-1H-benzoimidazol-2-yl)-4-methoxy-2-methyl-pyrrolidin-1-yl]-(5-methyl-           2-[1,2,3]triazol-2-yl-phenyl)-methanone. LC-MS: t R  = 0.82; [M + H] +  = 465.3       3.31   [(2S,4R)-2-(5-Chloro-4-methyl-1H-benzoimidazol-2-yl)-4-methoxy-2-methyl-pyrrolidin-1-yl]-[5-(3-           chloro-phenyl)-2-methyl-thiazol-4-yl]-methanone. LC-MS: t R  = 0.95; [M + H] +  = 515.2       3.32   [(2S,4R)-2-(6-Chloro-7-methyl-1H-benzoimidazol-2-yl)-4-methoxy-pyrrolidin-1-yl]-(2-methyl-5-m-tolyl-           thiazol-4-yl)-methanone. LC-MS: t R  = 0.90; [M + H] +  = 481.2       3.33   [(2S,4R)-2-(6-Chloro-7-methyl-1H-benzoimidazol-2-yl)-4-methoxy-pyrrolidin-1-yl]-[2-dimethylamino-5-           (3,4-dimethyl-phenyl)-thiazol-4-yl]-methanone. LC-MS: t R  = 0.97; [M + H] +  = 524.3       3.34   [(2S,4R)-2-(6-Chloro-7-methyl-1H-benzoimidazol-2-yl)-4-methoxy-pyrrolidin-1-yl]-[5-(3,4-dimethyl-           phenyl)-2-methyl-thiazol-4-yl]-methanone. LC-MS: t R  = 0.95; [M + H] +  = 495.3       3.35   [(2S,4R)-2-(6-Chloro-7-methyl-1H-benzoimidazol-2-yl)-4-methoxy-pyrrolidin-1-yl]-[5-(4-chloro-           phenyl)-2-methyl-thiazol-4-yl]-methanone. LC-MS: t R  = 0.94; [M + H] +  = 501.2       3.36   [(2S,4R)-2-(6-Chloro-7-methyl-1H-benzoimidazol-2-yl)-4-methoxy-pyrrolidin-1-yl]-(2-methyl-5-p-tolyl-           thiazol-4-yl)-methanone. LC-MS: t R  = 0.91; [M + H] +  = 481.2       3.37   [(2S,4R)-2-(6-Chloro-7-methyl-1H-benzoimidazol-2-yl)-4-methoxy-pyrrolidin-1-yl]-[5-(4-methoxy-           phenyl)-2-methyl-thiazol-4-yl]-methanone. LC-MS: t R  = 0.86; [M + H] +  = 497.2       3.38   [(2S,4R)-2-(6-Chloro-7-methyl-1H-benzoimidazol-2-yl)-4-methoxy-pyrrolidin-1-yl]-(3′,4′-dimethyl-           biphenyl-2-yl)-methanone. LC-MS: t R  = 0.97; [M + H] +  = 474.3       3.39   Biphenyl-2-yl-[(2S,4R)-2-(6-chloro-7-methyl-1H-benzoimidazol-2-yl)-4-methoxy-pyrrolidin-1-yl]-           methanone. LC-MS: t R  = 0.87; [M + H] +  = 446.3       3.40   [(2S,4R)-2-(6-Chloro-7-methyl-1H-benzoimidazol-2-yl)-4-methoxy-pyrrolidin-1-yl]-(4′-fluoro-3′-methyl-           biphenyl-2-yl)-methanone. LC-MS: t R  = 0.94; [M + H] +  = 478.3       3.41   [(2S,4R)-2-(6-Chloro-7-methyl-1H-benzoimidazol-2-yl)-4-methoxy-pyrrolidin-1-yl]-[5-(3-chloro-           phenyl)-2-dimethylamino-thiazol-4-yl]-methanone. LC-MS: t R  = 0.95; [M + H] +  = 530.3       3.42   [(2RS)-(4R)-2-(5-Chloro-4-methyl-1H-benzoimidazol-2-yl)-4-methoxy-2-methyl-pyrrolidin-1-yl]-(2-           fluoro-6-[1,2,3]triazol-2-yl-phenyl)-methanone. LC-MS: t R  = 0.80; [M + H] +  = 469.2       3.43   [(2RS)-(4R)-2-(5-Chloro-4-methyl-1H-benzoimidazol-2-yl)-4-methoxy-2-methyl-pyrrolidin-1-yl]-(5-           fluoro-2-[1,2,3]triazol-2-yl-phenyl)-methanone. LC-MS: t R  = 0.80; [M + H] +  = 469.3       3.44   [(2RS)-(4R)-2-(5-Chloro-4-methyl-1H-benzoimidazol-2-yl)-4-methoxy-2-methyl-pyrrolidin-1-yl]-(5-           chloro-2-[1,2,3]triazol-2-yl-phenyl)-methanone. LC-MS: t R  = 0.86; [M + H] +  = 485.2       3.45   [(2RS)-(4R)-2-(5-Chloro-4-methyl-1H-benzoimidazol-2-yl)-4-methoxy-2-methyl-pyrrolidin-1-yl]-(2-           [1,2,3]triazol-2-yl-phenyl)-methanone. LC-MS: t R  = 0.76; [M + H] +  = 451.3       3.46   [(2RS)-(4R)-2-(5-Chloro-4-methyl-1H-benzoimidazol-2-yl)-4-methoxy-2-methyl-pyrrolidin-1-yl]-(2-           fluoro-3-methoxy-6-[1,2,3]triazol-2-yl-phenyl)-methanone. LC-MS: t R  = 0.81; [M + H] +  = 499.2       3.47   [(2RS)-(4R)-2-(5-Chloro-4-methyl-1H-benzoimidazol-2-yl)-4-methoxy-2-methyl-pyrrolidin-1-yl]-(2-           fluoro-3-methyl-6-[1,2,3]triazol-2-yl-phenyl)-methanone. LC-MS: t R  = 0.85; [M + H] +  = 483.3       3.48   [(2RS)-(4R)-2-(5-Chloro-4-methyl-1H-benzoimidazol-2-yl)-4-methoxy-2-methyl-pyrrolidin-1-yl]-(4,5-           dimethyl-2-[1,2,3]triazol-2-yl-phenyl)-methanone. LC-MS: t R  = 0.87; [M + H] +  = 479.3       3.49   [(2RS)-(4R)-2-(5-Chloro-4-methyl-1H-benzoimidazol-2-yl)-4-methoxy-2-methyl-pyrrolidin-1-yl]-(4-           methyl-2-[1,2,3]triazol-2-yl-phenyl)-methanone. LC-MS: t R  = 0.83; [M + H] +  = 465.3       3.50   [(2RS)-(4R)-2-(5-Chloro-4-methyl-1H-benzoimidazol-2-yl)-4-methoxy-2-methyl-pyrrolidin-1-yl]-(2-           [1,2,3]triazol-2-yl-5-trifluoromethyl-phenyl)-methanone. LC-MS: t R  = 0.90; [M + H] +  = 519.3       3.51   [(2RS)-(4R)-2-(5-Chloro-4-methyl-1H-benzoimidazol-2-yl)-4-methoxy-2-methyl-pyrrolidin-1-yl]-(2-           [1,2,3]triazol-2-yl-5-trifluoromethoxy-phenyl)-methanone. LC-MS: t R  = 0.93; [M + H] +  = 535.2       3.52   [(2RS)-(4R)-2-(5-Chloro-4-methyl-1H-benzoimidazol-2-yl)-4-methoxy-2-methyl-pyrrolidin-1-yl]-(4,5-           dimethoxy-2-[1,2,3]triazol-2-yl-phenyl)-methanone. LC-MS: t R  = 0.77; [M + H] +  = 511.3       3.53   [(2RS)-(4R)-2-(5-Chloro-4-methyl-1H-benzoimidazol-2-yl)-4-methoxy-2-methyl-pyrrolidin-1-yl]-(5-           methyl-2-pyrazol-1-yl-phenyl)-methanone. LC-MS: t R  = 0.83; [M + H] +  = 464.3       3.54   [(2RS)-(4R)-2-(5-Chloro-4-methyl-1H-benzoimidazol-2-yl)-4-methoxy-2-methyl-pyrrolidin-1-yl]-(2-           pyrazol-1-yl-phenyl)-methanone. LC-MS: t R  = 0.77; [M + H] +  = 450.3       3.55   [(2RS)-(4R)-2-(5-Chloro-4-methyl-1H-benzoimidazol-2-yl)-4-methoxy-2-methyl-pyrrolidin-1-yl]-(6-           methyl-3-pyrazol-1-yl-pyridin-2-yl)-methanone. LC-MS: t R  = 0.74; [M + H] +  = 465.3       3.56   [(2RS)-(4R)-2-(5-Chloro-4-methyl-1H-benzoimidazol-2-yl)-4-methoxy-2-methyl-pyrrolidin-1-yl]-(6-           methyl-3-[1,2,3]triazol-2-yl-pyridin-2-yl)-methanone. LC-MS: t R  = 0.74; [M + H] +  = 466.3       4.1   [(2S,3S)-3-Methyl-2-(4-methyl-1H-benzoimidazol-2-yl)-pyrrolidin-1-yl]-(5-methyl-2-[1,2,3]triazol-2-yl-           phenyl)-methanone. LC-MS: t R  = 0.66; [M + H] +  = 401.3       4.2   [(2S,3S)-3-Methyl-2-(5-methyl-1H-benzoimidazol-2-yl)-pyrrolidin-1-yl]-(5-methyl-2-[1,2,3]triazol-2-yl-           phenyl)-methanone. LC-MS: t R  = 0.68; [M + H] +  = 401.2       4.3   [5-(3-Chloro-phenyl)-2-methyl-thiazol-4-yl]-[(2S,3S)-3-methyl-2-(5-methyl-1H-benzoimidazol-2-yl)-           pyrrolidin-1-yl]-methanone. LC-MS: t R  = 0.81; [M + H] +  = 451.2       4.4   [(2S,3S)-3-Methyl-2-(4-methyl-1H-benzoimidazol-2-yl)-pyrrolidin-1-yl]-(2-methyl-5-phenyl-thiazol-4-           yl)-methanone. LC-MS: t R  = 0.74; [M + H] +  = 417.2       4.5   [(2S,3S)-3-Methyl-2-(5-methyl-1H-benzoimidazol-2-yl)-pyrrolidin-1-yl]-(2-methyl-5-phenyl-thiazol-4-           yl)-methanone. LC-MS: t R  = 0.75; [M + H] +  = 417.2       4.6   [(2S,3S)-2-(1H-Benzoimidazol-2-yl)-3-methyl-pyrrolidin-1-yl]-[5-(3-chloro-phenyl)-2-methyl-thiazol-4-           yl]-methanone. LC-MS: t R  = 0.77; [M + H] +  = 437.2       4.7   [5-(3-Chloro-phenyl)-2-methyl-thiazol-4-yl]-[(2S,3S)-3-methyl-2-(4-methyl-1H-benzoimidazol-2-yl)-           pyrrolidin-1-yl]-methanone. LC-MS: t R  = 0.81; [M + H] +  = 451.2       4.8   2-{(2S,3S)-1-[5-(3-Chloro-phenyl)-2-methyl-thiazole-4-carbonyl]-3-methyl-pyrrolidin-2-yl}-1H-           benzoimidazole-5-carbonitrile. LC-MS: t R  = 0.88; [M + H] +  = 462.2       4.9   [5-(3-Chloro-phenyl)-2-methyl-thiazol-4-yl]-[(2S,3S)-3-methyl-2-(5-trifluoromethyl-1H-benzoimidazol-           2-yl)-pyrrolidin-1-yl]-methanone. LC-MS: t R  = 0.97; [M + H] +  = 505.2       4.10   [5-(3-Chloro-phenyl)-2-methyl-thiazol-4-yl]-[(2S,3S)-2-(5,6-dimethyl-1H-benzoimidazol-2-yl)-3-methyl-           pyrrolidin-1-yl]-methanone. LC-MS: t R  = 0.84; [M + H] +  = 465.2       4.11   [(2S,3S)-2-(5-Chloro-1H-benzoimidazol-2-yl)-3-methyl-pyrrolidin-1-yl]-[5-(3-chloro-phenyl)-2-methyl-           thiazol-4-yl]-methanone. LC-MS: t R  = 0.87; [M + H] +  = 471.2       4.12   [5-(3-Chloro-phenyl)-2-methyl-thiazol-4-yl]-[(2S,3S)-2-(5,6-difluoro-1H-benzoimidazol-2-yl)-3-methyl-           pyrrolidin-1-yl]-methanone. LC-MS: t R  = 0.88; [M + H] +  = 473.1       4.13   2-{(2S,3S)-1-[5-(3-Chloro-phenyl)-2-methyl-thiazole-4-carbonyl]-3-methyl-pyrrolidin-2-yl}-1H-           benzoimidazole-4-carboxylic acid methyl ester. LC-MS: t R  = 0.88; [M + H] +  = 495.2       4.14   [5-(3-Chloro-phenyl)-2-methyl-thiazol-4-yl]-[(2S,3S)-2-(4-methoxy-1H-benzoimidazol-2-yl)-3-methyl-           pyrrolidin-1-yl]-methanone. LC-MS: t R  = 0.79; [M + H] +  = 467.2       4.15   [(2S,3S)-2-(5-Chloro-6-methyl-1H-benzoimidazol-2-yl)-3-methyl-pyrrolidin-1-yl]-[5-(3-chloro-phenyl)-           2-methyl-thiazol-4-yl]-methanone. LC-MS: t R  = 0.89; [M + H] +  = 485.2       4.16   [5-(3-Chloro-phenyl)-2-methyl-thiazol-4-yl]-[(2S,3S)-2-(4,6-dimethyl-1H-benzoimidazol-2-yl)-3-methyl-           pyrrolidin-1-yl]-methanone. LC-MS: t R  = 0.85; [M + H] +  = 465.2       4.17   [5-(3-Chloro-phenyl)-2-methyl-thiazol-4-yl]-[(2S,3S)-2-(4-hydroxymethyl-1H-benzoimidazol-2-yl)-3-           methyl-pyrrolidin-1-yl]-methanone. LC-MS: t R  = 0.73; [M + H] +  = 467.2       4.18   [5-(3-Chloro-phenyl)-2-methyl-thiazol-4-yl]-[(2S,3S)-2-(4-fluoro-1H-benzoimidazol-2-yl)-3-methyl-           pyrrolidin-1-yl]-methanone. LC-MS: t R  = 0.87; [M + H] +  = 455.1       4.19   [5-(3-Chloro-phenyl)-2-methyl-thiazol-4-yl]-[(2S,3S)-3-methyl-2-(4-trifluoromethyl-1H-benzoimidazol-           2-yl)-pyrrolidin-1-yl]-methanone. LC-MS: t R  = 1.01; [M + H] +  = 505.2       4.20   [5-(3-Chloro-phenyl)-2-methyl-thiazol-4-yl]-[(2S,3S)-2-(5-fluoro-1H-benzoimidazol-2-yl)-3-methyl-           pyrrolidin-1-yl]-methanone. LC-MS: t R  = 0.81; [M + H] +  = 455.1       4.21   [(2S,3S)-2-(5-Chloro-4-methyl-1H-benzoimidazol-2-yl)-3-methyl-pyrrolidin-1-yl]-[5-(3-chloro-phenyl)-           2-methyl-thiazol-4-yl]-methanone. LC-MS: t R  = 0.9; [M + H] +  = 485.1       4.22   [(2S,3S)-2-(4-Chloro-1H-benzoimidazol-2-yl)-3-methyl-pyrrolidin-1-yl]-[5-(3-chloro-phenyl)-2-methyl-           thiazol-4-yl]-methanone. LC-MS: t R  = 0.91; [M + H] +  = 471.1       4.23   [5-(3-Chloro-phenyl)-2-methyl-thiazol-4-yl]-[(2S,3S)-2-(4,5-difluoro-1H-benzoimidazol-2-yl)-3-methyl-           pyrrolidin-1-yl]-methanone. LC-MS: t R  = 0.96; [M + H] +  = 473.2       4.24   [5-(3-Chloro-phenyl)-2-methyl-thiazol-4-yl]-[(2S,3S)-2-(4,5-dimethyl-1H-benzoimidazol-2-yl)-3-methyl-           pyrrolidin-1-yl]-methanone. LC-MS: t R  = 0.84; [M + H] +  = 465.2       4.25   [5-(3-Chloro-phenyl)-2-methyl-thiazol-4-yl]-[(2S,3S)-2-(4-isopropyl-1H-benzoimidazol-2-yl)-3-methyl-           pyrrolidin-1-yl]-methanone. LC-MS: t R  = 0.89; [M + H] +  = 479.2       4.26   [5-(3-Chloro-phenyl)-2-methyl-thiazol-4-yl]-[(2S,3S)-2-(5-methoxy-1H-benzoimidazol-2-yl)-3-methyl-           pyrrolidin-1-yl]-methanone. LC-MS: t R  = 0.79; [M + H] +  = 467.2       4.27   [5-(3-Chloro-phenyl)-2-methyl-thiazol-4-yl]-[(2S,3S)-2-(5-hydroxymethyl-1H-benzoimidazol-2-yl)-3-           methyl-pyrrolidin-1-yl]-methanone. LC-MS: t R  = 0.71; [M + H] +  = 467.2       4.28   [(2S,3S)-2-(5-Chloro-7-methyl-1H-benzoimidazol-2-yl)-3-methyl-pyrrolidin-1-yl]-[5-(3-chloro-phenyl)-           2-methyl-thiazol-4-yl]-methanone. LC-MS: t R  = 0.91; [M + H] +  = 485.1       4.29   (5-Methyl-2-[1,2,3]triazol-2-yl-phenyl)-[(2S,3S)-3-methyl-2-(5-trifluoromethyl-1H-benzoimidazol-2-yl)-           pyrrolidin-1-yl]-methanone. LC-MS: t R  = 0.85; [M + H] +  = 455.2       4.30   [(2S,3S)-2-(5,6-Dimethyl-1H-benzoimidazol-2-yl)-3-methyl-pyrrolidin-1-yl]-(5-methyl-2-[1,2,3]triazol-2-           yl-phenyl)-methanone. LC-MS: t R  = 0.72; [M + H] +  = 415.3       4.31   [(2S,3S)-2-(4-Methoxy-1H-benzoimidazol-2-yl)-3-methyl-pyrrolidin-1-yl]-(5-methyl-2-[1,2,3]triazol-2-           yl-phenyl)-methanone. LC-MS: t R  = 0.66; [M + H] +  = 417.2       4.32   [(2S,3S)-2-(5-Chloro-6-methyl-1H-benzoimidazol-2-yl)-3-methyl-pyrrolidin-1-yl]-(5-methyl-2-           [1,2,3]triazol-2-yl-phenyl)-methanone. LC-MS: t R  = 0.77; [M + H] +  = 435.2       4.33   [(2S,3S)-2-(4,6-Dimethyl-1H-benzoimidazol-2-yl)-3-methyl-pyrrolidin-1-yl]-(5-methyl-2-[1,2,3]triazol-2-           yl-phenyl)-methanone. LC-MS: t R  = 0.71; [M + H] +  = 415.3       4.34   (5-Methyl-2-[1,2,3]triazol-2-yl-phenyl)-[(2S,3S)-3-methyl-2-(4-trifluoromethyl-1H-benzoimidazol-2-yl)-           pyrrolidin-1-yl]-methanone. LC-MS: t R  = 0.89; [M + H] +  = 455.2       4.35   [(2S,3S)-2-(5-Chloro-4-methyl-1H-benzoimidazol-2-yl)-3-methyl-pyrrolidin-1-yl]-(5-methyl-2-           [1,2,3]triazol-2-yl-phenyl)-methanone. LC-MS: t R  = 0.76; [M + H] +  = 435.2       4.36   [(2S,3S)-2-(4-Chloro-1H-benzoimidazol-2-yl)-3-methyl-pyrrolidin-1-yl]-(5-methyl-2-[1,2,3]triazol-2-yl-           phenyl)-methanone. LC-MS: t R  = 0.77; [M + H] +  = 421.2       4.37   [(2S,3S)-2-(4,5-Dimethyl-1H-benzoimidazol-2-yl)-3-methyl-pyrrolidin-1-yl]-(5-methyl-2-[1,2,3]triazol-2-           yl-phenyl)-methanone. LC-MS: t R  = 0.7; [M + H] +  = 415.2       4.38   [(2S,3S)-2-(4-Isopropyl-1H-benzoimidazol-2-yl)-3-methyl-pyrrolidin-1-yl]-(5-methyl-2-[1,2,3]triazol-2-           yl-phenyl)-methanone. LC-MS: t R  = 0.75; [M + H] +  = 429.3       4.39   [(2S,3S)-2-(5-Chloro-7-methyl-1H-benzoimidazol-2-yl)-3-methyl-pyrrolidin-1-yl]-(5-methyl-2-           [1,2,3]triazol-2-yl-phenyl)-methanone. LC-MS: t R  = 0.77; [M + H] +  = 435.2       4.40   (5-Chloro-2-[1,2,3]triazol-2-yl-phenyl)-[(2S,3S)-2-(5,6-dimethoxy-1H-benzoimidazol-2-yl)-3-methyl-           pyrrolidin-1-yl]-methanone. LC-MS: t R  = 0.71; [M + H] +  = 467.2       4.41   [(2S,3S)-2-(5,6-Dimethoxy-1H-benzoimidazol-2-yl)-3-methyl-pyrrolidin-1-yl]-(5-fluoro-2-[1,2,3]triazol-           2-yl-phenyl)-methanone. LC-MS: t R  = 0.64; [M + H] +  = 451.3       4.42   [(2S,3S)-2-(5,6-Dimethoxy-1H-benzoimidazol-2-yl)-3-methyl-pyrrolidin-1-yl]-(2-fluoro-6-[1,2,3]triazol-           2-yl-phenyl)-methanone. LC-MS: t R  = 0.63; [M + H] +  = 451.3       4.43   [(2S,3S)-2-(5,6-Dimethoxy-1H-benzoimidazol-2-yl)-3-methyl-pyrrolidin-1-yl]-(5-methoxy-2-           [1,2,3]triazol-2-yl-phenyl)-methanone. LC-MS: t R  = 0.64; [M + H] +  = 463.3       4.44   [(2S,3S)-2-(5,6-Dimethoxy-1H-benzoimidazol-2-yl)-3-methyl-pyrrolidin-1-yl]-(2-fluoro-3-methyl-6-           [1,2,3]triazol-2-yl-phenyl)-methanone. LC-MS: t R  = 0.69; [M + H] +  = 465.3       4.45   [(2S,3S)-2-(5,6-Dimethoxy-1H-benzoimidazol-2-yl)-3-methyl-pyrrolidin-1-yl]-(2-fluoro-3-methoxy-6-           [1,2,3]triazol-2-yl-phenyl)-methanone. LC-MS: t R  = 0.65; [M + H] +  = 481.3       4.46   [(2S,3S)-2-(5,6-Dimethoxy-1H-benzoimidazol-2-yl)-3-methyl-pyrrolidin-1-yl]-(4-methyl-2-[1,2,3]triazol-           2-yl-phenyl)-methanone. LC-MS: t R  = 0.67; [M + H] +  = 447.3       4.47   [(2S,3S)-2-(5,6-Dimethoxy-1H-benzoimidazol-2-yl)-3-methyl-pyrrolidin-1-yl]-(2-[1,2,3]triazol-2-yl-5-           trifluoromethyl-phenyl)-methanone. LC-MS: t R  = 0.76; [M + H] +  = 501.3       4.48   [(2S,3S)-2-(5,6-Dimethoxy-1H-benzoimidazol-2-yl)-3-methyl-pyrrolidin-1-yl]-(2-methyl-6-[1,2,3]triazol-           2-yl-phenyl)-methanone. LC-MS: t R  = 0.66; [M + H] +  = 447.3       4.49   [(2S,3S)-2-(5,6-Dimethoxy-1H-benzoimidazol-2-yl)-3-methyl-pyrrolidin-1-yl]-(2-[1,2,3]triazol-2-yl-           phenyl)-methanone. LC-MS: t R  = 0.62; [M + H] +  = 433.3       4.50   [(2S,3S)-2-(5,6-Dimethoxy-1H-benzoimidazol-2-yl)-3-methyl-pyrrolidin-1-yl]-[2-methyl-5-(4-           trifluoromethyl-phenyl)-thiazol-4-yl]-methanone. LC-MS: t R  = 0.83; [M + H] +  = 531.3       4.51   [(2S,3S)-2-(5,6-Dimethoxy-1H-benzoimidazol-2-yl)-3-methyl-pyrrolidin-1-yl]-(2-methyl-4-p-tolyl-           thiazol-5-yl)-methanone. LC-MS: t R  = 0.7; [M + H] +  = 477.2       4.52   [5-(3,5-Difluoro-phenyl)-2-methyl-thiazol-4-yl]-[(2S,3S)-2-(5,6-dimethoxy-1H-benzoimidazol-2-yl)-3-           methyl-pyrrolidin-1-yl]-methanone. LC-MS: t R  = 0.75; [M + H] +  = 499.3       4.53   [(2S,3S)-2-(5,6-Dimethoxy-1H-benzoimidazol-2-yl)-3-methyl-pyrrolidin-1-yl]-[5-(6-methoxy-pyridin-3-           yl)-2-methyl-thiazol-4-yl]-methanone. LC-MS: t R  = 0.68; [M + H] +  = 494.4       4.54   [(2S,3S)-2-(5,6-Dimethoxy-1H-benzoimidazol-2-yl)-3-methyl-pyrrolidin-1-yl]-[5-(4-fluoro-phenyl)-2-           methyl-thiazol-4-yl]-methanone. LC-MS: t R  = 0.73; [M + H] +  = 481.3       4.55   [5-(3-Chloro-phenyl)-thiazol-4-yl]-[(2S,3S)-2-(5,6-dimethoxy-1H-benzoimidazol-2-yl)-3-methyl-           pyrrolidin-1-yl]-methanone. LC-MS: t R  = 0.72; [M + H] +  = 483.2       4.56   [(2S,3S)-2-(5,6-Dimethoxy-1H-benzoimidazol-2-yl)-3-methyl-pyrrolidin-1-yl]-(2-pyrazol-1-yl-phenyl)-           methanone. LC-MS: t R  = 0.62; [M + H] +  = 432.3       4.57   [(2S,3S)-2-(5,6-Dimethoxy-1H-benzoimidazol-2-yl)-3-methyl-pyrrolidin-1-yl]-(5-methyl-2-pyrazol-1-yl-           phenyl)-methanone. LC-MS: t R  = 0.66; [M + H] +  = 446.3       4.58   [(2S,3S)-2-(5,6-Dimethoxy-1H-benzoimidazol-2-yl)-3-methyl-pyrrolidin-1-yl]-(4′-methyl-biphenyl-2-yl)-           methanone. LC-MS: t R  = 0.80; [M + H] +  = 456.4       4.59   [(2S,3S)-2-(5-Chloro-4-methyl-1H-benzoimidazol-2-yl)-3-methyl-pyrrolidin-1-yl]-(2-[1,2,3]triazol-2-yl-           phenyl)-methanone. LC-MS: t R  = 0.74; [M + H] +  = 421.3       4.60   [(2S,3S)-2-(5-Chloro-4-methyl-1H-benzoimidazol-2-yl)-3-methyl-pyrrolidin-1-yl]-(5-chloro-2-           [1,2,3]triazol-2-yl-phenyl)-methanone. LC-MS: t R  = 0.84; [M + H] +  = 455.2       4.61   [(2S,3S)-2-(5-Chloro-4-methyl-1H-benzoimidazol-2-yl)-3-methyl-pyrrolidin-1-yl]-(4′-methyl-biphenyl-2-           yl)-methanone. LC-MS: t R  = 0.94; [M + H] +  = 444.3       4.62   [(2S,3S)-2-(5-Chloro-4-methyl-1H-benzoimidazol-2-yl)-3-methyl-pyrrolidin-1-yl]-(4-methyl-2-           [1,2,3]triazol-2-yl-phenyl)-methanone. LC-MS: t R  = 0.79; [M + H] +  = 435.3       4.63   [(2S,3S)-2-(5-Chloro-4-methyl-1H-benzoimidazol-2-yl)-3-methyl-pyrrolidin-1-yl]-[5-(4-chloro-phenyl)-           2-methyl-thiazol-4-yl]-methanone. LC-MS: t R  = 0.94; [M + H] +  = 485.2       4.64   [(2S,3S)-2-(5-Chloro-4-methyl-1H-benzoimidazol-2-yl)-3-methyl-pyrrolidin-1-yl]-(5-methyl-2-pyrazol-           1-yl-phenyl)-methanone. LC-MS: t R  = 0.80; [M + H] +  = 434.3       4.65   [(2S,3S)-2-(5-Chloro-4-methyl-1H-benzoimidazol-2-yl)-3-methyl-pyrrolidin-1-yl]-(2-methyl-4-p-tolyl-           thiazol-5-yl)-methanone. LC-MS: t R  = 0.88; [M + H] +  = 465.2       4.66   [(2S,3S)-2-(5-Chloro-4-methyl-1H-benzoimidazol-2-yl)-3-methyl-pyrrolidin-1-yl]-(5-methoxy-2-           [1,2,3]triazol-2-yl-phenyl)-methanone. LC-MS: t R  = 0.77; [M + H] +  = 451.3       4.67   [(2S,3S)-2-(5-Chloro-4-methyl-1H-benzoimidazol-2-yl)-3-methyl-pyrrolidin-1-yl]-[5-(3,5-difluoro-           phenyl)-2-methyl-thiazol-4-yl]-methanone. LC-MS: t R  = 0.92; [M + H] +  = 487.2       4.68   [(2S,3S)-2-(5-Chloro-4-methyl-1H-benzoimidazol-2-yl)-3-methyl-pyrrolidin-1-yl]-(2-fluoro-3-methyl-6-           [1,2,3]triazol-2-yl-phenyl)-methanone. LC-MS: t R  = 0.83; [M + H] +  = 453.2       4.69   [(2S,3S)-2-(5-Chloro-4-methyl-1H-benzoimidazol-2-yl)-3-methyl-pyrrolidin-1-yl]-[5-(6-methoxy-           pyridin-3-yl)-2-methyl-thiazol-4-yl]-methanone. LC-MS: t R  = 0.83; [M + H] +  = 482.2       4.70   [(2S,3S)-2-(5-Chloro-4-methyl-1H-benzoimidazol-2-yl)-3-methyl-pyrrolidin-1-yl]-[5-(4-fluoro-phenyl)-2-           methyl-thiazol-4-yl]-methanone. LC-MS: t R  = 0.89; [M + H] +  = 469.2       4.71   [(2S,3S)-2-(5-Chloro-6-methyl-1H-benzoimidazol-2-yl)-3-methyl-pyrrolidin-1-yl]-(5-chloro-2-           [1,2,3]triazol-2-yl-phenyl)-methanone. LC-MS: t R  = 0.83; [M + H] +  = 455.2       4.72   [(2S,3S)-2-(5-Chloro-6-methyl-1H-benzoimidazol-2-yl)-3-methyl-pyrrolidin-1-yl]-(4-methyl-2-           [1,2,3]triazol-2-yl-phenyl)-methanone. LC-MS: t R  = 0.80; [M + H] +  = 435.3       4.73   [(2S,3S)-2-(5-Chloro-6-methyl-1H-benzoimidazol-2-yl)-3-methyl-pyrrolidin-1-yl]-(5-methyl-2-pyrazol-           1-yl-phenyl)-methanone. LC-MS: t R  = 0.80; [M + H] +  = 434.3       4.74   [(2S,3S)-2-(5-Chloro-6-methyl-1H-benzoimidazol-2-yl)-3-methyl-pyrrolidin-1-yl]-(5-methoxy-2-           [1,2,3]triazol-2-yl-phenyl)-methanone. LC-MS: t R  = 0.78; [M + H] +  = 451.9       4.75   [(2S,3S)-2-(5-Chloro-6-methyl-1H-benzoimidazol-2-yl)-3-methyl-pyrrolidin-1-yl]-(2-fluoro-3-methyl-6-           [1,2,3]triazol-2-yl-phenyl)-methanone. LC-MS: t R  = 0.83; [M + H] +  = 453.3       4.76   [(2S,3S)-2-(5-Chloro-6-methyl-1H-benzoimidazol-2-yl)-3-methyl-pyrrolidin-1-yl]-(2-[1,2,3]triazol-2-yl-           phenyl)-methanone. LC-MS: t R  = 0.74; [M + H] +  = 421.2       4.77   [(2S,3S)-2-(5-Chloro-6-methyl-1H-benzoimidazol-2-yl)-3-methyl-pyrrolidin-1-yl]-(4′-methyl-biphenyl-2-           yl)-methanone. LC-MS: t R  = 0.93; [M + H] +  = 444.3       4.78   [(2S,3S)-2-(5-Chloro-6-methyl-1H-benzoimidazol-2-yl)-3-methyl-pyrrolidin-1-yl]-[5-(4-chloro-phenyl)-           2-methyl-thiazol-4-yl]-methanone. LC-MS: t R  = 0.93; [M + H] +  = 485.2       4.79   [(2S,3S)-2-(5-Chloro-6-methyl-1H-benzoimidazol-2-yl)-3-methyl-pyrrolidin-1-yl]-(2-methyl-4-p-tolyl-           thiazol-5-yl)-methanone. LC-MS: t R  = 0.86; [M + H] +  = 465.3       4.80   [(2S,3S)-2-(5-Chloro-6-methyl-1H-benzoimidazol-2-yl)-3-methyl-pyrrolidin-1-yl]-[5-(3,5-difluoro-           phenyl)-2-methyl-thiazol-4-yl]-methanone. LC-MS: t R  = 0.91; [M + H] +  = 487.2       4.81   (5-Chloro-2-[1,2,3]triazol-2-yl-phenyl)-[(2S,3S)-2-(5,6-dimethyl-1H-benzoimidazol-2-yl)-3-methyl-           pyrrolidin-1-yl]-methanone. LC-MS: t R  = 0.78; [M + H] +  = 435.3       4.82   [(2S,3S)-2-(5,6-Dimethyl-1H-benzoimidazol-2-yl)-3-methyl-pyrrolidin-1-yl]-(4-methyl-2-[1,2,3]triazol-2-           yl-phenyl)-methanone. LC-MS: t R  = 0.75; [M + H] +  = 415.3       4.83   [(2S,3S)-2-(5,6-Dimethyl-1H-benzoimidazol-2-yl)-3-methyl-pyrrolidin-1-yl]-(5-methyl-2-pyrazol-1-yl-           phenyl)-methanone. LC-MS: t R  = 0.75; [M + H] +  = 414.3       4.84   [(2S,3S)-2-(5,6-Dimethyl-1H-benzoimidazol-2-yl)-3-methyl-pyrrolidin-1-yl]-(5-methoxy-2-[1,2,3]triazol-           2-yl-phenyl)-methanone. LC-MS: t R  = 0.72; [M + H] +  = 431.3       4.85   [(2S,3S)-2-(5,6-Dimethyl-1H-benzoimidazol-2-yl)-3-methyl-pyrrolidin-1-yl]-(2-[1,2,3]triazol-2-yl-           phenyl)-methanone. LC-MS: t R  = 0.69; [M + H] +  = 401.3       4.86   [(2S,3S)-2-(5,6-Dimethyl-1H-benzoimidazol-2-yl)-3-methyl-pyrrolidin-1-yl]-(4′-methyl-biphenyl-2-yl)-           methanone. LC-MS: t R  = 0.87; [M + H] +  = 424.3       4.87   [5-(4-Chloro-phenyl)-2-methyl-thiazol-4-yl]-[(2S,3S)-2-(5,6-dimethyl-1H-benzoimidazol-2-yl)-3-methyl-           pyrrolidin-1-yl]-methanone. LC-MS: t R  = 0.87; [M + H] +  = 465.2       4.88   [(2S,3S)-2-(5,6-Dimethyl-1H-benzoimidazol-2-yl)-3-methyl-pyrrolidin-1-yl]-(2-methyl-4-p-tolyl-thiazol-           5-yl)-methanone. LC-MS: t R  = 0.78; [M + H] +  = 445.3       4.89   [5-(3,5-Difluoro-phenyl)-2-methyl-thiazol-4-yl]-[(2S,3S)-2-(5,6-dimethyl-1H-benzoimidazol-2-yl)-3-           methyl-pyrrolidin-1-yl]-methanone. LC-MS: t R  = 0.85; [M + H] +  = 467.3       4.90   [(2S,3S)-2-(5,6-Dimethyl-1H-benzoimidazol-2-yl)-3-methyl-pyrrolidin-1-yl]-[5-(4-fluoro-phenyl)-2-           methyl-thiazol-4-yl]-methanone. LC-MS: t R  = 0.82; [M + H] +  = 449.3       4.91   [(2S,3S)-2-(6-Chloro-4-methyl-1H-benzoimidazol-2-yl)-3-methyl-pyrrolidin-1-yl]-(5-chloro-2-           [1,2,3]triazol-2-yl-phenyl)-methanone. LC-MS: t R  = 0.84; [M + H] +  = 455.2       4.92   [(2S,3S)-2-(6-Chloro-4-methyl-1H-benzoimidazol-2-yl)-3-methyl-pyrrolidin-1-yl]-(4′-methyl-biphenyl-2-           yl)-methanone. LC-MS: t R  = 0.93; [M + H] +  = 444.3       4.93   [(2S,3S)-2-(6-Chloro-4-methyl-1H-benzoimidazol-2-yl)-3-methyl-pyrrolidin-1-yl]-(4-methyl-2-           [1,2,3]triazol-2-yl-phenyl)-methanone. LC-MS: t R  = 0.80; [M + H] +  = 435.2       4.94   [(2S,3S)-2-(6-Chloro-4-methyl-1H-benzoimidazol-2-yl)-3-methyl-pyrrolidin-1-yl]-[5-(4-chloro-phenyl)-           2-methyl-thiazol-4-yl]-methanone. LC-MS: t R  = 0.94; [M + H] +  = 485.2       4.95   [(2S,3S)-2-(6-Chloro-4-methyl-1H-benzoimidazol-2-yl)-3-methyl-pyrrolidin-1-yl]-(5-methyl-2-pyrazol-           1-yl-phenyl)-methanone. LC-MS: t R  = 0.80; [M + H] +  = 434.3       4.96   [(2S,3S)-2-(6-Chloro-4-methyl-1H-benzoimidazol-2-yl)-3-methyl-pyrrolidin-1-yl]-(2-methyl-4-p-tolyl-           thiazol-5-yl)-methanone. LC-MS: t R  = 0.88; [M + H] +  = 465.2       4.97   [(2S,3S)-2-(6-Chloro-4-methyl-1H-benzoimidazol-2-yl)-3-methyl-pyrrolidin-1-yl]-(5-methoxy-2-           [1,2,3]triazol-2-yl-phenyl)-methanone. LC-MS: t R  = 0.77; [M + H] +  = 451.3       4.98   [(2S,3S)-2-(6-Chloro-4-methyl-1H-benzoimidazol-2-yl)-3-methyl-pyrrolidin-1-yl]-[5-(3,5-difluoro-           phenyl)-2-methyl-thiazol-4-yl]-methanone. LC-MS: t R  = 0.92; [M + H] +  = 487.2       4.99   [(2S,3S)-2-(6-Chloro-4-methyl-1H-benzoimidazol-2-yl)-3-methyl-pyrrolidin-1-yl]-(2-fluoro-3-methyl-6-           [1,2,3]triazol-2-yl-phenyl)-methanone. LC-MS: t R  = 0.83; [M + H] +  = 453.2       4.100   [(2S,3S)-2-(6-Chloro-4-methyl-1H-benzoimidazol-2-yl)-3-methyl-pyrrolidin-1-yl]-[5-(4-fluoro-phenyl)-2-           methyl-thiazol-4-yl]-methanone. LC-MS: t R  = 0.89; [M + H] +  = 469.2       4.101   [(2S,3S)-2-(6-Chloro-4-methyl-1H-benzoimidazol-2-yl)-3-methyl-pyrrolidin-1-yl]-(2-[1,2,3]triazol-2-yl-           phenyl)-methanone. LC-MS: t R  = 0.74; [M + H] +  = 421.3       4.102   [(2S,3S)-2-(5-Chloro-6-methyl-1H-benzoimidazol-2-yl)-3-methyl-pyrrolidin-1-yl]-(5-methyl-2-pyridin-2-           yl-phenyl)-methanone. LC-MS: t R  = 0.91; [M + H] +  = 445.9       4.103   (4-Chloro-biphenyl-2-yl)-[(2S,3S)-2-(5-chloro-6-methyl-1H-benzoimidazol-2-yl)-3-methyl-pyrrolidin-1-           yl]-methanone. LC-MS: t R  = 0.99; [M + H] +  = 464.3       4.104   [(2S,3S)-2-(5-Chloro-6-methyl-1H-benzoimidazol-2-yl)-3-methyl-pyrrolidin-1-yl]-(5-methyl-2-pyridin-3-           yl-phenyl)-methanone. LC-MS: t R  = 0.72; [M + H] +  = 445.3       4.105   [(2S,3S)-2-(5-Chloro-6-methyl-1H-benzoimidazol-2-yl)-3-methyl-pyrrolidin-1-yl]-(4-fluoro-biphenyl-2-           yl)-methanone. LC-MS: t R  = 0.94; [M + H] +  = 448.3       4.106   [(2S,3S)-2-(5-Chloro-6-methyl-1H-benzoimidazol-2-yl)-3-methyl-pyrrolidin-1-yl]-(5-fluoro-2-pyridin-2-           yl-phenyl)-methanone. LC-MS: t R  = 0.81; [M + H] +  = 449.3       4.107   [(2S,3S)-2-(5-Chloro-6-methyl-1H-benzoimidazol-2-yl)-3-methyl-pyrrolidin-1-yl]-(2-fluoro-6-pyridin-3-           yl-phenyl)-methanone. LC-MS: t R  = 0.71; [M + H] +  = 449.3       4.108   2-[(2S,3S)-2-(5-Chloro-6-methyl-1H-benzoimidazol-2-yl)-3-methyl-pyrrolidine-1-carbonyl]-biphenyl-4-           carbonitrile. LC-MS: t R  = 0.91; [M + H] +  = 455.3       4.109   [(2S,3S)-2-(5-Chloro-6-methyl-1H-benzoimidazol-2-yl)-3-methyl-pyrrolidin-1-yl]-(4-methyl-2-pyridin-2-           yl-phenyl)-methanone. LC-MS: t R  = 0.81; [M + H] +  = 445.4       4.110   [(2S,3S)-2-(5-Chloro-6-methyl-1H-benzoimidazol-2-yl)-3-methyl-pyrrolidin-1-yl]-(4-methyl-2-pyridin-3-           yl-phenyl)-methanone. LC-MS: t R  = 0.72; [M + H] +  = 445.3       4.111   [(2S,3S)-2-(5-Chloro-6-methyl-1H-benzoimidazol-2-yl)-3-methyl-pyrrolidin-1-yl]-(5-methyl-biphenyl-2-           yl)-methanone. LC-MS: t R  = 0.96; [M + H] +  = 444.3       4.112   [(2S,3S)-2-(5-Chloro-6-methyl-1H-benzoimidazol-2-yl)-3-methyl-pyrrolidin-1-yl]-(3-fluoro-biphenyl-2-           yl)-methanone. LC-MS: t R  = 0.8; [M + H] +  = 449.3       4.113   [(2S,3S)-2-(5-Chloro-6-methyl-1H-benzoimidazol-2-yl)-3-methyl-pyrrolidin-1-yl]-(2-fluoro-3-methyl-6-           pyridin-2-yl-phenyl)-methanone. LC-MS: t R  = 0.83; [M + H] +  = 463.3       4.114   [(2S,3S)-2-(5-Chloro-6-methyl-1H-benzoimidazol-2-yl)-3-methyl-pyrrolidin-1-yl]-(4-trifluoromethyl-           biphenyl-2-yl)-methanone. LC-MS: t R  = 1.02; [M + H] +  = 498.3       4.115   [(2S,3S)-2-(5-Chloro-6-methyl-1H-benzoimidazol-2-yl)-3-methyl-pyrrolidin-1-yl]-(3-fluoro-4-methyl-           biphenyl-2-yl)-methanone. LC-MS: t R  = 0.99; [M + H] +  = 462.3       4.116   [(2S,3S)-2-(5-Chloro-6-methyl-1H-benzoimidazol-2-yl)-3-methyl-pyrrolidin-1-yl]-(4-methyl-biphenyl-2-           yl)-methanone. LC-MS: t R  = 0.95; [M + H] +  = 444.3       4.117   [(2S,3S)-2-(5-Chloro-6-methyl-1H-benzoimidazol-2-yl)-3-methyl-pyrrolidin-1-yl]-(2-fluoro-3-methyl-6-           pyridin-3-yl-phenyl)-methanone. LC-MS: t R  = 0.75; [M + H] +  = 463.3       4.118   [(2S,3S)-2-(4-Chloro-1H-benzoimidazol-2-yl)-3-methyl-pyrrolidin-1-yl]-[5-(4-fluoro-phenyl)-2-methyl-           thiazol-4-yl]-methanone. LC-MS: t R  = 0.92; [M + H] +  = 455.2       4.119   [(2S,3S)-2-(4-Chloro-1H-benzoimidazol-2-yl)-3-methyl-pyrrolidin-1-yl]-[5-(3,5-difluoro-phenyl)-2-           methyl-thiazol-4-yl]-methanone. LC-MS: t R  = 0.96; [M + H] +  = 473.2       4.120   [(2S,3S)-2-(4-Chloro-1H-benzoimidazol-2-yl)-3-methyl-pyrrolidin-1-yl]-[5-(4-chloro-phenyl)-2-methyl-           thiazol-4-yl]-methanone. LC-MS: t R  = 0.98; [M + H] +  = 471.2       4.121   [(2S,3S)-2-(4-Chloro-1H-benzoimidazol-2-yl)-3-methyl-pyrrolidin-1-yl]-[5-(3-methoxy-phenyl)-2-           methyl-thiazol-4-yl]-methanone. LC-MS: t R  = 0.9; [M + H] +  = 467.2       4.122   [(2S,3S)-2-(4-Chloro-1H-benzoimidazol-2-yl)-3-methyl-pyrrolidin-1-yl]-(2-methyl-5-m-tolyl-thiazol-4-           yl)-methanone. LC-MS: t R  = 0.95; [M + H] +  = 451.3       4.123   [5-(4-Bromo-phenyl)-2-methyl-thiazol-4-yl]-[(2S,3S)-2-(4-chloro-1H-benzoimidazol-2-yl)-3-methyl-           pyrrolidin-1-yl]-methanone. LC-MS: t R  = 1.0; [M + H] +  = 515.2       4.124   [(2S,3S)-2-(4-Chloro-1H-benzoimidazol-2-yl)-3-methyl-pyrrolidin-1-yl]-(2-methyl-5-p-tolyl-thiazol-4-yl)-           methanone. LC-MS: t R  = 0.95; [M + H] +  = 451.3       4.125   [(2S,3S)-2-(4-Chloro-1H-benzoimidazol-2-yl)-3-methyl-pyrrolidin-1-yl]-[5-(3,4-dimethyl-phenyl)-2-           methyl-thiazol-4-yl]-methanone. LC-MS: t R  = 0.99; [M + H] +  = 465.3       4.126   [(2S,3S)-2-(4-Chloro-1H-benzoimidazol-2-yl)-3-methyl-pyrrolidin-1-yl]-[5-(3,4-difluoro-phenyl)-2-           methyl-thiazol-4-yl]-methanone. LC-MS: t R  = 0.95; [M + H] +  = 473.2       4.127   [(2S,3S)-2-(4-Chloro-1H-benzoimidazol-2-yl)-3-methyl-pyrrolidin-1-yl]-[2-(3,4-dimethyl-phenyl)-           thiophen-3-yl]-methanone. LC-MS: t R  = 1.02; [M + H] +  = 450.3       4.128   [(2S,3S)-2-(4-Chloro-1H-benzoimidazol-2-yl)-3-methyl-pyrrolidin-1-yl]-[2-dimethylamino-5-(3,4-           dimethyl-phenyl)-thiazol-4-yl]-methanone. LC-MS: t R  = 1.0; [M + H] +  = 494.3       4.129   [(2S,3S)-2-(4-Chloro-1H-benzoimidazol-2-yl)-3-methyl-pyrrolidin-1-yl]-[5-(2-methoxy-phenyl)-2-           methyl-thiazol-4-yl]-methanone. LC-MS: t R  = 0.89; [M + H] +  = 467.3       4.130   [(2S,3S)-2-(5-Chloro-6-methyl-1H-benzoimidazol-2-yl)-3-methyl-pyrrolidin-1-yl]-(4-methyl-2-pyrimidin-           2-yl-phenyl)-methanone. LC-MS: t R  = 0.81; [M + H] +  = 446.3       4.131   [(2S,3S)-2-(5-Chloro-6-methyl-1H-benzoimidazol-2-yl)-3-methyl-pyrrolidin-1-yl]-(5-fluoro-2-pyrimidin-           2-yl-phenyl)-methanone. LC-MS: t R  = 0.81; [M + H] +  = 450.3       4.132   [(2S,3S)-2-(5-Chloro-6-methyl-1H-benzoimidazol-2-yl)-3-methyl-pyrrolidin-1-yl]-(2-fluoro-3-methyl-6-           pyrimidin-2-yl-phenyl)-methanone. LC-MS: t R  = 0.83; [M + H] +  = 464.3       4.133   [(2S,3S)-2-(5-Chloro-6-methyl-1H-benzoimidazol-2-yl)-3-methyl-pyrrolidin-1-yl]-(2-fluoro-6-pyrimidin-           2-yl-phenyl)-methanone. LC-MS: t R  = 0.80; [M + H] +  = 450.3       4.134   [(2S,3S)-2-(5-Chloro-4-methyl-1H-benzoimidazol-2-yl)-3-methyl-pyrrolidin-1-yl]-[2-(3-methoxy-           phenylethynyl)-phenyl]-methanone. LC-MS: t R =; [M + H] + =       4.135   [(2S,3S)-2-(5-Chloro-6-methyl-1H-benzoimidazol-2-yl)-3-methyl-pyrrolidin-1-yl]-[2-(3-methoxy-           phenylethynyl)-phenyl]-methanone. LC-MS: t R =; [M + H] + =       4.136   [5-(4-Fluoro-phenyl)-2-methyl-thiazol-4-yl]-[(2S,3S)-3-methyl-2-(5-trifluoromethyl-1H-benzoimidazol-           2-yl)-pyrrolidin-1-yl]-methanone. LC-MS: t R  = 0.99; [M + H] +  = 489.3       4.137   [5-(3-Methoxy-phenyl)-2-methyl-thiazol-4-yl]-[(2S,3S)-3-methyl-2-(5-trifluoromethyl-1H-           benzoimidazol-2-yl)-pyrrolidin-1-yl]-methanone. LC-MS: t R  = 0.98; [M + H] +  = 501.3       4.138   (2-Methyl-5-m-tolyl-thiazol-4-yl)-[(2S,3S)-3-methyl-2-(5-trifluoromethyl-1H-benzoimidazol-2-yl)-           pyrrolidin-1-yl]-methanone. LC-MS: t R  = 1.02; [M + H] +  = 485.3       4.139   [5-(4-Chloro-phenyl)-2-methyl-thiazol-4-yl]-[(2S,3S)-3-methyl-2-(5-trifluoromethyl-1H-benzoimidazol-           2-yl)-pyrrolidin-1-yl]-methanone. LC-MS: t R  = 1.05; [M + H] +  = 505.3       4.140   (2-Methyl-5-p-tolyl-thiazol-4-yl)-[(2S,3S)-3-methyl-2-(5-trifluoromethyl-1H-benzoimidazol-2-yl)-           pyrrolidin-1-yl]-methanone. LC-MS: t R  = 1.02; [M + H] +  = 485.3       4.141   [5-(4-Methoxy-phenyl)-2-methyl-thiazol-4-yl]-[(2S,3S)-3-methyl-2-(5-trifluoromethyl-1H-           benzoimidazol-2-yl)-pyrrolidin-1-yl]-methanone. LC-MS: t R  = 0.97; [M + H] +  = 501.3       4.142   [5-(4-Bromo-phenyl)-2-methyl-thiazol-4-yl]-[(2S,3S)-3-methyl-2-(5-trifluoromethyl-1H-benzoimidazol-           2-yl)-pyrrolidin-1-yl]-methanone. LC-MS: t R  = 1.06; [M + H] +  = 549.2       4.143   [5-(3,4-Difluoro-phenyl)-2-methyl-thiazol-4-yl]-[(2S,3S)-3-methyl-2-(5-trifluoromethyl-1H-           benzoimidazol-2-yl)-pyrrolidin-1-yl]-methanone. LC-MS: t R  = 1.02; [M + H] +  = 507.3       4.144   [2-(3,4-Dimethyl-phenyl)-thiophen-3-yl]-[(2S,3S)-3-methyl-2-(5-trifluoromethyl-1H-benzoimidazol-2-           yl)-pyrrolidin-1-yl]-methanone. LC-MS: t R  = 1.09; [M + H] +  = 484.3       4.145   [5-(3,4-Dimethyl-phenyl)-2-methyl-thiazol-4-yl]-[(2S,3S)-3-methyl-2-(5-trifluoromethyl-1H-           benzoimidazol-2-yl)-pyrrolidin-1-yl]-methanone. LC-MS: t R  = 1.06; [M + H] +  = 499.3       4.146   [5-(2-Chloro-phenyl)-2-methyl-thiazol-4-yl]-[(2S,3S)-3-methyl-2-(5-trifluoromethyl-1H-benzoimidazol-           2-yl)-pyrrolidin-1-yl]-methanone. LC-MS: t R  = 1.00; [M + H] +  = 505.2       4.147   [5-(2-Methoxy-phenyl)-2-methyl-thiazol-4-yl]-[(2S,3S)-3-methyl-2-(5-trifluoromethyl-1H-           benzoimidazol-2-yl)-pyrrolidin-1-yl]-methanone. LC-MS: t R  = 0.97; [M + H] +  = 501.3       4.148   [5-(3,5-Difluoro-phenyl)-2-methyl-thiazol-4-yl]-[(2S,3S)-3-methyl-2-(5-trifluoromethyl-1H-           benzoimidazol-2-yl)-pyrrolidin-1-yl]-methanone. LC-MS: t R  = 1.02; [M + H] +  = 507.3       4.149   [5-(4-Fluoro-phenyl)-2-methyl-thiazol-4-yl]-[(2S,3S)-3-methyl-2-(4-trifluoromethyl-1H-benzoimidazol-           2-yl)-pyrrolidin-1-yl]-methanone. LC-MS: t R  = 1.03; [M + H] +  = 489.3       4.150   [5-(4-Chloro-phenyl)-2-methyl-thiazol-4-yl]-[(2S,3S)-3-methyl-2-(4-trifluoromethyl-1H-benzoimidazol-           2-yl)-pyrrolidin-1-yl]-methanone. LC-MS: t R  = 1.09; [M + H] +  = 505.2       4.151   [5-(4-Bromo-phenyl)-2-methyl-thiazol-4-yl]-[(2S,3S)-3-methyl-2-(4-trifluoromethyl-1H-benzoimidazol-           2-yl)-pyrrolidin-1-yl]-methanone. LC-MS: t R  = 1.11; [M + H] +  = 549.2       4.152   [5-(3,4-Dimethyl-phenyl)-2-methyl-thiazol-4-yl]-[(2S,3S)-3-methyl-2-(4-trifluoromethyl-1H-           benzoimidazol-2-yl)-pyrrolidin-1-yl]-methanone. LC-MS: t R  = 1.1; [M + H] +  = 499.3       4.153   (2-Methyl-5-p-tolyl-thiazol-4-yl)-[(2S,3S)-3-methyl-2-(4-trifluoromethyl-1H-benzoimidazol-2-yl)-           pyrrolidin-1-yl]-methanone. LC-MS: t R  = 1.06; [M + H] +  = 485.3       4.154   [5-(3,4-Difluoro-phenyl)-2-methyl-thiazol-4-yl]-[(2S,3S)-3-methyl-2-(4-trifluoromethyl-1H-           benzoimidazol-2-yl)-pyrrolidin-1-yl]-methanone. LC-MS: t R  = 1.06; [M + H] +  = 507.3       4.155   [5-(2-Chloro-phenyl)-2-methyl-thiazol-4-yl]-[(2S,3S)-3-methyl-2-(4-trifluoromethyl-1H-benzoimidazol-           2-yl)-pyrrolidin-1-yl]-methanone. LC-MS: t R  = 1.04; [M + H] +  = 505.2       4.156   [5-(2-Methoxy-phenyl)-2-methyl-thiazol-4-yl]-[(2S,3S)-3-methyl-2-(4-trifluoromethyl-1H-           benzoimidazol-2-yl)-pyrrolidin-1-yl]-methanone. LC-MS: t R  = 0.99; [M + H] +  = 501.3       4.157   [5-(3,5-Difluoro-phenyl)-2-methyl-thiazol-4-yl]-[(2S,3S)-3-methyl-2-(4-trifluoromethyl-1H-           benzoimidazol-2-yl)-pyrrolidin-1-yl]-methanone. LC-MS: t R  = 1.06; [M + H] +  = 507.3       4.158   (2-Methyl-5-m-tolyl-thiazol-4-yl)-[(2S,3S)-3-methyl-2-(4-trifluoromethyl-1H-benzoimidazol-2-yl)-           pyrrolidin-1-yl]-methanone. LC-MS: t R  = 1.06; [M + H] +  = 485.3       4.159   [5-(4-Methoxy-phenyl)-2-methyl-thiazol-4-yl]-[(2S,3S)-3-methyl-2-(4-trifluoromethyl-1H-           benzoimidazol-2-yl)-pyrrolidin-1-yl]-methanone. LC-MS: t R  = 1.00; [M + H] +  = 501.3       4.160   [2-(3,4-Dimethyl-phenyl)-thiophen-3-yl]-[(2S,3S)-3-methyl-2-(4-trifluoromethyl-1H-benzoimidazol-2-           yl)-pyrrolidin-1-yl]-methanone. LC-MS: t R  = 1.14; [M + H] +  = 484.3       4.161   [(2S,3S)-2-(5-Chloro-4-methyl-1H-benzoimidazol-2-yl)-3-methyl-pyrrolidin-1-yl]-(5-methyl-2-pyridin-2-           yl-phenyl)-methanone. LC-MS: t R  = 0.81; [M + H] +  = 445.3       4.162   (4-Chloro-biphenyl-2-yl)-[(2S,3S)-2-(5-chloro-4-methyl-1H-benzoimidazol-2-yl)-3-methyl-pyrrolidin-1-           yl]-methanone. LC-MS: t R  = 0.99; [M + H] +  = 464.3       4.163   [(2S,3S)-2-(5-Chloro-4-methyl-1H-benzoimidazol-2-yl)-3-methyl-pyrrolidin-1-yl]-(5-methyl-2-pyridin-3-           yl-phenyl)-methanone. LC-MS: t R  = 0.73; [M + H] +  = 445.4       4.164   [(2S,3S)-2-(5-Chloro-4-methyl-1H-benzoimidazol-2-yl)-3-methyl-pyrrolidin-1-yl]-(4-fluoro-biphenyl-2-           yl)-methanone. LC-MS: t R  = 0.95; [M + H] +  = 448.3       4.165   [(2S,3S)-2-(5-Chloro-4-methyl-1H-benzoimidazol-2-yl)-3-methyl-pyrrolidin-1-yl]-(5-fluoro-2-pyridin-2-           yl-phenyl)-methanone. LC-MS: t R  = 0.81; [M + H] +  = 445.3       4.166   2-[(2S,3S)-2-(5-Chloro-4-methyl-1H-benzoimidazol-2-yl)-3-methyl-pyrrolidine-1-carbonyl]-biphenyl-4-           carbonitrile. LC-MS: t R  = 0.92; [M + H] +  = 455.3       4.167   [(2S,3S)-2-(5-Chloro-4-methyl-1H-benzoimidazol-2-yl)-3-methyl-pyrrolidin-1-yl]-(4-methyl-2-pyridin-2-           yl-phenyl)-methanone. LC-MS: t R  = 0.81; [M + H] +  = 445.3       4.168   [(2S,3S)-2-(5-Chloro-4-methyl-1H-benzoimidazol-2-yl)-3-methyl-pyrrolidin-1-yl]-(5-methyl-biphenyl-2-           yl)-methanone. LC-MS: t R  = 0.96; [M + H] +  = 444.3       4.169   [(2S,3S)-2-(5-Chloro-4-methyl-1H-benzoimidazol-2-yl)-3-methyl-pyrrolidin-1-yl]-(3-fluoro-biphenyl-2-           yl)-methanone. LC-MS: t R  = 0.94; [M + H] +  = 448.3       4.170   [(2S,3S)-2-(5-Chloro-4-methyl-1H-benzoimidazol-2-yl)-3-methyl-pyrrolidin-1-yl]-(4-trifluoromethyl-           biphenyl-2-yl)-methanone. LC-MS: t R  = 1.03; [M + H] +  = 498.3       4.171   [(2S,3S)-2-(5-Chloro-4-methyl-1H-benzoimidazol-2-yl)-3-methyl-pyrrolidin-1-yl]-(3-fluoro-4-methyl-           biphenyl-2-yl)-methanone. LC-MS: t R  = 1.00; [M + H] +  = 462.3       4.172   [(2S,3S)-2-(5-Chloro-4-methyl-1H-benzoimidazol-2-yl)-3-methyl-pyrrolidin-1-yl]-(4-methyl-biphenyl-2-           yl)-methanone. LC-MS: t R  = 0.95; [M + H] +  = 444.3       4.173   [(2S,3S)-2-(5-Chloro-4-methyl-1H-benzoimidazol-2-yl)-3-methyl-pyrrolidin-1-yl]-(2-fluoro-3-methyl-6-           pyridin-3-yl-phenyl)-methanone. LC-MS: t R  = 0.76; [M + H] +  = 463.3       4.174   [(2S,3S)-2-(5-Chloro-4-methyl-1H-benzoimidazol-2-yl)-3-methyl-pyrrolidin-1-yl]-(4-methyl-2-pyrimidin-           2-yl-phenyl)-methanone. LC-MS: t R  = 0.81; [M + H] +  = 446.3       4.175   [(2S,3S)-2-(5-Chloro-4-methyl-1H-benzoimidazol-2-yl)-3-methyl-pyrrolidin-1-yl]-(5-fluoro-2-pyrimidin-           2-yl-phenyl)-methanone. LC-MS: t R  = 0.81; [M + H] +  = 450.3       4.176   [(2S,3S)-2-(5-Chloro-4-methyl-1H-benzoimidazol-2-yl)-3-methyl-pyrrolidin-1-yl]-(2-fluoro-3-methyl-6-           pyrimidin-2-yl-phenyl)-methanone. LC-MS: t R  = 0.80; [M + H] +  = 464.3       4.177   [(2S,3S)-2-(5-Chloro-4-methyl-1H-benzoimidazol-2-yl)-3-methyl-pyrrolidin-1-yl]-(2-fluoro-6-pyrimidin-           2-yl-phenyl)-methanone. LC-MS: t R  = 0.80; [M + H] +  = 450.3       4.178   [(2S,3S)-2-(5-Chloro-4-methyl-1H-benzoimidazol-2-yl)-3-methyl-pyrrolidin-1-yl]-(5-methyl-2-pyrimidin-           2-yl-phenyl)-methanone. LC-MS: t R  = 0.80; [M + H] +  = 446.3       4.179   [(2S,3S)-2-(5,6-Dimethoxy-1H-benzoimidazol-2-yl)-3-methyl-pyrrolidin-1-yl]-(5-methyl-2-pyrimidin-2-           yl-phenyl)-methanone. LC-MS: t R  = 0.68; [M + H] +  = 458.4       4.180   [(2S,3S)-2-(5-Chloro-6-methyl-1H-benzoimidazol-2-yl)-3-methyl-pyrrolidin-1-yl]-(5-methyl-2-pyrimidin-           2-yl-phenyl)-methanone. LC-MS: t R  = 0.80; [M + H] +  = 446.3       4.181   [(2S,3S)-2-(6-Chloro-7-methyl-1H-benzoimidazol-2-yl)-3-methyl-pyrrolidin-1-yl]-(5-methyl-2-pyrimidin-           2-yl-phenyl)-methanone. LC-MS: t R  = 0.80; [M + H] +  = 446.3       4.182   [(2S,3S)-2-(5-Chloro-7-methyl-1H-benzoimidazol-2-yl)-3-methyl-pyrrolidin-1-yl]-(5-methyl-2-pyrimidin-           2-yl-phenyl)-methanone. LC-MS: t R  = 0.80; [M + H] +  = 446.3       4.183   [(2S,3S)-2-(5,6-Dimethyl-1H-benzoimidazol-2-yl)-3-methyl-pyrrolidin-1-yl]-(5-methyl-2-pyrimidin-2-yl-           phenyl)-methanone. LC-MS: t R  = 0.76; [M + H] +  = 426.4       5.1   [(S)-2-Methyl-2-(4-methyl-1H-benzoimidazol-2-yl)-pyrrolidin-1-yl]-(2-methyl-5-phenyl-thiazol-4-yl)-           methanone. LC-MS: t R  = 0.79; [M + H] +  = 417.3       5.2   [(S)-2-(5-Chloro-4-methyl-1H-benzoimidazol-2-yl)-2-methyl-pyrrolidin-1-yl]-(5-methyl-2-[1,2,3]triazol-           2-yl-phenyl)-methanone. LC-MS: t R  = 0.81; [M + H] +  = 435.3       5.3   [(S)-2-(5-Chloro-4-methyl-1H-benzoimidazol-2-yl)-2-methyl-pyrrolidin-1-yl]-(2-methyl-5-phenyl-           thiazol-4-yl)-methanone. LC-MS: t R  = 0.83; [M + H] +  = 451.2       5.4   [5-(3-Chloro-phenyl)-2-methyl-thiazol-4-yl]-[(S)-2-methyl-2-(4-methyl-1H-benzoimidazol-2-yl)-           pyrrolidin-1-yl]-methanone. LC-MS: t R  = 0.82; [M + H] +  = 451.2       5.5   [(S)-2-(5-Chloro-4-methyl-1H-benzoimidazol-2-yl)-2-methyl-pyrrolidin-1-yl]-[5-(3-chloro-phenyl)-2-           methyl-thiazol-4-yl]-methanone. LC-MS: t R  = 0.9; [M + H] +  = 485.2       5.6   [(S)-2-Methyl-2-(4-methyl-1H-benzoimidazol-2-yl)-pyrrolidin-1-yl]-(5-methyl-2-[1,2,3]triazol-2-yl-           phenyl)-methanone. LC-MS: t R  = 0.68; [M + H] +  = 401.2       5.7   [(S)-2-(5,6-Dichloro-1H-benzoimidazol-2-yl)-2-methyl-pyrrolidin-1-yl]-(5-methyl-2-[1,2,3]triazol-2-yl-           phenyl)-methanone. LC-MS: t R  = 0.92; [M + H] +  = 455.2       5.8   [(S)-2-(5-Bromo-1H-benzoimidazol-2-yl)-2-methyl-pyrrolidin-1-yl]-(5-methyl-2-[1,2,3]triazol-2-yl-           phenyl)-methanone. LC-MS: t R  = 0.74; [M + H] +  = 465.2       5.9   (5-Methyl-2-[1,2,3]triazol-2-yl-phenyl)-[(S)-2-methyl-2-(5-trifluoromethyl-1H-benzoimidazol-2-yl)-           pyrrolidin-1-yl]-methanone. LC-MS: t R  = 0.83; [M + H] +  = 455.3       5.10   [(S)-2-(5,6-Dimethyl-1H-benzoimidazol-2-yl)-2-methyl-pyrrolidin-1-yl]-(5-methyl-2-[1,2,3]triazol-2-yl-           phenyl)-methanone. LC-MS: t R  = 0.75; [M + H] +  = 415.4       5.11   [(S)-2-(5-Chloro-1H-benzoimidazol-2-yl)-2-methyl-pyrrolidin-1-yl]-(5-methyl-2-[1,2,3]triazol-2-yl-           phenyl)-methanone. LC-MS: t R  = 0.73; [M + H] +  = 421.2       5.12   [(S)-2-(6-Chloro-5-fluoro-1H-benzoimidazol-2-yl)-2-methyl-pyrrolidin-1-yl]-(5-methyl-2-[1,2,3]triazol-2-           yl-phenyl)-methanone. LC-MS: t R  = 0.81; [M + H] +  = 439.2       5.13   [(S)-2-(5-tert-Butyl-1H-benzoimidazol-2-yl)-2-methyl-pyrrolidin-1-yl]-(5-methyl-2-[1,2,3]triazol-2-yl-           phenyl)-methanone. LC-MS: t R  = 0.81; [M + H] +  = 443.3       5.14   [(S)-2-(4-Chloro-6-trifluoromethyl-1H-benzoimidazol-2-yl)-2-methyl-pyrrolidin-1-yl]-(5-methyl-2-           [1,2,3]triazol-2-yl-phenyl)-methanone. LC-MS: t R  = 1.11; [M + H] +  = 489.2       5.15   [(S)-2-(5-Chloro-6-methyl-1H-benzoimidazol-2-yl)-2-methyl-pyrrolidin-1-yl]-(5-methyl-2-[1,2,3]triazol-           2-yl-phenyl)-methanone. LC-MS: t R  = 0.76; [M + H] +  = 435.2       5.16   [(S)-2-(4,6-Dimethyl-1H-benzoimidazol-2-yl)-2-methyl-pyrrolidin-1-yl]-(5-methyl-2-[1,2,3]triazol-2-yl-           phenyl)-methanone. LC-MS: t R  = 0.76; [M + H] +  = 415.4       5.17   (5-Methyl-2-[1,2,3]triazol-2-yl-phenyl)-[(S)-2-methyl-2-(4-trifluoromethyl-1H-benzoimidazol-2-yl)-           pyrrolidin-1-yl]-methanone. LC-MS: t R  = 0.96; [M + H] +  = 455.2       5.18   [(S)-2-(4-Bromo-1H-benzoimidazol-2-yl)-2-methyl-pyrrolidin-1-yl]-(5-methyl-2-[1,2,3]triazol-2-yl-           phenyl)-methanone. LC-MS: t R  = 0.82; [M + H] +  = 465.2       5.19   [(S)-2-(5-Bromo-7-methyl-1H-benzoimidazol-2-yl)-2-methyl-pyrrolidin-1-yl]-(5-methyl-2-[1,2,3]triazol-           2-yl-phenyl)-methanone. LC-MS: t R  = 0.82; [M + H] +  = 479.2       5.20   (5-Methyl-2-[1,2,3]triazol-2-yl-phenyl)-[(S)-2-methyl-2-(5-trifluoromethoxy-1H-benzoimidazol-2-yl)-           pyrrolidin-1-yl]-methanone. LC-MS: t R  = 0.82; [M + H] +  = 471.2       5.21   [(S)-2-(5,6-Dimethoxy-1H-benzoimidazol-2-yl)-2-methyl-pyrrolidin-1-yl]-(5-methyl-2-[1,2,3]triazol-2-yl-           phenyl)-methanone. LC-MS: t R  = 0.68; [M + H] +  = 447.4       5.22   [(S)-2-(6-Fluoro-5-trifluoromethyl-1H-benzoimidazol-2-yl)-2-methyl-pyrrolidin-1-yl]-(5-methyl-2-           [1,2,3]triazol-2-yl-phenyl)-methanone. LC-MS: t R  = 0.95; [M + H] +  = 473.3       5.23   [(S)-2-(6-Bromo-5-fluoro-1H-benzoimidazol-2-yl)-2-methyl-pyrrolidin-1-yl]-(5-methyl-2-[1,2,3]triazol-2-           yl-phenyl)-methanone. LC-MS: t R  = 0.82; [M + H] +  = 483.2       5.24   [(S)-2-(6-Chloro-5-trifluoromethyl-1H-benzoimidazol-2-yl)-2-methyl-pyrrolidin-1-yl]-(5-methyl-2-           [1,2,3]triazol-2-yl-phenyl)-methanone. LC-MS: t R  = 1.01; [M + H] +  = 489.2       5.25   [(S)-2-(4-Bromo-6-fluoro-1H-benzoimidazol-2-yl)-2-methyl-pyrrolidin-1-yl]-(5-methyl-2-[1,2,3]triazol-2-           yl-phenyl)-methanone. LC-MS: t R  = 0.99; [M + H] +  = 483.2       5.26   [(S)-2-(4-Chloro-1H-benzoimidazol-2-yl)-2-methyl-pyrrolidin-1-yl]-(5-methyl-2-[1,2,3]triazol-2-yl-           phenyl)-methanone. LC-MS: t R  = 0.79; [M + H] +  = 421.2       5.27   [(S)-2-(4,5-Difluoro-1H-benzoimidazol-2-yl)-2-methyl-pyrrolidin-1-yl]-(5-methyl-2-[1,2,3]triazol-2-yl-           phenyl)-methanone. LC-MS: t R  = 0.88; [M + H] +  = 423.3       5.28   [(S)-2-(4,5-Dimethyl-1H-benzoimidazol-2-yl)-2-methyl-pyrrolidin-1-yl]-(5-methyl-2-[1,2,3]triazol-2-yl-           phenyl)-methanone. LC-MS: t R  = 0.73; [M + H] +  = 415.3       5.29   [(S)-2-(4-Isopropyl-1H-benzoimidazol-2-yl)-2-methyl-pyrrolidin-1-yl]-(5-methyl-2-[1,2,3]triazol-2-yl-           phenyl)-methanone. LC-MS: t R  = 0.81; [M + H] +  = 429.4       5.30   (5-Methyl-2-[1,2,3]triazol-2-yl-phenyl)-[(S)-2-methyl-2-(5-trifluoromethylsulfanyl-1H-benzoimidazol-2-           yl)-pyrrolidin-1-yl]-methanone. LC-MS: t R  = 0.89; [M + H] +  = 487.2       5.31   [(S)-2-(4,7-Dimethoxy-1H-benzoimidazol-2-yl)-2-methyl-pyrrolidin-1-yl]-(5-methyl-2-[1,2,3]triazol-2-yl-           phenyl)-methanone. LC-MS: t R  = 0.72; [M + H] +  = 447.3       5.32   [(S)-2-(5-Methoxy-1H-benzoimidazol-2-yl)-2-methyl-pyrrolidin-1-yl]-(5-methyl-2-[1,2,3]triazol-2-yl-           phenyl)-methanone. LC-MS: t R  = 0.66; [M + H] +  = 417.2       5.33   [(S)-2-(7,8-Dihydro-3H-6,9-dioxa-1,3-diaza-cyclopenta[a]naphthalen-2-yl)-2-methyl-pyrrolidin-1-yl]-(5-           methyl-2-[1,2,3]triazol-2-yl-phenyl)-methanone. LC-MS: t R  = 0.67; [M + H] +  = 445.2       5.34   [(S)-2-(5-Chloro-4-methyl-1H-benzoimidazol-2-yl)-2-methyl-pyrrolidin-1-yl]-(5-chloro-2-[1,2,3]triazol-           2-yl-phenyl)-methanone. LC-MS: t R  = 0.84; [M + H] +  = 455.2       5.35   [(S)-2-(5-Chloro-4-methyl-1H-benzoimidazol-2-yl)-2-methyl-pyrrolidin-1-yl]-(2-[1,2,3]triazol-2-yl-5-           trifluoromethoxy-phenyl)-methanone. LC-MS: t R  = 0.88; [M + H] +  = 505.2       5.36   [(S)-2-(5-Chloro-4-methyl-1H-benzoimidazol-2-yl)-2-methyl-pyrrolidin-1-yl]-(5-methoxy-2-           [1,2,3]triazol-2-yl-phenyl)-methanone. LC-MS: t R  = 0.78; [M + H] +  = 451.3       5.37   [(S)-2-(5-Chloro-4-methyl-1H-benzoimidazol-2-yl)-2-methyl-pyrrolidin-1-yl]-(2-fluoro-3-methoxy-6-           [1,2,3]triazol-2-yl-phenyl)-methanone. LC-MS: t R  = 0.79; [M + H] +  = 469.3       5.38   [(S)-2-(5-Chloro-4-methyl-1H-benzoimidazol-2-yl)-2-methyl-pyrrolidin-1-yl]-(4-methyl-2-[1,2,3]triazol-           2-yl-phenyl)-methanone. LC-MS: t R  = 0.77; [M + H] +  = 435.2       5.39   [(S)-2-(5-Chloro-4-methyl-1H-benzoimidazol-2-yl)-2-methyl-pyrrolidin-1-yl]-(4,5-dimethoxy-2-           [1,2,3]triazol-2-yl-phenyl)-methanone. LC-MS: t R  = 0.72; [M + H] +  = 481.2       5.40   [(S)-2-(5-Chloro-4-methyl-1H-benzoimidazol-2-yl)-2-methyl-pyrrolidin-1-yl]-(2-[1,2,3]triazol-2-yl-5-           trifluoromethyl-phenyl)-methanone. LC-MS: t R  = 0.86; [M + H] +  = 489.2       5.41   [(S)-2-(5-Chloro-4-methyl-1H-benzoimidazol-2-yl)-2-methyl-pyrrolidin-1-yl]-(4,5-dimethyl-2-           [1,2,3]triazol-2-yl-phenyl)-methanone. LC-MS: t R  = 0.82; [M + H] +  = 449.2       5.42   [(S)-2-(5-Chloro-4-methyl-1H-benzoimidazol-2-yl)-2-methyl-pyrrolidin-1-yl]-(2-pyrazol-1-yl-phenyl)-           methanone. LC-MS: t R  = 0.73; [M + H] +  = 420.2       5.43   [(S)-2-(5-Chloro-4-methyl-1H-benzoimidazol-2-yl)-2-methyl-pyrrolidin-1-yl]-(5-methyl-2-pyrazol-1-yl-           phenyl)-methanone. LC-MS: t R  = 0.78; [M + H] +  = 434.2       5.44   [(S)-2-(5-Chloro-4-methyl-1H-benzoimidazol-2-yl)-2-methyl-pyrrolidin-1-yl]-(6-methyl-3-pyrazol-1-yl-           pyridin-2-yl)-methanone. LC-MS: t R  = 0.71; [M + H] +  = 435.2       5.45   [(S)-2-(5-Chloro-4-methyl-1H-benzoimidazol-2-yl)-2-methyl-pyrrolidin-1-yl]-(5-fluoro-2-[1,2,3]triazol-2-           yl-phenyl)-methanone. LC-MS: t R  = 0.75; [M + H] +  = 439.1       5.46   [(S)-2-(5-Chloro-4-methyl-1H-benzoimidazol-2-yl)-2-methyl-pyrrolidin-1-yl]-(2-[1,2,3]triazol-2-yl-           phenyl)-methanone. LC-MS: t R  = 0.72; [M + H] +  = 421.2       5.47   [(S)-2-(5-Chloro-4-methyl-1H-benzoimidazol-2-yl)-2-methyl-pyrrolidin-1-yl]-(6-methyl-3-[1,2,3]triazol-           2-yl-pyridin-2-yl)-methanone. LC-MS: t R  = 0.71; [M + H] +  = 436.2       5.48   [(S)-2-(5-Chloro-4-methyl-1H-benzoimidazol-2-yl)-2-methyl-pyrrolidin-1-yl]-(2-fluoro-6-[1,2,3]triazol-2-           yl-phenyl)-methanone. LC-MS: t R  = 0.77; [M + H] +  = 439.3       5.49   (5-Chloro-2-[1,2,3]triazol-2-yl-phenyl)-[(S)-2-methyl-2-(4-methyl-1H-benzoimidazol-2-yl)-pyrrolidin-1-           yl]-methanone. LC-MS: t R  = 0.71; [M + H] +  = 421.2       5.50   (5-Methoxy-2-[1,2,3]triazol-2-yl-phenyl)-[(S)-2-methyl-2-(4-methyl-1H-benzoimidazol-2-yl)-pyrrolidin-           1-yl]-methanone. LC-MS: t R  = 0.65; [M + H] +  = 417.2       5.51   (4,5-Dimethyl-2-[1,2,3]triazol-2-yl-phenyl)-[(S)-2-methyl-2-(4-methyl-1H-benzoimidazol-2-yl)-           pyrrolidin-1-yl]-methanone. LC-MS: t R  = 0.76; [M + H] +  = 415.4       5.52   [(S)-2-Methyl-2-(4-methyl-1H-benzoimidazol-2-yl)-pyrrolidin-1-yl]-(2-[1,2,3]triazol-2-yl-phenyl)-           methanone. LC-MS: t R  = 0.65; [M + H] +  = 387.3       5.53   (5-Chloro-2-[1,2,3]triazol-2-yl-phenyl)-[(S)-2-(5,6-dimethyl-1H-benzoimidazol-2-yl)-2-methyl-           pyrrolidin-1-yl]-methanone. LC-MS: t R  = 0.75; [M + H] +  = 435.2       5.54   [(S)-2-(5,6-Dimethyl-1H-benzoimidazol-2-yl)-2-methyl-pyrrolidin-1-yl]-(5-methoxy-2-[1,2,3]triazol-2-yl-           phenyl)-methanone. LC-MS: t R  = 0.73; [M + H] +  = 431.4       5.55   [(S)-2-(5,6-Dimethyl-1H-benzoimidazol-2-yl)-2-methyl-pyrrolidin-1-yl]-(2-fluoro-3-methoxy-6-           [1,2,3]triazol-2-yl-phenyl)-methanone. LC-MS: t R  = 0.7; [M + H] +  = 449.3       5.56   [(S)-2-(5,6-Dimethyl-1H-benzoimidazol-2-yl)-2-methyl-pyrrolidin-1-yl]-(4-methyl-2-[1,2,3]triazol-2-yl-           phenyl)-methanone. LC-MS: t R  = 0.76; [M + H] +  = 415.4       5.57   (4,5-Dimethoxy-2-[1,2,3]triazol-2-yl-phenyl)-[(S)-2-(5,6-dimethyl-1H-benzoimidazol-2-yl)-2-methyl-           pyrrolidin-1-yl]-methanone. LC-MS: t R  = 0.67; [M + H] +  = 461.3       5.58   [(S)-2-(5,6-Dimethyl-1H-benzoimidazol-2-yl)-2-methyl-pyrrolidin-1-yl]-(4,5-dimethyl-2-[1,2,3]triazol-2-           yl-phenyl)-methanone. LC-MS: t R  = 0.77; [M + H] +  = 429.3       5.59   [(S)-2-(5,6-Dimethyl-1H-benzoimidazol-2-yl)-2-methyl-pyrrolidin-1-yl]-(5-methyl-2-pyrazol-1-yl-           phenyl)-methanone. LC-MS: t R  = 0.77; [M + H] +  = 414.4       5.60   [(S)-2-(5,6-Dimethyl-1H-benzoimidazol-2-yl)-2-methyl-pyrrolidin-1-yl]-(5-fluoro-2-[1,2,3]triazol-2-yl-           phenyl)-methanone. LC-MS: t R  = 0.7; [M + H] +  = 419.2       5.61   [(S)-2-(5,6-Dimethyl-1H-benzoimidazol-2-yl)-2-methyl-pyrrolidin-1-yl]-(2-[1,2,3]triazol-2-yl-phenyl)-           methanone. LC-MS: t R  = 0.67; [M + H] +  = 401.2       5.62   [(S)-2-(5,6-Dimethyl-1H-benzoimidazol-2-yl)-2-methyl-pyrrolidin-1-yl]-(6-methyl-3-[1,2,3]triazol-2-yl-           pyridin-2-yl)-methanone. LC-MS: t R  = 0.68; [M + H] +  = 416.2       5.64   (5-Chloro-2-[1,2,3]triazol-2-yl-phenyl)-[(S)-2-(5,6-dimethoxy-1H-benzoimidazol-2-yl)-2-methyl-           pyrrolidin-1-yl]-methanone. LC-MS: t R  = 0.69; [M + H] +  = 467.2       5.65   [(S)-2-(5,6-Dimethoxy-1H-benzoimidazol-2-yl)-2-methyl-pyrrolidin-1-yl]-(5-fluoro-2-[1,2,3]triazol-2-yl-           phenyl)-methanone. LC-MS: t R  = 0.63; [M + H] +  = 451.3       5.66   [(S)-2-(5,6-Dimethoxy-1H-benzoimidazol-2-yl)-2-methyl-pyrrolidin-1-yl]-(2-fluoro-6-[1,2,3]triazol-2-yl-           phenyl)-methanone. LC-MS: t R  = 0.61; [M + H] +  = 451.3       5.67   [(S)-2-(5,6-Dimethoxy-1H-benzoimidazol-2-yl)-2-methyl-pyrrolidin-1-yl]-(5-methoxy-2-[1,2,3]triazol-2-           yl-phenyl)-methanone. LC-MS: t R  = 0.64; [M + H] +  = 463.3       5.68   [(S)-2-(5,6-Dimethoxy-1H-benzoimidazol-2-yl)-2-methyl-pyrrolidin-1-yl]-(2-fluoro-3-methyl-6-           [1,2,3]triazol-2-yl-phenyl)-methanone. LC-MS: t R  = 0.67; [M + H] +  = 465.3       5.69   [(S)-2-(5,6-Dimethoxy-1H-benzoimidazol-2-yl)-2-methyl-pyrrolidin-1-yl]-(2-fluoro-3-methoxy-6-           [1,2,3]triazol-2-yl-phenyl)-methanone. LC-MS: t R  = 0.63; [M + H] +  = 481.3       5.70   [(S)-2-(5,6-Dimethoxy-1H-benzoimidazol-2-yl)-2-methyl-pyrrolidin-1-yl]-(4-methyl-2-[1,2,3]triazol-2-yl-           phenyl)-methanone. LC-MS: t R  = 0.67; [M + H] +  = 447.3       5.71   [(S)-2-(5,6-Dimethoxy-1H-benzoimidazol-2-yl)-2-methyl-pyrrolidin-1-yl]-(2-[1,2,3]triazol-2-yl-5-           trifluoromethyl-phenyl)-methanone. LC-MS: t R  = 0.75; [M + H] +  = 501.3       5.72   [(S)-2-(5,6-Dimethoxy-1H-benzoimidazol-2-yl)-2-methyl-pyrrolidin-1-yl]-(4,5-dimethyl-2-[1,2,3]triazol-           2-yl-phenyl)-methanone. LC-MS: t R  = 0.72; [M + H] +  = 461.3       5.73   [(S)-2-(5,6-Dimethoxy-1H-benzoimidazol-2-yl)-2-methyl-pyrrolidin-1-yl]-(2-[1,2,3]triazol-2-yl-phenyl)-           methanone. LC-MS: t R  = 0.61; [M + H] +  = 433.3       5.74   [(S)-2-(5,6-Dimethoxy-1H-benzoimidazol-2-yl)-2-methyl-pyrrolidin-1-yl]-[2-methyl-5-(4-trifluoromethyl-           phenyl)-thiazol-4-yl]-methanone. LC-MS: t R  = 0.85; [M + H] +  = 531.3       5.75   [(S)-2-(5,6-Dimethoxy-1H-benzoimidazol-2-yl)-2-methyl-pyrrolidin-1-yl]-(2-methyl-4-p-tolyl-thiazol-5-           yl)-methanone. LC-MS: t R  = 0.71; [M + H] +  = 477.2       5.76   [5-(3,5-Difluoro-phenyl)-2-methyl-thiazol-4-yl]-[(S)-2-(5,6-dimethoxy-1H-benzoimidazol-2-yl)-2-           methyl-pyrrolidin-1-yl]-methanone. LC-MS: t R  = 0.77; [M + H] +  = 499.3       5.77   [(S)-2-(5,6-Dimethoxy-1H-benzoimidazol-2-yl)-2-methyl-pyrrolidin-1-yl]-[5-(6-methoxy-pyridin-3-yl)-2-           methyl-thiazol-4-yl]-methanone. LC-MS: t R  = 0.69; [M + H] +  = 494.3       5.78   [(S)-2-(5,6-Dimethoxy-1H-benzoimidazol-2-yl)-2-methyl-pyrrolidin-1-yl]-[5-(4-fluoro-phenyl)-2-methyl-           thiazol-4-yl]-methanone. LC-MS: t R  = 0.75; [M + H] +  = 481.2       5.79   [5-(4-Chloro-phenyl)-2-methyl-thiazol-4-yl]-[(S)-2-(5,6-dimethoxy-1H-benzoimidazol-2-yl)-2-methyl-           pyrrolidin-1-yl]-methanone. LC-MS: t R  = 0.81; [M + H] +  = 497.3       5.80   [5-(3-Chloro-phenyl)-thiazol-4-yl]-[(S)-2-(5,6-dimethoxy-1H-benzoimidazol-2-yl)-2-methyl-pyrrolidin-1-           yl]-methanone. LC-MS: t R  = 0.74; [M + H] +  = 483.2       5.81   [(S)-2-(5,6-Dimethoxy-1H-benzoimidazol-2-yl)-2-methyl-pyrrolidin-1-yl]-(2-pyrazol-1-yl-phenyl)-           methanone. LC-MS: t R  = 0.61; [M + H] +  = 432.3       5.82   [(S)-2-(5,6-Dimethoxy-1H-benzoimidazol-2-yl)-2-methyl-pyrrolidin-1-yl]-(5-methyl-2-pyrazol-1-yl-           phenyl)-methanone. LC-MS: t R  = 0.67; [M + H] +  = 446.3       5.83   [(S)-2-(5,6-Dimethoxy-1H-benzoimidazol-2-yl)-2-methyl-pyrrolidin-1-yl]-(6-methyl-3-pyrazol-1-yl-           pyridin-2-yl)-methanone. LC-MS: t R  = 0.61; [M + H] +  = 447.3       5.84   [(S)-2-(5,6-Dimethoxy-1H-benzoimidazol-2-yl)-2-methyl-pyrrolidin-1-yl]-(2-[1,2,3]triazol-2-yl-5-           trifluoromethoxy-phenyl)-methanone. LC-MS: t R  = 0.77; [M + H] +  = 517.3       5.85   [(S)-2-(5,6-Dimethoxy-1H-benzoimidazol-2-yl)-2-methyl-pyrrolidin-1-yl]-(6-methyl-3-[1,2,3]triazol-2-yl-           pyridin-2-yl)-methanone. LC-MS: t R  = 0.62; [M + H] +  = 448.3       5.86   [(S)-2-(5,6-Dimethoxy-1H-benzoimidazol-2-yl)-2-methyl-pyrrolidin-1-yl]-(4,5-dimethoxy-2-           [1,2,3]triazol-2-yl-phenyl)-methanone. LC-MS: t R  = 0.62; [M + H] +  = 493.3       5.87   [(S)-2-(5,6-Dimethoxy-1H-benzoimidazol-2-yl)-2-methyl-pyrrolidin-1-yl]-(3′-methyl-biphenyl-2-yl)-           methanone. LC-MS: t R  = 0.8; [M + H] +  = 456.3       5.88   [(S)-2-(5,6-Dimethoxy-1H-benzoimidazol-2-yl)-2-methyl-pyrrolidin-1-yl]-(4′-methyl-biphenyl-2-yl)-           methanone. LC-MS: t R  = 0.8; [M + H] +  = 456.3       5.89   [(S)-2-(5,6-Dimethoxy-1H-benzoimidazol-2-yl)-2-methyl-pyrrolidin-1-yl]-(2-methyl-4-m-tolyl-pyrimidin-           5-yl)-methanone. LC-MS: t R  = 0.68; [M + H] +  = 472.3       5.90   [(S)-2-(5,6-Dimethoxy-1H-benzoimidazol-2-yl)-2-methyl-pyrrolidin-1-yl]-(4-phenyl-pyrimidin-5-yl)-           methanone. LC-MS: t R  = 0.59; [M + H] +  = 444.3       5.91   [(S)-2-(5,6-Dimethyl-1H-benzoimidazol-2-yl)-2-methyl-pyrrolidin-1-yl]-(4′-fluoro-4,2′-dimethyl-           biphenyl-2-yl)-methanone. LC-MS: t R  = 0.95; [M + H] +  = 456.4       5.92   [(S)-2-(5,6-Dimethyl-1H-benzoimidazol-2-yl)-2-methyl-pyrrolidin-1-yl]-(2′-methoxy-4-methyl-biphenyl-           2-yl)-methanone. LC-MS: t R  = 0.89; [M + H] +  = 454.4       5.93   [(S)-2-(5,6-Dimethyl-1H-benzoimidazol-2-yl)-2-methyl-pyrrolidin-1-yl]-(3′-methoxy-4-methyl-biphenyl-           2-yl)-methanone. LC-MS: t R  = 0.89; [M + H] +  = 454.3       5.94   [(S)-2-(5,6-Dimethyl-1H-benzoimidazol-2-yl)-2-methyl-pyrrolidin-1-yl]-(4′-methoxy-4-methyl-biphenyl-           2-yl)-methanone. LC-MS: t R  = 0.89; [M + H] +  = 454.4       5.95   [(S)-2-(5,6-Dimethyl-1H-benzoimidazol-2-yl)-2-methyl-pyrrolidin-1-yl]-(2′-fluoro-4-methyl-biphenyl-2-           yl)-methanone. LC-MS: t R  = 0.88; [M + H] +  = 442.3       5.96   [(S)-2-(5,6-Dimethyl-1H-benzoimidazol-2-yl)-2-methyl-pyrrolidin-1-yl]-(4′-fluoro-4-methyl-biphenyl-2-           yl)-methanone. LC-MS: t R  = 0.89; [M + H] +  = 442.3       5.97   [(S)-2-(5,6-Dimethyl-1H-benzoimidazol-2-yl)-2-methyl-pyrrolidin-1-yl]-(3′-fluoro-4-methyl-biphenyl-2-           yl)-methanone. LC-MS: t R  = 0.9; [M + H] +  = 442.3       5.98   [(S)-2-(5,6-Dimethyl-1H-benzoimidazol-2-yl)-2-methyl-pyrrolidin-1-yl]-(4,2′-dimethyl-biphenyl-2-yl)-           methanone. LC-MS: t R  = 0.93; [M + H] +  = 438.4       5.99   [(S)-2-(5,6-Dimethyl-1H-benzoimidazol-2-yl)-2-methyl-pyrrolidin-1-yl]-(4,3′-dimethyl-biphenyl-2-yl)-           methanone. LC-MS: t R  = 0.93; [M + H] +  = 438.4       5.100   [(S)-2-(5,6-Dimethyl-1H-benzoimidazol-2-yl)-2-methyl-pyrrolidin-1-yl]-(4,4′-dimethyl-biphenyl-2-yl)-           methanone. LC-MS: t R  = 0.93; [M + H] +  = 438.4       5.101   [(S)-2-(5,6-Dimethyl-1H-benzoimidazol-2-yl)-2-methyl-pyrrolidin-1-yl]-(3′-methoxy-biphenyl-2-yl)-           methanone. LC-MS: t R  = 0.83; [M + H] +  = 440.3       5.102   [(S)-2-(5,6-Dimethyl-1H-benzoimidazol-2-yl)-2-methyl-pyrrolidin-1-yl]-(4′-methoxy-biphenyl-2-yl)-           methanone. LC-MS: t R  = 0.82; [M + H] +  = 440.3       5.103   [(S)-2-(5,6-Dimethyl-1H-benzoimidazol-2-yl)-2-methyl-pyrrolidin-1-yl]-(2′-fluoro-biphenyl-2-yl)-           methanone. LC-MS: t R  = 0.82; [M + H] +  = 428.3       5.104   [(S)-2-(5,6-Dimethyl-1H-benzoimidazol-2-yl)-2-methyl-pyrrolidin-1-yl]-(4′-fluoro-biphenyl-2-yl)-           methanone. LC-MS: t R  = 0.83; [M + H] +  = 428.3       5.105   [(S)-2-(5,6-Dimethyl-1H-benzoimidazol-2-yl)-2-methyl-pyrrolidin-1-yl]-(3′-fluoro-biphenyl-2-yl)-           methanone. LC-MS: t R  = 0.83; [M + H] +  = 428.3       5.106   [(S)-2-(5,6-Dimethyl-1H-benzoimidazol-2-yl)-2-methyl-pyrrolidin-1-yl]-(3′-methyl-biphenyl-2-yl)-           methanone. LC-MS: t R  = 0.87; [M + H] +  = 424.4       5.107   [(S)-2-(5,6-Dimethyl-1H-benzoimidazol-2-yl)-2-methyl-pyrrolidin-1-yl]-(4′-methyl-biphenyl-2-yl)-           methanone. LC-MS: t R  = 0.87; [M + H] +  = 424.3       5.108   [(S)-2-(4,5-Dimethyl-1H-benzoimidazol-2-yl)-2-methyl-pyrrolidin-1-yl]-(4′-fluoro-4,2′-dimethyl-           biphenyl-2-yl)-methanone. LC-MS: t R  = 0.95; [M + H] +  = 456.4       5.109   [(S)-2-(4,5-Dimethyl-1H-benzoimidazol-2-yl)-2-methyl-pyrrolidin-1-yl]-(3′-fluoro-4-methyl-biphenyl-2-           yl)-methanone. LC-MS: t R  = 0.9; [M + H] +  = 442.3       5.110   [(S)-2-(4,5-Dimethyl-1H-benzoimidazol-2-yl)-2-methyl-pyrrolidin-1-yl]-(3′-methoxy-4-methyl-biphenyl-           2-yl)-methanone. LC-MS: t R  = 0.89; [M + H] +  = 454.4       5.111   [(S)-2-(4,5-Dimethyl-1H-benzoimidazol-2-yl)-2-methyl-pyrrolidin-1-yl]-(4,3′-dimethyl-biphenyl-2-yl)-           methanone. LC-MS: t R  = 0.93; [M + H] +  = 438.4       5.112   [(S)-2-(4,5-Dimethyl-1H-benzoimidazol-2-yl)-2-methyl-pyrrolidin-1-yl]-(4′-methoxy-4-methyl-biphenyl-           2-yl)-methanone. LC-MS: t R  = 0.89; [M + H] +  = 454.3       5.113   [(S)-2-(4,5-Dimethyl-1H-benzoimidazol-2-yl)-2-methyl-pyrrolidin-1-yl]-(4,4′-dimethyl-biphenyl-2-yl)-           methanone. LC-MS: t R  = 0.94; [M + H] +  = 438.4       5.114   [(S)-2-(4,5-Dimethyl-1H-benzoimidazol-2-yl)-2-methyl-pyrrolidin-1-yl]-(2′-fluoro-4-methyl-biphenyl-2-           yl)-methanone. LC-MS: t R  = 0.89; [M + H] +  = 442.3       5.115   [(S)-2-(4,5-Dimethyl-1H-benzoimidazol-2-yl)-2-methyl-pyrrolidin-1-yl]-(4′-fluoro-4-methyl-biphenyl-2-           yl)-methanone. LC-MS: t R  = 0.90; [M + H] +  = 442.3       5.116   [(S)-2-(4,5-Dimethyl-1H-benzoimidazol-2-yl)-2-methyl-pyrrolidin-1-yl]-(3′-fluoro-biphenyl-2-yl)-           methanone. LC-MS: t R  = 0.84; [M + H] +  = 428.3       5.117   [(S)-2-(4,5-Dimethyl-1H-benzoimidazol-2-yl)-2-methyl-pyrrolidin-1-yl]-(3′-methoxy-biphenyl-2-yl)-           methanone. LC-MS: t R  = 0.83; [M + H] +  = 440.3       5.118   [(S)-2-(4,5-Dimethyl-1H-benzoimidazol-2-yl)-2-methyl-pyrrolidin-1-yl]-(3′-methyl-biphenyl-2-yl)-           methanone. LC-MS: t R  = 0.88; [M + H] +  = 424.3       5.119   [(S)-2-(4,5-Dimethyl-1H-benzoimidazol-2-yl)-2-methyl-pyrrolidin-1-yl]-(4′-methoxy-biphenyl-2-yl)-           methanone. LC-MS: t R  = 0.83; [M + H] +  = 440.3       5.120   [(S)-2-(4,5-Dimethyl-1H-benzoimidazol-2-yl)-2-methyl-pyrrolidin-1-yl]-(4′-methyl-biphenyl-2-yl)-           methanone. LC-MS: t R  = 0.88; [M + H] +  = 424.4       5.121   [(S)-2-(4,5-Dimethyl-1H-benzoimidazol-2-yl)-2-methyl-pyrrolidin-1-yl]-(2′-fluoro-biphenyl-2-yl)-           methanone. LC-MS: t R  = 0.83; [M + H] +  = 428.3       5.122   [(S)-2-(4,5-Dimethyl-1H-benzoimidazol-2-yl)-2-methyl-pyrrolidin-1-yl]-(4′-fluoro-biphenyl-2-yl)-           methanone. LC-MS: t R  = 0.84; [M + H] +  = 428.3       5.123   [(S)-2-(6-Bromo-5-fluoro-1H-benzoimidazol-2-yl)-2-methyl-pyrrolidin-1-yl]-(2-fluoro-6-[1,2,3]triazol-2-           yl-phenyl)-methanone. LC-MS: t R  = 0.83; [M + H] +  = 487.1       5.124   [(S)-2-(6-Bromo-5-fluoro-1H-benzoimidazol-2-yl)-2-methyl-pyrrolidin-1-yl]-(2-fluoro-3-methyl-6-           [1,2,3]triazol-2-yl-phenyl)-methanone. LC-MS: t R  = 0.90; [M + H] +  = 501.1       5.125   [(S)-2-(6-Bromo-5-fluoro-1H-benzoimidazol-2-yl)-2-methyl-pyrrolidin-1-yl]-(4,5-dimethoxy-2-           [1,2,3]triazol-2-yl-phenyl)-methanone. LC-MS: t R  = 0.79; [M + H] +  = 529.2       5.126   [(S)-2-(6-Bromo-5-fluoro-1H-benzoimidazol-2-yl)-2-methyl-pyrrolidin-1-yl]-(5-fluoro-2-[1,2,3]triazol-2-           yl-phenyl)-methanone. LC-MS: t R  = 0.83; [M + H] +  = 487.2       5.127   [(S)-2-(6-Bromo-5-fluoro-1H-benzoimidazol-2-yl)-2-methyl-pyrrolidin-1-yl]-(4,5-dimethyl-2-           [1,2,3]triazol-2-yl-phenyl)-methanone. LC-MS: t R  = 0.90; [M + H] +  = 497.2       5.128   [(S)-2-(6-Bromo-5-fluoro-1H-benzoimidazol-2-yl)-2-methyl-pyrrolidin-1-yl]-(5-methyl-2-pyrazol-1-yl-           phenyl)-methanone. LC-MS: t R  = 0.86; [M + H] +  = 482.2       5.129   [(S)-2-(6-Bromo-5-fluoro-1H-benzoimidazol-2-yl)-2-methyl-pyrrolidin-1-yl]-(5-chloro-2-[1,2,3]triazol-2-           yl-phenyl)-methanone. LC-MS: t R  = 0.90; [M + H] +  = 503.1       5.130   [(S)-2-(6-Bromo-5-fluoro-1H-benzoimidazol-2-yl)-2-methyl-pyrrolidin-1-yl]-(4-methyl-2-[1,2,3]triazol-2-           yl-phenyl)-methanone. LC-MS: t R  = 0.85; [M + H] +  = 483.2       5.131   [(S)-2-(6-Bromo-5-fluoro-1H-benzoimidazol-2-yl)-2-methyl-pyrrolidin-1-yl]-(6-methyl-3-[1,2,3]triazol-2-           yl-pyridin-2-yl)-methanone. LC-MS: t R  = 0.75; [M + H] +  = 484.2       5.132   [(S)-2-(6-Bromo-5-fluoro-1H-benzoimidazol-2-yl)-2-methyl-pyrrolidin-1-yl]-(2-fluoro-3-methoxy-6-           [1,2,3]triazol-2-yl-phenyl)-methanone. LC-MS: t R  = 0.85; [M + H] +  = 517.2       5.133   [(S)-2-(6-Chloro-5-trifluoromethyl-1H-benzoimidazol-2-yl)-2-methyl-pyrrolidin-1-yl]-(2-fluoro-6-           [1,2,3]triazol-2-yl-phenyl)-methanone. LC-MS: t R  = 1.04; [M + H] +  = 493.2       5.134   [(S)-2-(6-Chloro-5-trifluoromethyl-1H-benzoimidazol-2-yl)-2-methyl-pyrrolidin-1-yl]-(2-fluoro-3-methyl-           6-[1,2,3]triazol-2-yl-phenyl)-methanone. LC-MS: t R  = 1.14; [M + H] +  = 507.2       5.135   [(S)-2-(6-Chloro-5-trifluoromethyl-1H-benzoimidazol-2-yl)-2-methyl-pyrrolidin-1-yl]-(4,5-dimethoxy-2-           [1,2,3]triazol-2-yl-phenyl)-methanone. LC-MS: t R  = 0.98; [M + H] +  = 535.2       5.136   [(S)-2-(6-Chloro-5-trifluoromethyl-1H-benzoimidazol-2-yl)-2-methyl-pyrrolidin-1-yl]-(5-fluoro-2-           [1,2,3]triazol-2-yl-phenyl)-methanone. LC-MS: t R  = 1.03; [M + H] +  = 493.2       5.137   [(S)-2-(6-Chloro-5-trifluoromethyl-1H-benzoimidazol-2-yl)-2-methyl-pyrrolidin-1-yl]-(4,5-dimethyl-2-           [1,2,3]triazol-2-yl-phenyl)-methanone. LC-MS: t R  = 1.09.; [M + H] +  = 503.3       5.138   [(S)-2-(6-Chloro-5-trifluoromethyl-1H-benzoimidazol-2-yl)-2-methyl-pyrrolidin-1-yl]-(5-methyl-2-           pyrazol-1-yl-phenyl)-methanone. LC-MS: t R  = 1.05.; [M + H] +  = 488.2       5.139   (5-Chloro-2-[1,2,3]triazol-2-yl-phenyl)-[(S)-2-(6-chloro-5-trifluoromethyl-1H-benzoimidazol-2-yl)-2-           methyl-pyrrolidin-1-yl]-methanone. LC-MS: t R  = 1.09; [M + H] +  = 509.2       5.140   [(S)-2-(6-Chloro-5-trifluoromethyl-1H-benzoimidazol-2-yl)-2-methyl-pyrrolidin-1-yl]-(4-methyl-2-           [1,2,3]triazol-2-yl-phenyl)-methanone. LC-MS: t R  = 1.05; [M + H] +  = 489.2       5.141   [(S)-2-(6-Chloro-5-trifluoromethyl-1H-benzoimidazol-2-yl)-2-methyl-pyrrolidin-1-yl]-(2-pyrazol-1-yl-           phenyl)-methanone. LC-MS: t R  = 1.00; [M + H] +  = 474.2       5.142   [(S)-2-(6-Chloro-5-trifluoromethyl-1H-benzoimidazol-2-yl)-2-methyl-pyrrolidin-1-yl]-(2-[1,2,3]triazol-2-           yl-phenyl)-methanone. LC-MS: t R  = 0.99; [M + H] +  = 475.2       5.143   [(S)-2-(6-Chloro-5-trifluoromethyl-1H-benzoimidazol-2-yl)-2-methyl-pyrrolidin-1-yl]-(6-methyl-3-           pyrazol-1-yl-pyridin-2-yl)-methanone. LC-MS: t R  = 0.94; [M + H] +  = 489.2       5.144   [(S)-2-(6-Chloro-5-trifluoromethyl-1H-benzoimidazol-2-yl)-2-methyl-pyrrolidin-1-yl]-(2-[1,2,3]triazol-2-           yl-5-trifluoromethyl-phenyl)-methanone. LC-MS: t R  = 1.12; [M + H] +  = 543.2       5.145   [(S)-2-(6-Chloro-5-trifluoromethyl-1H-benzoimidazol-2-yl)-2-methyl-pyrrolidin-1-yl]-(6-methyl-3-           [1,2,3]triazol-2-yl-pyridin-2-yl)-methanone. LC-MS: t R  = 0.94; [M + H] +  = 490.2       5.146   [(S)-2-(6-Chloro-5-trifluoromethyl-1H-benzoimidazol-2-yl)-2-methyl-pyrrolidin-1-yl]-(2-fluoro-3-           methoxy-6-[1,2,3]triazol-2-yl-phenyl)-methanone. LC-MS: t R  = 1.05; [M + H] +  = 523.2       5.147   [(S)-2-(6-Chloro-5-trifluoromethyl-1H-benzoimidazol-2-yl)-2-methyl-pyrrolidin-1-yl]-(2-[1,2,3]triazol-2-           yl-5-trifluoromethoxy-phenyl)-methanone. LC-MS: t R  = 1.14; [M + H] +  = 559.2       5.148   [(S)-2-(6-Chloro-5-trifluoromethyl-1H-benzoimidazol-2-yl)-2-methyl-pyrrolidin-1-yl]-(2′-methoxy-4-           methyl-biphenyl-2-yl)-methanone. LC-MS: t R  = 1.18; [M + H] +  = 528.2       5.149   [(S)-2-(6-Chloro-5-trifluoromethyl-1H-benzoimidazol-2-yl)-2-methyl-pyrrolidin-1-yl]-(3′-methoxy-4-           methyl-biphenyl-2-yl)-methanone. LC-MS: t R  = 1.18; [M + H] +  = 528.3       5.150   [(S)-2-(6-Chloro-5-trifluoromethyl-1H-benzoimidazol-2-yl)-2-methyl-pyrrolidin-1-yl]-(4′-methoxy-4-           methyl-biphenyl-2-yl)-methanone. LC-MS: t R  = 1.19; [M + H] +  = 528.2       5.151   [(S)-2-(6-Chloro-5-trifluoromethyl-1H-benzoimidazol-2-yl)-2-methyl-pyrrolidin-1-yl]-(2′-fluoro-4-methyl-           biphenyl-2-yl)-methanone. LC-MS: t R  = 1.18; [M + H] +  = 516.2       5.152   [(S)-2-(6-Chloro-5-trifluoromethyl-1H-benzoimidazol-2-yl)-2-methyl-pyrrolidin-1-yl]-(4′-fluoro-4-methyl-           biphenyl-2-yl)-methanone. LC-MS: t R  = 1.19; [M + H] +  = 516.2       5.153   [(S)-2-(6-Chloro-5-trifluoromethyl-1H-benzoimidazol-2-yl)-2-methyl-pyrrolidin-1-yl]-(3′-fluoro-4-methyl-           biphenyl-2-yl)-methanone. LC-MS: t R  = 1.19; [M + H] +  = 516.2       5.154   [(S)-2-(6-Chloro-5-trifluoromethyl-1H-benzoimidazol-2-yl)-2-methyl-pyrrolidin-1-yl]-(4,4′-dimethyl-           biphenyl-2-yl)-methanone. LC-MS: t R  = 1.24; [M + H] +  = 512.3       5.155   [(S)-2-(6-Chloro-5-trifluoromethyl-1H-benzoimidazol-2-yl)-2-methyl-pyrrolidin-1-yl]-(4-methyl-3′-           trifluoromethyl-biphenyl-2-yl)-methanone. LC-MS: t R  = 1.25; [M + H] +  = 566.2       5.156   (2-Benzo[1,3]dioxol-5-yl-5-methyl-phenyl)-[(S)-2-(6-chloro-5-trifluoromethyl-1H-benzoimidazol-2-yl)-           2-methyl-pyrrolidin-1-yl]-methanone. LC-MS: t R  = 1.16; [M + H] +  = 542.2       5.157   [(S)-2-(6-Chloro-5-trifluoromethyl-1H-benzoimidazol-2-yl)-2-methyl-pyrrolidin-1-yl]-(4-methyl-4′-           trifluoromethyl-biphenyl-2-yl)-methanone. LC-MS: t R  = 1.26; [M + H] +  = 566.2       5.158   [(S)-2-(6-Chloro-5-trifluoromethyl-1H-benzoimidazol-2-yl)-2-methyl-pyrrolidin-1-yl]-(4-methyl-4′-           trifluoromethoxy-biphenyl-2-yl)-methanone. LC-MS: t R  = 1.28; [M + H] +  = 582.3       5.159   2′-[(S)-2-(6-Chloro-5-trifluoromethyl-1H-benzoimidazol-2-yl)-2-methyl-pyrrolidine-1-carbonyl]-4′-           methyl-biphenyl-3-carbonitrile. LC-MS: t R  = 1.13; [M + H] +  = 523.2       5.160   2′-[(S)-2-(6-Chloro-5-trifluoromethyl-1H-benzoimidazol-2-yl)-2-methyl-pyrrolidine-1-carbonyl]-4′-           methyl-biphenyl-4-carbonitrile. LC-MS: t R  = 1.13; [M + H] +  = 523.3       5.161   [(S)-2-(6-Chloro-5-trifluoromethyl-1H-benzoimidazol-2-yl)-2-methyl-pyrrolidin-1-yl]-(4,2′,3′-trimethyl-           biphenyl-2-yl)-methanone. LC-MS: t R  = 1.27; [M + H] +  = 526.3       5.162   [(S)-2-(6-Chloro-5-trifluoromethyl-1H-benzoimidazol-2-yl)-2-methyl-pyrrolidin-1-yl]-(4′-ethoxy-4-           methyl-biphenyl-2-yl)-methanone. LC-MS: t R  = 1.24; [M + H] +  = 542.3       5.163   [(S)-2-(6-Chloro-5-trifluoromethyl-1H-benzoimidazol-2-yl)-2-methyl-pyrrolidin-1-yl]-(4-methyl-3′-           trifluoromethoxy-biphenyl-2-yl)-methanone. LC-MS: t R  = 1.27; [M + H] +  = 582.2       5.164   (2-Fluoro-6-[1,2,3]triazol-2-yl-phenyl)-[(S)-2-methyl-2-(5-trifluoromethyl-1H-benzoimidazol-2-yl)-           pyrrolidin-1-yl]-methanone. LC-MS: t R  = 0.82; [M + H] +  = 459.2       5.165   (5-Fluoro-2-[1,2,3]triazol-2-yl-phenyl)-[(S)-2-methyl-2-(5-trifluoromethyl-1H-benzoimidazol-2-yl)-           pyrrolidin-1-yl]-methanone. LC-MS: t R  = 0.82; [M + H] +  = 459.2       5.166   (5-Chloro-2-[1,2,3]triazol-2-yl-phenyl)-[(S)-2-methyl-2-(5-trifluoromethyl-1H-benzoimidazol-2-yl)-           pyrrolidin-1-yl]-methanone. LC-MS: t R  = 0.89; [M + H] +  = 475.2       5.167   [(S)-2-Methyl-2-(5-trifluoromethyl-1H-benzoimidazol-2-yl)-pyrrolidin-1-yl]-(2-[1,2,3]triazol-2-yl-phenyl)-           methanone. LC-MS: t R  = 078.; [M + H] +  = 441.3       5.168   (2-Fluoro-3-methoxy-6-[1,2,3]triazol-2-yl-phenyl)-[(S)-2-methyl-2-(5-trifluoromethyl-1H-           benzoimidazol-2-yl)-pyrrolidin-1-yl]-methanone. LC-MS: t R  = 0.84; [M + H] +  = 489.3       5.169   (2-Fluoro-3-methyl-6-[1,2,3]triazol-2-yl-phenyl)-[(S)-2-methyl-2-(5-trifluoromethyl-1H-benzoimidazol-           2-yl)-pyrrolidin-1-yl]-methanone. LC-MS: t R  = 0.89; [M + H] +  = 473.3       5.170   (4,5-Dimethyl-2-[1,2,3]triazol-2-yl-phenyl)-[(S)-2-methyl-2-(5-trifluoromethyl-1H-benzoimidazol-2-yl)-           pyrrolidin-1-yl]-methanone. LC-MS: t R  = 0.89; [M + H] +  = 469.3       5.171   (4-Methyl-2-[1,2,3]triazol-2-yl-phenyl)-[(S)-2-methyl-2-(5-trifluoromethyl-1H-benzoimidazol-2-yl)-           pyrrolidin-1-yl]-methanone. LC-MS: t R  = 0.84; [M + H] +  = 455.3       5.172   [(S)-2-Methyl-2-(5-trifluoromethyl-1H-benzoimidazol-2-yl)-pyrrolidin-1-yl]-(2-[1,2,3]triazol-2-yl-5-           trifluoromethyl-phenyl)-methanone. LC-MS: t R  = 0.93; [M + H] +  = 509.2       5.173   [(S)-2-Methyl-2-(5-trifluoromethyl-1H-benzoimidazol-2-yl)-pyrrolidin-1-yl]-(2-[1,2,3]triazol-2-yl-5-           trifluoromethoxy-phenyl)-methanone. LC-MS: t R  = 0.95; [M + H] +  = 525.3       5.174   (4,5-Dimethoxy-2-[1,2,3]triazol-2-yl-phenyl)-[(S)-2-methyl-2-(5-trifluoromethyl-1H-benzoimidazol-2-           yl)-pyrrolidin-1-yl]-methanone. LC-MS: t R  = 0.78; [M + H] +  = 501.3       5.175   (5-Methyl-2-pyrazol-1-yl-phenyl)-[(S)-2-methyl-2-(5-trifluoromethyl-1H-benzoimidazol-2-yl)-pyrrolidin-           1-yl]-methanone. LC-MS: t R  = 0.85; [M + H] +  = 454.3       5.176   [(S)-2-Methyl-2-(5-trifluoromethyl-1H-benzoimidazol-2-yl)-pyrrolidin-1-yl]-(2-pyrazol-1-yl-phenyl)-           methanone. LC-MS: t R  = 0.79; [M + H] +  = 440.3       5.177   (6-Methyl-3-pyrazol-1-yl-pyridin-2-yl)-[(S)-2-methyl-2-(5-trifluoromethyl-1H-benzoimidazol-2-yl)-           pyrrolidin-1-yl]-methanone. LC-MS: t R  = 0.75; [M + H] +  = 455.3       5.178   (6-Methyl-3-[1,2,3]triazol-2-yl-pyridin-2-yl)-[(S)-2-methyl-2-(5-trifluoromethyl-1H-benzoimidazol-2-yl)-           pyrrolidin-1-yl]-methanone. LC-MS: t R  = 0.75; [M + H] +  = 456.3       5.179   (3-Methyl-2-[1,2,3]triazol-2-yl-phenyl)-[(S)-2-methyl-2-(5-trifluoromethyl-1H-benzoimidazol-2-yl)-           pyrrolidin-1-yl]-methanone. LC-MS: t R  = 0.80; [M + H] +  = 455.3       5.180   3-[(S)-2-Methyl-2-(5-trifluoromethyl-1H-benzoimidazol-2-yl)-pyrrolidine-1-carbonyl]4-[1,2,3]triazol-2-           yl-benzonitrile. LC-MS: t R  = 0.80; [M + H] +  = 466.2       5.181   (4′-Fluoro-4,2′-dimethyl-biphenyl-2-yl)-[(S)-2-methyl-2-(5-trifluoromethyl-1H-benzoimidazol-2-yl)-           pyrrolidin-1-yl]-methanone. LC-MS: t R  = 1.03; [M + H] +  = 496.3       5.182   (3′-Fluoro-4-methyl-biphenyl-2-yl)-[(S)-2-methyl-2-(5-trifluoromethyl-1H-benzoimidazol-2-yl)-           pyrrolidin-1-yl]-methanone. LC-MS: t R  = 0.99; [M + H] +  = 482.3       5.183   [(S)-2-Methyl-2-(5-trifluoromethyl-1H-benzoimidazol-2-yl)-pyrrolidin-1-yl]-(4-methyl-4′-trifluoromethyl-           biphenyl-2-yl)-methanone. LC-MS: t R  = 1.08; [M + H] +  = 532.3       5.184   (4-Methyl-3′-trifluoromethoxy-biphenyl-2-yl)-[(S)-2-methyl-2-(5-trifluoromethyl-1H-benzoimidazol-2-           yl)-pyrrolidin-1-yl]-methanone. LC-MS: t R  = 1.09; [M + H] +  = 548.3       5.185   (2′-Methoxy-4-methyl-biphenyl-2-yl)-[(S)-2-methyl-2-(5-trifluoromethyl-1H-benzoimidazol-2-yl)-           pyrrolidin-1-yl]-methanone. LC-MS: t R  = 0.98; [M + H] +  = 494.3       5.186   (4,2′-Dimethyl-biphenyl-2-yl)-[(S)-2-methyl-2-(5-trifluoromethyl-1H-benzoimidazol-2-yl)-pyrrolidin-1-           yl]-methanone. LC-MS: t R  = 1.02; [M + H] +  = 478.3       5.187   (4-Methyl-4′-trifluoromethoxy-biphenyl-2-yl)-[(S)-2-methyl-2-(5-trifluoromethyl-1H-benzoimidazol-2-           yl)-pyrrolidin-1-yl]-methanone. LC-MS: t R  = 1.09; [M + H] +  = 548.3       5.188   (3′-Methoxy-4-methyl-biphenyl-2-yl)-[(S)-2-methyl-2-(5-trifluoromethyl-1H-benzoimidazol-2-yl)-           pyrrolidin-1-yl]-methanone. LC-MS: t R  = 0.98; [M + H] +  = 494.3       5.189   (4,3′-Dimethyl-biphenyl-2-yl)-[(S)-2-methyl-2-(5-trifluoromethyl-1H-benzoimidazol-2-yl)-pyrrolidin-1-           yl]-methanone. LC-MS: t R  = 1.03; [M + H] +  = 478.3       5.190   4′-Methyl-2′-[(S)-2-methyl-2-(5-trifluoromethyl-1H-benzoimidazol-2-yl)-pyrrolidine-1-carbonyl]-           biphenyl-3-carbonitrile. LC-MS: t R  = 0.94; [M + H] +  = 489.3       5.191   (4′-Methoxy-4-methyl-biphenyl-2-yl)-[(S)-2-methyl-2-(5-trifluoromethyl-1H-benzoimidazol-2-yl)-           pyrrolidin-1-yl]-methanone. LC-MS: t R  = 0.98; [M + H] +  = 494.3       5.192   (4,4′-Dimethyl-biphenyl-2-yl)-[(S)-2-methyl-2-(5-trifluoromethyl-1H-benzoimidazol-2-yl)-pyrrolidin-1-           yl]-methanone. LC-MS: t R  = 1.04; [M + H] +  = 478.3       5.193   4′-Methyl-2′-[(S)-2-methyl-2-(5-trifluoromethyl-1H-benzoimidazol-2-yl)-pyrrolidine-1-carbonyl]-           biphenyl-4-carbonitrile. LC-MS: t R  = 0.95; [M + H] +  = 489.3       5.194   (2′-Fluoro-4-methyl-biphenyl-2-yl)-[(S)-2-methyl-2-(5-trifluoromethyl-1H-benzoimidazol-2-yl)-           pyrrolidin-1-yl]-methanone. LC-MS: t R  = 0.98; [M + H] +  = 482.3       5.195   [(S)-2-Methyl-2-(5-trifluoromethyl-1H-benzoimidazol-2-yl)-pyrrolidin-1-yl]-(4-methyl-3′-trifluoromethyl-           biphenyl-2-yl)-methanone. LC-MS: t R  = 1.07; [M + H] +  = 532.3       5.196   [(S)-2-Methyl-2-(5-trifluoromethyl-1H-benzoimidazol-2-yl)-pyrrolidin-1-yl]-(4,2′,3′-trimethyl-biphenyl-2-           yl)-methanone. LC-MS: t R  = 1.06; [M + H] +  = 492.3       5.197   (4′-Fluoro-4-methyl-biphenyl-2-yl)-[(S)-2-methyl-2-(5-trifluoromethyl-1H-benzoimidazol-2-yl)-           pyrrolidin-1-yl]-methanone. LC-MS: t R  = 0.99; [M + H] +  = 482.2       5.198   (2-Benzo[1,3]dioxol-5-yl-5-methyl-phenyl)-[(S)-2-methyl-2-(5-trifluoromethyl-1H-benzoimidazol-2-yl)-           pyrrolidin-1-yl]-methanone. LC-MS: t R  = 0.96; [M + H] +  = 508.3       5.199   [(S)-2-(4,5-Difluoro-1H-benzoimidazol-2-yl)-2-methyl-pyrrolidin-1-yl]-(4,5-dimethyl-2-[1,2,3]triazol-2-           yl-phenyl)-methanone. LC-MS: t R  = 0.92; [M + H] +  = 437.3       5.200   (5-Chloro-2-[1,2,3]triazol-2-yl-phenyl)-[(S)-2-(4,5-difluoro-1H-benzoimidazol-2-yl)-2-methyl-pyrrolidin-           1-yl]-methanone. LC-MS: t R  = 0.90; [M + H] +  = 443.2       5.201   [(S)-2-(4,5-Difluoro-1H-benzoimidazol-2-yl)-2-methyl-pyrrolidin-1-yl]-(5-methyl-2-pyrazol-1-yl-phenyl)-           methanone. LC-MS: t R  = 0.86; [M + H] +  = 422.3       5.202   [(S)-2-(4,5-Difluoro-1H-benzoimidazol-2-yl)-2-methyl-pyrrolidin-1-yl]-(4-methyl-2-[1,2,3]triazol-2-yl-           phenyl)-methanone. LC-MS: t R  = 0.86; [M + H] +  = 423.3       5.203   [(S)-2-(4,5-Difluoro-1H-benzoimidazol-2-yl)-2-methyl-pyrrolidin-1-yl]-(2-fluoro-3-methoxy-6-           [1,2,3]triazol-2-yl-phenyl)-methanone. LC-MS: t R  = 0.85; [M + H] +  = 457.3       5.204   [(S)-2-(4,5-Difluoro-1H-benzoimidazol-2-yl)-2-methyl-pyrrolidin-1-yl]-(5-fluoro-2-[1,2,3]triazol-2-yl-           phenyl)-methanone. LC-MS: t R  = 0.83; [M + H] +  = 427.3       5.205   [(S)-2-(4,5-Difluoro-1H-benzoimidazol-2-yl)-2-methyl-pyrrolidin-1-yl]-(6-methyl-3-[1,2,3]triazol-2-yl-           pyridin-2-yl)-methanone. LC-MS: t R  = 0.73; [M + H] +  = 424.2       5.206   [(S)-2-(4,5-Difluoro-1H-benzoimidazol-2-yl)-2-methyl-pyrrolidin-1-yl]-(2-methyl-5-phenyl-thiazol-4-yl)-           methanone. LC-MS: t R  = 0.90; [M + H] +  = 439.2       5.207   [5-(3-Chloro-phenyl)-2-methyl-thiazol-4-yl]-[(S)-2-(4,5-difluoro-1H-benzoimidazol-2-yl)-2-methyl-           pyrrolidin-1-yl]-methanone. LC-MS: t R  = 0.98; [M + H] +  = 473.2       5.208   [(S)-2-(4,5-Difluoro-1H-benzoimidazol-2-yl)-2-methyl-pyrrolidin-1-yl]-[5-(4-fluoro-phenyl)-2-methyl-           thiazol-4-yl]-methanone. LC-MS: t R  = 0.92; [M + H] +  = 457.3       5.209   [(S)-2-(4,5-Difluoro-1H-benzoimidazol-2-yl)-2-methyl-pyrrolidin-1-yl]-(2-methyl-5-p-tolyl-thiazol-4-yl)-           methanone. LC-MS: t R  = 0.97; [M + H] +  = 453.3       5.210   [(S)-2-(4,5-Difluoro-1H-benzoimidazol-2-yl)-2-methyl-pyrrolidin-1-yl]-(2-methyl-5-m-tolyl-thiazol-4-yl)-           methanone. LC-MS: t R  = 0.96; [M + H] +  = 453.3       5.211   [5-(4-Chloro-phenyl)-2-methyl-thiazol-4-yl]-[(S)-2-(4,5-difluoro-1H-benzoimidazol-2-yl)-2-methyl-           pyrrolidin-1-yl]-methanone. LC-MS: t R  = 0.99; [M + H] +  = 473.2       5.212   [(S)-2-(4,5-Difluoro-1H-benzoimidazol-2-yl)-2-methyl-pyrrolidin-1-yl]-[5-(3-fluoro-phenyl)-2-methyl-           thiazol-4-yl]-methanone. LC-MS: t R  = 0.92; [M + H] +  = 457.2       5.213   [(S)-2-(4,5-Difluoro-1H-benzoimidazol-2-yl)-2-methyl-pyrrolidin-1-yl]-[5-(3-methoxy-phenyl)-2-methyl-           thiazol-4-yl]-methanone. LC-MS: t R  = 0.91; [M + H] +  = 469.3       5.214   [(S)-2-(5-Chloro-4-methyl-1H-benzoimidazol-2-yl)-2-methyl-pyrrolidin-1-yl]-(5-methyl-2-pyrimidin-2-yl-           phenyl)-methanone. LC-MS: t R  = 77; [M + H] +  = 446.2       5.215   [(S)-2-(5-Chloro-4-methyl-1H-benzoimidazol-2-yl)-2-methyl-pyrrolidin-1-yl]-(5-methyl-2-pyridin-2-yl-           phenyl)-methanone. LC-MS: t R  = 0.75; [M + H] +  = 445.2       5.216   [(S)-2-(5-Chloro-4-methyl-1H-benzoimidazol-2-yl)-2-methyl-pyrrolidin-1-yl]-(5-methyl-2-pyridin-3-yl-           phenyl)-methanone. LC-MS: t R  = 0.66; [M + H] +  = 445.2       5.217   [(S)-2-(5-Chloro-4-methyl-1H-benzoimidazol-2-yl)-2-methyl-pyrrolidin-1-yl]-(5-methyl-2-pyridin-3-yl-           phenyl)-methanone. LC-MS: t R  = 0.7; [M + H] +  = 445.3       5.218   [(S)-2-(5-Chloro-4-methyl-1H-benzoimidazol-2-yl)-2-methyl-pyrrolidin-1-yl]-(4-fluoro-biphenyl-2-yl)-           methanone. LC-MS: t R  = 0.95; [M + H] +  = 448.3       5.219   [(S)-2-(5-Chloro-4-methyl-1H-benzoimidazol-2-yl)-2-methyl-pyrrolidin-1-yl]-(5-fluoro-2-pyridin-2-yl-           phenyl)-methanone. LC-MS: t R  = 0.8; [M + H] +  = 449.3       5.220   [(S)-2-(5-Chloro-4-methyl-1H-benzoimidazol-2-yl)-2-methyl-pyrrolidin-1-yl]-(5-fluoro-2-pyridin-3-yl-           phenyl)-methanone. LC-MS: t R  = 0.7; [M + H] +  = 449.3       5.221   [(S)-2-(5-Chloro-4-methyl-1H-benzoimidazol-2-yl)-2-methyl-pyrrolidin-1-yl]-(2-fluoro-6-pyridin-2-yl-           phenyl)-methanone. LC-MS: t R  = 0.82; [M + H] +  = 449.3       5.222   [(S)-2-(5-Chloro-4-methyl-1H-benzoimidazol-2-yl)-2-methyl-pyrrolidin-1-yl]-(2-fluoro-6-pyrimidin-2-yl-           phenyl)-methanone. LC-MS: t R  = 0.8; [M + H] +  = 450.3       5.223   [(S)-2-(5-Chloro-4-methyl-1H-benzoimidazol-2-yl)-2-methyl-pyrrolidin-1-yl]-(4-methyl-biphenyl-2-yl)-           methanone. LC-MS: t R  = 0.82; [M + H] +  = 446.3       5.224   [(S)-2-(5-Chloro-4-methyl-1H-benzoimidazol-2-yl)-2-methyl-pyrrolidin-1-yl]-(5-fluoro-2-pyrimidin-2-yl-           phenyl)-methanone. LC-MS: t R  = 0.81; [M + H] +  = 450.3       5.225   [(S)-2-(5-Chloro-4-methyl-1H-benzoimidazol-2-yl)-2-methyl-pyrrolidin-1-yl]-(3-fluoro-biphenyl-2-yl)-           methanone. LC-MS: t R  = 0.94; [M + H] +  = 448.3       5.226   [(S)-2-(5-Chloro-4-methyl-1H-benzoimidazol-2-yl)-2-methyl-pyrrolidin-1-yl]-[5-(4-fluoro-phenyl)-2-           phenyl-thiazol-4-yl]-methanone. LC-MS: t R  = 1.09; [M + H] +  = 531.3       5.227   [2,5-Bis-(4-fluoro-phenyl)-thiazol-4-yl]-[(S)-2-(5-chloro-4-methyl-1H-benzoimidazol-2-yl)-2-methyl-           pyrrolidin-1-yl]-methanone. LC-MS: t R  = 1.09; [M + H] +  = 549.4       5.228   [(S)-2-(5-Chloro-4-methyl-1H-benzoimidazol-2-yl)-2-methyl-pyrrolidin-1-yl]-[5-(4-fluoro-phenyl)-2-#o!-           tolyl-thiazol-4-yl]-methanone. LC-MS: t R  = 1.12.; [M + H] +  = 545.3       5.229   [(S)-2-(5-Chloro-4-methyl-1H-benzoimidazol-2-yl)-2-methyl-pyrrolidin-1-yl]-[5-(4-fluoro-phenyl)-2-(2-           methoxy-phenyl)-thiazol-4-yl]-methanone. LC-MS: t R  = 1.09; [M + H] +  = 561.3       5.230   [(S)-2-(5-Chloro-4-methyl-1H-benzoimidazol-2-yl)-2-methyl-pyrrolidin-1-yl]-[5-(4-fluoro-phenyl)-2-m-           tolyl-thiazol-4-yl]-methanone. LC-MS: t R  = 1.14; [M + H] +  = 545.3       5.231   [(S)-2-(5-Chloro-4-methyl-1H-benzoimidazol-2-yl)-2-methyl-pyrrolidin-1-yl]-[5-(4-fluoro-phenyl)-2-(3-           methoxy-phenyl)-thiazol-4-yl]-methanone. LC-MS: t R  = 1.1; [M + H] +  = 561.3       5.232   [(S)-2-(5-Chloro-4-methyl-1H-benzoimidazol-2-yl)-2-methyl-pyrrolidin-1-yl]-[5-(4-fluoro-phenyl)-2-p-           tolyl-thiazol-4-yl]-methanone. LC-MS: t R  = 1.14; [M + H] +  = 545.3       5.233   [(S)-2-(5-Chloro-4-methyl-1H-benzoimidazol-2-yl)-2-methyl-pyrrolidin-1-yl]-[5-(4-fluoro-phenyl)-2-(2-           fluoro-phenyl)-thiazol-4-yl]-methanone. LC-MS: t R  = 1.1; [M + H] +  = 549.3       5.234   [(S)-2-(5-Chloro-4-methyl-1H-benzoimidazol-2-yl)-2-methyl-pyrrolidin-1-yl]-[5-(4-fluoro-phenyl)-2-(3-           fluoro-phenyl)-thiazol-4-yl]-methanone. LC-MS: t R  = 1.1; [M + H] +  = 549.3       5.235   (4,5-Dimethyl-2-[1,2,3]triazol-2-yl-phenyl)-[(S)-2-methyl-2-(5-trifluoromethoxy-1H-benzoimidazol-2-           yl)-pyrrolidin-1-yl]-methanone. LC-MS: t R  = 0.93; [M + H] +  = 485.3       5.236   (4-Methyl-biphenyl-2-yl)-[(S)-2-methyl-2-(5-trifluoromethoxy-1H-benzoimidazol-2-yl)-pyrrolidin-1-yl]-           methanone. LC-MS: t R  = 1.01; [M + H] +  = 480.3       5.237   (5-Methoxy-2-[1,2,3]triazol-2-yl-phenyl)-[(S)-2-methyl-2-(5-trifluoromethoxy-1H-benzoimidazol-2-yl)-           pyrrolidin-1-yl]-methanone. LC-MS: t R  = 0.85; [M + H] +  = 487.3       5.238   (4-Methyl-2-[1,2,3]triazol-2-yl-phenyl)-[(S)-2-methyl-2-(5-trifluoromethoxy-1H-benzoimidazol-2-yl)-           pyrrolidin-1-yl]-methanone. LC-MS: t R  = 0.88; [M + H] +  = 471.3       5.239   (5-Methyl-2-pyridin-2-yl-phenyl)-[(S)-2-methyl-2-(5-trifluoromethoxy-1H-benzoimidazol-2-yl)-           pyrrolidin-1-yl]-methanone. LC-MS: t R  = 0.83; [M + H] +  = 481.3       5.240   (4-Methyl-2-pyridin-2-yl-phenyl)-[(S)-2-methyl-2-(5-trifluoromethoxy-1H-benzoimidazol-2-yl)-           pyrrolidin-1-yl]-methanone. LC-MS: t R  = 0.83; [M + H] +  = 481.3       5.241   (4-Methyl-2-pyridin-3-yl-phenyl)-[(S)-2-methyl-2-(5-trifluoromethoxy-1H-benzoimidazol-2-yl)-           pyrrolidin-1-yl]-methanone. LC-MS: t R  = 0.74; [M + H] +  = 481.3       5.242   (5-Methyl-biphenyl-2-yl)-[(S)-2-methyl-2-(5-trifluoromethoxy-1H-benzoimidazol-2-yl)-pyrrolidin-1-yl]-           methanone. LC-MS: t R  = 1.01; [M + H] +  = 480.3       5.243   (2-Methyl-5-o-tolyl-thiazol-4-yl)-[(S)-2-methyl-2-(5-trifluoromethoxy-1H-benzoimidazol-2-yl)-pyrrolidin-           1-yl]-methanone. LC-MS: t R  = 0.98; [M + H] +  = 501.3       5.244   [5-(2,3-Dichloro-phenyl)-2-methyl-thiazol-4-yl]-[(S)-2-methyl-2-(5-trifluoromethoxy-1H-benzoimidazol-           2-yl)-pyrrolidin-1-yl]-methanone. LC-MS: t R  = 1.03; [M + H] +  = 555.2       5.245   [5-(3,4-Dimethyl-phenyl)-2-methyl-thiazol-4-yl]-[(S)-2-methyl-2-(5-trifluoromethoxy-1H-benzoimidazol-           2-yl)-pyrrolidin-1-yl]-methanone. LC-MS: t R  = 1.03; [M + H] +  = 515.3       5.246   [5-(3,5-Difluoro-phenyl)-2-methyl-thiazol-4-yl]-[(S)-2-methyl-2-(5-trifluoromethoxy-1H-benzoimidazol-           2-yl)-pyrrolidin-1-yl]-methanone. LC-MS: t R  = 0.99; [M + H] +  = 523.3       5.247   [5-(3-Methoxy-phenyl)-2-methyl-thiazol-4-yl]-[(S)-2-methyl-2-(5-trifluoromethoxy-1H-benzoimidazol-2-           yl)-pyrrolidin-1-yl]-methanone. LC-MS: t R  = 0.95; [M + H] +  = 517.3       5.248   [5-(4-Fluoro-phenyl)-2-methyl-thiazol-4-yl]-[(S)-2-methyl-2-(5-trifluoromethoxy-1H-benzoimidazol-2-           yl)-pyrrolidin-1-yl]-methanone. LC-MS: t R  = 0.96; [M + H] +  = 505.3       5.249   [(S)-2-(6-Bromo-4-methyl-1H-benzoimidazol-2-yl)-2-methyl-pyrrolidin-1-yl]-[2-(3-methoxy-           phenylethynyl)-phenyl]-methanone. LC-MS: t R  = 1.0; [M + H] +  = 528.3       5.250   [2-(3-Methoxy-phenylethynyl)-phenyl]-[(S)-2-methyl-2-(5-trifluoromethyl-1H-benzoimidazol-2-yl)-           pyrrolidin-1-yl]-methanone. LC-MS: t R  = 1.05; [M + H] +  = 504.4       5.251   [(S)-2-(5-Chloro-4-methyl-1H-benzoimidazol-2-yl)-2-methyl-pyrrolidin-1-yl]-[2-(2,3-difluoro-phenyl)-5-           (4-fluoro-phenyl)-thiazol-4-yl]-methanone. LC-MS: t R  = 1.12; [M + H] +  = 567.3       5.252   [(S)-2-(5-Chloro-4-methyl-1H-benzoimidazol-2-yl)-2-methyl-pyrrolidin-1-yl]-[2-(4-fluoro-3-methyl-           phenyl)-5-(4-fluoro-phenyl)-thiazol-4-yl]-methanone. LC-MS: t R  = 1.15; [M + H] +  = 563.3       5.253   [(S)-2-(5-Chloro-4-methyl-1H-benzoimidazol-2-yl)-2-methyl-pyrrolidin-1-yl]-[2-(2-fluoro-4-methyl-           phenyl)-5-(4-fluoro-phenyl)-thiazol-4-yl]-methanone. LC-MS: t R  = 1.15; [M + H] +  = 563.3       5.254   [(S)-2-(5-Chloro-4-methyl-1H-benzoimidazol-2-yl)-2-methyl-pyrrolidin-1-yl]-[2-(3,4-dimethyl-phenyl)-5-           (4-fluoro-phenyl)-thiazol-4-yl]-methanone. LC-MS: t R  = 1.18; [M + H] +  = 559.4       5.255   3-[4-[(S)-2-(5-Chloro-4-methyl-1H-benzoimidazol-2-yl)-2-methyl-pyrrolidine-1-carbonyl]-5-(4-fluoro-           phenyl)-thiazol-2-yl]-benzonitrile. LC-MS: t R  = 1.03; [M + H] +  = 556.3       5.256   [(S)-2-(5-Chloro-4-methyl-1H-benzoimidazol-2-yl)-2-methyl-pyrrolidin-1-yl]-[2-(2-chloro-phenyl)-5-(4-           fluoro-phenyl)-thiazol-4-yl]-methanone. LC-MS: t R  = 1.13; [M + H] +  = 565.3       5.257   [(S)-2-(5-Chloro-4-methyl-1H-benzoimidazol-2-yl)-2-methyl-pyrrolidin-1-yl]-[2-(3-chloro-phenyl)-5-(4-           fluoro-phenyl)-thiazol-4-yl]-methanone. LC-MS: t R  = 1.15; [M + H] +  = 565.3       5.258   [(S)-2-(5-Chloro-4-methyl-1H-benzoimidazol-2-yl)-2-methyl-pyrrolidin-1-yl]-[2-(3-chloro-4-methyl-           phenyl)-5-(4-fluoro-phenyl)-thiazol-4-yl]-methanone. LC-MS: t R  = 1.2; [M + H] +  = 579.3       5.259   [(S)-2-(5-Chloro-4-methyl-1H-benzoimidazol-2-yl)-2-methyl-pyrrolidin-1-yl]-[2-(4-fluoro-2-methyl-           phenyl)-5-(4-fluoro-phenyl)-thiazol-4-yl]-methanone. LC-MS: t R  = 1.13; [M + H] +  = 563.3       5.260   [(S)-2-(5-Chloro-4-methyl-1H-benzoimidazol-2-yl)-2-methyl-pyrrolidin-1-yl]-[2-(4-fluoro-2-methoxy-           phenyl)-5-(4-fluoro-phenyl)-thiazol-4-yl]-methanone. LC-MS: t R  = 1.1; [M + H] +  = 579.4       5.261   [(S)-2-(5-Chloro-4-methyl-1H-benzoimidazol-2-yl)-2-methyl-pyrrolidin-1-yl]-[2-(2,5-difluoro-phenyl)-5-           (4-fluoro-phenyl)-thiazol-4-yl]-methanone. LC-MS: t R  = 1.11; [M + H] +  = 567.3       5.262   (4-Bromo-biphenyl-2-yl)-[(S)-2-methyl-2-(5-trifluoromethyl-1H-benzoimidazol-2-yl)-pyrrolidin-1-yl]-           methanone. LC-MS: t R  = 1.08; [M + H] +  = 528.2       5.263   [(S)-2-(5-Chloro-4-methyl-1H-benzoimidazol-2-yl)-2-methyl-pyrrolidin-1-yl]-(2-methyl-5-[1,2,3]triazol-           2-yl-pyridin-4-yl)-methanone. LC-MS: t R  = 0.73; [M + H] +  = 436.3       5.264   [(S)-2-(5-Chloro-4-methyl-1H-benzoimidazol-2-yl)-2-methyl-pyrrolidin-1-yl]-(2-methyl-5-phenyl-           pyridin-4-yl)-methanone. LC-MS: t R  = 0.73; [M + H] +  = 445.3       5.265   [(S)-2-Methyl-2-(5-trifluoromethyl-1H-benzoimidazol-2-yl)-pyrrolidin-1-yl]-(4-pyridin-3-yl-biphenyl-2-           yl)-methanone. LC-MS: t R  = 0.82; [M + H] +  = 527.3       5.266   [(S)-2-(6-Bromo-4,5-dimethyl-1H-benzoimidazol-2-yl)-2-methyl-pyrrolidin-1-yl]-(5-methyl-2-           [1,2,3]triazol-2-yl-phenyl)-methanone. LC-MS: t R  = 0.89; [M + H] +  = 493.3       5.267   [(S)-2-(6-Bromo-4,5-dimethyl-1H-benzoimidazol-2-yl)-2-methyl-pyrrolidin-1-yl]-(3,4-dimethyl-2-           [1,2,3]triazol-2-yl-phenyl)-methanone. LC-MS: t R  = 0.88; [M + H] +  = 507.3       5.268   [(S)-2-(6-Bromo-4,5-dimethyl-1H-benzoimidazol-2-yl)-2-methyl-pyrrolidin-1-yl]-(2-fluoro-6-           [1,2,3]triazol-2-yl-phenyl)-methanone. LC-MS: t R  = 0.86; [M + H] +  = 497.3       5.269   Biphenyl-2-yl-[(S)-2-(6-bromo-4,5-dimethyl-1H-benzoimidazol-2-yl)-2-methyl-pyrrolidin-1-yl]-           methanone. LC-MS: t R  = 0.96; [M + H] +  = 488.3       5.270   [(S)-2-(6-Bromo-4,5-dimethyl-1H-benzoimidazol-2-yl)-2-methyl-pyrrolidin-1-yl]-(4-methyl-biphenyl-2-           yl)-methanone. LC-MS: t R  = 1.01; [M + H] +  = 502.3       5.271   [(S)-2-(6-Bromo-4,5-dimethyl-1H-benzoimidazol-2-yl)-2-methyl-pyrrolidin-1-yl]-(2-methyl-5-o-tolyl-           thiazol-4-yl)-methanone. LC-MS: t R  = 1.0; [M + H] +  = 523.3       5.272   [(S)-2-(6-Bromo-4,5-dimethyl-1H-benzoimidazol-2-yl)-2-methyl-pyrrolidin-1-yl]-[5-(2,3-dichloro-           phenyl)-2-methyl-thiazol-4-yl]-methanone. LC-MS: t R  = 1.04; [M + H] +  = 577.2       5.273   [(S)-2-(6-Bromo-4,5-dimethyl-1H-benzoimidazol-2-yl)-2-methyl-pyrrolidin-1-yl]-[5-(3,4-dimethyl-           phenyl)-2-methyl-thiazol-4-yl]-methanone. LC-MS: t R  = 1.04; [M + H] +  = 537.3       5.274   [(S)-2-(6-Bromo-4,5-dimethyl-1H-benzoimidazol-2-yl)-2-methyl-pyrrolidin-1-yl]-[5-(3,5-difluoro-           phenyl)-2-methyl-thiazol-4-yl]-methanone. LC-MS: t R  = 0.99; [M + H] +  = 545.3       5.275   [(S)-2-(6-Bromo-4,5-dimethyl-1H-benzoimidazol-2-yl)-2-methyl-pyrrolidin-1-yl]-[5-(3-methoxy-phenyl)-           2-methyl-thiazol-4-yl]-methanone. LC-MS: t R  = 0.96; [M + H] +  = 539.3       5.276   [(S)-2-(6-Bromo-4,5-dimethyl-1H-benzoimidazol-2-yl)-2-methyl-pyrrolidin-1-yl]-[5-(4-fluoro-phenyl)-2-           methyl-thiazol-4-yl]-methanone. LC-MS: t R  = 0.97; [M + H] +  = 527.3       5.277   [(S)-2-(5-Bromo-7-methyl-1H-benzoimidazol-2-yl)-2-methyl-pyrrolidin-1-yl]-(5-methyl-2-pyrimidin-2-yl-           phenyl)-methanone. LC-MS: t R  = 0.84; [M + H] +  = 490.3       5.278   [(S)-2-Methyl-2-(7-methyl-1H-benzoimidazol-2-yl)-pyrrolidin-1-yl]-(5-methyl-2-pyrimidin-2-yl-phenyl)-           methanone. LC-MS: t R  = 0.73; [M + H] +  = 412.3       5.279   [(S)-2-(6-Chloro-5-trifluoromethyl-1H-benzoimidazol-2-yl)-2-methyl-pyrrolidin-1-yl]-(5-methyl-2-           pyrimidin-2-yl-phenyl)-methanone. LC-MS: t R  = 1.07; [M + H] +  = 500.3       5.280   [(S)-2-(5,6-Dimethoxy-1H-benzoimidazol-2-yl)-2-methyl-pyrrolidin-1-yl]-(5-methyl-2-pyrimidin-2-yl-           phenyl)-methanone. LC-MS: t R  = 0.7; [M + H] +  = 458.4       5.281   (5-Methyl-2-pyrimidin-2-yl-phenyl)-[(S)-2-methyl-2-(5-trifluoromethoxy-1H-benzoimidazol-2-yl)-           pyrrolidin-1-yl]-methanone. LC-MS: t R  = 0.86; [M + H] +  = 482.3       5.282   [(S)-2-(6-Bromo-5-fluoro-1H-benzoimidazol-2-yl)-2-methyl-pyrrolidin-1-yl]-(5-methyl-2-pyrimidin-2-yl-           phenyl)-methanone. LC-MS: t R  = 0.86; [M + H] +  = 494.2       5.283   [(S)-2-(6,7-Difluoro-1H-benzoimidazol-2-yl)-2-methyl-pyrrolidin-1-yl]-(5-methyl-2-pyrimidin-2-yl-           phenyl)-methanone. LC-MS: t R  = 0.89; [M + H] +  = 434.3       5.284   [(S)-2-(5,6-Dimethyl-1H-benzoimidazol-2-yl)-2-methyl-pyrrolidin-1-yl]-(5-methyl-2-pyrimidin-2-yl-           phenyl)-methanone. LC-MS: t R  = 0.77; [M + H] +  = 426.4       5.285   [(S)-2-(5-Chloro-6-trifluoromethyl-1H-benzoimidazol-2-yl)-2-methyl-pyrrolidin-1-yl]-[5-(4-fluoro-           phenyl)-2-phenyl-thiazol-4-yl]-methanone. LC-MS: t R  = 1.29; [M + H] +  = 585.3       5.286   [(S)-2-(5-Chloro-6-trifluoromethyl-1H-benzoimidazol-2-yl)-2-methyl-pyrrolidin-1-yl]-[5-(4-fluoro-           phenyl)-2-o-tolyl-thiazol-4-yl]-methanone. LC-MS: t R  = 1.32; [M + H] +  = 599.3       5.287   [(S)-2-(5-Chloro-6-trifluoromethyl-1H-benzoimidazol-2-yl)-2-methyl-pyrrolidin-1-yl]-[5-(4-fluoro-           phenyl)-2-m-tolyl-thiazol-4-yl]-methanone. LC-MS: t R  = 1.34; [M + H] +  = 599.3       5.288   [(S)-2-(5-Chloro-6-trifluoromethyl-1H-benzoimidazol-2-yl)-2-methyl-pyrrolidin-1-yl]-[5-(4-fluoro-           phenyl)-2-p-tolyl-thiazol-4-yl]-methanone. LC-MS: t R  = 1.34; [M + H] +  = 599.3       5.289   [(S)-2-(5-Chloro-6-trifluoromethyl-1H-benzoimidazol-2-yl)-2-methyl-pyrrolidin-1-yl]-[5-(4-fluoro-           phenyl)-2-(2-fluoro-phenyl)-thiazol-4-yl]-methanone. LC-MS: t R  = 1.31; [M + H] +  = 603.3       5.290   [(S)-2-(5-Chloro-6-trifluoromethyl-1H-benzoimidazol-2-yl)-2-methyl-pyrrolidin-1-yl]-[5-(4-fluoro-           phenyl)-2-(3-fluoro-phenyl)-thiazol-4-yl]-methanone. LC-MS: t R  = 1.30; [M + H] +  = 603.3       5.291   [2,5-Bis-(4-fluoro-phenyl)-thiazol-4-yl]-[(S)-2-(5-chloro-6-trifluoromethyl-1H-benzoimidazol-2-yl)-2-           methyl-pyrrolidin-1-yl]-methanone. LC-MS: t R  = 1.30; [M + H] +  = 603.3       5.292   [(S)-2-(5-Chloro-6-trifluoromethyl-1H-benzoimidazol-2-yl)-2-methyl-pyrrolidin-1-yl]-[5-(4-fluoro-           phenyl)-2-(3-methoxy-phenyl)-thiazol-4-yl]-methanone. LC-MS: t R  = 1.30; [M + H] +  = 615.3       5.293   [(S)-2-(5-Chloro-6-trifluoromethyl-1H-benzoimidazol-2-yl)-2-methyl-pyrrolidin-1-yl]-[5-(4-fluoro-           phenyl)-2-(4-methoxy-phenyl)-thiazol-4-yl]-methanone. LC-MS: t R  = 1.28; [M + H] +  = 615.3       5.294   [5-(4-Fluoro-phenyl)-2-(2-fluoro-phenyl)-thiazol-4-yl]-[(S)-2-methyl-2-(6-trifluoromethyl-1H-           benzoimidazol-2-yl)-pyrrolidin-1-yl]-methanone. LC-MS: t R  = 1.15; [M + H] +  = 569.3       5.295   3′-[(S)-2-Methyl-2-(5-trifluoromethyl-1H-benzoimidazol-2-yl)-pyrrolidine-1-carbonyl]-4′-[1,2,3]triazol-2-           yl-biphenyl-3-carbonitrile. LC-MS: t R  = 0.99; [M + H] +  = 542.3       5.296   [(S)-2-(5-Chloro-4-methyl-1H-benzoimidazol-2-yl)-2-methyl-pyrrolidin-1-yl]-(3-fluoro-4,3′-dimethoxy-           biphenyl-2-yl)-methanone. LC-MS: t R  = 0.95; [M + H] +  = 508.3       5.297   [(S)-2-(5-Chloro-4-methyl-1H-benzoimidazol-2-yl)-2-methyl-pyrrolidin-1-yl]-(3-fluoro-4,4′-dimethoxy-           biphenyl-2-yl)-methanone. LC-MS: t R  = 0.93; [M + H] +  = 508.3       5.298   [(S)-2-(5-Chloro-4-methyl-1H-benzoimidazol-2-yl)-2-methyl-pyrrolidin-1-yl]-(3,2′-difluoro-4-methoxy-           biphenyl-2-yl)-methanone. LC-MS: t R  = 0.95; [M + H] +  = 496.3       5.299   [(S)-2-(5-Chloro-4-methyl-1H-benzoimidazol-2-yl)-2-methyl-pyrrolidin-1-yl]-(3,4′-difluoro-4-methoxy-           biphenyl-2-yl)-methanone. LC-MS: t R  = 0.96; [M + H] +  = 496.3       5.300   [(S)-2-(5-Chloro-4-methyl-1H-benzoimidazol-2-yl)-2-methyl-pyrrolidin-1-yl]-(3,3′-difluoro-4-methoxy-           biphenyl-2-yl)-methanone. LC-MS: t R  = 0.96; [M + H] +  = 496.3       5.301   [(S)-2-(5-Chloro-4-methyl-1H-benzoimidazol-2-yl)-2-methyl-pyrrolidin-1-yl]-(3-fluoro-4-methoxy-3′-           methyl-biphenyl-2-yl)-methanone. LC-MS: t R  = 1.00; [M + H] +  = 492.3       5.302   [(S)-2-(5-Chloro-4-methyl-1H-benzoimidazol-2-yl)-2-methyl-pyrrolidin-1-yl]-(3-fluoro-4-methoxy-4′-           methyl-biphenyl-2-yl)-methanone. LC-MS: t R  = 1.01; [M + H] +  = 492.3       5.303   [(S)-2-(5-Chloro-4-methyl-1H-benzoimidazol-2-yl)-2-methyl-pyrrolidin-1-yl]-(3-fluoro-4-methoxy-3′-           trifluoromethyl-biphenyl-2-yl)-methanone. LC-MS: t R  = 1.05; [M + H] +  = 546.3       5.304   (6-Benzo[1,3]dioxol-5-yl-2-fluoro-3-methoxy-phenyl)-[(S)-2-(5-chloro-4-methyl-1H-benzoimidazol-2-           yl)-2-methyl-pyrrolidin-1-yl]-methanone. LC-MS: t R  = 0.93; [M + H] +  = 522.3       5.305   [(S)-2-(5-Chloro-4-methyl-1H-benzoimidazol-2-yl)-2-methyl-pyrrolidin-1-yl]-(3-fluoro-4-methoxy-4′-           trifluoromethyl-biphenyl-2-yl)-methanone. LC-MS: t R  = 1.06; [M + H] +  = 546.3       5.306   [(S)-2-(5-Chloro-4-methyl-1H-benzoimidazol-2-yl)-2-methyl-pyrrolidin-1-yl]-(3-fluoro-4-methoxy-4′-           trifluoromethoxy-biphenyl-2-yl)-methanone. LC-MS: t R  = 1.07; [M + H] +  = 562.4       5.307   2′-[(S)-2-(5-Chloro-4-methyl-1H-benzoimidazol-2-yl)-2-methyl-pyrrolidine-1-carbonyl]-3′-fluoro-4′-           methoxy-biphenyl-3-carbonitrile. LC-MS: t R  = 0.92; [M + H] +  = 503.3       5.308   2′-[(S)-2-(5-Chloro-4-methyl-1H-benzoimidazol-2-yl)-2-methyl-pyrrolidine-1-carbonyl]-3′-fluoro-4′-           methoxy-biphenyl-4-carbonitrile. LC-MS: t R  = 0.93; [M + H] +  = 503.3       5.309   [(S)-2-(5-Chloro-4-methyl-1H-benzoimidazol-2-yl)-2-methyl-pyrrolidin-1-yl]-(3-fluoro-4-methoxy-3′-           trifluoromethoxy-biphenyl-2-yl)-methanone. LC-MS: t R  = 1.07; [M + H] +  = 562.3       5.310   [(S)-2-(6-Bromo-4-methyl-1H-benzoimidazol-2-yl)-2-methyl-pyrrolidin-1-yl]-(2-methyl-5-phenyl-           pyridin-4-yl)-methanone. LC-MS: t R  = 0.75; [M + H] +  = 489.3       6.1   [5-(4-Fluoro-phenyl)-2-methyl-thiazol-4-yl]-[(S)-2-(5-methoxy-1H-benzoimidazol-2-yl)-4-methylene-           pyrrolidin-1-yl]-methanone. LC-MS: t R  = 0.74; [M + H] +  = 449.2       6.2   [(S)-2-(5-Methoxy-1H-benzoimidazol-2-yl)-4-methylene-pyrrolidin-1-yl]-[5-(4-methoxy-phenyl)-2-           methyl-thiazol-4-yl]-methanone. LC-MS: t R  = 0.73; [M + H] +  = 461.2       6.3   [(S)-2-(5-Methoxy-1H-benzoimidazol-2-yl)-4-methylene-pyrrolidin-1-yl]-(2-methyl-5-phenyl-thiazol-4-           yl)-methanone. LC-MS: t R  = 0.72; [M + H] +  = 431.2       6.4   [(S)-2-(5-Methoxy-1H-benzoimidazol-2-yl)-4-methylene-pyrrolidin-1-yl]-(3-p-tolyl-pyrazin-2-yl)-           methanone. LC-MS: t R  = 0.67; [M + H] +  = 426.2       6.5   [5-(4-Chloro-phenyl)-2-methyl-thiazol-4-yl]-[(S)-2-(5-methoxy-1H-benzoimidazol-2-yl)-4-methylene-           pyrrolidin-1-yl]-methanone. LC-MS: t R  = 0.79; [M + H] +  = 465.2       6.6   [(S)-2-(5-Methoxy-1H-benzoimidazol-2-yl)-4-methylene-pyrrolidin-1-yl]-(3-m-tolyl-pyrazin-2-yl)-           methanone. LC-MS: t R  = 0.67; [M + H] +  = 426.2       6.7   [(S)-2-(5-Methoxy-1H-benzoimidazol-2-yl)-4-methylene-pyrrolidin-1-yl]-(2-methyl-5-m-tolyl-thiazol-4-           yl)-methanone. LC-MS: t R  = 0.77; [M + H] +  = 445.2       6.8   [5-(3-Chloro-phenyl)-2-methyl-thiazol-4-yl]-[(S)-2-(5-methoxy-1H-benzoimidazol-2-yl)-4-methylene-           pyrrolidin-1-yl]-methanone. LC-MS: t R  = 0.79; [M + H] +  = 465.1       6.9   [5-(3,4-Dimethyl-phenyl)-2-methyl-thiazol-4-yl]-[(S)-2-(5-methoxy-1H-benzoimidazol-2-yl)-4-           methylene-pyrrolidin-1-yl]-methanone. LC-MS: t R  = 0.81; [M + H] +  = 459.3       6.10   (2-Cyclopropyl-5-phenyl-thiazol-4-yl)-[(S)-2-(5-methoxy-1H-benzoimidazol-2-yl)-4-methylene-           pyrrolidin-1-yl]-methanone. LC-MS: t R  = 0.80; [M + H] +  = 457.2       6.11   [(S)-2-(5-Methoxy-1H-benzoimidazol-2-yl)-4-methylene-pyrrolidin-1-yl]-(2-methyl-4-m-tolyl-pyrimidin-           5-yl)-methanone. LC-MS: t R  = 0.68; [M + H] +  = 440.2       6.12   [(S)-2-(5-Methoxy-1H-benzoimidazol-2-yl)-4-methylene-pyrrolidin-1-yl]-(5-methyl-2-[1,2,3]triazol-2-yl-           phenyl)-methanone. LC-MS: t R  = 0.67; [M + H] +  = 415.2       6.13   [(S)-2-(5-Methoxy-1H-benzoimidazol-2-yl)-4-methylene-pyrrolidin-1-yl]-(2-[1,2,3]triazol-2-yl-phenyl)-           methanone. LC-MS: t R  = 0.61; [M + H] +  = 401.2       6.14   [(S)-2-(5-Methoxy-1H-benzoimidazol-2-yl)-4-methylene-pyrrolidin-1-yl]-(3′-methyl-biphenyl-2-yl)-           methanone. LC-MS: t R  = 0.79; [M + H] +  = 424.2       6.15   [(S)-2-(5-Methoxy-1H-benzoimidazol-2-yl)-4-methylene-pyrrolidin-1-yl]-(4′-methyl-biphenyl-2-yl)-           methanone. LC-MS: t R  = 0.79; [M + H] +  = 424.2       6.16   [(S)-2-(5-Methoxy-1H-benzoimidazol-2-yl)-4-methylene-pyrrolidin-1-yl]-(2-methyl-4-phenyl-pyrimidin-           5-yl)-methanone. LC-MS: t R  = 0.62; [M + H] +  = 426.2       6.17   [(S)-2-(5-Methoxy-1H-benzoimidazol-2-yl)-4-methylene-pyrrolidin-1-yl]-(4-m-tolyl-pyrimidin-5-yl)-           methanone. LC-MS: t R  = 0.64; [M + H] +  = 426.3       6.18   (5-Fluoro-2-[1,2,3]triazol-2-yl-phenyl)-[(S)-2-(5-methoxy-1H-benzoimidazol-2-yl)-4-methylene-           pyrrolidin-1-yl]-methanone. LC-MS: t R  = 0.64; [M + H] +  = 419.2       6.19   (2-Fluoro-6-[1,2,3]triazol-2-yl-phenyl)-[(S)-2-(5-methoxy-1H-benzoimidazol-2-yl)-4-methylene-           pyrrolidin-1-yl]-methanone. LC-MS: t R  = 0.63; [M + H] +  = 419.2       6.20   [(S)-2-(5-Methoxy-1H-benzoimidazol-2-yl)-4-methylene-pyrrolidin-1-yl]-[2-(3-methyl-[1,2,4]oxadiazol-           5-yl)-phenyl]-methanone. LC-MS: t R  = 0.62; [M + H] +  = 416.2       6.21   [(S)-2-(5-Methoxy-1H-benzoimidazol-2-yl)-4-methylene-pyrrolidin-1-yl]-[2-(2-methyl-thiazol-4-yl)-           phenyl]-methanone. LC-MS: t R  = 0.67; [M + H] +  = 431.2       6.22   [5-(4-Bromo-phenyl)-2-methyl-thiazol-4-yl]-[(S)-2-(5-methoxy-1H-benzoimidazol-2-yl)-4-methylene-           pyrrolidin-1-yl]-methanone. LC-MS: t R  = 0.80; [M + H] +  = 509.1       6.23   [5-(2,3-Dichloro-phenyl)-2-methyl-thiazol-4-yl]-[(S)-2-(5-methoxy-1H-benzoimidazol-2-yl)-4-           methylene-pyrrolidin-1-yl]-methanone. LC-MS: t R  = 0.84; [M + H] +  = 499.2       6.24   [5-(3-Bromo-4-fluoro-phenyl)-2-methyl-thiazol-4-yl]-[(S)-2-(5-methoxy-1H-benzoimidazol-2-yl)-4-           methylene-pyrrolidin-1-yl]-methanone. LC-MS: t R  = 0.81; [M + H] +  = 527.1       6.25   [2-Cyclopropyl-5-(3-fluoro-4-methyl-phenyl)-thiazol-4-yl]-[(S)-2-(5-methoxy-1H-benzoimidazol-2-yl)-4-           methylene-pyrrolidin-1-yl]-methanone. LC-MS: t R  = 0.87; [M + H] +  = 489.2       6.26   (2-Cyclopropyl-5-m-tolyl-thiazol-4-yl)-[(S)-2-(5-methoxy-1H-benzoimidazol-2-yl)-4-methylene-           pyrrolidin-1-yl]-methanone. LC-MS: t R  = 0.85; [M + H] +  = 471.3       6.27   [2-Dimethylamino-5-(3,4-dimethyl-phenyl)-thiazol-4-yl]-[(S)-2-(5-methoxy-1H-benzoimidazol-2-yl)-4-           methylene-pyrrolidin-1-yl]-methanone. LC-MS: t R  = 0.85; [M + H] +  = 488.3       6.28   [5-(3-Bromo-phenyl)-2-cyclopropyl-thiazol-4-yl]-[(S)-2-(5-methoxy-1H-benzoimidazol-2-yl)-4-           methylene-pyrrolidin-1-yl]-methanone. LC-MS: t R  = 0.88; [M + H] +  = 535.1       6.29   [5-(3-Fluoro-phenyl)-2-pyrrolidin-1-yl-thiazol-4-yl]-[(S)-2-(5-methoxy-1H-benzoimidazol-2-yl)-4-           methylene-pyrrolidin-1-yl]-methanone. LC-MS: t R  = 0.86; [M + H] +  = 504.3       6.30   [(S)-2-(5-Methoxy-1H-benzoimidazol-2-yl)-4-methylene-pyrrolidin-1-yl]-[2-methyl-5-(3-trifluoromethyl-           phenyl)-thiazol-4-yl]-methanone. LC-MS: t R  = 0.83; [M + H] +  = 499.2       6.31   [2-Cyclopropyl-5-(3-methoxy-phenyl)-thiazol-4-yl]-[(S)-2-(5-methoxy-1H-benzoimidazol-2-yl)-4-           methylene-pyrrolidin-1-yl]-methanone. LC-MS: t R  = 0.81; [M + H] +  = 487.2       6.32   [5-(3-Chloro-phenyl)-thiazol-4-yl]-[(S)-2-(5-methoxy-1H-benzoimidazol-2-yl)-4-methylene-pyrrolidin-1-           yl]-methanone. LC-MS: t R  = 0.74; [M + H] +  = 451.1       6.33   [5-(3-Fluoro-phenyl)-2-methyl-thiazol-4-yl]-[(S)-2-(5-methoxy-1H-benzoimidazol-2-yl)-4-methylene-           pyrrolidin-1-yl]-methanone. LC-MS: t R  = 0.74; [M + H] +  = 449.2       6.34   [5-(2-Chloro-phenyl)-2-methyl-thiazol-4-yl]-[(S)-2-(5-methoxy-1H-benzoimidazol-2-yl)-4-methylene-           pyrrolidin-1-yl]-methanone. LC-MS: t R  = 0.79; [M + H] +  = 465.2       6.35   (2-Cyclopropyl-5-p-tolyl-thiazol-4-yl)-[(S)-2-(5-methoxy-1H-benzoimidazol-2-yl)-4-methylene-           pyrrolidin-1-yl]-methanone. LC-MS: t R  = 0.85; [M + H] +  = 471.3       6.36   [2-(3,4-Dimethyl-phenyl)-5-methyl-thiophen-3-yl]-[(S)-2-(5-methoxy-1H-benzoimidazol-2-yl)-4-           methylene-pyrrolidin-1-yl]-methanone. LC-MS: t R  = 0.86; [M + H] +  = 458.2       6.37   [5-(3,5-Difluoro-phenyl)-2-methyl-thiazol-4-yl]-[(S)-2-(5-methoxy-1H-benzoimidazol-2-yl)-4-           methylene-pyrrolidin-1-yl]-methanone. LC-MS: t R  = 0.76; [M + H] +  = 467.2       6.38   [(S)-2-(5-Methoxy-1H-benzoimidazol-2-yl)-4-methylene-pyrrolidin-1-yl]-(2-m-tolyl-thiophen-3-yl)-           methanone. LC-MS: t R  = 0.77; [M + H] +  = 430.1       6.39   [2-(3,4-Dimethyl-phenyl)-thiophen-3-yl]-[(S)-2-(5-methoxy-1H-benzoimidazol-2-yl)-4-methylene-           pyrrolidin-1-yl]-methanone. LC-MS: t R  = 0.81; [M + H] +  = 444.2       6.40   [(S)-2-(4-Methyl-1H-benzoimidazol-2-yl)-4-methylene-pyrrolidin-1-yl]-(2-methyl-5-phenyl-thiazol-4-yl)-           methanone. LC-MS: t R  = 0.74; [M + H] +  = 415.2       6.41   [(S)-2-(5-Chloro-4-methyl-1H-benzoimidazol-2-yl)-4-methylene-pyrrolidin-1-yl]-(2-methyl-5-phenyl-           thiazol-4-yl)-methanone. LC-MS: t R  = 0.86; [M + H] +  = 449.2       6.42   [(S)-2-(5-Chloro-4-methyl-1H-benzoimidazol-2-yl)-4-methylene-pyrrolidin-1-yl]-(5-methyl-2-           [1,2,3]triazol-2-yl-phenyl)-methanone. LC-MS: t R  = 0.80; [M + H] +  = 433.2       6.43   [(S)-2-(1H-Benzoimidazol-2-yl)-4-methylene-pyrrolidin-1-yl]-[5-(3-chloro-phenyl)-2-methyl-thiazol-4-           yl]-methanone. LC-MS: t R  = 0.78; [M + H] +  = 435.1       6.44   [5-(3-Chloro-phenyl)-2-methyl-thiazol-4-yl]-[(S)-2-(4-methyl-1H-benzoimidazol-2-yl)-4-methylene-           pyrrolidin-1-yl]-methanone. LC-MS: t R  = 0.81; [M + H] +  = 449.2       6.45   [(S)-2-(5-Chloro-4-methyl-1H-benzoimidazol-2-yl)-4-methylene-pyrrolidin-1-yl]-[5-(3-chloro-phenyl)-2-           methyl-thiazol-4-yl]-methanone. LC-MS: t R  = 0.93; [M + H] +  = 483.1       6.46   [5-(3,4-Dimethyl-phenyl)-2-methyl-thiazol-4-yl]-[(S)-2-(6-methoxy-1H-benzoimidazol-2-yl)-4-           methylene-pyrrolidin-1-yl]-methanone. LC-MS: t R  = 0.81; [M + H] +  = 459.2       6.47   [(S)-2-(4,5-Dimethyl-1H-benzoimidazol-2-yl)-4-methylene-pyrrolidin-1-yl]-[5-(3,4-dimethyl-phenyl)-2-           methyl-thiazol-4-yl]-methanone. LC-MS: t R  = 0.86; [M + H] +  = 457.2       6.48   [(S)-2-(4,7-Dimethoxy-1H-benzoimidazol-2-yl)-4-methylene-pyrrolidin-1-yl]-[5-(3,4-dimethyl-phenyl)-           2-methyl-thiazol-4-yl]-methanone. LC-MS: t R  = 0.85; [M + H] +  = 489.3       6.49   [5-(3,4-Dimethyl-phenyl)-2-methyl-thiazol-4-yl]-[(S)-4-methylene-2-(4-methylsulfanyl-1H-           benzoimidazol-2-yl)-pyrrolidin-1-yl]-methanone. LC-MS: t R  = 0.88; [M + H] +  = 475.3       6.50   [(S)-2-(4-Bromo-1H-benzoimidazol-2-yl)-4-methylene-pyrrolidin-1-yl]-[5-(3,4-dimethyl-phenyl)-2-           methyl-thiazol-4-yl]-methanone. LC-MS: t R  = 0.97; [M + H] +  = 507.2       6.51   [(S)-2-(4-Chloro-1H-benzoimidazol-2-yl)-4-methylene-pyrrolidin-1-yl]-[5-(3,4-dimethyl-phenyl)-2-           methyl-thiazol-4-yl]-methanone. LC-MS: t R  = 0.96; [M + H] +  = 463.2       6.52   [5-(3,4-Dimethyl-phenyl)-2-methyl-thiazol-4-yl]-[(S)-4-methylene-2-(5-methylsulfanyl-1H-           benzoimidazol-2-yl)-pyrrolidin-1-yl]-methanone. LC-MS: t R  = 0.86; [M + H] +  = 475.3       6.53   [5-(3,4-Dimethyl-phenyl)-2-methyl-thiazol-4-yl]-[(S)-2-(4-methyl-1H-benzoimidazol-2-yl)-4-methylene-           pyrrolidin-1-yl]-methanone. LC-MS: t R  = 0.83; [M + H] +  = 443.2       6.54   [(S)-2-(5-Chloro-4-methyl-1H-benzoimidazol-2-yl)-4-methylene-pyrrolidin-1-yl]-[5-(3,4-dimethyl-           phenyl)-2-methyl-thiazol-4-yl]-methanone. LC-MS: t R  = 0.94; [M + H] +  = 477.2       6.55   [(S)-2-(5-Chloro-6-methyl-1H-benzoimidazol-2-yl)-4-methylene-pyrrolidin-1-yl]-[5-(3,4-dimethyl-           phenyl)-2-methyl-thiazol-4-yl]-methanone. LC-MS: t R  = 0.92; [M + H] +  = 477.2       6.56   [(S)-2-(5,6-Dimethyl-1H-benzoimidazol-2-yl)-4-methylene-pyrrolidin-1-yl]-[5-(3,4-dimethyl-phenyl)-2-           methyl-thiazol-4-yl]-methanone. LC-MS: t R  = 0.86; [M + H] +  = 457.3       6.57   [(S)-2-(5-tert-Butyl-1H-benzoimidazol-2-yl)-4-methylene-pyrrolidin-1-yl]-[5-(3,4-dimethyl-phenyl)-2-           methyl-thiazol-4-yl]-methanone. LC-MS: t R  = 0.95; [M + H] +  = 485.3       6.58   [(S)-2-(4,6-Dimethyl-1H-benzoimidazol-2-yl)-4-methylene-pyrrolidin-1-yl]-[5-(3,4-dimethyl-phenyl)-2-           methyl-thiazol-4-yl]-methanone. LC-MS: t R  = 0.87; [M + H] +  = 457.2       6.59   [(S)-4-Methylene-2-(7-methylsulfanyl-1H-benzoimidazol-2-yl)-pyrrolidin-1-yl]-(5-methyl-2-           [1,2,3]triazol-2-yl-phenyl)-methanone. LC-MS: t R  = 0.74; [M + H] +  = 431.2       6.60   [(S)-4-Methylene-2-(5-methylsulfanyl-1H-benzoimidazol-2-yl)-pyrrolidin-1-yl]-(5-methyl-2-           [1,2,3]triazol-2-yl-phenyl)-methanone. LC-MS: t R  = 0.73; [M + H] +  = 431.2       6.61   [(S)-2-(5,6-Dimethyl-1H-benzoimidazol-2-yl)-4-methylene-pyrrolidin-1-yl]-(5-methyl-2-[1,2,3]triazol-2-           yl-phenyl)-methanone. LC-MS: t R  = 0.73; [M + H] +  = 413.2       6.62   [(S)-2-(4,6-Dimethyl-1H-benzoimidazol-2-yl)-4-methylene-pyrrolidin-1-yl]-(5-methyl-2-[1,2,3]triazol-2-           yl-phenyl)-methanone. LC-MS: t R  = 0.72; [M + H] +  = 413.2       6.63   [(S)-2-(4,5-Dimethyl-1H-benzoimidazol-2-yl)-4-methylene-pyrrolidin-1-yl]-(5-methyl-2-[1,2,3]triazol-2-           yl-phenyl)-methanone. LC-MS: t R  = 0.72; [M + H] +  = 413.2       6.64   [(S)-2-(4-Bromo-1H-benzoimidazol-2-yl)-4-methylene-pyrrolidin-1-yl]-(5-methyl-2-[1,2,3]triazol-2-yl-           phenyl)-methanone. LC-MS: t R  = 0.84; [M + H] +  = 463.1       6.65   [(S)-2-(5-Chloro-6-methyl-1H-benzoimidazol-2-yl)-4-methylene-pyrrolidin-1-yl]-(5-methyl-2-           [1,2,3]triazol-2-yl-phenyl)-methanone. LC-MS: t R  = 0.80; [M + H] +  = 433.2       6.66   [(S)-2-(5-tert-Butyl-1H-benzoimidazol-2-yl)-4-methylene-pyrrolidin-1-yl]-(5-methyl-2-[1,2,3]triazol-2-yl-           phenyl)-methanone. LC-MS: t R  = 0.82; [M + H] +  = 441.3       6.67   [(S)-2-(5-Chloro-6-trifluoromethyl-1H-benzoimidazol-2-yl)-4-methylene-pyrrolidin-1-yl]-(5-methyl-2-           [1,2,3]triazol-2-yl-phenyl)-methanone. LC-MS: t R  = 1.05; [M + H] +  = 487.2       6.68   [(S)-2-(4,7-Dimethoxy-1H-benzoimidazol-2-yl)-4-methylene-pyrrolidin-1-yl]-(5-methyl-2-[1,2,3]triazol-           2-yl-phenyl)-methanone. LC-MS: t R  = 0.73; [M + H] +  = 445.2       6.69   [(S)-2-(7-Chloro-1H-benzoimidazol-2-yl)-4-methylene-pyrrolidin-1-yl]-(5-methyl-2-[1,2,3]triazol-2-yl-           phenyl)-methanone. LC-MS: t R  = 0.82; [M + H] +  = 419.1       6.71   rac-[2-(3,4-Dimethyl-phenyl)-5-methyl-thiophen-3-yl]-[2-(5-methoxy-1H-benzoimidazol-2-yl)-4-           methylene-pyrrolidin-1-yl]-methanone. LC-MS: t R  = 0.86; [M + H] +  = 458.2       6.72   rac-[2-(3,4-Dimethyl-phenyl)-5-methyl-thiophen-3-yl]-[4-methylene-2-(7-methylsulfanyl-1H-           benzoimidazol-2-yl)-pyrrolidin-1-yl]-methanone. LC-MS: t R  = 0.94; [M + H] +  = 474.2       6.73   rac-[2-(3,4-Dimethyl-phenyl)-5-methyl-thiophen-3-yl]-[4-methylene-2-(5-methylsulfanyl-1H-           benzoimidazol-2-yl)-pyrrolidin-1-yl]-methanone. LC-MS: t R  = 0.92; [M + H] +  = 474.2       6.74   rac-[2-(5-Chloro-4-methyl-1H-benzoimidazol-2-yl)-4-methylene-pyrrolidin-1-yl]-[2-(3,4-dimethyl-           phenyl)-5-methyl-thiophen-3-yl]-methanone. LC-MS: t R  = 0.99; [M + H] +  = 476.2       6.75   rac-[2-(5,6-Dimethyl-1H-benzoimidazol-2-yl)-4-methylene-pyrrolidin-1-yl]-[2-(3,4-dimethyl-phenyl)-5-           methyl-thiophen-3-yl]-methanone. LC-MS: t R  = 0.76; [M + H] +  = 456.1       6.76   rac-[2-(4,6-Dimethyl-1H-benzoimidazol-2-yl)-4-methylene-pyrrolidin-1-yl]-[2-(3,4-dimethyl-phenyl)-5-           methyl-thiophen-3-yl]-methanone. LC-MS: t R  = 0.91; [M + H] +  = 456.3       6.77   rac-[2-(4,5-Dimethyl-1H-benzoimidazol-2-yl)-4-methylene-pyrrolidin-1-yl]-[2-(3,4-dimethyl-phenyl)-5-           methyl-thiophen-3-yl]-methanone. LC-MS: t R  = 0.90; [M + H] +  = 456.2       6.78   rac-[2-(4-Bromo-1H-benzoimidazol-2-yl)-4-methylene-pyrrolidin-1-yl]-[2-(3,4-dimethyl-phenyl)-5-           methyl-thiophen-3-yl]-methanone. LC-MS: t R  = 1.06; [M + H] +  = 506.2       6.79   rac-[2-(3,4-Dimethyl-phenyl)-5-methyl-thiophen-3-yl]-[2-(4-methyl-1H-benzoimidazol-2-yl)-4-           methylene-pyrrolidin-1-yl]-methanone. LC-MS: t R  = 0.88; [M + H] +  = 442.2       6.80   rac-[2-(5-Chloro-6-methyl-1H-benzoimidazol-2-yl)-4-methylene-pyrrolidin-1-yl]-[2-(3,4-dimethyl-           phenyl)-5-methyl-thiophen-3-yl]-methanone. LC-MS: t R  = 1.00; [M + H] +  = 476.2       6.81   rac-[2-(5-tert-Butyl-1H-benzoimidazol-2-yl)-4-methylene-pyrrolidin-1-yl]-[2-(3,4-dimethyl-phenyl)-5-           methyl-thiophen-3-yl]-methanone. LC-MS: t R  = 0.99; [M + H] +  = 484.3       6.82   rac-[2-(5-Chloro-6-trifluoromethyl-1H-benzoimidazol-2-yl)-4-methylene-pyrrolidin-1-yl]-[2-(3,4-           dimethyl-phenyl)-5-methyl-thiophen-3-yl]-methanone. LC-MS: t R  = 1.24; [M + H] +  = 530.2       6.83   rac-[2-(4,7-Dimethoxy-1H-benzoimidazol-2-yl)-4-methylene-pyrrolidin-1-yl]-[2-(3,4-dimethyl-phenyl)-           5-methyl-thiophen-3-yl]-methanone. LC-MS: t R  = 0.90; [M + H] +  = 488.3       6.84   rac-[2-(7-Chloro-1H-benzoimidazol-2-yl)-4-methylene-pyrrolidin-1-yl]-[2-(3,4-dimethyl-phenyl)-5-           methyl-thiophen-3-yl]-methanone. LC-MS: t R  = 1.04; [M + H] +  = 462.2       6.85   rac-[2-(3,4-Dimethyl-phenyl)-5-methyl-thiophen-3-yl]-[4-methylene-2-(1H-naphtho[2,3-d]imidazol-2-           yl)-pyrrolidin-1-yl]-methanone. LC-MS: t R  = 0.94; [M + H] +  = 478.3       6.86   rac-(2-Cyclopropyl-5-m-tolyl-thiazol-4-yl)-[2-(5-methoxy-1H-benzoimidazol-2-yl)-4-methylene-           pyrrolidin-1-yl]-methanone. LC-MS: t R  = 0.85; [M + H] +  = 471.3       6.87   rac-(2-Cyclopropyl-5-m-tolyl-thiazol-4-yl)-[4-methylene-2-(7-methylsulfanyl-1H-benzoimidazol-2-yl)-           pyrrolidin-1-yl]-methanone. LC-MS: t R  = 0.92; [M + H] +  = 487.2       6.88   rac-(2-Cyclopropyl-5-m-tolyl-thiazol-4-yl)-[4-methylene-2-(5-methylsulfanyl-1H-benzoimidazol-2-yl)-           pyrrolidin-1-yl]-methanone. LC-MS: t R  = 0.90; [M + H] +  = 487.2       6.89   rac-[2-(5-Chloro-4-methyl-1H-benzoimidazol-2-yl)-4-methylene-pyrrolidin-1-yl]-(2-cyclopropyl-5-m-           tolyl-thiazol-4-yl)-methanone. LC-MS: t R  = 0.97; [M + H] +  = 489.2       6.90   rac-(2-Cyclopropyl-5-m-tolyl-thiazol-4-yl)-[2-(5,6-dimethyl-1H-benzoimidazol-2-yl)-4-methylene-           pyrrolidin-1-yl]-methanone. LC-MS: t R  = 0.90; [M + H] +  = 469.3       6.91   rac-(2-Cyclopropyl-5-m-tolyl-thiazol-4-yl)-[2-(4,6-dimethyl-1H-benzoimidazol-2-yl)-4-methylene-           pyrrolidin-1-yl]-methanone. LC-MS: t R  = 0.91; [M + H] +  = 469.3       6.92   rac-(2-Cyclopropyl-5-m-tolyl-thiazol-4-yl)-[2-(4,5-dimethyl-1H-benzoimidazol-2-yl)-4-methylene-           pyrrolidin-1-yl]-methanone. LC-MS: t R  = 0.90; [M + H] +  = 469.3       6.93   rac-[2-(4-Bromo-1H-benzoimidazol-2-yl)-4-methylene-pyrrolidin-1-yl]-(2-cyclopropyl-5-m-tolyl-thiazol-           4-yl)-methanone. LC-MS: t R  = 1.01; [M + H] +  = 519.1       6.94   rac-(2-Cyclopropyl-5-m-tolyl-thiazol-4-yl)-[2-(4-methyl-1H-benzoimidazol-2-yl)-4-methylene-pyrrolidin-           1-yl]-methanone. LC-MS: t R  = 0.87; [M + H] +  = 455.3       6.95   rac-[2-(5-Chloro-6-methyl-1H-benzoimidazol-2-yl)-4-methylene-pyrrolidin-1-yl]-(2-cyclopropyl-5-m-           tolyl-thiazol-4-yl)-methanone. LC-MS: t R  = 0.96; [M + H] +  = 489.2       6.96   rac-[2-(5-tert-Butyl-1H-benzoimidazol-2-yl)-4-methylene-pyrrolidin-1-yl]-(2-cyclopropyl-5-m-tolyl-           thiazol-4-yl)-methanone. LC-MS: t R  = 0.98; [M + H] +  = 497.3       6.97   rac-[2-(5-Chloro-6-trifluoromethyl-1H-benzoimidazol-2-yl)-4-methylene-pyrrolidin-1-yl]-(2-cyclopropyl-           5-m-tolyl-thiazol-4-yl)-methanone. LC-MS: t R  = 1.19; [M + H] +  = 543.1       6.98   rac-(2-Cyclopropyl-5-m-tolyl-thiazol-4-yl)-[2-(4,7-dimethoxy-1H-benzoimidazol-2-yl)-4-methylene-           pyrrolidin-1-yl]-methanone. LC-MS: t R  = 0.89; [M + H] +  = 501.3       6.99   rac-[2-(7-Chloro-1H-benzoimidazol-2-yl)-4-methylene-pyrrolidin-1-yl]-(2-cyclopropyl-5-m-tolyl-thiazol-           4-yl)-methanone. LC-MS: t R  = 1.00; [M + H] +  = 475.2       6.100   [5-(4-Bromo-phenyl)-2-methyl-thiazol-4-yl]-[(S)-2-(7-methyl-1H-benzoimidazol-2-yl)-4-methylene-           pyrrolidin-1-yl]-methanone. LC-MS: t R  = 0.83; [M + H] +  = 493.2       6.101   [(S)-2-(7-Methyl-1H-benzoimidazol-2-yl)-4-methylene-pyrrolidin-1-yl]-(2-methyl-5-m-tolyl-thiazol-4-yl)-           methanone. LC-MS: t R  = 0.80; [M + H] +  = 429.2       6.102   (5-Chloro-2-[1,2,3]triazol-2-yl-phenyl)-[(S)-2-(7-methyl-1H-benzoimidazol-2-yl)-4-methylene-           pyrrolidin-1-yl]-methanone. LC-MS: t R  = 0.71; [M + H] +  = 419.2       6.103   [5-(6-Methoxy-pyridin-3-yl)-2-methyl-thiazol-4-yl]-[(S)-2-(7-methyl-1H-benzoimidazol-2-yl)-4-           methylene-pyrrolidin-1-yl]-methanone. LC-MS: t R  = 0.71; [M + H] +  = 446.2       6.104   [5-(3-Bromo-phenyl)-2-methyl-thiazol-4-yl]-[(S)-2-(7-methyl-1H-benzoimidazol-2-yl)-4-methylene-           pyrrolidin-1-yl]-methanone. LC-MS: t R  = 0.83; [M + H] +  = 493.1       6.105   [(S)-2-(7-Methyl-1H-benzoimidazol-2-yl)-4-methylene-pyrrolidin-1-yl]-(6-methyl-3-pyrazol-1-yl-pyridin-           2-yl)-methanone. LC-MS: t R  = 0.65; [M + H] +  = 399.2       6.106   [5-(4-Fluoro-phenyl)-2-methyl-thiazol-4-yl]-[(S)-2-(7-methyl-1H-benzoimidazol-2-yl)-4-methylene-           pyrrolidin-1-yl]-methanone. LC-MS: t R  = 0.76; [M + H] +  = 433.2       6.107   [5-(3,5-Dimethyl-phenyl)-2-methyl-thiazol-4-yl]-[(S)-2-(7-methyl-1H-benzoimidazol-2-yl)-4-methylene-           pyrrolidin-1-yl]-methanone. LC-MS: t R  = 0.85; [M + H] +  = 443.2       6.108   (4,5-Dimethyl-2-[1,2,3]triazol-2-yl-phenyl)-[(S)-2-(7-methyl-1H-benzoimidazol-2-yl)-4-methylene-           pyrrolidin-1-yl]-methanone. LC-MS: t R  = 0.72; [M + H] +  = 413.2       6.109   [5-(4-Chloro-phenyl)-2-methyl-thiazol-4-yl]-[(S)-2-(7-methyl-1H-benzoimidazol-2-yl)-4-methylene-           pyrrolidin-1-yl]-methanone. LC-MS: t R  = 0.81; [M + H] +  = 449.1       6.110   [5-(3-Bromo-4-fluoro-phenyl)-2-methyl-thiazol-4-yl]-[(S)-2-(7-methyl-1H-benzoimidazol-2-yl)-4-           methylene-pyrrolidin-1-yl]-methanone. LC-MS: t R  = 0.84; [M + H] +  = 511.1       6.111   (5-Methoxy-2-[1,2,3]triazol-2-yl-phenyl)-[(S)-2-(7-methyl-1H-benzoimidazol-2-yl)-4-methylene-           pyrrolidin-1-yl]-methanone. LC-MS: t R  = 0.65; [M + H] +  = 415.2       6.112   [(S)-2-(7-Methyl-1H-benzoimidazol-2-yl)-4-methylene-pyrrolidin-1-yl]-[2-methyl-5-(3-trifluoromethyl-           phenyl)-thiazol-4-yl]-methanone. LC-MS: t R  = 0.85; [M + H] +  = 483.2       6.113   [5-(3,4-Dichloro-phenyl)-2-methyl-thiazol-4-yl]-[(S)-2-(7-methyl-1H-benzoimidazol-2-yl)-4-methylene-           pyrrolidin-1-yl]-methanone. LC-MS: t R  = 0.87; [M + H] +  = 483.1       6.114   [5-(3-Methoxy-phenyl)-2-methyl-thiazol-4-yl]-[(S)-2-(7-methyl-1H-benzoimidazol-2-yl)-4-methylene-           pyrrolidin-1-yl]-methanone. LC-MS: t R  = 0.75; [M + H] +  = 445.2       6.115   [(S)-2-(7-Methyl-1H-benzoimidazol-2-yl)-4-methylene-pyrrolidin-1-yl]-(6-methyl-3-[1,2,3]triazol-2-yl-           pyridin-2-yl)-methanone. LC-MS: t R  = 0.65; [M + H] +  = 400.2       6.116   [5-(4-Bromo-phenyl)-2-methyl-thiazol-4-yl]-[(S)-2-(6-chloro-7-methyl-1H-benzoimidazol-2-yl)-4-           methylene-pyrrolidin-1-yl]-methanone. LC-MS: t R  = 0.95; [M + H] +  = 527.2       6.117   [(S)-2-(6-Chloro-7-methyl-1H-benzoimidazol-2-yl)-4-methylene-pyrrolidin-1-yl]-[5-(6-methoxy-pyridin-           3-yl)-2-methyl-thiazol-4-yl]-methanone. LC-MS: t R  = 0.82; [M + H] +  = 480.2       6.118   [(S)-2-(6-Chloro-7-methyl-1H-benzoimidazol-2-yl)-4-methylene-pyrrolidin-1-yl]-[5-(4-fluoro-phenyl)-2-           methyl-thiazol-4-yl]-methanone. LC-MS: t R  = 0.88; [M + H] +  = 467.2       6.119   [(S)-2-(6-Chloro-7-methyl-1H-benzoimidazol-2-yl)-4-methylene-pyrrolidin-1-yl]-[5-(4-chloro-phenyl)-2-           methyl-thiazol-4-yl]-methanone. LC-MS: t R  = 0.93; [M + H] +  = 483.1       6.120   [(S)-2-(6-Chloro-7-methyl-1H-benzoimidazol-2-yl)-4-methylene-pyrrolidin-1-yl]-[2-methyl-5-(3-           trifluoromethyl-phenyl)-thiazol-4-yl]-methanone. LC-MS: t R  = 0.96; [M + H] +  = 517.2       6.121   [(S)-2-(6-Chloro-7-methyl-1H-benzoimidazol-2-yl)-4-methylene-pyrrolidin-1-yl]-[5-(3-methoxy-phenyl)-           2-methyl-thiazol-4-yl]-methanone. LC-MS: t R  = 0.86; [M + H] +  = 479.2       6.122   [(S)-2-(6-Chloro-7-methyl-1H-benzoimidazol-2-yl)-4-methylene-pyrrolidin-1-yl]-(2-methyl-5-m-tolyl-           thiazol-4-yl)-methanone. LC-MS: t R  = 0.90; [M + H] +  = 463.2       6.123   [5-(3-Bromo-phenyl)-2-methyl-thiazol-4-yl]-[(S)-2-(6-chloro-7-methyl-1H-benzoimidazol-2-yl)-4-           methylene-pyrrolidin-1-yl]-methanone. LC-MS: t R  = 0.94; [M + H] +  = 527.1       6.124   [(S)-2-(6-Chloro-7-methyl-1H-benzoimidazol-2-yl)-4-methylene-pyrrolidin-1-yl]-[5-(3,5-dimethyl-           phenyl)-2-methyl-thiazol-4-yl]-methanone. LC-MS: t R  = 0.95; [M + H] +  = 477.2       6.125   [5-(3-Bromo-4-fluoro-phenyl)-2-methyl-thiazol-4-yl]-[(S)-2-(6-chloro-7-methyl-1H-benzoimidazol-2-yl)-           4-methylene-pyrrolidin-1-yl]-methanone. LC-MS: t R  = 0.95; [M + H] +  = 545.1       6.126   [(S)-2-(6-Chloro-7-methyl-1H-benzoimidazol-2-yl)-4-methylene-pyrrolidin-1-yl]-[5-(3,4-dichloro-           phenyl)-2-methyl-thiazol-4-yl]-methanone. LC-MS: t R  = 0.99; [M + H] +  = 517       6.127   [(S)-2-(6-Chloro-7-methyl-1H-benzoimidazol-2-yl)-4-methylene-pyrrolidin-1-yl]-(6-methyl-3-           [1,2,3]triazol-2-yl-pyridin-2-yl)-methanone. LC-MS: t R  = 0.74; [M + H] +  = 434.2       6.128   [(S)-2-(6-Chloro-7-methyl-1H-benzoimidazol-2-yl)-4-methylene-pyrrolidin-1-yl]-(5-chloro-2-           [1,2,3]triazol-2-yl-phenyl)-methanone. LC-MS: t R  = 0.84; [M + H] +  = 453.1       6.129   [(S)-2-(6-Chloro-7-methyl-1H-benzoimidazol-2-yl)-4-methylene-pyrrolidin-1-yl]-(2-[1,2,3]triazol-2-yl-5-           trifluoromethyl-phenyl)-methanone. LC-MS: t R  = 0.89; [M + H] +  = 487.2       6.130   [(S)-2-(6-Chloro-7-methyl-1H-benzoimidazol-2-yl)-4-methylene-pyrrolidin-1-yl]-(4,5-dimethyl-2-           [1,2,3]triazol-2-yl-phenyl)-methanone. LC-MS: t R  = 0.84; [M + H] +  = 447.2       6.131   [(S)-2-(6-Chloro-7-methyl-1H-benzoimidazol-2-yl)-4-methylene-pyrrolidin-1-yl]-(5-methoxy-2-           [1,2,3]triazol-2-yl-phenyl)-methanone. LC-MS: t R  = 0.78; [M + H] +  = 449.2       6.132   [(S)-2-(6-Chloro-7-methyl-1H-benzoimidazol-2-yl)-4-methylene-pyrrolidin-1-yl]-(2-fluoro-3-methyl-6-           [1,2,3]triazol-2-yl-phenyl)-methanone. LC-MS: t R  = 0.83; [M + H] +  = 451.2       6.133   [(S)-2-(6-Chloro-7-methyl-1H-benzoimidazol-2-yl)-4-methylene-pyrrolidin-1-yl]-(2-fluoro-3-methoxy-6-           [1,2,3]triazol-2-yl-phenyl)-methanone. LC-MS: t R  = 0.80; [M + H] +  = 467.2       6.134   [(S)-2-(6-Chloro-7-methyl-1H-benzoimidazol-2-yl)-4-methylene-pyrrolidin-1-yl]-(5-methyl-2-pyrazol-1-           yl-phenyl)-methanone. LC-MS: t R  = 0.81; [M + H] +  = 432.2       6.135   [(S)-2-(6-Chloro-7-methyl-1H-benzoimidazol-2-yl)-4-methylene-pyrrolidin-1-yl]-(6-methyl-3-pyrazol-1-           yl-pyridin-2-yl)-methanone. LC-MS: t R  = 0.75; [M + H] +  = 433.2       6.136   (5-Chloro-2-[1,2,3]triazol-2-yl-phenyl)-[(S)-2-(6-methoxy-1H-benzoimidazol-2-yl)-4-methylene-           pyrrolidin-1-yl]-methanone. LC-MS: t R  = 0.70; [M + H] +  = 435.1       6.137   [(S)-2-(6-Methoxy-1H-benzoimidazol-2-yl)-4-methylene-pyrrolidin-1-yl]-(5-methyl-2-pyrazol-1-yl-           phenyl)-methanone. LC-MS: t R  = 0.67; [M + H] +  = 414.2       6.138   [(S)-2-(6-Methoxy-1H-benzoimidazol-2-yl)-4-methylene-pyrrolidin-1-yl]-(6-methyl-3-pyrazol-1-yl-           pyridin-2-yl)-methanone. LC-MS: t R  = 0.63; [M + H] +  = 415.2       6.139   (4,5-Dimethyl-2-[1,2,3]triazol-2-yl-phenyl)-[(S)-2-(6-methoxy-1H-benzoimidazol-2-yl)-4-methylene-           pyrrolidin-1-yl]-methanone. LC-MS: t R  = 0.72; [M + H] +  = 429.2       6.140   [(S)-2-(6-Methoxy-1H-benzoimidazol-2-yl)-4-methylene-pyrrolidin-1-yl]-(5-methoxy-2-[1,2,3]triazol-2-           yl-phenyl)-methanone. LC-MS: t R  = 0.65; [M + H] +  = 431.2       6.141   (2-Fluoro-3-methyl-6-[1,2,3]triazol-2-yl-phenyl)-[(S)-2-(6-methoxy-1H-benzoimidazol-2-yl)-4-           methylene-pyrrolidin-1-yl]-methanone. LC-MS: t R  = 0.69; [M + H] +  = 433.2       6.142   [(S)-2-(6-Chloro-5-trifluoromethyl-1H-benzoimidazol-2-yl)-4-methylene-pyrrolidin-1-yl]-[5-(3,4-           dimethyl-phenyl)-2-methyl-thiazol-4-yl]-methanone. LC-MS: t R  = 1.15; [M + H] +  = 531.2       6.143   rac-[2-(5-Methoxy-1H-benzoimidazol-2-yl)-2-methyl-4-methylene-pyrrolidin-1-yl]-(2-methyl-5-m-tolyl-           thiazol-4-yl)-methanone. LC-MS: t R  = 0.85; [M + H] +  = 459.3       6.144   rac-[2-Dimethylamino-5-(3,4-dimethyl-phenyl)-thiazol-4-yl]-[2-(5-methoxy-1H-benzoimidazol-2-yl)-2-           methyl-4-methylene-pyrrolidin-1-yl]-methanone. LC-MS: t R  = 0.96; [M + H] +  = 502.3       6.145   rac-[5-(3,4-Dimethyl-phenyl)-2-methyl-thiazol-4-yl]-[2-(5-methoxy-1H-benzoimidazol-2-yl)-2-methyl-4-           methylene-pyrrolidin-1-yl]-methanone. LC-MS: t R  = 0.90; [M + H] +  = 473.3       6.146   rac-[5-(4-Chloro-phenyl)-2-methyl-thiazol-4-yl]-[2-(5-methoxy-1H-benzoimidazol-2-yl)-2-methyl-4-           methylene-pyrrolidin-1-yl]-methanone. LC-MS: t R  = 0.86; [M + H] +  = 479.2       6.147   rac-[2-(5-Methoxy-1H-benzoimidazol-2-yl)-2-methyl-4-methylene-pyrrolidin-1-yl]-[5-(4-methoxy-           phenyl)-2-methyl-thiazol-4-yl]-methanone. LC-MS: t R  = 0.80; [M + H] +  = 475.3       6.148   rac-[2-(5-Methoxy-1H-benzoimidazol-2-yl)-2-methyl-4-methylene-pyrrolidin-1-yl]-(2-methyl-5-p-tolyl-           thiazol-4-yl)-methanone. LC-MS: t R  = 0.85; [M + H] +  = 459.3       6.149   rac-(3′,4′-Dimethyl-biphenyl-2-yl)-[2-(5-methoxy-1H-benzoimidazol-2-yl)-2-methyl-4-methylene-           pyrrolidin-1-yl]-methanone. LC-MS: t R  = 0.90; [M + H] +  = 452.3       6.150   rac-Biphenyl-2-yl-[2-(5-methoxy-1H-benzoimidazol-2-yl)-2-methyl-4-methylene-pyrrolidin-1-yl]-           methanone. LC-MS: t R  = 0.80; [M + H] +  = 424.3       6.151   rac-(4′-Fluoro-3′-methyl-biphenyl-2-yl)-[2-(5-methoxy-1H-benzoimidazol-2-yl)-2-methyl-4-methylene-           pyrrolidin-1-yl]-methanone. LC-MS: t R  = 0.87; [M + H] +  = 456.3       6.152   rac-[5-(3-Chloro-phenyl)-2-dimethylamino-thiazol-4-yl]-[2-(5-methoxy-1H-benzoimidazol-2-yl)-2-           methyl-4-methylene-pyrrolidin-1-yl]-methanone. LC-MS: t R  = 0.92; [M + H] +  = 508.2       6.153   rac-[5-(3-Chloro-phenyl)-2-methyl-thiazol-4-yl]-[2-(5-methoxy-1H-benzoimidazol-2-yl)-2-methyl-4-           methylene-pyrrolidin-1-yl]-methanone. LC-MS: t R  = 0.86; [M + H] +  = 479.2       6.154   rac-[2-(5-Methoxy-1H-benzoimidazol-2-yl)-2-methyl-4-methylene-pyrrolidin-1-yl]-(2-methyl-5-phenyl-           thiazol-4-yl)-methanone. LC-MS: t R  = 0.79; [M + H] +  = 445.3       6.155   rac-[2-(5-Methoxy-1H-benzoimidazol-2-yl)-2-methyl-4-methylene-pyrrolidin-1-yl]-(2-[1,2,3]triazol-2-yl-           phenyl)-methanone. LC-MS: t R  = 0.66; [M + H] +  = 415.3       6.156   rac-[2-(5-Methoxy-1H-benzoimidazol-2-yl)-2-methyl-4-methylene-pyrrolidin-1-yl]-(5-methyl-2-           [1,2,3]triazol-2-yl-phenyl)-methanone. LC-MS: t R  = 0.72; [M + H] +  = 429.3       6.157   rac-(5-Chloro-2-[1,2,3]triazol-2-yl-phenyl)-[2-(5-methoxy-1H-benzoimidazol-2-yl)-2-methyl-4-           methylene-pyrrolidin-1-yl]-methanone. LC-MS: t R  = 0.75; [M + H] +  = 449.2       6.158   rac-[2-(5-Methoxy-1H-benzoimidazol-2-yl)-2-methyl-4-methylene-pyrrolidin-1-yl]-(5-methoxy-2-           [1,2,3]triazol-2-yl-phenyl)-methanone. LC-MS: t R  = 0.70; [M + H] +  = 445.3       6.159   rac-(4,5-Dimethyl-2-[1,2,3]triazol-2-yl-phenyl)-[2-(5-methoxy-1H-benzoimidazol-2-yl)-2-methyl-4-           methylene-pyrrolidin-1-yl]-methanone. LC-MS: t R  = 0.78; [M + H] +  = 443.3       6.160   [(S)-2-(5-tert-Butyl-1H-benzoimidazol-2-yl)-4-methylene-pyrrolidin-1-yl]-(5-fluoro-2-[1,2,3]triazol-2-yl-           phenyl)-methanone. LC-MS: t R  = 0.81; [M + H] +  = 445.3       6.161   [(S)-2-(5-tert-Butyl-1H-benzoimidazol-2-yl)-4-methylene-pyrrolidin-1-yl]-(5-chloro-2-[1,2,3]triazol-2-yl-           phenyl)-methanone. LC-MS: t R  = 0.86; [M + H] +  = 461.3       6.162   [(S)-2-(5-tert-Butyl-1H-benzoimidazol-2-yl)-4-methylene-pyrrolidin-1-yl]-(2-[1,2,3]triazol-2-yl-phenyl)-           methanone. LC-MS: t R  = 0.79; [M + H] +  = 427.3       6.163   [(S)-2-(5-tert-Butyl-1H-benzoimidazol-2-yl)-4-methylene-pyrrolidin-1-yl]-(2-fluoro-3-methoxy-6-           [1,2,3]triazol-2-yl-phenyl)-methanone. LC-MS: t R  = 0.81; [M + H] +  = 475.3       6.164   [(S)-2-(5-tert-Butyl-1H-benzoimidazol-2-yl)-4-methylene-pyrrolidin-1-yl]-(2-fluoro-3-methyl-6-           [1,2,3]triazol-2-yl-phenyl)-methanone. LC-MS: t R  = 0.84; [M + H] +  = 459.3       6.165   [(S)-2-(5-tert-Butyl-1H-benzoimidazol-2-yl)-4-methylene-pyrrolidin-1-yl]-(4,5-dimethyl-2-[1,2,3]triazol-           2-yl-phenyl)-methanone. LC-MS: t R  = 0.87; [M + H] +  = 455.3       6.166   [(S)-2-(5-tert-Butyl-1H-benzoimidazol-2-yl)-4-methylene-pyrrolidin-1-yl]-(4-methyl-2-[1,2,3]triazol-2-yl-           phenyl)-methanone. LC-MS: t R  = 0.84; [M + H] +  = 441.4       6.167   [(S)-2-(5-tert-Butyl-1H-benzoimidazol-2-yl)-4-methylene-pyrrolidin-1-yl]-(2-methyl-6-[1,2,3]triazol-2-yl-           phenyl)-methanone. LC-MS: t R  = 0.83; [M + H] +  = 441.3       6.168   [(S)-2-(5-tert-Butyl-1H-benzoimidazol-2-yl)-4-methylene-pyrrolidin-1-yl]-(2-[1,2,3]triazol-2-yl-5-           trifluoromethyl-phenyl)-methanone. LC-MS: t R  = 0.91; [M + H] +  = 495.3       6.169   [(S)-2-(5-tert-Butyl-1H-benzoimidazol-2-yl)-4-methylene-pyrrolidin-1-yl]-(2-[1,2,3]triazol-2-yl-5-           trifluoromethoxy-phenyl)-methanone. LC-MS: t R  = 0.93; [M + H] +  = 511.3       6.170   [(S)-2-(5-tert-Butyl-1H-benzoimidazol-2-yl)-4-methylene-pyrrolidin-1-yl]-(4,5-dimethoxy-2-           [1,2,3]triazol-2-yl-phenyl)-methanone. LC-MS: t R  = 0.78; [M + H] +  = 487.3       6.171   [(S)-2-(5-tert-Butyl-1H-benzoimidazol-2-yl)-4-methylene-pyrrolidin-1-yl]-(5-methyl-2-pyrazol-1-yl-           phenyl)-methanone. LC-MS: t R  = 0.84; [M + H] +  = 440.3       6.172   [(S)-2-(5-tert-Butyl-1H-benzoimidazol-2-yl)-4-methylene-pyrrolidin-1-yl]-(2-pyrazol-1-yl-phenyl)-           methanone. LC-MS: t R  = 0.8; [M + H] +  = 426.3       6.173   [(S)-2-(5-tert-Butyl-1H-benzoimidazol-2-yl)-4-methylene-pyrrolidin-1-yl]-(6-methyl-3-pyrazol-1-yl-           pyridin-2-yl)-methanone. LC-MS: t R  = 0.80; [M + H] +  = 441.3       6.174   [(S)-2-(5-tert-Butyl-1H-benzoimidazol-2-yl)-4-methylene-pyrrolidin-1-yl]-(6-methyl-3-[1,2,3]triazol-2-yl-           pyridin-2-yl)-methanone. LC-MS: t R  = 0.80; [M + H] +  = 442.3       6.175   [(S)-2-(5-Chloro-6-trifluoromethyl-1H-benzoimidazol-2-yl)-4-methylene-pyrrolidin-1-yl]-(2-fluoro-6-           [1,2,3]triazol-2-yl-phenyl)-methanone. LC-MS: t R  = 1.05; [M + H] +  = 491.2       6.176   [(S)-2-(5-Chloro-6-trifluoromethyl-1H-benzoimidazol-2-yl)-4-methylene-pyrrolidin-1-yl]-(5-fluoro-2-           [1,2,3]triazol-2-yl-phenyl)-methanone. LC-MS: t R  = 1.04; [M + H] +  = 491.2       6.177   (5-Chloro-2-[1,2,3]triazol-2-yl-phenyl)-[(S)-2-(5-chloro-6-trifluoromethyl-1H-benzoimidazol-2-yl)-4-           methylene-pyrrolidin-1-yl]-methanone. LC-MS: t R  = 1.09.; [M + H] +  = 507.2       6.178   [(S)-2-(5-Chloro-6-trifluoromethyl-1H-benzoimidazol-2-yl)-4-methylene-pyrrolidin-1-yl]-(2-           [1,2,3]triazol-2-yl-phenyl)-methanone. LC-MS: t R  = 1.01; [M + H] +  = 473.2       6.179   [(S)-2-(5-Chloro-6-trifluoromethyl-1H-benzoimidazol-2-yl)-4-methylene-pyrrolidin-1-yl]-(2-fluoro-3-           methoxy-6-[1,2,3]triazol-2-yl-phenyl)-methanone. LC-MS: t R  = 1.06; [M + H] +  = 521.2       6.180   [(S)-2-(5-Chloro-6-trifluoromethyl-1H-benzoimidazol-2-yl)-4-methylene-pyrrolidin-1-yl]-(2-fluoro-3-           methyl-6-[1,2,3]triazol-2-yl-phenyl)-methanone. LC-MS: t R  = 1.11; [M + H] +  = 505.2       6.181   [(S)-2-(5-Chloro-6-trifluoromethyl-1H-benzoimidazol-2-yl)-4-methylene-pyrrolidin-1-yl]-(4,5-dimethyl-           2-[1,2,3]triazol-2-yl-phenyl)-methanone. LC-MS: t R  = 1.1; [M + H] +  = 501.2       6.182   [(S)-2-(5-Chloro-6-trifluoromethyl-1H-benzoimidazol-2-yl)-4-methylene-pyrrolidin-1-yl]-(4-methyl-2-           [1,2,3]triazol-2-yl-phenyl)-methanone. LC-MS: t R  = 1.07; [M + H] +  = 487.2       6.183   [(S)-2-(5-Chloro-6-trifluoromethyl-1H-benzoimidazol-2-yl)-4-methylene-pyrrolidin-1-yl]-(2-methyl-6-           [1,2,3]triazol-2-yl-phenyl)-methanone. LC-MS: t R  = 1.09; [M + H] +  = 487.3       6.184   [(S)-2-(5-Chloro-6-trifluoromethyl-1H-benzoimidazol-2-yl)-4-methylene-pyrrolidin-1-yl]-(2-           [1,2,3]triazol-2-yl-5-trifluoromethyl-phenyl)-methanone. LC-MS: t R  = 1.12; [M + H] +  = 541.1       6.185   [(S)-2-(5-Chloro-6-trifluoromethyl-1H-benzoimidazol-2-yl)-4-methylene-pyrrolidin-1-yl]-(2-           [1,2,3]triazol-2-yl-5-trifluoromethoxy-phenyl)-methanone. LC-MS: t R  = 1.14; [M + H] +  = 557.2       6.186   [(S)-2-(5-Chloro-6-trifluoromethyl-1H-benzoimidazol-2-yl)-4-methylene-pyrrolidin-1-yl]-(4,5-           dimethoxy-2-[1,2,3]triazol-2-yl-phenyl)-methanone. LC-MS: t R  = 0.99; [M + H] +  = 533.2       6.187   [(S)-2-(5-Chloro-6-trifluoromethyl-1H-benzoimidazol-2-yl)-4-methylene-pyrrolidin-1-yl]-(5-methyl-2-           pyrazol-1-yl-phenyl)-methanone. LC-MS: t R  = 1.06; [M + H] +  = 486.2       6.188   [(S)-2-(5-Chloro-6-trifluoromethyl-1H-benzoimidazol-2-yl)-4-methylene-pyrrolidin-1-yl]-(2-pyrazol-1-yl-           phenyl)-methanone. LC-MS: t R  = 1.02; [M + H] +  = 472.2       6.189   [(S)-2-(5-Chloro-6-trifluoromethyl-1H-benzoimidazol-2-yl)-4-methylene-pyrrolidin-1-yl]-(6-methyl-3-           pyrazol-1-yl-pyridin-2-yl)-methanone. LC-MS: t R  = 0.98; [M + H] +  = 487.3       6.190   [(S)-2-(5-Chloro-6-trifluoromethyl-1H-benzoimidazol-2-yl)-4-methylene-pyrrolidin-1-yl]-(6-methyl-3-           [1,2,3]triazol-2-yl-pyridin-2-yl)-methanone. LC-MS: t R  = 0.98; [M + H] +  = 488.2       6.191   [(S)-2-(5,6-Dimethyl-1H-benzoimidazol-2-yl)-4-methylene-pyrrolidin-1-yl]-(2-fluoro-6-[1,2,3]triazol-2-           yl-phenyl)-methanone. LC-MS: t R  = 0.69; [M + H] +  = 417.3       6.192   [(S)-2-(5,6-Dimethyl-1H-benzoimidazol-2-yl)-4-methylene-pyrrolidin-1-yl]-(5-fluoro-2-[1,2,3]triazol-2-           yl-phenyl)-methanone. LC-MS: t R  = 0.70; [M + H] +  = 417.3       6.193   (5-Chloro-2-[1,2,3]triazol-2-yl-phenyl)-[(S)-2-(5,6-dimethyl-1H-benzoimidazol-2-yl)-4-methylene-           pyrrolidin-1-yl]-methanone. LC-MS: t R  = 0.76; [M + H] +  = 433.2       6.194   [(S)-2-(5,6-Dimethyl-1H-benzoimidazol-2-yl)-4-methylene-pyrrolidin-1-yl]-(2-[1,2,3]triazol-2-yl-           phenyl)-methanone. LC-MS: t R  = 0.68; [M + H] +  = 399.3       6.195   [(S)-2-(5,6-Dimethyl-1H-benzoimidazol-2-yl)-4-methylene-pyrrolidin-1-yl]-(2-fluoro-3-methoxy-6-           [1,2,3]triazol-2-yl-phenyl)-methanone. LC-MS: t R  = 0.70; [M + H] +  = 447.3       6.196   [(S)-2-(5,6-Dimethyl-1H-benzoimidazol-2-yl)-4-methylene-pyrrolidin-1-yl]-(2-fluoro-3-methyl-6-           [1,2,3]triazol-2-yl-phenyl)-methanone. LC-MS: t R  = 0.74; [M + H] +  = 431.3       6.197   [(S)-2-(5,6-Dimethyl-1H-benzoimidazol-2-yl)-4-methylene-pyrrolidin-1-yl]-(4,5-dimethyl-2-           [1,2,3]triazol-2-yl-phenyl)-methanone. LC-MS: t R  = 0.78; [M + H] +  = 427.3       6.198   [(S)-2-(5,6-Dimethyl-1H-benzoimidazol-2-yl)-4-methylene-pyrrolidin-1-yl]-(4-methyl-2-[1,2,3]triazol-2-           yl-phenyl)-methanone. LC-MS: t R  = 0.8; [M + H] +  = 413.4       6.199   [(S)-2-(5,6-Dimethyl-1H-benzoimidazol-2-yl)-4-methylene-pyrrolidin-1-yl]-(2-methyl-6-[1,2,3]triazol-2-           yl-phenyl)-methanone. LC-MS: t R  = 0.79; [M + H] +  = 413.4       6.200   (4,5-Dimethoxy-2-[1,2,3]triazol-2-yl-phenyl)-[(S)-2-(5,6-dimethyl-1H-benzoimidazol-2-yl)-4-           methylene-pyrrolidin-1-yl]-methanone. LC-MS: t R  = 0.74; [M + H] +  = 459.4       6.201   [(S)-2-(5,6-Dimethyl-1H-benzoimidazol-2-yl)-4-methylene-pyrrolidin-1-yl]-(5-methyl-2-pyrazol-1-yl-           phenyl)-methanone. LC-MS: t R  = 0.8; [M + H] +  = 412.4       6.202   [(S)-2-(5,6-Dimethyl-1H-benzoimidazol-2-yl)-4-methylene-pyrrolidin-1-yl]-(6-methyl-3-[1,2,3]triazol-2-           yl-pyridin-2-yl)-methanone. LC-MS: t R  = 0.75; [M + H] +  = 414.4       7.1   [(2S,4R)-2-(6-Chloro-1,7-dimethyl-1H-benzoimidazol-2-yl)-4-methoxy-pyrrolidin-1-yl]-(5-methoxy-2-           [1,2,3]triazol-2-yl-phenyl)-methanone and/or [(2S,4R)-2-(5-Chloro-1,4-dimethyl-1H-benzoimidazol-2-           yl)-4-methoxy-pyrrolidin-1-yl]-(5-methoxy-2-[1,2,3]triazol-2-yl-phenyl)-methanone (mixture of           isomers). LC-MS: t R  = 0.78; [M + H] +  = 481.3       7.2   [(S)-4-Methylene-2-(1,5,6-trimethyl-1H-benzoimidazol-2-yl)-pyrrolidin-1-yl]-(5-methyl-2-[1,2,3]triazol-           2-yl-phenyl)-methanone. LC-MS: t R  = 0.77; [M + H] +  = 427.4       7.3   [(S)-2-(5-Chloro-1,4-dimethyl-1H-benzoimidazol-2-yl)-2-methyl-pyrrolidin-1-yl]-(5-methyl-2-           [1,2,3]triazol-2-yl-phenyl)-methanone and/or [(S)-2-(6-Chloro-1,7-dimethyl-1H-benzoimidazol-2-yl)-2-           methyl-pyrrolidin-1-yl]-(5-methyl-2-[1,2,3]triazol-2-yl-phenyl)-methanone (mixture of isomers). LC-MS:           t R  = 0.84; [M + H] +  = 449.3       7.4   [(S)-2-(5-Bromo-1,7-dimethyl-1H-benzoimidazol-2-yl)-2-methyl-pyrrolidin-1-yl]-(5-methyl-2-           [1,2,3]triazol-2-yl-phenyl)-methanone and/or [(S)-2-(6-Bromo-1,4-dimethyl-1H-benzoimidazol-2-yl)-2-           methyl-pyrrolidin-1-yl]-(5-methyl-2-[1,2,3]triazol-2-yl-phenyl)-methanone (mixture of isomers). LC-MS:           t R  = 0.86; [M + H] +  = 493.2       7.5   (S)-(5-(3-chlorophenyl)-2-methylthiazol-4-yl)(2-(1,4-dimethyl-1H-benzo[d]imidazol-2-yl)-2-           methylpyrrolidin-1-yl)methanone and/or (S)-(5-(3-chlorophenyl)-2-methylthiazol-4-yl)(2-(1,7-dimethyl-           1H-benzo[d]imidazol-2-yl)-2-methylpyrrolidin-1-yl)methanone (mixture of isomers). LC-MS: t R  = 0.88;           [M + H]+ = 465.1       7.6   (S)-(5-(3-chlorophenyl)-2-methylthiazol-4-yl)(2-(1-ethyl-4-methyl-1H-benzo[d]imidazol-2-yl)-2-           methylpyrrolidin-1-yl)methanone and/or (S)-(5-(3-chlorophenyl)-2-methylthiazol-4-yl)(2-(1-ethyl-7-           methyl-1H-benzo[d]imidazol-2-yl)-2-methylpyrrolidin-1-yl)methanone (mixture of isomers). LC-MS:           t R  = 0.93; [M + H]+ = 479.1       7.7   (S)-(2-(5-chloro-1,4-dimethyl-1H-benzo[d]imidazol-2-yl)-2-methylpyrrolidin-1-yl)(2-methyl-5-           phenylthiazol-4-yl)methanone and/or (S)-(2-(6-chloro-1,7-dimethyl-1H-benzo[d]imidazol-2-yl)-2-           methylpyrrolidin-1-yl)(2-methyl-5-phenylthiazol-4-yl)methanone (mixture of isomers). LC-MS: t R  =           0.93; [M + H]+ = 465.1       7.8   (S)-(2-(5-chloro-1-ethyl-4-methyl-1H-benzo[d]imidazol-2-yl)-2-methylpyrrolidin-1-yl)(2-methyl-5-           phenylthiazol-4-yl)methanone and/or (S)-(2-(6-chloro-1-ethyl-7-methyl-1H-benzo[d]imidazol-2-yl)-2-           methylpyrrolidin-1-yl)(2-methyl-5-phenylthiazol-4-yl)methanone (mixture of isomers). LC-MS: t R  =           0.97; [M + H]+ = 479.2       7.9   [(S)-2-(5,6-Dimethoxy-1-methyl-1H-benzoimidazol-2-yl)-2-methyl-pyrrolidin-1-yl]-(5-methyl-2-           [1,2,3]triazol-2-yl-phenyl)-methanone. LC-MS: t R  = 0.74; [M + H]+ = 461.4       7.10   [(S)-2-(1-Ethyl-5,6-dimethoxy-1H-benzoimidazol-2-yl)-2-methyl-pyrrolidin-1-yl]-(5-methyl-2-           [1,2,3]triazol-2-yl-phenyl)-methanone. LC-MS: t R  = 0.78; [M + H]+ = 475.4       7.11   (4-Methyl-2-[1,2,3]triazol-2-yl-phenyl)-[(S)-2-methyl-2-(1,5,6-trimethyl-1H-benzoimidazol-2-yl)-           pyrrolidin-1-yl]-methanone. LC-MS: t R  = 0.82; [M + H]+ = 429.4       7.12   [(S)-2-(1-Ethyl-5,6-dimethyl-1H-benzoimidazol-2-yl)-2-methyl-pyrrolidin-1-yl]-(4-methyl-2-           [1,2,3]triazol-2-yl-phenyl)-methanone. LC-MS: t R  = 0.87; [M + H]+ = 443.4       7.13   [(S)-2-(5,6-Dimethoxy-1-methyl-1H-benzoimidazol-2-yl)-2-methyl-pyrrolidin-1-yl]-(4,5-dimethyl-2-           [1,2,3]triazol-2-yl-phenyl)-methanone. LC-MS: t R  = 0.80; [M + H]+ = 475.4       7.14   (4,5-Dimethyl-2-[1,2,3]triazol-2-yl-phenyl)-[(S)-2-(1-ethyl-5,6-dimethoxy-1H-benzoimidazol-2-yl)-2-           methyl-pyrrolidin-1-yl]-methanone. LC-MS: t R  = 0.83; [M + H]+ = 489.4       7.15   (4′-Fluoro-4-methyl-biphenyl-2-yl)-[(S)-2-methyl-2-(1,5,6-trimethyl-1H-benzoimidazol-2-yl)-pyrrolidin-           1-yl]-methanone. LC-MS: t R  = 0.97; [M + H]+ = 456.4       7.16   [(S)-2-(1-Ethyl-5,6-dimethyl-1H-benzoimidazol-2-yl)-2-methyl-pyrrolidin-1-yl]-(4′-fluoro-4-methyl-           biphenyl-2-yl)-methanone. LC-MS: t R  = 1.0; [M + H]+ = 470.4       7.17   (4,5-Dimethyl-2-[1,2,3]triazol-2-yl-phenyl)-[(S)-2-methyl-2-(1,5,6-trimethyl-1H-benzoimidazol-2-yl)-           pyrrolidin-1-yl]-methanone. LC-MS: t R  = 0.87; [M + H]+ = 443.4       7.18   [(S)-2-(5-Chloro-1,4-dimethyl-1H-benzoimidazol-2-yl)-2-methyl-pyrrolidin-1-yl]-(6-methyl-3-           [1,2,3]triazol-2-yl-pyridin-2-yl)-methanone and/or [(S)-2-(3-Chloro-1,2-dimethyl-1H-benzoimidazol-2-           yl)-2-methyl-pyrrolidin-1-yl]-(6-methyl-3-[1,2,3]triazol-2-yl-pyridin-2-yl)-methanone (mixture of           isomers). LC-MS: t R  = 0.83; [M + H]+ = 450.3       7.19   [(S)-2-(5-Chloro-1,4-dimethyl-1H-benzoimidazol-2-yl)-2-methyl-pyrrolidin-1-yl]-(2-[1,2,3]triazol-2-yl-           phenyl)-methanone and/or [(S)-2-(3-Chloro-1,2-dimethyl-1H-benzoimidazol-2-yl)-2-methyl-           pyrrolidin-1-yl]-(2-[1,2,3]triazol-2-yl-phenyl)-methanone (mixtures of isomers). LC-MS: t R  = 0.81;           [M + H]+ = 435.3       7.20   [(S)-2-(6-Chloro-1-methyl-5-trifluoromethyl-1H-benzoimidazol-2-yl)-2-methyl-pyrrolidin-1-yl]-(5-           methyl-2-[1,2,3]triazol-2-yl-phenyl)-methanone and or [(S)-2-(5-Chloro-1-methyl-6-trifluoromethyl-1H-           benzoimidazol-2-yl)-2-methyl-pyrrolidin-1-yl]-(5-methyl-2-[1,2,3]triazol-2-yl-phenyl)-methanone           (mixtures of isomers). LC-MS: t R  = 1.09; [M + H]+ = 531.3       7.21   [(S)-2-(5-Chloro-1-ethyl-4-methyl-1H-benzoimidazol-2-yl)-2-methyl-pyrrolidin-1-yl]-(5-methyl-2-           [1,2,3]triazol-2-yl-phenyl)-methanone and/or [(S)-2-(3-Chloro-1-ethyl-2-methyl-1H-benzoimidazol-2-           yl)-2-methyl-pyrrolidin-1-yl]-(5-methyl-2-[1,2,3]triazol-2-yl-phenyl)-methanone (mixtures of isomers).           LC-MS: t R  = 0.93; [M + H]+ = 463.3       7.22   [(S)-2-(5-Chloro-1,4-dimethyl-1H-benzoimidazol-2-yl)-2-methyl-pyrrolidin-1-yl]-(5-chloro-2-           [1,2,3]triazol-2-yl-phenyl)-methanone and/or [(S)-2-(3-Chloro-1,2-dimethyl-1H-benzoimidazol-2-yl)-           2-methyl-pyrrolidin-1-yl]-(5-chloro-2-[1,2,3]triazol-2-yl-phenyl)-methanone (mixtures of isomers). LC-           MS: t R  = 0.93; [M + H]+ = 469.3       7.23   [(S)-2-(5-Chloro-1,4-dimethyl-1H-benzoimidazol-2-yl)-2-methyl-pyrrolidin-1-yl]-(5-methoxy-2-           [1,2,3]triazol-2-yl-phenyl)-methanone and/or [(S)-2-(3-Chloro-1,2-dimethyl-1H-benzoimidazol-2-yl)-           2-methyl-pyrrolidin-1-yl]-(5-methoxy-2-[1,2,3]triazol-2-yl-phenyl)-methanone (mixtures of isomers).           LC-MS: t R  = 0.86; [M + H]+ = 465.4       7.24   (5-Chloro-2-[1,2,3]triazol-2-yl-phenyl)-[(S)-2-(5,6-dimethoxy-1-methyl-1H-benzoimidazol-2-yl)-2-           methyl-pyrrolidin-1-yl]-methanone. LC-MS: t R  = 0.77; [M + H]+ = 481.3       7.25   (4,3′-Dimethyl-biphenyl-2-yl)-[(S)-2-methyl-2-(1,5,6-trimethyl-1H-benzoimidazol-2-yl)-pyrrolidin-1-yl]-           methanone. LC-MS: t R  = 1.01; [M + H]+ = 452.4       7.26   [(S)-2-(1-Cyclopropylmethyl-5,6-dimethyl-1H-benzoimidazol-2-yl)-2-methyl-pyrrolidin-1-yl]-(4,3′-           dimethyl-biphenyl-2-yl)-methanone. LC-MS: t R  = 1.1; [M + H]+ = 492.4       7.27   (4,3′-Dimethyl-biphenyl-2-yl)-[(S)-2-(1-ethyl-5,6-dimethyl-1H-benzoimidazol-2-yl)-2-methyl-pyrrolidin-           1-yl]-methanone. LC-MS: t R  = 1.04; [M + H]+ = 466.4       7.28   (4,3′-Dimethyl-biphenyl-2-yl)-{(S)-2-[1-(2-fluoro-ethyl)-5,6-dimethyl-1H-benzoimidazol-2-yl]-2-methyl-           pyrrolidin-1-yl}-methanone. LC-MS: t R  = 1.03; [M + H]+ = 484.4       7.29   (4,3′-Dimethyl-biphenyl-2-yl)-{(S)-2-[1-(2-methoxy-ethyl)-5,6-dimethyl-1H-benzoimidazol-2-yl]-2-           methyl-pyrrolidin-1-yl}-methanone. LC-MS: t R  = 1.06; [M + H]+ = 496.4       7.30   (3′-Fluoro-4-methyl-biphenyl-2-yl)-[(S)-2-methyl-2-(1,5,6-trimethyl-1H-benzoimidazol-2-yl)-pyrrolidin-           1-yl]-methanone. LC-MS: t R  = 0.97; [M + H]+ = 456.4       7.31   [(S)-2-(1-Ethyl-5,6-dimethyl-1H-benzoimidazol-2-yl)-2-methyl-pyrrolidin-1-yl]-(3′-fluoro-4-methyl-           biphenyl-2-yl)-methanone. LC-MS: t R  = 1.0; [M + H]+ = 470.4       7.32   [(S)-2-(6-Bromo-5-fluoro-1-methyl-1H-benzoimidazol-2-yl)-2-methyl-pyrrolidin-1-yl]-(5-methyl-2-           [1,2,3]triazol-2-yl-phenyl)-methanone and/or [(S)-2-(4-Bromo-3-fluoro-1-methyl-1H-benzoimidazol-           2-yl)-2-methyl-pyrrolidin-1-yl]-(5-methyl-2-[1,2,3]triazol-2-yl-phenyl)-methanone (mixtures of isomers).           LC-MS: t R  = 0.89; [M + H]+ = 497.3       7.33   [(S)-2-(5-Chloro-1,4-dimethyl-1H-benzoimidazol-2-yl)-2-methyl-pyrrolidin-1-yl]-[5-(3-chloro-phenyl)-2-           methyl-thiazol-4-yl]-methanone and/or [(S)-2-(3-Chloro-1,2-dimethyl-1H-benzoimidazol-2-yl)-2-           methyl-pyrrolidin-1-yl]-[5-(3-chloro-phenyl)-2-methyl-thiazol-4-yl]-methanone (mixtures of isomers).           LC-MS: t R  = 1.05; [M + H]+ = 499.2       7.34   [(S)-2-(1-Cyclopropylmethyl-5,6-dimethyl-1H-benzoimidazol-2-yl)-2-methyl-pyrrolidin-1-yl]-(3′-fluoro-           4-methyl-biphenyl-2-yl)-methanone. LC-MS: t R  = 1.06; [M + H]+ = 496.4       7.35   {(S)-2-[1-(2-Fluoro-ethyl)-5,6-dimethyl-1H-benzoimidazol-2-yl]-2-methyl-pyrrolidin-1-yl}-(3′-fluoro-4-           methyl-biphenyl-2-yl)-methanone. LC-MS: t R  = 0.99; [M + H]+ = 488.4       7.36   (3′-Fluoro-4-methyl-biphenyl-2-yl)-{(S)-2-[1-(2-methoxy-ethyl)-5,6-dimethyl-1H-benzoimidazol-2-yl]-2-           methyl-pyrrolidin-1-yl}-methanone. LC-MS: t R  = 1.02; [M + H]+ = 500.4       7.37   (4,4′-Dimethyl-biphenyl-2-yl)-[(S)-2-methyl-2-(1,5,6-trimethyl-1H-benzoimidazol-2-yl)-pyrrolidin-1-yl]-           methanone. LC-MS: t R  = 1.02; [M + H]+ = 452.5       7.38   (4,4′-Dimethyl-biphenyl-2-yl)-[(S)-2-(1-ethyl-5,6-dimethyl-1H-benzoimidazol-2-yl)-2-methyl-pyrrolidin-           1-yl]-methanone. LC-MS: t R  = 1.04; [M + H]+ = 466.4       7.39   [(S)-2-(1-Cyclopropylmethyl-5,6-dimethyl-1H-benzoimidazol-2-yl)-2-methyl-pyrrolidin-1-yl]-(4,4′-           dimethyl-biphenyl-2-yl)-methanone. LC-MS: t R  = 1.1; [M + H]+ = 492.4       7.40   (4,4′-Dimethyl-biphenyl-2-yl)-{(S)-2-[1-(2-fluoro-ethyl)-5,6-dimethyl-1H-benzoimidazol-2-yl]-2-methyl-           pyrrolidin-1-yl}-methanone. LC-MS: t R  = 1.03; [M + H]+ = 484.4       7.41   (4,4′-Dimethyl-biphenyl-2-yl)-{(S)-2-[1-(2-methoxy-ethyl)-5,6-dimethyl-1H-benzoimidazol-2-yl]-2-           methyl-pyrrolidin-1-yl}-methanone. LC-MS: t R  = 1.06; [M + H]+ = 496.4       7.42   (3′-Methoxy-4-methyl-biphenyl-2-yl)-[(S)-2-methyl-2-(1,5,6-trimethyl-1H-benzoimidazol-2-yl)-           pyrrolidin-1-yl]-methanone. LC-MS: t R  = 0.98; [M + H]+ = 468.4       7.43   (2′-Fluoro-4-methyl-biphenyl-2-yl)-[(S)-2-methyl-2-(1,5,6-trimethyl-1H-benzoimidazol-2-yl)-pyrrolidin-           1-yl]-methanone. LC-MS: t R  = 0.97; [M + H]+ = 456.4       7.44   [(S)-2-(1-Ethyl-5,6-dimethyl-1H-benzoimidazol-2-yl)-2-methyl-pyrrolidin-1-yl]-(3′-methoxy-4-methyl-           biphenyl-2-yl)-methanone. LC-MS: t R  = 1.01; [M + H]+ = 482.4       7.45   [(S)-2-(1-Ethyl-5,6-dimethyl-1H-benzoimidazol-2-yl)-2-methyl-pyrrolidin-1-yl]-(2′-fluoro-4-methyl-           biphenyl-2-yl)-methanone. LC-MS: t R  = 1.00; [M + H]+ = 470.4       7.46   {(S)-2-[5,6-Dimethoxy-1-(2-methoxy-ethyl)-1H-benzoimidazol-2-yl]-2-methyl-pyrrolidin-1-yl}-(5-           methyl-2-[1,2,3]triazol-2-yl-phenyl)-methanone. LC-MS: t R  = 0.81; [M + H]+ = 505.4       7.47   [(S)-2-(1-Cyclopropylmethyl-5,6-dimethoxy-1H-benzoimidazol-2-yl)-2-methyl-pyrrolidin-1-yl]-(5-           methyl-2-[1,2,3]triazol-2-yl-phenyl)-methanone. LC-MS: t R  = 0.86; [M + H]+ = 501.4       7.48   {(S)-2-[1-(2-Fluoro-ethyl)-5,6-dimethoxy-1H-benzoimidazol-2-yl]-2-methyl-pyrrolidin-1-yl}-(5-methyl-2-           [1,2,3]triazol-2-yl-phenyl)-methanone. LC-MS: t R  = 0.78; [M + H]+ = 493.4       7.49   [(S)-2-(1-Cyclopropylmethyl-5,6-dimethyl-1H-benzoimidazol-2-yl)-2-methyl-pyrrolidin-1-yl]-(3′-           methoxy-4-methyl-biphenyl-2-yl)-methanone. LC-MS: t R  = 1.07; [M + H]+ = 508.4       7.50   [(S)-2-(1-Cyclopropylmethyl-5,6-dimethyl-1H-benzoimidazol-2-yl)-2-methyl-pyrrolidin-1-yl]-(2′-fluoro-           4-methyl-biphenyl-2-yl)-methanone. LC-MS: t R  = 1.06; [M + H]+ = 496.4       7.51   {(S)-2-[1-(2-Fluoro-ethyl)-5,6-dimethyl-1H-benzoimidazol-2-yl]-2-methyl-pyrrolidin-1-yl}-(3′-methoxy-           4-methyl-biphenyl-2-yl)-methanone. LC-MS: t R  = 0.99; [M + H]+ = 500.4       7.52   {(S)-2-[1-(2-Fluoro-ethyl)-5,6-dimethyl-1H-benzoimidazol-2-yl]-2-methyl-pyrrolidin-1-yl}-(2′-fluoro-4-           methyl-biphenyl-2-yl)-methanone. LC-MS: t R  = 0.99; [M + H]+ = 488.4       7.53   {(S)-2-[1-(2-Methoxy-ethyl)-5,6-dimethyl-1H-benzoimidazol-2-yl]-2-methyl-pyrrolidin-1-yl}-(3′-           methoxy-4-methyl-biphenyl-2-yl)-methanone. LC-MS: t R  = 1.02; [M + H]+ = 512.4       7.54   (2′-Fluoro-4-methyl-biphenyl-2-yl)-{(S)-2-[1-(2-methoxy-ethyl)-5,6-dimethyl-1H-benzoimidazol-2-yl]-2-           methyl-pyrrolidin-1-yl}-methanone. LC-MS: t R  = 1.02; [M + H]+ = 500.4                    
II-Biological Assays
 
     Antagonistic activities on both orexin receptors have been measured for each example compound using the following procedure: 
     In Vitro Assay: Intracellular Calcium Measurements: 
     Chinese hamster ovary (CHO) cells expressing the human orexin-1 receptor and the human orexin-2 receptor, respectively, are grown in culture medium (Ham F-12 with L-Glutamine) containing 300 μg/ml G418, 100 U/ml penicillin, 100 μg/ml streptomycin and 10% heat inactivated fetal calf serum (FCS). The cells are seeded at 20′000 cells/well into 384-well black clear bottom sterile plates (Greiner). The seeded plates are incubated overnight at 37° C. in 5% CO 2 . 
     Human orexin-A as an agonist is prepared as 1 mM stock solution in MeOH: water (1:1), diluted in HBSS containing 0.1% bovine serum albumin (BSA), NaHCO 3 : 0.375 g/l and 20 mM HEPES for use in the assay at a final concentration of 3 nM. 
     Antagonists are prepared as 10 mM stock solution in DMSO, then diluted in 384-well plates using DMSO followed by a transfer of the dilutions into in HBSS containing 0.1% bovine serum albumin (BSA), NaHCO 3 : 0.375 g/l and 20 mM HEPES. On the day of the assay, 50 μl of staining buffer (HBSS containing 1% FCS, 20 mM HEPES, NaHCO 3 : 0.375 g/l, 5 mM probenecid (Sigma) and 3 μM of the fluorescent calcium indicator fluo-4 AM (1 mM stock solution in DMSO, containing 10% pluronic) is added to each well. The 384-well cell-plates are incubated for 50 min at 37° C. in 5% CO 2  followed by equilibration at RT for 30 min before measurement. 
     Within the Fluorescent Imaging Plate Reader (FLIPR Tetra, Molecular Devices), antagonists are added to the plate in a volume of 10 l/well, incubated for 120 min and finally 10 l/well of agonist is added. Fluorescence is measured for each well at 1 second intervals, and the height of each fluorescence peak is compared to the height of the fluorescence peak induced by an approximate EC 70  (for example 5 nM) of orexin-A with vehicle in place of antagonist. The IC 50  value (the concentration of compound needed to inhibit 50% of the agonistic response) is determined and may be normalized using the obtained IC 50  value of a on-plate reference compound. Optimized conditions are achieved by adjustment of pipetting speed and cell splitting regime. The calculated IC 50  values may fluctuate depending on the daily cellular assay performance. Fluctuations of this kind are known to those skilled in the art. Average IC 50  values from several measurements are given as geometric mean values. 
     Antagonistic activities of example compounds with respect to the Ox 1  and the Ox 2  receptor are displayed in Table 1. 
     
       
         
           
               
               
               
               
             
               
                   
                 TABLE 1 
               
               
                   
                   
               
               
                   
                 Example 
                 IC 50  Ox1 
                 IC 50  Ox2 
               
               
                   
                 Number 
                 [nM] 
                 [nM] 
               
               
                   
                   
               
             
            
               
                   
               
            
           
           
               
               
               
               
            
               
                   
                 Ex. 1.1 
                 1500 
                 108 
               
               
                   
                 Ex. 1.10 
                 98 
                 248 
               
               
                   
                 Ex. 1.100 
                 27 
                 104 
               
               
                   
                 Ex. 1.101 
                 21 
                 50 
               
               
                   
                 Ex. 1.102 
                 17 
                 17 
               
               
                   
                 Ex. 1.103 
                 364 
                 112 
               
               
                   
                 Ex. 1.104 
                 657 
                 769 
               
               
                   
                 Ex. 1.105 
                 45 
                 89 
               
               
                   
                 Ex. 1.106 
                 17 
                 31 
               
               
                   
                 Ex. 1.107 
                 28 
                 58 
               
               
                   
                 Ex. 1.108 
                 171 
                 835 
               
               
                   
                 Ex. 1.109 
                 5 
                 10 
               
               
                   
                 Ex. 1.11 
                 110 
                 54 
               
               
                   
                 Ex. 1.110 
                 164 
                 46 
               
               
                   
                 Ex. 1.111 
                 32 
                 243 
               
               
                   
                 Ex. 1.112 
                 69 
                 289 
               
               
                   
                 Ex. 1.113 
                 5 
                 58 
               
               
                   
                 Ex. 1.114 
                 30 
                 74 
               
               
                   
                 Ex. 1.115 
                 37 
                 19 
               
               
                   
                 Ex. 1.116 
                 86 
                 248 
               
               
                   
                 Ex. 1.117 
                 136 
                 56 
               
               
                   
                 Ex. 1.118 
                 191 
                 364 
               
               
                   
                 Ex. 1.119 
                 27 
                 77 
               
               
                   
                 Ex. 1.12 
                 273 
                 344 
               
               
                   
                 Ex. 1.120 
                 147 
                 557 
               
               
                   
                 Ex. 1.121 
                 76 
                 287 
               
               
                   
                 Ex. 1.122 
                 55 
                 45 
               
               
                   
                 Ex. 1.123 
                 147 
                 70 
               
               
                   
                 Ex. 1.124 
                 119 
                 42 
               
               
                   
                 Ex. 1.125 
                 39 
                 73 
               
               
                   
                 Ex. 1.126 
                 18 
                 24 
               
               
                   
                 Ex. 1.127 
                 33 
                 22 
               
               
                   
                 Ex. 1.128 
                 1480 
                 331 
               
               
                   
                 Ex. 1.129 
                 93 
                 124 
               
               
                   
                 Ex. 1.13 
                 15 
                 24 
               
               
                   
                 Ex. 1.130 
                 113 
                 75 
               
               
                   
                 Ex. 1.131 
                 37 
                 48 
               
               
                   
                 Ex. 1.132 
                 90 
                 614 
               
               
                   
                 Ex. 1.133 
                 4 
                 11 
               
               
                   
                 Ex. 1.134 
                 116 
                 26 
               
               
                   
                 Ex. 1.135 
                 32 
                 194 
               
               
                   
                 Ex. 1.136 
                 81 
                 278 
               
               
                   
                 Ex. 1.137 
                 4 
                 33 
               
               
                   
                 Ex. 1.138 
                 35 
                 109 
               
               
                   
                 Ex. 1.139 
                 103 
                 26 
               
               
                   
                 Ex. 1.14 
                 34 
                 32 
               
               
                   
                 Ex. 1.140 
                 192 
                 46 
               
               
                   
                 Ex. 1.141 
                 507 
                 13 
               
               
                   
                 Ex. 1.142 
                 24 
                 13 
               
               
                   
                 Ex. 1.143 
                 14 
                 16 
               
               
                   
                 Ex. 1.144 
                 33 
                 27 
               
               
                   
                 Ex. 1.145 
                 3 
                 7 
               
               
                   
                 Ex. 1.146 
                 7 
                 23 
               
               
                   
                 Ex. 1.147 
                 685 
                 24 
               
               
                   
                 Ex. 1.148 
                 1170 
                 44 
               
               
                   
                 Ex. 1.149 
                 143 
                 9 
               
               
                   
                 Ex. 1.15 
                 67 
                 45 
               
               
                   
                 Ex. 1.150 
                 301 
                 11 
               
               
                   
                 Ex. 1.151 
                 763 
                 110 
               
               
                   
                 Ex. 1.152 
                 282 
                 23 
               
               
                   
                 Ex. 1.153 
                 40 
                 3 
               
               
                   
                 Ex. 1.154 
                 483 
                 21 
               
               
                   
                 Ex. 1.155 
                 36 
                 16 
               
               
                   
                 Ex. 1.156 
                 1810 
                 29 
               
               
                   
                 Ex. 1.157 
                 419 
                 10 
               
               
                   
                 Ex. 1.158 
                 538 
                 20 
               
               
                   
                 Ex. 1.159 
                 903 
                 23 
               
               
                   
                 Ex. 1.16 
                 245 
                 5 
               
               
                   
                 Ex. 1.160 
                 245 
                 5 
               
               
                   
                 Ex. 1.161 
                 1450 
                 22 
               
               
                   
                 Ex. 1.162 
                 458 
                 27 
               
               
                   
                 Ex. 1.163 
                 167 
                 17 
               
               
                   
                 Ex. 1.164 
                 217 
                 24 
               
               
                   
                 Ex. 1.165 
                 76 
                 9 
               
               
                   
                 Ex. 1.166 
                 45 
                 4 
               
               
                   
                 Ex. 1.167 
                 97 
                 15 
               
               
                   
                 Ex. 1.168 
                 20 
                 57 
               
               
                   
                 Ex. 1.169 
                 37 
                 3 
               
               
                   
                 Ex. 1.17 
                 97 
                 8 
               
               
                   
                 Ex. 1.170 
                 258 
                 20 
               
               
                   
                 Ex. 1.171 
                 2210 
                 36 
               
               
                   
                 Ex. 1.172 
                 1160 
                 19 
               
               
                   
                 Ex. 1.173 
                 3930 
                 54 
               
               
                   
                 Ex. 1.174 
                 68 
                 87 
               
               
                   
                 Ex. 1.175 
                 528 
                 76 
               
               
                   
                 Ex. 1.176 
                 2190 
                 99 
               
               
                   
                 Ex. 1.177 
                 842 
                 30 
               
               
                   
                 Ex. 1.178 
                 2680 
                 96 
               
               
                   
                 Ex. 1.179 
                 486 
                 28 
               
               
                   
                 Ex. 1.18 
                 935 
                 153 
               
               
                   
                 Ex. 1.180 
                 1490 
                 50 
               
               
                   
                 Ex. 1.19 
                 660 
                 76 
               
               
                   
                 Ex. 1.2 
                 349 
                 7 
               
               
                   
                 Ex. 1.20 
                 692 
                 121 
               
               
                   
                 Ex. 1.21 
                 1180 
                 149 
               
               
                   
                 Ex. 1.22 
                 415 
                 52 
               
               
                   
                 Ex. 1.23 
                 523 
                 212 
               
               
                   
                 Ex. 1.24 
                 850 
                 81 
               
               
                   
                 Ex. 1.25 
                 364 
                 90 
               
               
                   
                 Ex. 1.26 
                 125 
                 22 
               
               
                   
                 Ex. 1.27 
                 1040 
                 35 
               
               
                   
                 Ex. 1.28 
                 114 
                 110 
               
               
                   
                 Ex. 1.29 
                 369 
                 182 
               
               
                   
                 Ex. 1.3 
                 265 
                 51 
               
               
                   
                 Ex. 1.30 
                 624 
                 147 
               
               
                   
                 Ex. 1.31 
                 195 
                 78 
               
               
                   
                 Ex. 1.32 
                 347 
                 139 
               
               
                   
                 Ex. 1.33 
                 76 
                 48 
               
               
                   
                 Ex. 1.34 
                 124 
                 56 
               
               
                   
                 Ex. 1.35 
                 117 
                 99 
               
               
                   
                 Ex. 1.36 
                 109 
                 27 
               
               
                   
                 Ex. 1.37 
                 154 
                 62 
               
               
                   
                 Ex. 1.38 
                 360 
                 110 
               
               
                   
                 Ex. 1.39 
                 157 
                 73 
               
               
                   
                 Ex. 1.4 
                 241 
                 30 
               
               
                   
                 Ex. 1.40 
                 74 
                 23 
               
               
                   
                 Ex. 1.41 
                 115 
                 64 
               
               
                   
                 Ex. 1.42 
                 263 
                 65 
               
               
                   
                 Ex. 1.43 
                 97 
                 58 
               
               
                   
                 Ex. 1.44 
                 404 
                 120 
               
               
                   
                 Ex. 1.45 
                 501 
                 109 
               
               
                   
                 Ex. 1.46 
                 128 
                 13 
               
               
                   
                 Ex. 1.47 
                 446 
                 13 
               
               
                   
                 Ex. 1.49 
                 32 
                 42 
               
               
                   
                 Ex. 1.5 
                 56 
                 23 
               
               
                   
                 Ex. 1.50 
                 394 
                 107 
               
               
                   
                 Ex. 1.51 
                 66 
                 21 
               
               
                   
                 Ex. 1.52 
                 737 
                 121 
               
               
                   
                 Ex. 1.53 
                 616 
                 90 
               
               
                   
                 Ex. 1.54 
                 726 
                 80 
               
               
                   
                 Ex. 1.55 
                 35 
                 10 
               
               
                   
                 Ex. 1.56 
                 252 
                 88 
               
               
                   
                 Ex. 1.57 
                 76 
                 22 
               
               
                   
                 Ex. 1.58 
                 32 
                 24 
               
               
                   
                 Ex. 1.59 
                 77 
                 252 
               
               
                   
                 Ex. 1.6 
                 202 
                 46 
               
               
                   
                 Ex. 1.60 
                 61 
                 48 
               
               
                   
                 Ex. 1.61 
                 21 
                 21 
               
               
                   
                 Ex. 1.62 
                 128 
                 197 
               
               
                   
                 Ex. 1.63 
                 12 
                 9 
               
               
                   
                 Ex. 1.64 
                 12 
                 18 
               
               
                   
                 Ex. 1.65 
                 63 
                 147 
               
               
                   
                 Ex. 1.66 
                 20 
                 47 
               
               
                   
                 Ex. 1.67 
                 127 
                 84 
               
               
                   
                 Ex. 1.68 
                 7 
                 8 
               
               
                   
                 Ex. 1.69 
                 37 
                 31 
               
               
                   
                 Ex. 1.7 
                 93 
                 5 
               
               
                   
                 Ex. 1.70 
                 26 
                 26 
               
               
                   
                 Ex. 1.71 
                 95 
                 162 
               
               
                   
                 Ex. 1.72 
                 112 
                 180 
               
               
                   
                 Ex. 1.73 
                 136 
                 282 
               
               
                   
                 Ex. 1.74 
                 52 
                 100 
               
               
                   
                 Ex. 1.75 
                 5 
                 9 
               
               
                   
                 Ex. 1.76 
                 279 
                 17 
               
               
                   
                 Ex. 1.78 
                 102 
                 408 
               
               
                   
                 Ex. 1.79 
                 5 
                 46 
               
               
                   
                 Ex. 1.80 
                 41 
                 564 
               
               
                   
                 Ex. 1.81 
                 20 
                 116 
               
               
                   
                 Ex. 1.82 
                 13 
                 17 
               
               
                   
                 Ex. 1.83 
                 17 
                 36 
               
               
                   
                 Ex. 1.84 
                 14 
                 20 
               
               
                   
                 Ex. 1.85 
                 5 
                 23 
               
               
                   
                 Ex. 1.86 
                 56 
                 118 
               
               
                   
                 Ex. 1.87 
                 30 
                 77 
               
               
                   
                 Ex. 1.88 
                 102 
                 109 
               
               
                   
                 Ex. 1.89 
                 39 
                 180 
               
               
                   
                 Ex. 1.9 
                 337 
                 69 
               
               
                   
                 Ex. 1.90 
                 2 
                 14 
               
               
                   
                 Ex. 1.91 
                 13 
                 25 
               
               
                   
                 Ex. 1.92 
                 23 
                 69 
               
               
                   
                 Ex. 1.93 
                 102 
                 458 
               
               
                   
                 Ex. 1.94 
                 42 
                 414 
               
               
                   
                 Ex. 1.95 
                 18 
                 15 
               
               
                   
                 Ex. 1.96 
                 54 
                 43 
               
               
                   
                 Ex. 1.97 
                 95 
                 314 
               
               
                   
                 Ex. 1.98 
                 105 
                 387 
               
               
                   
                 Ex. 1.99 
                 58 
                 50 
               
               
                   
                 Ex. 2.1 
                 56 
                 53 
               
               
                   
                 Ex. 2.10 
                 5 
                 8 
               
               
                   
                 Ex. 2.11 
                 69 
                 124 
               
               
                   
                 Ex. 2.2 
                 1300 
                 317 
               
               
                   
                 Ex. 2.3 
                 67 
                 61 
               
               
                   
                 Ex. 2.4 
                 425 
                 131 
               
               
                   
                 Ex. 2.5 
                 6 
                 12 
               
               
                   
                 Ex. 2.6 
                 52 
                 59 
               
               
                   
                 Ex. 2.7 
                 66 
                 42 
               
               
                   
                 Ex. 2.8 
                 70 
                 51 
               
               
                   
                 Ex. 2.9 
                 17 
                 18 
               
               
                   
                 Ex. 3.1 
                 102 
                 69 
               
               
                   
                 Ex. 3.10 
                 45 
                 5 
               
               
                   
                 Ex. 3.11 
                 6 
                 9 
               
               
                   
                 Ex. 3.12 
                 13 
                 1 
               
               
                   
                 Ex. 3.13 
                 16 
                 7 
               
               
                   
                 Ex. 3.14 
                 674 
                 23 
               
               
                   
                 Ex. 3.15 
                 96 
                 4 
               
               
                   
                 Ex. 3.16 
                 24 
                 2 
               
               
                   
                 Ex. 3.17 
                 368 
                 51 
               
               
                   
                 Ex. 3.18 
                 97 
                 4 
               
               
                   
                 Ex. 3.19 
                 1930 
                 21 
               
               
                   
                 Ex. 3.2 
                 13 
                 6 
               
               
                   
                 Ex. 3.20 
                 1860 
                 40 
               
               
                   
                 Ex. 3.21 
                 2510 
                 33 
               
               
                   
                 Ex. 3.22 
                 576 
                 9 
               
               
                   
                 Ex. 3.23 
                 3890 
                 67 
               
               
                   
                 Ex. 3.24 
                 5 
                 12 
               
               
                   
                 Ex. 3.25 
                 5 
                 7 
               
               
                   
                 Ex. 3.26 
                 50 
                 66 
               
               
                   
                 Ex. 3.27 
                 5 
                 16 
               
               
                   
                 Ex. 3.28 
                 10 
                 19 
               
               
                   
                 Ex. 3.29 
                 28 
                 20 
               
               
                   
                 Ex. 3.3 
                 1290 
                 255 
               
               
                   
                 Ex. 3.30 
                 2 
                 2 
               
               
                   
                 Ex. 3.31 
                 5 
                 4 
               
               
                   
                 Ex. 3.32 
                 0.9 
                 5 
               
               
                   
                 Ex. 3.33 
                 0.8 
                 10 
               
               
                   
                 Ex. 3.34 
                 0.9 
                 8 
               
               
                   
                 Ex. 3.35 
                 3 
                 4 
               
               
                   
                 Ex. 3.36 
                 5 
                 9 
               
               
                   
                 Ex. 3.37 
                 8 
                 8 
               
               
                   
                 Ex. 3.38 
                 6 
                 13 
               
               
                   
                 Ex. 3.39 
                 74 
                 57 
               
               
                   
                 Ex. 3.4 
                 44 
                 14 
               
               
                   
                 Ex. 3.40 
                 8 
                 7 
               
               
                   
                 Ex. 3.41 
                 0.7 
                 7 
               
               
                   
                 Ex. 3.42 
                 193 
                 395 
               
               
                   
                 Ex. 3.43 
                 10 
                 13 
               
               
                   
                 Ex. 3.44 
                 3 
                 6 
               
               
                   
                 Ex. 3.45 
                 16 
                 19 
               
               
                   
                 Ex. 3.46 
                 223 
                 288 
               
               
                   
                 Ex. 3.47 
                 225 
                 471 
               
               
                   
                 Ex. 3.48 
                 3 
                 4 
               
               
                   
                 Ex. 3.49 
                 13 
                 18 
               
               
                   
                 Ex. 3.5 
                 109 
                 74 
               
               
                   
                 Ex. 3.50 
                 232 
                 252 
               
               
                   
                 Ex. 3.51 
                 94 
                 44 
               
               
                   
                 Ex. 3.52 
                 28 
                 27 
               
               
                   
                 Ex. 3.53 
                 10 
                 20 
               
               
                   
                 Ex. 3.54 
                 52 
                 44 
               
               
                   
                 Ex. 3.55 
                 18 
                 45 
               
               
                   
                 Ex. 3.56 
                 18 
                 37 
               
               
                   
                 Ex. 3.6 
                 5 
                 4 
               
               
                   
                 Ex. 3.7 
                 9 
                 5 
               
               
                   
                 Ex. 3.8 
                 22 
                 12 
               
               
                   
                 Ex. 3.9 
                 1 
                 2 
               
               
                   
                 Ex. 4.1 
                 29 
                 778 
               
               
                   
                 Ex. 4.10 
                 2 
                 833 
               
               
                   
                 Ex. 4.100 
                 6 
                 1280 
               
               
                   
                 Ex. 4.101 
                 18 
                 183 
               
               
                   
                 Ex. 4.11 
                 10 
                 4060 
               
               
                   
                 Ex. 4.12 
                 23 
                 4870 
               
               
                   
                 Ex. 4.13 
                 26 
                 4910 
               
               
                   
                 Ex. 4.14 
                 15 
                 4030 
               
               
                   
                 Ex. 4.15 
                 2 
                 670 
               
               
                   
                 Ex. 4.16 
                 1 
                 250 
               
               
                   
                 Ex. 4.17 
                 14 
                 1670 
               
               
                   
                 Ex. 4.18 
                 43 
                 2930 
               
               
                   
                 Ex. 4.19 
                 2 
                 422 
               
               
                   
                 Ex. 4.2 
                 132 
                 669 
               
               
                   
                 Ex. 4.20 
                 28 
                 2450 
               
               
                   
                 Ex. 4.21 
                 1 
                 133 
               
               
                   
                 Ex. 4.22 
                 6 
                 1075 
               
               
                   
                 Ex. 4.23 
                 9 
                 1940 
               
               
                   
                 Ex. 4.24 
                 2 
                 367 
               
               
                   
                 Ex. 4.25 
                 4 
                 441 
               
               
                   
                 Ex. 4.26 
                 17 
                 2280 
               
               
                   
                 Ex. 4.27 
                 59 
                 5590 
               
               
                   
                 Ex. 4.28 
                 2 
                 486 
               
               
                   
                 Ex. 4.29 
                 30 
                 353 
               
               
                   
                 Ex. 4.3 
                 8 
                 1350 
               
               
                   
                 Ex. 4.30 
                 12 
                 155 
               
               
                   
                 Ex. 4.31 
                 77 
                 774 
               
               
                   
                 Ex. 4.32 
                 7 
                 156 
               
               
                   
                 Ex. 4.33 
                 9 
                 294 
               
               
                   
                 Ex. 4.34 
                 37 
                 1880 
               
               
                   
                 Ex. 4.35 
                 3 
                 193 
               
               
                   
                 Ex. 4.36 
                 70 
                 2740 
               
               
                   
                 Ex. 4.37 
                 24 
                 988 
               
               
                   
                 Ex. 4.38 
                 55 
                 756 
               
               
                   
                 Ex. 4.39 
                 14 
                 315 
               
               
                   
                 Ex. 4.4 
                 11 
                 1170 
               
               
                   
                 Ex. 4.40 
                 21 
                 28 
               
               
                   
                 Ex. 4.41 
                 182 
                 248 
               
               
                   
                 Ex. 4.42 
                 365 
                 1130 
               
               
                   
                 Ex. 4.43 
                 39 
                 97 
               
               
                   
                 Ex. 4.44 
                 38 
                 246 
               
               
                   
                 Ex. 4.45 
                 124 
                 5780 
               
               
                   
                 Ex. 4.46 
                 14 
                 51 
               
               
                   
                 Ex. 4.47 
                 176 
                 281 
               
               
                   
                 Ex. 4.48 
                 391 
                 1320 
               
               
                   
                 Ex. 4.49 
                 221 
                 533 
               
               
                   
                 Ex. 4.5 
                 29 
                 3190 
               
               
                   
                 Ex. 4.50 
                 373 
                 4220 
               
               
                   
                 Ex. 4.51 
                 99 
                 677 
               
               
                   
                 Ex. 4.52 
                 19 
                 1067 
               
               
                   
                 Ex. 4.53 
                 111 
                 4440 
               
               
                   
                 Ex. 4.54 
                 21 
                 2322 
               
               
                   
                 Ex. 4.55 
                 167 
                 7970 
               
               
                   
                 Ex. 4.56 
                 283 
                 2620 
               
               
                   
                 Ex. 4.57 
                 59 
                 250 
               
               
                   
                 Ex. 4.58 
                 66 
                 2170 
               
               
                   
                 Ex. 4.59 
                 6 
                 67 
               
               
                   
                 Ex. 4.6 
                 29 
                 3890 
               
               
                   
                 Ex. 4.60 
                 2 
                 65 
               
               
                   
                 Ex. 4.61 
                 0.9 
                 72 
               
               
                   
                 Ex. 4.62 
                 3 
                 19 
               
               
                   
                 Ex. 4.63 
                 0.8 
                 122 
               
               
                   
                 Ex. 4.64 
                 5 
                 800 
               
               
                   
                 Ex. 4.65 
                 8 
                 207 
               
               
                   
                 Ex. 4.66 
                 1 
                 23 
               
               
                   
                 Ex. 4.67 
                 0.9 
                 251 
               
               
                   
                 Ex. 4.68 
                 2 
                 400 
               
               
                   
                 Ex. 4.69 
                 2 
                 191 
               
               
                   
                 Ex. 4.7 
                 2 
                 603 
               
               
                   
                 Ex. 4.70 
                 0.6 
                 404 
               
               
                   
                 Ex. 4.71 
                 7 
                 133 
               
               
                   
                 Ex. 4.72 
                 4 
                 51 
               
               
                   
                 Ex. 4.73 
                 17 
                 1290 
               
               
                   
                 Ex. 4.74 
                 4 
                 78 
               
               
                   
                 Ex. 4.75 
                 8 
                 636 
               
               
                   
                 Ex. 4.76 
                 8 
                 113 
               
               
                   
                 Ex. 4.77 
                 5 
                 790 
               
               
                   
                 Ex. 4.78 
                 3 
                 1630 
               
               
                   
                 Ex. 4.79 
                 18 
                 541 
               
               
                   
                 Ex. 4.8 
                 68 
                 9930 
               
               
                   
                 Ex. 4.80 
                 3 
                 2020 
               
               
                   
                 Ex. 4.81 
                 4 
                 79 
               
               
                   
                 Ex. 4.82 
                 4 
                 32 
               
               
                   
                 Ex. 4.83 
                 159 
                 2322 
               
               
                   
                 Ex. 4.84 
                 8 
                 58 
               
               
                   
                 Ex. 4.85 
                 7 
                 43 
               
               
                   
                 Ex. 4.86 
                 7 
                 352 
               
               
                   
                 Ex. 4.87 
                 4 
                 2076 
               
               
                   
                 Ex. 4.88 
                 11 
                 182 
               
               
                   
                 Ex. 4.89 
                 3 
                 2170 
               
               
                   
                 Ex. 4.9 
                 2 
                 2780 
               
               
                   
                 Ex. 4.90 
                 6 
                 2350 
               
               
                   
                 Ex. 4.91 
                 17 
                 183 
               
               
                   
                 Ex. 4.92 
                 5 
                 212 
               
               
                   
                 Ex. 4.93 
                 4 
                 74 
               
               
                   
                 Ex. 4.94 
                 3 
                 543 
               
               
                   
                 Ex. 4.95 
                 28 
                 1170 
               
               
                   
                 Ex. 4.96 
                 31 
                 996 
               
               
                   
                 Ex. 4.97 
                 4 
                 129 
               
               
                   
                 Ex. 4.98 
                 4 
                 1300 
               
               
                   
                 Ex. 4.99 
                 13 
                 981 
               
               
                   
                 Ex. 4.102 
                 10 
                 103 
               
               
                   
                 Ex. 4.103 
                 4 
                 178 
               
               
                   
                 Ex. 4.104 
                 14 
                 1660 
               
               
                   
                 Ex. 4.105 
                 5 
                 177 
               
               
                   
                 Ex. 4.106 
                 23 
                 529 
               
               
                   
                 Ex. 4.107 
                 47 
                 1760 
               
               
                   
                 Ex. 4.108 
                 7 
                 419 
               
               
                   
                 Ex. 4.109 
                 3 
                 108 
               
               
                   
                 Ex. 4.110 
                 13 
                 1520 
               
               
                   
                 Ex. 4.111 
                 2 
                 110 
               
               
                   
                 Ex. 4.112 
                 3 
                 1060 
               
               
                   
                 Ex. 4.113 
                 9 
                 2040 
               
               
                   
                 Ex. 4.114 
                 33 
                 1360 
               
               
                   
                 Ex. 4.115 
                 7 
                 754 
               
               
                   
                 Ex. 4.116 
                 6 
                 198 
               
               
                   
                 Ex. 4.117 
                 16 
                 2570 
               
               
                   
                 Ex. 4.118 
                 50 
                 4350 
               
               
                   
                 Ex. 4.119 
                 21 
                 2050 
               
               
                   
                 Ex. 4.120 
                 14 
                 725 
               
               
                   
                 Ex. 4.121 
                 6 
                 475 
               
               
                   
                 Ex. 4.122 
                 3 
                 610 
               
               
                   
                 Ex. 4.123 
                 21 
                 871 
               
               
                   
                 Ex. 4.124 
                 8 
                 591 
               
               
                   
                 Ex. 4.125 
                 1 
                 81 
               
               
                   
                 Ex. 4.126 
                 43 
                 2380 
               
               
                   
                 Ex. 4.127 
                 1 
                 19 
               
               
                   
                 Ex. 4.128 
                 1 
                 387 
               
               
                   
                 Ex. 4.129 
                 35 
                 2750 
               
               
                   
                 Ex. 4.130 
                 11 
                 128 
               
               
                   
                 Ex. 4.131 
                 23 
                 501 
               
               
                   
                 Ex. 4.132 
                 87 
                 1320 
               
               
                   
                 Ex. 4.133 
                 25 
                 359 
               
               
                   
                 Ex. 4.134 
                 1 
                 86 
               
               
                   
                 Ex. 4.135 
                 4 
                 203 
               
               
                   
                 Ex. 4.136 
                 14 
                 4360 
               
               
                   
                 Ex. 4.137 
                 5 
                 3090 
               
               
                   
                 Ex. 4.138 
                 2 
                 1340 
               
               
                   
                 Ex. 4.139 
                 5 
                 2260 
               
               
                   
                 Ex. 4.140 
                 7 
                 2170 
               
               
                   
                 Ex. 4.141 
                 5 
                 2760 
               
               
                   
                 Ex. 4.142 
                 6 
                 2160 
               
               
                   
                 Ex. 4.143 
                 24 
                 3680 
               
               
                   
                 Ex. 4.144 
                 9 
                 463 
               
               
                   
                 Ex. 4.145 
                 3 
                 635 
               
               
                   
                 Ex. 4.146 
                 6 
                 2110 
               
               
                   
                 Ex. 4.147 
                 13 
                 9650 
               
               
                   
                 Ex. 4.148 
                 7 
                 3180 
               
               
                   
                 Ex. 4.149 
                 14 
                 752 
               
               
                   
                 Ex. 4.150 
                 6 
                 180 
               
               
                   
                 Ex. 4.151 
                 5 
                 185 
               
               
                   
                 Ex. 4.152 
                 2 
                 40 
               
               
                   
                 Ex. 4.153 
                 3 
                 80 
               
               
                   
                 Ex. 4.154 
                 26 
                 4800 
               
               
                   
                 Ex. 4.155 
                 42 
                 891 
               
               
                   
                 Ex. 4.156 
                 14 
                 489 
               
               
                   
                 Ex. 4.157 
                 13 
                 1710 
               
               
                   
                 Ex. 4.158 
                 2 
                 308 
               
               
                   
                 Ex. 4.159 
                 4 
                 215 
               
               
                   
                 Ex. 4.160 
                 2 
                 27 
               
               
                   
                 Ex. 4.161 
                 2 
                 191 
               
               
                   
                 Ex. 4.162 
                 2 
                 299 
               
               
                   
                 Ex. 4.163 
                 20 
                 4400 
               
               
                   
                 Ex. 4.164 
                 7 
                 725 
               
               
                   
                 Ex. 4.165 
                 20 
                 968 
               
               
                   
                 Ex. 4.166 
                 2 
                 568 
               
               
                   
                 Ex. 4.167 
                 13 
                 144 
               
               
                   
                 Ex. 4.168 
                 10 
                 486 
               
               
                   
                 Ex. 4.169 
                 4 
                 892 
               
               
                   
                 Ex. 4.170 
                 11 
                 1430 
               
               
                   
                 Ex. 4.171 
                 1.5 
                 571 
               
               
                   
                 Ex. 4.172 
                 2 
                 457 
               
               
                   
                 Ex. 4.173 
                 13 
                 6330 
               
               
                   
                 Ex. 4.174 
                 12 
                 132 
               
               
                   
                 Ex. 4.175 
                 14 
                 249 
               
               
                   
                 Ex. 4.176 
                 15 
                 1067 
               
               
                   
                 Ex. 4.177 
                 9 
                 219 
               
               
                   
                 Ex. 4.178 
                 7 
                 350 
               
               
                   
                 Ex. 4.179 
                 27 
                 69 
               
               
                   
                 Ex. 4.180 
                 8 
                 304 
               
               
                   
                 Ex. 4.181 
                 3 
                 230 
               
               
                   
                 Ex. 4.182 
                 7 
                 694 
               
               
                   
                 Ex. 4.183 
                 93 
                 2256 
               
               
                   
                 Ex. 5.1 
                 26 
                 13 
               
               
                   
                 Ex. 5.10 
                 6 
                 16 
               
               
                   
                 Ex. 5.100 
                 17 
                 27 
               
               
                   
                 Ex. 5.101 
                 59 
                 54 
               
               
                   
                 Ex. 5.102 
                 34 
                 82 
               
               
                   
                 Ex. 5.103 
                 46 
                 70 
               
               
                   
                 Ex. 5.104 
                 92 
                 97 
               
               
                   
                 Ex. 5.105 
                 24 
                 28 
               
               
                   
                 Ex. 5.106 
                 25 
                 37 
               
               
                   
                 Ex. 5.107 
                 58 
                 53 
               
               
                   
                 Ex. 5.108 
                 265 
                 161 
               
               
                   
                 Ex. 5.109 
                 3 
                 4 
               
               
                   
                 Ex. 5.11 
                 29 
                 413 
               
               
                   
                 Ex. 5.110 
                 13 
                 14 
               
               
                   
                 Ex. 5.111 
                 5 
                 7 
               
               
                   
                 Ex. 5.112 
                 12 
                 16 
               
               
                   
                 Ex. 5.113 
                 12 
                 15 
               
               
                   
                 Ex. 5.114 
                 10 
                 21 
               
               
                   
                 Ex. 5.115 
                 22 
                 18 
               
               
                   
                 Ex. 5.116 
                 39 
                 19 
               
               
                   
                 Ex. 5.117 
                 57 
                 38 
               
               
                   
                 Ex. 5.118 
                 25 
                 35 
               
               
                   
                 Ex. 5.119 
                 30 
                 29 
               
               
                   
                 Ex. 5.12 
                 15 
                 134 
               
               
                   
                 Ex. 5.120 
                 48 
                 26 
               
               
                   
                 Ex. 5.121 
                 56 
                 43 
               
               
                   
                 Ex. 5.122 
                 99 
                 74 
               
               
                   
                 Ex. 5.123 
                 146 
                 304 
               
               
                   
                 Ex. 5.124 
                 113 
                 411 
               
               
                   
                 Ex. 5.125 
                 84 
                 126 
               
               
                   
                 Ex. 5.126 
                 117 
                 396 
               
               
                   
                 Ex. 5.127 
                 1 
                 6 
               
               
                   
                 Ex. 5.128 
                 20 
                 219 
               
               
                   
                 Ex. 5.129 
                 20 
                 62 
               
               
                   
                 Ex. 5.13 
                 6 
                 31 
               
               
                   
                 Ex. 5.130 
                 24 
                 58 
               
               
                   
                 Ex. 5.131 
                 15 
                 178 
               
               
                   
                 Ex. 5.132 
                 54 
                 615 
               
               
                   
                 Ex. 5.133 
                 11 
                 45 
               
               
                   
                 Ex. 5.134 
                 8 
                 20 
               
               
                   
                 Ex. 5.135 
                 10 
                 49 
               
               
                   
                 Ex. 5.136 
                 6 
                 35 
               
               
                   
                 Ex. 5.137 
                 3 
                 6 
               
               
                   
                 Ex. 5.138 
                 2 
                 10 
               
               
                   
                 Ex. 5.139 
                 2 
                 21 
               
               
                   
                 Ex. 5.14 
                 6 
                 31 
               
               
                   
                 Ex. 5.140 
                 5 
                 28 
               
               
                   
                 Ex. 5.141 
                 27 
                 244 
               
               
                   
                 Ex. 5.142 
                 8 
                 24 
               
               
                   
                 Ex. 5.143 
                 7 
                 82 
               
               
                   
                 Ex. 5.144 
                 20 
                 210 
               
               
                   
                 Ex. 5.145 
                 6 
                 30 
               
               
                   
                 Ex. 5.146 
                 15 
                 43 
               
               
                   
                 Ex. 5.147 
                 27 
                 112 
               
               
                   
                 Ex. 5.148 
                 35 
                 159 
               
               
                   
                 Ex. 5.149 
                 21 
                 26 
               
               
                   
                 Ex. 5.15 
                 5 
                 22 
               
               
                   
                 Ex. 5.150 
                 37 
                 49 
               
               
                   
                 Ex. 5.151 
                 20 
                 40 
               
               
                   
                 Ex. 5.152 
                 24 
                 51 
               
               
                   
                 Ex. 5.153 
                 22 
                 35 
               
               
                   
                 Ex. 5.154 
                 59 
                 61 
               
               
                   
                 Ex. 5.155 
                 134 
                 249 
               
               
                   
                 Ex. 5.156 
                 38 
                 54 
               
               
                   
                 Ex. 5.157 
                 367 
                 538 
               
               
                   
                 Ex. 5.158 
                 525 
                 879 
               
               
                   
                 Ex. 5.159 
                 23 
                 37 
               
               
                   
                 Ex. 5.16 
                 16 
                 18 
               
               
                   
                 Ex. 5.160 
                 38 
                 113 
               
               
                   
                 Ex. 5.161 
                 405 
                 388 
               
               
                   
                 Ex. 5.162 
                 252 
                 250 
               
               
                   
                 Ex. 5.163 
                 142 
                 401 
               
               
                   
                 Ex. 5.164 
                 104 
                 419 
               
               
                   
                 Ex. 5.165 
                 65 
                 355 
               
               
                   
                 Ex. 5.166 
                 13 
                 59 
               
               
                   
                 Ex. 5.167 
                 91 
                 351 
               
               
                   
                 Ex. 5.168 
                 64 
                 570 
               
               
                   
                 Ex. 5.169 
                 63 
                 197 
               
               
                   
                 Ex. 5.17 
                 11 
                 76 
               
               
                   
                 Ex. 5.170 
                 2 
                 13 
               
               
                   
                 Ex. 5.171 
                 12 
                 58 
               
               
                   
                 Ex. 5.172 
                 92 
                 704 
               
               
                   
                 Ex. 5.173 
                 290 
                 1138 
               
               
                   
                 Ex. 5.174 
                 59 
                 133 
               
               
                   
                 Ex. 5.175 
                 24 
                 355 
               
               
                   
                 Ex. 5.176 
                 389 
                 1067 
               
               
                   
                 Ex. 5.177 
                 76 
                 860 
               
               
                   
                 Ex. 5.178 
                 20 
                 280 
               
               
                   
                 Ex. 5.179 
                 368 
                 1125 
               
               
                   
                 Ex. 5.18 
                 23 
                 84 
               
               
                   
                 Ex. 5.180 
                 42 
                 261 
               
               
                   
                 Ex. 5.181 
                 385 
                 556 
               
               
                   
                 Ex. 5.182 
                 10 
                 55 
               
               
                   
                 Ex. 5.183 
                 339 
                 1165 
               
               
                   
                 Ex. 5.184 
                 300 
                 413 
               
               
                   
                 Ex. 5.185 
                 91 
                 283 
               
               
                   
                 Ex. 5.186 
                 120 
                 294 
               
               
                   
                 Ex. 5.187 
                 310 
                 &gt;2589 
               
               
                   
                 Ex. 5.188 
                 23 
                 119 
               
               
                   
                 Ex. 5.189 
                 16 
                 62 
               
               
                   
                 Ex. 5.19 
                 9 
                 20 
               
               
                   
                 Ex. 5.190 
                 58 
                 119 
               
               
                   
                 Ex. 5.191 
                 18 
                 69 
               
               
                   
                 Ex. 5.192 
                 23 
                 88 
               
               
                   
                 Ex. 5.193 
                 24 
                 203 
               
               
                   
                 Ex. 5.194 
                 13 
                 98 
               
               
                   
                 Ex. 5.195 
                 73 
                 102 
               
               
                   
                 Ex. 5.196 
                 91 
                 199 
               
               
                   
                 Ex. 5.197 
                 18 
                 166 
               
               
                   
                 Ex. 5.198 
                 18 
                 34 
               
               
                   
                 Ex. 5.199 
                 12 
                 83 
               
               
                   
                 Ex. 5.2 
                 2 
                 5 
               
               
                   
                 Ex. 5.20 
                 19 
                 161 
               
               
                   
                 Ex. 5.200 
                 115 
                 517 
               
               
                   
                 Ex. 5.201 
                 265 
                 861 
               
               
                   
                 Ex. 5.202 
                 227 
                 924 
               
               
                   
                 Ex. 5.203 
                 195 
                 1380 
               
               
                   
                 Ex. 5.204 
                 360 
                 900 
               
               
                   
                 Ex. 5.205 
                 149 
                 852 
               
               
                   
                 Ex. 5.206 
                 19 
                 117 
               
               
                   
                 Ex. 5.207 
                 15 
                 78 
               
               
                   
                 Ex. 5.208 
                 53 
                 284 
               
               
                   
                 Ex. 5.209 
                 17 
                 101 
               
               
                   
                 Ex. 5.21 
                 22 
                 18 
               
               
                   
                 Ex. 5.210 
                 3 
                 27 
               
               
                   
                 Ex. 5.211 
                 27 
                 159 
               
               
                   
                 Ex. 5.212 
                 26 
                 239 
               
               
                   
                 Ex. 5.213 
                 16 
                 51 
               
               
                   
                 Ex. 5.214 
                 2 
                 4 
               
               
                   
                 Ex. 5.215 
                 4 
                 11 
               
               
                   
                 Ex. 5.216 
                 15 
                 45 
               
               
                   
                 Ex. 5.22 
                 7 
                 86 
               
               
                   
                 Ex. 5.23 
                 15 
                 80 
               
               
                   
                 Ex. 5.24 
                 2 
                 9 
               
               
                   
                 Ex. 5.25 
                 27 
                 81 
               
               
                   
                 Ex. 5.26 
                 39 
                 197 
               
               
                   
                 Ex. 5.27 
                 46 
                 507 
               
               
                   
                 Ex. 5.28 
                 4 
                 19 
               
               
                   
                 Ex. 5.29 
                 13 
                 59 
               
               
                   
                 Ex. 5.3 
                 2 
                 4 
               
               
                   
                 Ex. 5.30 
                 57 
                 164 
               
               
                   
                 Ex. 5.31 
                 44 
                 740 
               
               
                   
                 Ex. 5.32 
                 90 
                 46 
               
               
                   
                 Ex. 5.33 
                 25 
                 29 
               
               
                   
                 Ex. 5.34 
                 2 
                 9 
               
               
                   
                 Ex. 5.35 
                 102 
                 99 
               
               
                   
                 Ex. 5.36 
                 2 
                 3 
               
               
                   
                 Ex. 5.37 
                 10 
                 16 
               
               
                   
                 Ex. 5.38 
                 4 
                 12 
               
               
                   
                 Ex. 5.39 
                 36 
                 20 
               
               
                   
                 Ex. 5.4 
                 10 
                 6 
               
               
                   
                 Ex. 5.40 
                 44 
                 91 
               
               
                   
                 Ex. 5.41 
                 2 
                 2 
               
               
                   
                 Ex. 5.42 
                 49 
                 75 
               
               
                   
                 Ex. 5.43 
                 3 
                 14 
               
               
                   
                 Ex. 5.44 
                 8 
                 29 
               
               
                   
                 Ex. 5.45 
                 5 
                 12 
               
               
                   
                 Ex. 5.46 
                 6 
                 14 
               
               
                   
                 Ex. 5.47 
                 5 
                 15 
               
               
                   
                 Ex. 5.48 
                 12 
                 25 
               
               
                   
                 Ex. 5.49 
                 85 
                 114 
               
               
                   
                 Ex. 5.5 
                 3 
                 5 
               
               
                   
                 Ex. 5.50 
                 49 
                 33 
               
               
                   
                 Ex. 5.51 
                 10 
                 18 
               
               
                   
                 Ex. 5.52 
                 107 
                 43 
               
               
                   
                 Ex. 5.53 
                 24 
                 23 
               
               
                   
                 Ex. 5.54 
                 33 
                 20 
               
               
                   
                 Ex. 5.55 
                 113 
                 202 
               
               
                   
                 Ex. 5.56 
                 12 
                 15 
               
               
                   
                 Ex. 5.57 
                 57 
                 55 
               
               
                   
                 Ex. 5.58 
                 3 
                 6 
               
               
                   
                 Ex. 5.59 
                 42 
                 84 
               
               
                   
                 Ex. 5.6 
                 32 
                 59 
               
               
                   
                 Ex. 5.60 
                 156 
                 54 
               
               
                   
                 Ex. 5.61 
                 112 
                 26 
               
               
                   
                 Ex. 5.62 
                 35 
                 130 
               
               
                   
                 Ex. 5.64 
                 17 
                 19 
               
               
                   
                 Ex. 5.65 
                 200 
                 154 
               
               
                   
                 Ex. 5.66 
                 872 
                 458 
               
               
                   
                 Ex. 5.67 
                 27 
                 23 
               
               
                   
                 Ex. 5.68 
                 141 
                 150 
               
               
                   
                 Ex. 5.69 
                 414 
                 1200 
               
               
                   
                 Ex. 5.7 
                 5 
                 29 
               
               
                   
                 Ex. 5.70 
                 31 
                 83 
               
               
                   
                 Ex. 5.71 
                 56 
                 22 
               
               
                   
                 Ex. 5.72 
                 19 
                 16 
               
               
                   
                 Ex. 5.73 
                 98 
                 57 
               
               
                   
                 Ex. 5.74 
                 592 
                 414 
               
               
                   
                 Ex. 5.75 
                 300 
                 126 
               
               
                   
                 Ex. 5.76 
                 33 
                 47 
               
               
                   
                 Ex. 5.77 
                 64 
                 153 
               
               
                   
                 Ex. 5.78 
                 31 
                 72 
               
               
                   
                 Ex. 5.79 
                 43 
                 97 
               
               
                   
                 Ex. 5.8 
                 13 
                 129 
               
               
                   
                 Ex. 5.80 
                 548 
                 360 
               
               
                   
                 Ex. 5.81 
                 258 
                 130 
               
               
                   
                 Ex. 5.82 
                 27 
                 15 
               
               
                   
                 Ex. 5.83 
                 426 
                 104 
               
               
                   
                 Ex. 5.84 
                 138 
                 76 
               
               
                   
                 Ex. 5.85 
                 316 
                 114 
               
               
                   
                 Ex. 5.86 
                 94 
                 85 
               
               
                   
                 Ex. 5.87 
                 203 
                 157 
               
               
                   
                 Ex. 5.88 
                 192 
                 166 
               
               
                   
                 Ex. 5.89 
                 148 
                 119 
               
               
                   
                 Ex. 5.9 
                 8 
                 81 
               
               
                   
                 Ex. 5.90 
                 232 
                 473 
               
               
                   
                 Ex. 5.91 
                 217 
                 1290 
               
               
                   
                 Ex. 5.92 
                 62 
                 177 
               
               
                   
                 Ex. 5.93 
                 15 
                 19 
               
               
                   
                 Ex. 5.94 
                 14 
                 37 
               
               
                   
                 Ex. 5.95 
                 11 
                 29 
               
               
                   
                 Ex. 5.96 
                 13 
                 32 
               
               
                   
                 Ex. 5.97 
                 6 
                 11 
               
               
                   
                 Ex. 5.98 
                 120 
                 264 
               
               
                   
                 Ex. 5.99 
                 6 
                 11 
               
               
                   
                 Ex. 5.217 
                 98 
                 274 
               
               
                   
                 Ex. 5.218 
                 13 
                 36 
               
               
                   
                 Ex. 5.219 
                 19 
                 72 
               
               
                   
                 Ex. 5.220 
                 98 
                 249 
               
               
                   
                 Ex. 5.221 
                 19 
                 83 
               
               
                   
                 Ex. 5.222 
                 26 
                 68 
               
               
                   
                 Ex. 5.223 
                 3 
                 12 
               
               
                   
                 Ex. 5.224 
                 7 
                 21 
               
               
                   
                 Ex. 5.225 
                 16 
                 44 
               
               
                   
                 Ex. 5.226 
                 7 
                 155 
               
               
                   
                 Ex. 5.227 
                 20 
                 521 
               
               
                   
                 Ex. 5.228 
                 56 
                 2030 
               
               
                   
                 Ex. 5.229 
                 54 
                 858 
               
               
                   
                 Ex. 5.230 
                 21 
                 530 
               
               
                   
                 Ex. 5.231 
                 15 
                 135 
               
               
                   
                 Ex. 5.232 
                 20 
                 2055 
               
               
                   
                 Ex. 5.233 
                 5 
                 263 
               
               
                   
                 Ex. 5.234 
                 8 
                 131 
               
               
                   
                 Ex. 5.235 
                 5 
                 16.5 
               
               
                   
                 Ex. 5.236 
                 26 
                 173 
               
               
                   
                 Ex. 5.237 
                 58 
                 223 
               
               
                   
                 Ex. 5.238 
                 23 
                 91 
               
               
                   
                 Ex. 5.239 
                 35 
                 594 
               
               
                   
                 Ex. 5.240 
                 38 
                 232 
               
               
                   
                 Ex. 5.241 
                 54 
                 1000 
               
               
                   
                 Ex. 5.242 
                 56 
                 401 
               
               
                   
                 Ex. 5.243 
                 88 
                 1120 
               
               
                   
                 Ex. 5.244 
                 62 
                 641 
               
               
                   
                 Ex. 5.245 
                 14 
                 80 
               
               
                   
                 Ex. 5.246 
                 28 
                 533 
               
               
                   
                 Ex. 5.247 
                 10 
                 136 
               
               
                   
                 Ex. 5.248 
                 22 
                 494 
               
               
                   
                 Ex. 5.249 
                 38 
                 53 
               
               
                   
                 Ex. 5.250 
                 184 
                 992 
               
               
                   
                 Ex. 5.251 
                 13 
                 774 
               
               
                   
                 Ex. 5.252 
                 20 
                 1640 
               
               
                   
                 Ex. 5.253 
                 12 
                 1187 
               
               
                   
                 Ex. 5.254 
                 39 
                 9270 
               
               
                   
                 Ex. 5.255 
                 1 
                 145 
               
               
                   
                 Ex. 5.256 
                 13 
                 402 
               
               
                   
                 Ex. 5.257 
                 13 
                 329 
               
               
                   
                 Ex. 5.258 
                 36 
                 6520 
               
               
                   
                 Ex. 5.259 
                 29 
                 4660 
               
               
                   
                 Ex. 5.260 
                 20 
                 2870 
               
               
                   
                 Ex. 5.261 
                 4 
                 466 
               
               
                   
                 Ex. 5.262 
                 113 
                 1 
               
               
                   
                 Ex. 5.263 
                 56 
                 304 
               
               
                   
                 Ex. 5.264 
                 25 
                 65 
               
               
                   
                 Ex. 5.265 
                 9 
                 32 
               
               
                   
                 Ex. 5.266 
                 1 
                 1 
               
               
                   
                 Ex. 5.267 
                 12 
                 105 
               
               
                   
                 Ex. 5.268 
                 6 
                 9 
               
               
                   
                 Ex. 5.269 
                 15 
                 22 
               
               
                   
                 Ex. 5.270 
                 7 
                 9 
               
               
                   
                 Ex. 5.271 
                 5 
                 6 
               
               
                   
                 Ex. 5.272 
                 8 
                 12 
               
               
                   
                 Ex. 5.273 
                 7 
                 12 
               
               
                   
                 Ex. 5.274 
                 3 
                 8 
               
               
                   
                 Ex. 5.275 
                 5 
                 6 
               
               
                   
                 Ex. 5.276 
                 3 
                 8 
               
               
                   
                 Ex. 5.277 
                 6 
                 21 
               
               
                   
                 Ex. 5.278 
                 22 
                 31 
               
               
                   
                 Ex. 5.279 
                 3 
                 8 
               
               
                   
                 Ex. 5.280 
                 36 
                 16 
               
               
                   
                 Ex. 5.281 
                 34 
                 380 
               
               
                   
                 Ex. 5.282 
                 47 
                 97 
               
               
                   
                 Ex. 5.283 
                 87 
                 397 
               
               
                   
                 Ex. 5.284 
                 10 
                 18 
               
               
                   
                 Ex. 5.285 
                 32 
                 452 
               
               
                   
                 Ex. 5.286 
                 40 
                 4592 
               
               
                   
                 Ex. 5.287 
                 53 
                 1165 
               
               
                   
                 Ex. 5.288 
                 38 
                 1340 
               
               
                   
                 Ex. 5.289 
                 38 
                 532 
               
               
                   
                 Ex. 5.290 
                 33 
                 2140 
               
               
                   
                 Ex. 5.291 
                 48 
                 347 
               
               
                   
                 Ex. 5.292 
                 34 
                 671 
               
               
                   
                 Ex. 5.293 
                 77 
                 4040 
               
               
                   
                 Ex. 5.294 
                 39 
                 714 
               
               
                   
                 Ex. 5.295 
                 8 
                 254 
               
               
                   
                 Ex. 5.296 
                 25 
                 31 
               
               
                   
                 Ex. 5.297 
                 41 
                 57 
               
               
                   
                 Ex. 5.298 
                 15 
                 21 
               
               
                   
                 Ex. 5.299 
                 17 
                 21 
               
               
                   
                 Ex. 5.300 
                 10 
                 18 
               
               
                   
                 Ex. 5.301 
                 24 
                 16 
               
               
                   
                 Ex. 5.302 
                 28 
                 42 
               
               
                   
                 Ex. 5.303 
                 29 
                 21 
               
               
                   
                 Ex. 5.304 
                 19 
                 86 
               
               
                   
                 Ex. 5.305 
                 35 
                 41 
               
               
                   
                 Ex. 5.306 
                 33 
                 69 
               
               
                   
                 Ex. 5.307 
                 20 
                 49 
               
               
                   
                 Ex. 5.308 
                 21 
                 122 
               
               
                   
                 Ex. 5.309 
                 23 
                 21 
               
               
                   
                 Ex. 5.310 
                 32 
                 70 
               
               
                   
                 Ex. 6.1 
                 367 
                 33 
               
               
                   
                 Ex. 6.10 
                 206 
                 81 
               
               
                   
                 Ex. 6.100 
                 55 
                 4 
               
               
                   
                 Ex. 6.101 
                 10 
                 0.9 
               
               
                   
                 Ex. 6.102 
                 364 
                 32 
               
               
                   
                 Ex. 6.103 
                 184 
                 6 
               
               
                   
                 Ex. 6.104 
                 13 
                 0.8 
               
               
                   
                 Ex. 6.105 
                 1060 
                 77 
               
               
                   
                 Ex. 6.106 
                 99 
                 5 
               
               
                   
                 Ex. 6.107 
                 74 
                 16 
               
               
                   
                 Ex. 6.108 
                 414 
                 7 
               
               
                   
                 Ex. 6.109 
                 112 
                 7 
               
               
                   
                 Ex. 6.11 
                 135 
                 56 
               
               
                   
                 Ex. 6.110 
                 15 
                 1 
               
               
                   
                 Ex. 6.111 
                 272 
                 14 
               
               
                   
                 Ex. 6.112 
                 15 
                 0.7 
               
               
                   
                 Ex. 6.113 
                 5 
                 1 
               
               
                   
                 Ex. 6.114 
                 16 
                 0.7 
               
               
                   
                 Ex. 6.115 
                 333 
                 9 
               
               
                   
                 Ex. 6.116 
                 14 
                 3 
               
               
                   
                 Ex. 6.117 
                 19 
                 3 
               
               
                   
                 Ex. 6.118 
                 21 
                 4 
               
               
                   
                 Ex. 6.119 
                 14 
                 3 
               
               
                   
                 Ex. 6.12 
                 317 
                 6 
               
               
                   
                 Ex. 6.120 
                 8 
                 0.6 
               
               
                   
                 Ex. 6.121 
                 1 
                 0.5 
               
               
                   
                 Ex. 6.122 
                 0.9 
                 0.6 
               
               
                   
                 Ex. 6.123 
                 2 
                 0.7 
               
               
                   
                 Ex. 6.124 
                 15 
                 4 
               
               
                   
                 Ex. 6.125 
                 2 
                 0.8 
               
               
                   
                 Ex. 6.126 
                 3 
                 0.8 
               
               
                   
                 Ex. 6.127 
                 17 
                 4 
               
               
                   
                 Ex. 6.128 
                 20 
                 1 
               
               
                   
                 Ex. 6.129 
                 215 
                 39 
               
               
                   
                 Ex. 6.13 
                 155 
                 17 
               
               
                   
                 Ex. 6.130 
                 11 
                 0.6 
               
               
                   
                 Ex. 6.131 
                 9 
                 0.5 
               
               
                   
                 Ex. 6.132 
                 13 
                 4 
               
               
                   
                 Ex. 6.133 
                 3 
                 2 
               
               
                   
                 Ex. 6.134 
                 75 
                 10 
               
               
                   
                 Ex. 6.135 
                 83 
                 5 
               
               
                   
                 Ex. 6.136 
                 765 
                 4 
               
               
                   
                 Ex. 6.137 
                 4950 
                 23 
               
               
                   
                 Ex. 6.138 
                 &gt;6970 
                 34 
               
               
                   
                 Ex. 6.139 
                 137 
                 0.6 
               
               
                   
                 Ex. 6.14 
                 87 
                 12 
               
               
                   
                 Ex. 6.140 
                 667 
                 10 
               
               
                   
                 Ex. 6.141 
                 883 
                 9 
               
               
                   
                 Ex. 6.142 
                 17 
                 22 
               
               
                   
                 Ex. 6.143 
                 13 
                 32 
               
               
                   
                 Ex. 6.144 
                 15 
                 56 
               
               
                   
                 Ex. 6.145 
                 21 
                 75 
               
               
                   
                 Ex. 6.146 
                 16 
                 33 
               
               
                   
                 Ex. 6.147 
                 13 
                 34 
               
               
                   
                 Ex. 6.148 
                 19 
                 40 
               
               
                   
                 Ex. 6.149 
                 59 
                 90 
               
               
                   
                 Ex. 6.15 
                 298 
                 37 
               
               
                   
                 Ex. 6.150 
                 218 
                 91 
               
               
                   
                 Ex. 6.151 
                 46 
                 44 
               
               
                   
                 Ex. 6.152 
                 5 
                 20 
               
               
                   
                 Ex. 6.153 
                 8 
                 16 
               
               
                   
                 Ex. 6.154 
                 32 
                 38 
               
               
                   
                 Ex. 6.155 
                 649 
                 105 
               
               
                   
                 Ex. 6.156 
                 34 
                 12 
               
               
                   
                 Ex. 6.157 
                 70 
                 21 
               
               
                   
                 Ex. 6.158 
                 57 
                 35 
               
               
                   
                 Ex. 6.159 
                 11 
                 10 
               
               
                   
                 Ex. 6.16 
                 307 
                 151 
               
               
                   
                 Ex. 6.160 
                 326 
                 8 
               
               
                   
                 Ex. 6.161 
                 51 
                 3 
               
               
                   
                 Ex. 6.162 
                 330 
                 7 
               
               
                   
                 Ex. 6.163 
                 259 
                 72 
               
               
                   
                 Ex. 6.164 
                 100 
                 9 
               
               
                   
                 Ex. 6.165 
                 9 
                 3 
               
               
                   
                 Ex. 6.166 
                 33 
                 4 
               
               
                   
                 Ex. 6.167 
                 573 
                 25 
               
               
                   
                 Ex. 6.168 
                 261 
                 54 
               
               
                   
                 Ex. 6.169 
                 344 
                 479 
               
               
                   
                 Ex. 6.17 
                 308 
                 47 
               
               
                   
                 Ex. 6.170 
                 18 
                 15 
               
               
                   
                 Ex. 6.171 
                 162 
                 19 
               
               
                   
                 Ex. 6.172 
                 1260 
                 67 
               
               
                   
                 Ex. 6.173 
                 842 
                 64 
               
               
                   
                 Ex. 6.174 
                 233 
                 15 
               
               
                   
                 Ex. 6.175 
                 77 
                 19 
               
               
                   
                 Ex. 6.176 
                 58 
                 18 
               
               
                   
                 Ex. 6.177 
                 13 
                 6 
               
               
                   
                 Ex. 6.178 
                 44 
                 10 
               
               
                   
                 Ex. 6.179 
                 6 
                 7 
               
               
                   
                 Ex. 6.18 
                 1530 
                 29 
               
               
                   
                 Ex. 6.180 
                 5 
                 4 
               
               
                   
                 Ex. 6.181 
                 2 
                 2 
               
               
                   
                 Ex. 6.182 
                 12 
                 6 
               
               
                   
                 Ex. 6.183 
                 127 
                 21 
               
               
                   
                 Ex. 6.184 
                 67 
                 73 
               
               
                   
                 Ex. 6.185 
                 239 
                 103 
               
               
                   
                 Ex. 6.186 
                 27 
                 6 
               
               
                   
                 Ex. 6.187 
                 24 
                 15 
               
               
                   
                 Ex. 6.188 
                 115 
                 66 
               
               
                   
                 Ex. 6.189 
                 47 
                 25 
               
               
                   
                 Ex. 6.19 
                 1530 
                 61 
               
               
                   
                 Ex. 6.190 
                 10 
                 9 
               
               
                   
                 Ex. 6.191 
                 134 
                 7 
               
               
                   
                 Ex. 6.192 
                 48 
                 7 
               
               
                   
                 Ex. 6.193 
                 41 
                 4 
               
               
                   
                 Ex. 6.194 
                 51 
                 5 
               
               
                   
                 Ex. 6.195 
                 43 
                 11 
               
               
                   
                 Ex. 6.196 
                 59 
                 12 
               
               
                   
                 Ex. 6.197 
                 6 
                 2 
               
               
                   
                 Ex. 6.2 
                 223 
                 17 
               
               
                   
                 Ex. 6.20 
                 1750 
                 49 
               
               
                   
                 Ex. 6.21 
                 1970 
                 76 
               
               
                   
                 Ex. 6.22 
                 410 
                 19 
               
               
                   
                 Ex. 6.23 
                 452 
                 67 
               
               
                   
                 Ex. 6.24 
                 53 
                 17 
               
               
                   
                 Ex. 6.25 
                 154 
                 52 
               
               
                   
                 Ex. 6.26 
                 26 
                 24 
               
               
                   
                 Ex. 6.27 
                 5 
                 9 
               
               
                   
                 Ex. 6.28 
                 20 
                 15 
               
               
                   
                 Ex. 6.29 
                 69 
                 92 
               
               
                   
                 Ex. 6.3 
                 243 
                 18 
               
               
                   
                 Ex. 6.30 
                 203 
                 31 
               
               
                   
                 Ex. 6.31 
                 41 
                 22 
               
               
                   
                 Ex. 6.32 
                 814 
                 103 
               
               
                   
                 Ex. 6.33 
                 213 
                 23 
               
               
                   
                 Ex. 6.34 
                 398 
                 66 
               
               
                   
                 Ex. 6.35 
                 146 
                 80 
               
               
                   
                 Ex. 6.36 
                 15 
                 2 
               
               
                   
                 Ex. 6.37 
                 422 
                 45 
               
               
                   
                 Ex. 6.38 
                 269 
                 19 
               
               
                   
                 Ex. 6.39 
                 106 
                 9 
               
               
                   
                 Ex. 6.4 
                 2510 
                 118 
               
               
                   
                 Ex. 6.40 
                 70 
                 9 
               
               
                   
                 Ex. 6.41 
                 4 
                 2 
               
               
                   
                 Ex. 6.42 
                 12 
                 2 
               
               
                   
                 Ex. 6.43 
                 368 
                 62 
               
               
                   
                 Ex. 6.44 
                 10 
                 2 
               
               
                   
                 Ex. 6.45 
                 1 
                 1 
               
               
                   
                 Ex. 6.46 
                 30 
                 4 
               
               
                   
                 Ex. 6.47 
                 6 
                 1 
               
               
                   
                 Ex. 6.48 
                 14 
                 7 
               
               
                   
                 Ex. 6.49 
                 3 
                 1 
               
               
                   
                 Ex. 6.5 
                 216 
                 19 
               
               
                   
                 Ex. 6.50 
                 5 
                 1 
               
               
                   
                 Ex. 6.51 
                 8 
                 3 
               
               
                   
                 Ex. 6.52 
                 8 
                 2 
               
               
                   
                 Ex. 6.53 
                 4 
                 1 
               
               
                   
                 Ex. 6.54 
                 3 
                 1 
               
               
                   
                 Ex. 6.55 
                 5 
                 1 
               
               
                   
                 Ex. 6.56 
                 6 
                 1 
               
               
                   
                 Ex. 6.57 
                 11 
                 11 
               
               
                   
                 Ex. 6.58 
                 4 
                 1 
               
               
                   
                 Ex. 6.59 
                 76 
                 10 
               
               
                   
                 Ex. 6.6 
                 477 
                 52 
               
               
                   
                 Ex. 6.60 
                 83 
                 3 
               
               
                   
                 Ex. 6.61 
                 41 
                 4 
               
               
                   
                 Ex. 6.62 
                 44 
                 4 
               
               
                   
                 Ex. 6.63 
                 88 
                 3 
               
               
                   
                 Ex. 6.64 
                 142 
                 33 
               
               
                   
                 Ex. 6.65 
                 34 
                 3 
               
               
                   
                 Ex. 6.66 
                 57 
                 2 
               
               
                   
                 Ex. 6.67 
                 9 
                 5 
               
               
                   
                 Ex. 6.68 
                 767 
                 62 
               
               
                   
                 Ex. 6.69 
                 389 
                 51 
               
               
                   
                 Ex. 6.7 
                 15 
                 3 
               
               
                   
                 Ex. 6.71 
                 24 
                 2 
               
               
                   
                 Ex. 6.72 
                 4 
                 6 
               
               
                   
                 Ex. 6.73 
                 10 
                 4 
               
               
                   
                 Ex. 6.74 
                 4 
                 11 
               
               
                   
                 Ex. 6.75 
                 8 
                 4 
               
               
                   
                 Ex. 6.76 
                 4 
                 4 
               
               
                   
                 Ex. 6.77 
                 3 
                 9 
               
               
                   
                 Ex. 6.78 
                 5 
                 12 
               
               
                   
                 Ex. 6.79 
                 2 
                 4 
               
               
                   
                 Ex. 6.8 
                 21 
                 7 
               
               
                   
                 Ex. 6.80 
                 13 
                 19 
               
               
                   
                 Ex. 6.81 
                 19 
                 23 
               
               
                   
                 Ex. 6.82 
                 36 
                 208 
               
               
                   
                 Ex. 6.83 
                 8 
                 23 
               
               
                   
                 Ex. 6.84 
                 8 
                 14 
               
               
                   
                 Ex. 6.85 
                 108 
                 42 
               
               
                   
                 Ex. 6.86 
                 22 
                 20 
               
               
                   
                 Ex. 6.87 
                 1 
                 2 
               
               
                   
                 Ex. 6.88 
                 20 
                 15 
               
               
                   
                 Ex. 6.89 
                 2 
                 2 
               
               
                   
                 Ex. 6.9 
                 7 
                 4 
               
               
                   
                 Ex. 6.90 
                 6 
                 1 
               
               
                   
                 Ex. 6.91 
                 2 
                 1 
               
               
                   
                 Ex. 6.92 
                 4 
                 2 
               
               
                   
                 Ex. 6.93 
                 0.9 
                 3 
               
               
                   
                 Ex. 6.94 
                 2 
                 1 
               
               
                   
                 Ex. 6.95 
                 9 
                 2 
               
               
                   
                 Ex. 6.96 
                 234 
                 68 
               
               
                   
                 Ex. 6.97 
                 14 
                 10 
               
               
                   
                 Ex. 6.98 
                 4 
                 3 
               
               
                   
                 Ex. 6.99 
                 5 
                 1 
               
               
                   
                 Ex. 6.198 
                 12 
                 3 
               
               
                   
                 Ex. 6.199 
                 143 
                 6 
               
               
                   
                 Ex. 6.200 
                 58 
                 10 
               
               
                   
                 Ex. 6.201 
                 148 
                 25 
               
               
                   
                 Ex. 6.202 
                 89 
                 13 
               
               
                   
                 Ex. 7.1 
                 16 
                 162 
               
               
                   
                 Ex. 7.2 
                 420 
                 69 
               
               
                   
                 Ex. 7.3 
                 1 
                 3 
               
               
                   
                 Ex. 7.4 
                 7 
                 6 
               
               
                   
                 Ex. 7.5 
                 9 
                 2 
               
               
                   
                 Ex. 7.6 
                 5 
                 6 
               
               
                   
                 Ex. 7.7 
                 2 
                 3 
               
               
                   
                 Ex. 7.8 
                 2 
                 4 
               
               
                   
                 Ex. 7.9 
                 28 
                 28 
               
               
                   
                 Ex. 7.10 
                 33 
                 42 
               
               
                   
                 Ex. 7.11 
                 17 
                 720 
               
               
                   
                 Ex. 7.12 
                 15 
                 52 
               
               
                   
                 Ex. 7.13 
                 21 
                 49 
               
               
                   
                 Ex. 7.14 
                 23 
                 50 
               
               
                   
                 Ex. 7.15 
                 11 
                 65 
               
               
                   
                 Ex. 7.16 
                 8 
                 21 
               
               
                   
                 Ex. 7.17 
                 4 
                 19 
               
               
                   
                 Ex. 7.18 
                 1 
                 4 
               
               
                   
                 Ex. 7.19 
                 5 
                 8 
               
               
                   
                 Ex. 7.20 
                 2 
                 14 
               
               
                   
                 Ex. 7.21 
                 1 
                 2 
               
               
                   
                 Ex. 7.22 
                 1 
                 4 
               
               
                   
                 Ex. 7.23 
                 1 
                 3 
               
               
                   
                 Ex. 7.24 
                 33 
                 33 
               
               
                   
                 Ex. 7.25 
                 15 
                 18 
               
               
                   
                 Ex. 7.26 
                 42 
                 54 
               
               
                   
                 Ex. 7.27 
                 23 
                 17 
               
               
                   
                 Ex. 7.28 
                 14 
                 19 
               
               
                   
                 Ex. 7.29 
                 23 
                 70 
               
               
                   
                 Ex. 7.30 
                 9 
                 12 
               
               
                   
                 Ex. 7.31 
                 8 
                 19 
               
               
                   
                 Ex. 7.32 
                 7 
                 124 
               
               
                   
                 Ex. 7.33 
                 1 
                 3 
               
               
                   
                 Ex. 7.34 
                 16 
                 84 
               
               
                   
                 Ex. 7.35 
                 6 
                 20 
               
               
                   
                 Ex. 7.36 
                 16 
                 115 
               
               
                   
                 Ex. 7.37 
                 11 
                 20 
               
               
                   
                 Ex. 7.38 
                 8 
                 30 
               
               
                   
                 Ex. 7.39 
                 43 
                 61 
               
               
                   
                 Ex. 7.40 
                 23 
                 39 
               
               
                   
                 Ex. 7.41 
                 44 
                 106 
               
               
                   
                 Ex. 7.42 
                 38 
                 28 
               
               
                   
                 Ex. 7.43 
                 24 
                 42 
               
               
                   
                 Ex. 7.44 
                 21 
                 35 
               
               
                   
                 Ex. 7.45 
                 31 
                 60 
               
               
                   
                 Ex. 7.46 
                 78 
                 77 
               
               
                   
                 Ex. 7.47 
                 39 
                 60 
               
               
                   
                 Ex. 7.48 
                 33 
                 40 
               
               
                   
                 Ex. 7.49 
                 96 
                 173 
               
               
                   
                 Ex. 7.50 
                 66 
                 171 
               
               
                   
                 Ex. 7.51 
                 19 
                 27 
               
               
                   
                 Ex. 7.52 
                 27 
                 60 
               
               
                   
                 Ex. 7.53 
                 46 
                 190 
               
               
                   
                 Ex. 7.54 
                 87 
                 270 
               
               
                   
                   
               
            
           
         
       
     
     Compounds of the present invention may be further characterized with regard to their general pharmacokinetic and pharmacological properties using conventional assays well known in the art; for example relating to their bioavailablility in different species (such as rat or dog); or relating to their ability to cross the blood-brain barrier, using for example a human P-glycoprotein 1 (MDR 1) substrate assay, or an in vivo assay to determine drug concentrations in the brain, e.g. in rats after oral dosing; or relating to their functional behavior in different disease related animal models {for example: the sedative effect of the compound using Electroencephalography (EEG) and Electromyography (EMG) signal measurements [F. Jenck et al., Nature Medicine 2007, 13, 150-155]; the effect of the compound in the fear-potentiated startle paradigm [Fendt M et al., Neuroscience Biobehav Rev. 1999, 23, 743-760; WO2009/0047723]; the effect of the compound on stress-induced hyperthermia [Vinkers C H et al., European J Pharmacol. 2008, 585, 407-425]; the effect of the compound on morphine-induced locomotor sensitization [Vanderschuren L J M J et al., in Self D W, Staley J K (eds.) “Behavioral Neuroscience of Drug Addiction”, Current Topics in Behavioral Neurosciences 3 (2009), 179-195]}; or for their properties with regard to drug safety and/or toxicological properties using conventional assays well known in the art, for example relating to cytochrome P450 enzyme inhibition and time dependent inhibition, pregnane X receptor (PXR) activation, glutathione binding, or phototoxic behavior. 
     Measurement of Brain and Systemic Concentration after Oral Administration: 
     In order to assess brain penetration, the concentration of the compound is measured in plasma ([P]), and brain ([B]), sampled 3 h (or at different time points) following oral administration (e.g. 100 mg/kg) to male wistar rats. The compounds are formulated e.g. in 100% PEG 400. Samples are collected in the same animal at the same time point (+/−5 min). Blood is sampled from the vena cava caudalis into containers with EDTA as anticoagulant and centrifuged to yield plasma. Brain is sampled after cardiac perfusion of 10 mL NaCl 0.9% and homogenized into one volume of cold phosphate buffer (pH 7.4). All samples are extracted with MeOH and analyzed by LC-MS/MS. Concentrations are determined with the help of calibration curves. 
     Results obtained for the compound of Example 5.19: 
     (3 h after oral administration (100 mg/kg), n=3): [P]=2095 ng/ml; [B]=3880 ng/g. 
     Results obtained for the compound of Example 5.36: 
     (3 h after oral administration (100 mg/kg), n=3): [P]=1280 ng/ml; [B]=1808 ng/g. 
     Results obtained for the compound of Example 5.277: 
     (3 h after oral administration (100 mg/kg), n=3): [P]=3560 ng/ml; [B]=5880 ng/g. 
     Sedative Effects: EEG, EMG and Behavioural Indices of Alertness Recorded by Radiotelemetry In Vivo in Wistar Rats. 
     Electroencephalography (EEG) and Electromyography (EMG) signals were measured by telemetry using TL11M2-F20-EET miniature radiotelemetric implants (Data Science Int.) with two pairs of differential leads. 
     Surgical implantation was performed under general anesthesia with Ketamin/Xylazin, for cranial placement of one differential pair of EEG electrodes and one pair of EMG leads inserted in either side of the muscles of the neck. After surgery, rats recovered in a thermoregulated chamber and received analgesic treatment with subcutaneous buprenorphine twice a day for 2 d. They were then housed individually and allowed to recover for a minimum of 2 weeks. Thereafter, rats—in their home cage—were placed in a ventilated sound-attenuating box, on a 12-h light/12-h dark cycle, for acclimatization before continuous EEG/EMG recordings started. The telemetric technology that we used in this study allows accurate and stress-free acquisition of biosignals in rats placed in their familiar home cage environment, with no recording leads restricting their movements. Variables analyzed included four different stages of vigilance and sleep, spontaneous activity in the home cage and body temperature. Sleep and wake stages were evaluated using a rodent scoring software (Somnologica Science) directly processing electrical biosignals on 10 s contiguous epochs. The scoring is based on frequency estimation for EEG and amplitude discrimination for EMG and locomotor activity. Using these measurements, the software determines the probability that all components within each epoch best represent active waking (AW), quiet waking (QW), non-REM-sleep (NREM) or REM-sleep (REM). The percentage of total time spent in AW, QW, NREM- and REM-sleep was calculated per 12 h light or dark period. The latency to the onset of the first significant NREM- and REM-sleep episodes and the frequency and duration of those episodes were also calculated. AW, QW, NREM- and REM-sleep, home cage activity and body temperature were measured at baseline for at least one total circadian cycle (12 h-night, 12 h-day) before a test compound was administered. If baseline measurements indicated that animals were stable, test compound or vehicle was given in the evening by oral gavage at the end of the baseline 12-h day period, immediately before the nocturnal rise in orexin and activity in rats. All variables were subsequently recorded for 12 h following administration of the orexin receptor antagonist. 
     The compound of Example 5.19 has been tested in this assay (oral dosage: 30 mg/kg po; effects analyzed over 6 hours): Results are: −28% on active wake, −46% on home cage activity, +31% on NREM sleep, +69% on REM sleep; when compared to vehicle controls. 
     The compound of Example 5.36 has been tested in this assay (oral dosage: 30 mg/kg po; effects analyzed over 6 hours): Results are: −24% on active wake, −31% on home cage activity, +27% on NREM sleep, +53% on REM sleep; when compared to vehicle controls. 
     The compound of Example 5.277 has been tested in this assay (oral dosage: 30 mg/kg po; effects analyzed over 6 hours): Results are: −22% on active wake, −42% on home cage activity, +21% on NREM sleep, +52% on REM sleep; when compared to vehicle controls.